monday posters sessions - European Society of Cardiology

The scientific committee has designed a programme to address 

the most important requests from our past Heart Failure Congresses 

More learning and Interaction: 

5 Clinical Interactive Educational Sessions 

Clinical case review and knowledge sharing in a most practical manner 

Audience will be called upon by the presenters to interact on the management 

of the cases presented 

Each session is dedicated to a specific core topic 

We are bound to address your specific field of interest! 

Come and participate! Come and interact! Come and learn! 

Debate sessions 

Two high profile debate sessions, come and listen to the arguments on 

Saturday 29 (14:30 - 16:00), Room Hamburg and Monday 31 (14:30 - 15:45), Room Berlin 

Make sure you check the programme for the learning objectives designed for each session 

Latest updates: 

Heart failure: latest updates and beyond! 

The Late Breaking Clinical Trials 

sessions 

are innovative and provide the latest 

breakthroughs in clinical science. 

6 Trials will be presented and discussed 

in each session 

Don’t miss these animated 

interactive sessions! 

Make sure you visit the 

Late Breaking Trials 

and Late Breaking Research Posters 

Presenters will be available to discuss 

their research during coffee breaks 

New solutions for acute 

and chronic heart failure: 

update from industry 

We have asked the industry to present 

highlights of their current programme 

of research in heart failure and their views 

about the field more generally. 

Each presentation will be concluded 

by panel discussions. 

Questions from the audience 

are encouraged 

Clinical Trial Forum: 

Outlook on ongoing trials 

and networking opportunities 

Webcasts 

Catch highlight presentations hot off the press. The HFA Scientific Committee has specially 

chosen a number of presentations to be available online for immediate consultation after the 

end of the session. Web link: www.escardio.org/HFA (Scientific Reports) 

Meet colleagues and peers: 

Visit the Exhibition and Poster areas and attend the moderated poster sessions. 

Interact during the session in discussions engaged by panels of experts

14:30 - 16:00 

• The Presidents Debate Hamburg 

• The way forward for improving heart failure care Cologne 

16:15 - 17:45 

• Best Papers 2009/2010 and What did I miss at ESC09, Hamburg 

AHA09 and ACC10 

• Telehealth for heart failure: what is the evidence Cologne 

from early trials 

08:30 - 10:00 

• Difficult chronic heart failure cases Berlin 

• Major new developments in telehealth Hamburg 

• Managing Congestion Munich 

• Cardiotoxicity Cologne 

• The predominance of women with heart failure: Frankfurt 

a global perspective 

• Back to the future: engineering for myocardial Stuttgart 

reconstruction 

• Alles was Sie wissen sollten über... Leipzig 

10:00 - 11:00 

• Moderated Poster Session 1 Moderated Poster Area 

11:00 - 12:30 

• Acute heart failure Berlin 

• Telehealth: the next generation Hamburg 

• Major co-morbidities in heart failure: diagnosis Munich 

and treatment 

• Predicting and monitoring of cardiotoxicity? Cologne 

• Quality of life in heart failure: how do the available Frankfurt 

measurement tools perform in practice? 

• The Philip Poole-Wilson Young Investigator Award Stuttgart 

for Clinical Research 

• Aus dem Labor ans Krankenbett – Klinische Leipzig 

Anwendung grundlagenwissenschaftlicher Erkenntnisse 

12:45 - 13:30 

• Biomarkers: optimising treatment guidance in heart Leipzig 

failure 

Mini-Satellite Symposium organised by Pfizer, Ltd 

• New hope, new life. The era of mechanical Hannover 

circulatory support is upon us 

Mini-Satellite Symposium organised by Thoratec Europe Ltd 

12:45 - 14:00 

• Device therapy for heart failure: current and Munich 

new indications 

Satellite Symposium organised by Medtronic 

• Managing heart failure by slowing heart rate with Hamburg 

ivabradine 

Satellite Symposium organised by Servier 

PRo GRAMME AT A GLANCE 

Saturday 29 May 2010 

Sunday 30 May 2010 

P 

O 

S 

t 

E 

r 

S 

18:00 - 19:15 

OPENING CEREMONY 

Room Berlin 

19:15 - 21:00 

Welcome Cocktail 

Exhibition (Level 2) 

12:45 - 14:00 

• Emerging treatment opportunities in the Frankfurt 

management of heart failure: exploring novel strategies 

to optimize outcomes 

Satellite Symposium organised by Novartis Pharma AG 

• Die erweiterte nutzung kardialer marker von der Stuttgart 

akutversorgung bis in die arztpraxis 

Satellite Symposium organised by ALERE 

(formerly Inverness Medical) 

14:15 - 15:45 

• Late Breaking Trials - Session I Berlin 

• Troubleshooting in heart failure management Hamburg 

• Atrial fibrillation and heart failure Munich 

• Cardiology meets oncology: problems beyond Cologne 

cardiotoxicity 

• How to deal with pain in the heart failure patient Frankfurt 

• Advances in hypertrophic signalling Stuttgart 

• Das kardio-renale Syndrom und Ko-Morbiditäten Leipzig 

bei Herzinsuffizienz 

15:45 - 16:30 


16:30 - 18:00 

• Atrial fibrillation Berlin 

• Imaging heart failure Hamburg 

• Nutrition for Heart Failure ?! Munich 

• Targeting anaemia and/or iron deficiency in heart Cologne 

failure – ready for prime time?! 

• Nursing Investigator Award Frankfurt 

• State of the art: genomics in heart failure research Stuttgart 

• Technologie-basierte Ansätze bei Diagnostik und Leipzig 

Therapie der Herzinsuffizienz 

18:15 - 19:00 

• Remote disease management in the heart failure Frankfurt 

patient 

Satellite Symposium organised by St Jude Medical 

• MADIT-CRT: Impact on clinical practice Leipzig 

Mini-Satellite Symposium organised by Boston Scientific 

P 

O 

S 

t 

E 

r 

S 

08:30 - 10:00 

• Devices Berlin 

• Biomarkers in heart failure: what is their value Hamburg 

compared to clinical assessments and routine 

laboratory values? - 

• New solutions for acute and chronic heart failure: Munich 

update from industry 

• Heart failure and diabetes Cologne 

• Heart failure management 2010 and beyond: Frankfurt 

what are the key issues for nursing? 

• The sarcoplasmic calcium pump as a therapeutic Stuttgart 

target in heart failure 

• The Helmut Drexler Young Investigator Award Leipzig 

for Basic Science 

10:00 - 11:00 


11:00 - 12:30 

• Hypertension Berlin 

• New biomarkers in heart failure: ready for Hamburg 

prime time? 

• The adenosine antagonists story of targeting Munich 

the kidney in heart failure: status May 2010 

• Heart failure and Diabetes: a challenge for Cologne 

the 21st century 

• What do we need to know about the indication Frankfurt 

for surgery in heart failure patient? 

• New drugs for heart failure: update 2010 Stuttgart 

• Judges choice: Basic Science Leipzig 

12:45 - 13:30 

• Galectin-3: a novel biomarker of fibrosis in Leipzig 

heart failure 

Mini-Satellite Symposium organised by BG Medicine, Inc 

• Which patients should be considered for cardiac Hannover 

resynchronization therapy? 

Mini-Satellite Symposium organised by Biotronik 

08:30 - 10:00 

• Device therapy for heart failure with normal Hamburg 

ejection fraction: why should we try? 

• The cardio-renal syndrome in heart failure today Munich 

• Blocking the RAAS in heart failure – past, present Cologne 

and future 

• cGMP signaling in the failing heart: beyond NO? Stuttgart 

10:00 - 11:00 


MOnday 31 May 2010 

P 

O 

S 

t 

E 

r 

S 

12:45 - 14:00 

• Helping patients with chronic heart failure: Berlin 

time to think again? 

Satellite Symposium organised by Vifor Pharma 

• Changing heart failure risk assessment Frankfurt 

Satellite Symposium organised by GE Healthcare 

• The dynamic clinical utility of biomarkers Stuttgart 

across the spectrum of cardiovascular diseases 

Satellite Symposium organised by ALERE 

(formerly Inverness Medical) 

14:15 - 15:45 

• Award Ceremony followed by a Debate Session Berlin 

• Fancy new devices for heart failure Hamburg 

• HFPEF – all you need to know on Heart Failure Munich 

with Preserved Ejection Fraction 

• Judges choice: Clinical Research Cologne 

• Pregnancy associated heart disease Frankfurt 

• Embryonic stem cells or iPS: what is the future? Stuttgart 

• Targeting fibrosis in the heart: the forgotten problem Leipzig 

15:45 - 16:30 


16:30 - 18:00 

• Late Breaking Trials - Session II Berlin 

• Devices in heart failure: Update 2010 Hamburg 

• Acute heart failure – what you need to know Munich 

to take care of your patient 

• Judges choice: Treatment Research Cologne 

• Heart failure from a primary care perspective Frankfurt 

• Targeting integrins and arterial stiffness in Stuttgart 

heart failure 

• Oral abstract session: Basic Science Leipzig 

18:15 - 19:45 

• Biomarkers as an aid in cardio-pulmonary Frankfurt 

acute diseases 

Satellite Symposium organised by B.R.A.H.M.S 

TUESDAY 1 JUNE 2010 

P 

O 

S 

t 

E 

r 

S 

11:00 - 12:30 

• Highlights of the congress Hamburg 

• Ageing and heart failure: difficult issues Munich 

• Exercise in chronic heart failure: translation Cologne 

in progress 

• Highlights of the congress: Basic Science translated Stuttgart 

for the clinician 

P 

O 

S 

t 

E 

r 

S 

P 

O 

S 

t 

E 

r 

S 

OB1 d4628

Dear Friends and Colleagues, 

W elC ome a DDreSS 

Share new insights, improve your knowledge and enhance your clinical practice! 

It is our great pleasure to welcome you to the Heart Failure Congress 2010, organised by 

the Heart Failure Association of the European Society of Cardiology (HFA of the ESC). 

The Heart Failure Congress is a unique forum where cardiologists, internists, practising 

general physicians, basic scientists, epidemiologists, cardiac nurses, industry affiliates and 

others have the opportunity to meet and exchange ideas and information. 

This congress is an international event open to anyone interested in any aspect of 

heart failure. It covers all aspects of heart failure from epidemiology, through basic 

and translational science to prevention (including treatment of hypertension and postinfarction 

care), diagnosis (including imaging and biomarkers), monitoring (including 

remote monitoring), prognostication (risk stratification, including use of biomarkers), 

medical and nursing management (including drugs, devices, tele-care and surgery). 

All of the clinical aspects are reinforced in clinical case and “Meet the Expert“ sessions. The 

programme also includes updates on the latest clinical trials, reviews of the best published 

papers and a summary of the most important heart failure presentations at the major 

international cardiology conferences. 

There will also be presentations of new clinically relevant areas such as the influence 

of diabetes in heart failure and the interaction of cancer therapies and heart failure. 

Additionally, several international Associations and Heart Failure National Societies will 

bring their contribution, in joint sessions, to highlight different perspectives of clinical 

management. 

Berlin is the ideal venue for a Congress with our profile and scope. The city’s wealth 

of historical, cultural and social attractions will undoubtedly be the perfect addition to 

complete your congress experience! 

Once again, welcome to Berlin and welcome to your Congress! 

J. mcmurray 

(Glasgow, GB) 

HFA President 

S. anker 

(Berlin, DE) 

HFA Treasurer & Heart Failure 

2010 Scientific Chairperson 

P. Ponikowski 

(Wroclaw, PL) 

HFA President-Elect 

t. eschenhagen 

(Hamburg, DE) 

Heart Failure 2010 Scientific 

Co-Chairperson 

1 

general 

information

general 

information 

H eart failU re 2010 CommitteeS 

Board of the Heart failure association of the eSC 

J. McMurray (Glasgow, GB), President 

P. Ponikowski (Wroclaw, PL), President-elect 

K. Dickstein (Stavanger, NO), immediate Past-President 

G. Filippatos (Athens, GR), Chairperson Clinical Science Section 

A. Shah (London, GB), Chairperson Basic Science Section 

T. Jaarsma (Groningen, NL), Secretary 

S. Anker (Berlin, DE), treasurer 

M. Cowie (London, GB) 

U. Dahlstrom (Linköping, SE) 

I. Ekman (Gothenburg, SE) 

T. Eschenhagen (Hamburg, DE) 

G. Hasenfuss (Goettingen, DE) 

S. Janssens (Leuven, BE) 

A. Maggioni (Florence, IT) 

ex-officii: 

K. Swedberg (Gothenburg, SE), 

D. Brutsaert (Brussels, BE) 

Scientific Committee 

All HFA Board Members are part of the Scientific Committee 

S. Anker (Berlin, DE), Scientific Chairperson 

T. Eschenhagen (Hamburg, DE), Scientific Co-Chairperson 

R. Dietz (Berlin, DE) 

H.-P. Schultheiss (Berlin, DE) 

T. Unger (Konigswinter, DE) 

W. Haverkamp (Berlin, DE) 

M. Böhm (Hamburg, DE) 

A. Zeiher (Frankfurt, DE) 

T. Thum (Wurzburg, DE) 

Honorary members of the Scientific Committee: 

R. Ferrari (Ferrara, IT), eSC President 

M. Komajda (Paris, FR), eSC President-elect 

Heart failure 2010 secretariat 

European Society of Cardiology 

2035 Route des Colles - Les Templiers - 06903 Sophia Antipolis - France 

For general information, please contact: 

Tel: + 33 4 92 94 76 00 - Fax: + 33 4 92 94 86 29 

Email: Hfsecretariat@escardio.org 

2 

Z. Papp (Debrecen, HU) 

W. Paulus (Amsterdam, NL) 

B. Pieske (Graz, AT) 

M. Ryder (Dublin, IE) 

P. Seferovic (Belgrade, RS) 

D. Van Veldhuisen (Groningen, NL) 

F. Zannad (Dommartin-les-Toul, FR)

opening hours 

maK e Yo U r Wa Y t H roU g H t H e CongreSS 

Venue registration 

friday 28 may 14:00 - 18:00 

Congress Badge 

For security reasons, please have your badge visible at all times during the congress. 

Accompanying persons and exhibitors may access the scientific sessions if seats remain 

available. 

lost badges: a fixed price of € 45 will be charged for the replacement of lost badges at 

the Assistance Registration desk on the ground floor. 

Delegate Bag 

Each delegate is entitled to a congress bag to be picked up from the appropriate desk 

in the Registration Area. It contains the Final Programme, Abstract CD-Rom voucher, 

notepad, pen and information packages from the industry. 

registration 

The Heart Failure 2010 registration fees (apart from the Accompanying Person fee) entitle 

delegates to the following: 

• Entry to all scientific sessions and the Exhibition 

• Entry to the Opening Ceremony and Opening Cocktail on Saturday 29 May 2010 

• A copy of the Final Programme and the Abstract CD-Rom 

• Lunches and coffee breaks from Sunday 30 May to Tuesday 1 June 2010 

Cloakroom 

The cloakroom is located on the ground floor opposite the Registration desks. 

abstract CD-rom 

The Abstract CD-Rom is available from the Medtronic 

stand (A4) in the Exhibition Area. You will find a voucher 

in your delegate bag to collect your copy. 

Speakers’ Service 

Centre 

Saturday 29 may 12:00 - 21:00 08:30 - 20:30 12:00 - 18:30 17:15 - 21:00 

Sunday 30 may 07:30 - 19:30 07:30 - 18:30 07:30 - 18:30 09:00 - 18:00 

monday 31 may 07:30 - 19:30 07:30 - 18:30 07:30 - 18:30 09:00 - 18:00 

tuesday 1 June 07:30 - 13:00 07:30 - 13:00 07:30 - 13:00 09:00 - 12:30 

Speakers’ Service Centre 

All speakers giving a presentation in the scientific sessions are requested to upload and 

validate their presentation in the Speakers’ Service Centre (SSC) located close to the 

Registration Area, a minimum of 3 hours before the session starts or the day before if 

the session is at 08:30. 

Certificate of attendance 

Certificates will be available from the Registration desks as from Monday 31 May 2010 

at 12:00. 

3 

exhibition 

Supported by Medtronic in the form 

of an unrestricted educational grant 

general 

information

general 

information 

maK e Yo U r Wa Y t H roU g H t H e CongreSS 

WebSpace 

The Heart Failure Congress 2010 is pleased to provide attendees with free internet facilities. 

The WebSpace is located in the Exhibition Area above the Moderated Posters. 

Business Centre 

A Business Centre is at your disposal in the Registration Area. 

Browse, scan, fax and print! 

Journal 

Delegates paying the standard fee will receive a two-year subscription to the European 

Journal of Heart Failure (valid for 2011 and 2012). 

language 

The official language of the congress is English. No translation is available. German 

speaking sessions will be held all Sunday in room Leipzig on Level 3. 

lunch & Coffee Breaks 

From Sunday morning to Tuesday morning, open buffets are located in the Exhibition 

Area during break hours. 

first aid 

Participants in need of medical assistance should refer to the First Aid centre behind the 

Speakers' Service Centre on ground floor. 

Connect with your community 

u Connect with your peers 

The Heart Failure Congress is a unique opportunity to meet and exchange with colleagues 

and friends from over 50 countries. Heart Failure 2010 will also help you connect with 

related communities, such as General Practitioners, rehabilitation experts, internists & 

geriatricians. 

l Visit the large poster area 

l Use the extended coffee breaks to network 

l Come to the Clinical Trial Forum on the Bridge, Level 2. The ideal platform for 

organisers and sponsors of ongoing clinical trials to inform about their trials, find new 

sites and help in the recruitment and follow-up of patients 

u Connect with the industry 

l Exhibition area of more than 2000 m² 

l 14 Industry supported Educational sessions in the form of Satellite and Mini-satellite 

symposia 

l Lunch/Coffee Breaks served in the Exhibition 

u Connect with the Heart failure association of the eSC... 

4

H fa of t H e e SC a C tiV itieS 

Heart Failure Association of the ESC 

The Heart failure association of the eSC was founded to create a broad European 

platform where individuals interested and actively involved in managing the growing 

burden of heart failure can interact, network and participate in our numerous initiatives 

and activities. 

Over 3,400 practising cardiologists, basic scientists, nurses and members of the industry 

have joined us in our mission “to improve quality of life and longevity, through better 

prevention, diagnosis and treatment of heart failure, including the establishment of 

networks for its management, education and research”. 

Meetings at Heart Failure 2010 

Hfa general assembly Monday 31 May 10:00 - 11:00 in Room Leipzig 

awards Ceremony Monday 31 May 14:15 in Room Berlin 

ESC/HFA stand (A2) 

Come and meet us on the ESC/HFA stand, where our staff will be available to answer 

questions and provide you with the latest information on the Heart Failure Association 

and the European Society of Cardiology overall. 

You can directly apply for Hfa membership on the stand, using the interactive terminals in 

our “membership online” corner and pick up your Heart failure Journal. 

Join us on the stand to discover all our activities, such as guidelines, journals, educational 

courses and initiatives, the ESC Congress and the various sub-specialty congresses. We 

also already have information available on Heart Failure 2011 and members will receive a 

free pocket guideline, so don’t miss this opportunity to visit our stand! 

exhibition opening Hours: 

Saturday 29 May: 17:15 - 21:00 

Sunday 30 May: 09:00 - 18:00 

Monday 31 May: 09:00 - 18:00 

Tuesday 1 June: 09:00 - 12:30 

Don't miss the 

HFA General Assembly 

Monday 31 May 

10:00 - 11:00 

Room Leipzig 

5 

general 

information

general 

information 

SCientifiC reS o U r C e S 

Heart Failure 2010, the perfect opportunity to learn and share knowledge with 

your colleagues and peers! 

u Heart failure Core topic 

Essential learning topics relating to heart failure. 

u Clinical interactive education 

The case-based interactive sessions have been specifically designed to answer the 

demand for more educational and interactive sessions. 

u technology solutions for Heart failure: a 2010 update on devices & technology 

New technologies have been developed to diagnose, prevent and treat heart failure, 

with promising results. Experts will bring you up-to-date with these! 

u Co-morbidities & heart failure 

To discuss the impact of co-morbidities on outcome and clinical management in 

heart failure. Target audience: General Practitioners, rehabilitation experts, internists & 

geriatricians. 

u oncology and Heart failure: from onco-cardiology to cardio-oncology 

Educate heart failure specialists on relevant oncology areas. Educate Oncologists on 

Cardiology and heart failure. 

u Diabetes and Heart failure 

When diabetes develops in heart failure this has a major impact on the disease 

progression and outcome. Heart failure can also be a complication of diabetes. Patients 

with diabetes are at high risk for heart failure and may develop cardiovascular disease. 

u Caring for the patient with heart failure: gPs and nurses based heart failure care - 

Symptoms / assessment / therapy 

Discuss the real problems of patient care with peers specialised in heart failure patient 

care management. 

u Basic Science translated for clinicians 

Bridge the gap between Clinical and Basic Science. Sessions focusing on emerging 

clinically relevant research that potentially has an impact on daily practice. State-of- 

the-art presentations by the top scientists in the field containing the latest data and its 

significance in the context of cardiovascular disease. 

u Joint sessions 

With colleagues from related disciplines and international Heart Failure Societies 

highlighting different perspectives of clinical management. 

u industry supported educational sessions 

Industry will present their findings and results in the form of Satellite and Mini-satellite 

symposia; these scientific sessions offer delegates the opportunity to access some of the 

most recent scientific developments in an interesting and interactive format. 

6

NEW THIS YEAR! the Clinical interactive educational sessions 

SCientifiC reS o U r C e S 

The case-based interactive sessions have been specifically designed to answer the 

demand for more educational and interactive sessions. 

5 sessions, held in Room Berlin on Level 3, based on practical clinical cases will each 

be addressing a core topic related to heart failure. 

Come and interact with your peers, share knowledge and develop your level of 

understanding. 

ALSO NEW THIS YEAR, 

oncology and Heart failure: from onco-cardiology to cardio-oncology 

When cardiology meets oncology for sessions of exchange: heart failure specialists 

will get information on relevant oncology areas while oncologists will be edified on 

cardiology and heart failure. 

three sessions of great interest in room Cologne (level 1) on Sunday 30 may from 

08:30 to 15:45. 

Diabetes and Heart failure 

When diabetes develops in heart failure this has a major impact on the disease 

progression and outcome. Heart failure can also be a complication of diabetes. 

the answers to your questions will be presented in room Cologne (level 1) on 

Sunday 30 may at 16:30 and monday 31 may from 08:30 to 12:30. 

Webcasts 

Catch highlight presentations hot off the press. The HFA Scientific Committee has specially 

chosen a number of presentations to be available online for immediate consultation after 

the end of the session. Web link: www.escardio.org/HFA (Scientific Reports). 

Cme accreditation 

The Heart Failure Congress 2010 is accredited by the European Board for Accreditation in 

Cardiology (EBAC) for 18 hours of External CME credits. 

Each participant should claim only those hours of credit that have actually been spent in 

the educational activity. 

EBAC works in cooperation with the European Accreditation Council 

for Continuing Medical Education (EACCME) which is an institution of 

the European Union of Medical Specialists (UEMS). 

EBAC credits are recognised by the American Medical Association 

towards the Physician’s Recognition Award (PRA). Detailed instructions 

for converting these credits to AMA PRA Category 1 Credits are available 

on the AMA website. 

eBaC Certificates will be available at the registration desks from monday 31 may in 

the afternoon. 

7 

general 

information

general 

information 

Y o U r Ho S t CitY 

Berlin 

The capital of Germany is dynamic, cosmopolitan and creative, allowing for every kind of 

lifestyle. East meets West in the metropolis at the heart of a changing Europe. Germany’s 

largest city is a city of opportunities 

just waiting to be seized in all areas, like 

entertainment, recreation, economy, 

science and academic life. Berlin is home 

to world-renowned universities, research 

institutes, sporting events, orchestras and 

museums. 

A secret no more, Berlin emerges as the 

“Cultural Capital of Europe”! 

Public transportation 

Berlin has an extensive network of underground lines (U-Bahn), urban railway lines 

(S-Bahn), buses and tramways (Tram), allowing you to reach every location and sight in 

town in a safe and convenient way. 

from airports transport in direction of Stop / Station 

Berlin tegel X9 (Express) Zoologischer Garten S-Bhf. Jungfernheide 

then S 42 Schöneberg Messe Nord / ICC 

Schönefeld 9 Flughafen Schönefeld Westkreuz / Messe Süd 

from railway Stations transport in direction of Stop / Station 

Berlin Central Station 

Zoologischer garten 

Charlottenburg 9,75 Spandau Messe Süd 

ostbahnhof 

lichtenberg 

gesundbrunnen 42 Schöneberg Messe Nord / ICC 

Südkreuz 41 Gesundbrunnen Messe Nord / ICC 

/ Schöneberg 

46 Westend Messe Nord / ICC 

Spandau 9 Flughafen Schönefeld Messe Süd 

75 Wartenberg Messe Süd 

Potsdam 7 Ahrensfelde WestKreuz 

from City transport in direction of Stop / Station 

2 Ruhleben Kaiserdamm 

9, 75 Messe Süd 

Public transport 41, 42, 46 Messe Nord / ICC 

5, 7, 9, 41, 42, 45, 46, 47, 75 Westkreuz 

M 49, X 34, X 49, 104, 139 Messedamm / ZOB / ICC 

U-Bahn S-Bahn Bus System 

8

Car information 

The motorway exit "Messegelände“ leads you directly under the ICC Berlin. 

Parking spaces are available there or in close vicinity. 

Since January 1, 2008 Berlin’s inner city is an environmental zone - 

“Umwelt zone“ - where only cars that are up to emission standards are 

allowed. You need a sticker with information about the emission standard 

of your car. You can get these stickers in authorised garages. 

getting to the airport 

tranSPortation 

airport tegel (tXl) 

Tegel is situated in the northwest of Berlin, approximately 8 km from the city centre. You 

can reach the airport from western city centre conveniently within 15 minutes and from 

the ICC Berlin in approximately 20 minutes. 

Taxi fare: 15 e from ICC Berlin - 20 e from the city centre 

airport Schönefeld (SXf) 

Schönefeld is situated in the southeast of Berlin, approximately 18 km from the city centre. 

It will take you approximately 40 minutes to reach Schönefeld from the ICC Berlin. 

Taxi fare: 50 e from ICC Berlin - 44 e from the city centre 

9 

general 

information

general 

information 

C ongreSS floor Plan 

room leipzig eipzig 

LEVEL 2 

moderated oderated 

Posters 

Posters 

assistance 

Desk 

Access only possible with badge - NO BADGE NO ENTRY! 

room 

Hannover 

late Breaking 

trials 

10 

room 

Stuttgart 

access to level 2 

Posters 

area 

access ccess to 

level 3 

Speakers' Service 

Centre 

access ccess to 

level evel 2 

room oom Berlin 

Clinical interactive educational sessions 

exhibition xhibition area 

room 

frankfurt 

rankfurt 

meeting 

rooms ooms 

Posters 

area 

late Breaking 

Basic Science & 

translational research 

Clinical trial 

forum orum 

room Cologne 

aaccess 

to level 3 

Business 

Centre 

LEVEL 3 

access to 

level 2 

room oom munich 

aaccess 

to level 0 

room 

Hamburg 

LEVEL 0

millions of people in the world have 

heart failure 

One website can help them understand their condition 

and take the necessary steps to live full and active lives 

www.heartfailurematters.org 

Captivating animations Personal experience 

videos 

Practical patient 

information 

Heartfailurematters.org is an educational website for people with heart failure, 

their families and carers. It was developed by cardiologists, nurses and primary care 

physicians from the Heart Failure Association of the European Society of Cardiology. 

What are 

the warning signs? 

Helping you understand 

heart failure 

Advice on what 

you can do 

Tips for living 

with heart failure 

Downloadable tools 

SatUrDaY

SatUrDaY 

SatUrDaY 29 maY 2010 - afternoon 

14:30 - 16:00 Debate Hamburg 

The Presidents Debate 

Chairperson(s): D. Mann (St. Louis, US); J.J.V. McMurray (Glasgow, GB) 

Does ICD work for heart failure patients in every day life 

14:30 Pro. 1 

K. Dickstein (Stavanger, NO) 

14:45 Contra. 2 

B.M. Massie (San Francisco, US) 

15:00 rebutals and conclusions. 

Low dose diuretics are the most appropriate strategy for treating patients 

with acute decompensated heart failure 

15:15 Pro. 3 

M. Metra (Brescia, IT) 

15:30 Contra. 4 

G.M. Felker (Durham, US) 


14:30 - 16:00 Symposium Cologne 

The way forward for improving heart failure care 

Joint session with the european Commission, Unit “iCt for Health“ 

Chairperson(s): L. Gatzoulis (Brussels, BE); M.R. Costanzo (Naperville, US) 

technology solutions for heart failure: a 2010 update on devices and technologies 

14:30 opening remarks 5 

L. Gatzoulis (Brussels, BE) 

14:48 State of the art 2010: usual care in heart failure 6 

M. Komajda (Paris, FR) 

15:06 What is the potential for telemedicine in heart failure 7 

J. G. F. Cleland (Kingston Upon Hull, GB) 

15:24 major technical challenges in implementing telehealth 8 

C. Westerteicher (Boeblingen, DE) 

15:42 What is the main barrier to the implementation of telemedicine: patients, 

clinicians or managers? 9 

C. Zugck (Heidelberg, DE) 

12

SatUrDaY 29 maY 2010 - afternoon 

16:15 - 17:45 Special Session Hamburg 

Best Papers 2009/2010 and What did I miss at ESC09, AHA09 and ACC10 

Chairperson(s): R. Ferrari (Ferrara, IT); L. Tavazzi (Cotignola, IT) 

Learning objectives: 

- Be updated on the most recent presentations relevant to heart failure at major medical 

congresses. 

- Be updated on the key papers published on heart failure in the past year. 

16:15 nursing 10 

S. Stewart (Melbourne, AU) 

16:33 Biomarkers 11 

A. A. Voors (Groningen, NL) 

16:51 imaging 12 

To be announced 

17:09 Devices 13 

C. Linde (Stockholm, SE) 

17:27 Drugs 14 

J. J. V. McMurray (Glasgow, GB) 


Telehealth for heart failure: what is the evidence from early trials 


Chairperson(s): M.R. Cowie (London, GB); F.M. Fruhwald (Graz, AT) 


16:15 Home telemonitoring monitoring: experience from patients and health care 

providers: data from the Home-Hf study 15 

J. Riley (London, GB) 

16:33 Home telemonitoring versus usual care 16 

S. Inglis (Melbourne, AU) 

16:51 intensified care versus home telemonitoring 17 


17:09 Which approach is the most cost-effective 18 

S. Robinson (Bonn, DE) 

17:27 Designing telemedicine studies: what can be learnt from drug trials? 19 

W. Levy (Seattle, US) 

13 

SatUrDaY

SatUrDaY 

S atU r D aY 29 maY 2010 - e V ening 

18:00 - 19:15 Special Session Berlin 

14 

OPENING CEREMONY 

Chairperson(s): 

J.J.V. McMurray (Glasgow, GB); 

P. Ponikowski (Wroclaw, PL) 

Welcome from the President of the Hfa 


address from the President of the eSC 

R. Ferrari (Ferrara, IT) 

Scientific programme presentation 

S. D. Anker (Berlin, DE) 

in memory of Professor Drexler 

F.J.G.H. Just (Freiburg, DE) 

Hfa Honorary lecture: adventures in Cardiovascular research 

E. Braunwald (Boston, US) 

Closing remarks 

The Heart Failure Association 

of the ESC 

is glad to invite you to 

a Welcome Cocktail 

in the Exhibition (Level 2) 

19:15 - 21:00

the Heart failure Congress 2010 is pleased 

to provide attendees with free internet facilities 

SUnDaY

SUnDaY 

SUnDaY 30 maY 2010 - morning 

08:30 - 10:00 Clinical Interactive Educational Session Berlin 

Difficult chronic heart failure cases 

Chairperson(s): P. Ponikowski (Wroclaw, PL); F. Ruschitzka (Zurich, CH) 

Learning objective: 

- To discuss how to optimally manage a patient with heart failure and concomitant diabetes 

mellitus in everyday clinical practice 

Session objectives: 

- Clinical case review and knowledge sharing in a most practical manner. 

- Audience will be called upon by the presenters to interact on the management of the cases 

presented. 

- Voting system, advance audio-visual and sound system will facilitate the interactivity of this 

session. 

Case presentations and panel discussions 20 

J. R. Gonzalez Juanatey (Santiago De Compostela, ES), G. Jondeau (Paris, FR), 

H. Persson (Stockholm, SE), C. Ronco (Vicenza, IT) 

08:30 - 10:00 Symposium Hamburg 

Major new developments in telehealth 


Chairperson(s): J.G.F. Cleland (Kingston Upon Hull, GB); 

S. Robinson (Bonn, DE) 



- This session will showcase four major telehealth initiatives in Europe, reporting on new lessons 

learned and giving a ‘tomorrow’s world’ view of likely evolution over the next 3-5 years. 

- Practical experience, barriers to success and future aspirations will be discussed against the 

perspective of telehealth soon becoming part of the foundation of good clinical care for heart 

failure 

08:30 the Whole System Demonstrator Project 21 

T. Ellis (London, GB) 

08:52 my heart and heartcycle 22 

J. Wals (Eindhoven, NL) 

09:15 Partnership for heart 23 

F. Koehler (Berlin, DE) 

09:37 CorBene 24 

H. Korb (Koln, DE) 

16


08:30 - 10:00 Symposium Munich 

Managing Congestion 

Chairperson(s): G.S. Filippatos (Athens, GR); V. Conraads (Edegem, BE) 

Co-morbidities and heart failure 


- Participants should be able to diagnose and treat patients with acute heart failure and 

congestion. 

08:30 Congestion: what is it? 25 

T. A. McDonagh (London, GB) 

08:48 Diuretics: a necessary evil? 26 

R. Dietz (Berlin, DE) 

09:06 adenosine antagonists: is there still hope? 27 


09:24 Ultrafiltration: why are we waiting? 28 

M. R. Costanzo (Naperville, US) 

09:42 aVP antagonists: is water important? 29 

F. Zannad (Nancy, FR) 


Cardiotoxicity 

Chairperson(s): A.M. Shah (London, GB); S.D. Anker (Berlin, DE) 

Cardio-oncology 

08:30 overview of the problem from the clinical perspective 30 

T. M. Suter (Bern, CH) 

08:48 Understanding the carditoxicity of the new therapeutics: is toxicity predictable? 31 

T. Force (Philadelphia, US) 

09:06 What’s in the future: a look at drugs in the pipeline - is there cause for concern? 32 

M. Rauchhaus (Rostock, DE) 

09:24 How should we follow these patients: are we ready for guidelines? 33 

J. L. Lopez-Sendon (Madrid, ES) 

09:42 adult survivors of childhood cancer: what can we expect? 34 

M. Ewer (Houston, US) 

17 

SUnDaY

SUnDaY 


08:30 - 10:00 Symposium Frankfurt 

The predominance of women with heart failure: a global perspective 

Joint session with the asia-Pacific Society of Cardiology (aPSC) 

Chairperson(s): C.E. Angermann (Wurzburg, DE); H. Krum (Melbourne, AU) 

Caring for the patient with heart failure 

08:30 europe 35 

A. Rosengren (Gothenburg, SE) 

08:48 USa 36 

I. L. Pina (Cleveland Heights, US) 

09:06 Sub-saharan africa 37 

K. Sliwa-Hahnle (Cape Town, ZA) 

09:24 China 38 

D.S.-F. Yu (Hong Kong, HK) 

09:42 indigenous australia 39 


08:30 - 10:00 Symposium Stuttgart 

Back to the future: engineering for myocardial reconstruction 

Chairperson(s): S. Janssens (Leuven, BE); Z. Papp (Debrecen, HU) 

Basic science translated for the clinician 


- Participants should be able to appreciate the most advanced methods for myocardial 

reconstruction and the challenges in translation to clinical practice 

- Participants should be able to appreciate current state of the art in experimental research and 

future perspectives of myocardial tissue engineering and reconstruction 

08:30 tissue engineering of heart valves 40 

S. P. Hoerstrup (Zurich, CH) 

08:48 Creating a cardiac path for a wounded heart 41 

T. Eschenhagen (Hamburg, DE) 

09:06 large scale production of cardiac myocytes from human to embryonic stem cells 42 

C. Denning (Nottingham, GB) 

09:24 injectable biomaterials for infarct repair: from bench to bedside 43 

J. Leor (Tel Hashomer, IL) 

09:42 Surgical alternatives to remodel the ventricle 44 

R. Hetzer (Berlin, DE) 

18


08:30 - 10:00 Symposium Leipzig 

Alles was Sie wissen sollten über... 

in collaboration with the german Competence network Heart failure – CnHf 

in Zusammenarbeit mit dem Kompetenznetz Herzinsuffizienz – KnHi 

Chairperson(s): E. Erdmann (Koeln, DE); F. Follath (Zurich, CH) 


- Leitlinien und weitere wichtige Fakten mit Bedeutung für den klinisch tätigen Arzt in der 

Versorgung herzinsuffizienter Patienten 

08:30 Behandlungsoptionen bei akuter Herzinsuffizienz 45 

M. Boehm (Homburg/Saar, DE) 

08:48 Die Blockade des raS bei chronischer Herzinsuffizienz 46 

T. Unger (Berlin, DE) 

09:06 Diagnostik und Behandlung der diastolischen Herzinsuffizienz 47 

B. M. Pieske (Graz, AT) 

09:24 Diagnostik und Behandlung der myokarditis 48 

H. P. Schultheiss (Berlin, DE) 

09:42 Biomarker in der Diagnostik der Herzinsuffizienz 49 

C. Mueller (Basel, CH) 

CLINICAL TRIAL FORUM - Sunday from 10:00 to 11:00 

Bridge Level 2 

19 

SUnDaY

SUnDaY 



Acute heart failure 

Case based interactive session 

Chairperson(s): G.S. Filippatos (Athens, GR); J.R. Teerlink (San Francisco, US) 

Heart failure core topic 


- Participants should be able to appreciate evidence base treatment of patients with acute heart failure. 




presented. 

- Voting system, advance audio-visual and sound system will facilitate the interactivity of this session. 

aCS and heart failure 50 

M.S. Nieminen (Helsinki, FI) 

Case presentation 51 

M.R. Costanzo (Naperville, US) 

Panel 52 

M.R. Costanzo (Naperville, US), A. Mebazaa (Paris, FR), B. Meyns (Leuven, BE), 

M.S. Nieminen (Helsinki, FI), H.P. Schultheiss (Berlin, DE) 


Telehealth: the next generation 


Chairperson(s): B. Celler (Sydney, AU); L. Gatzoulis (Brussels, BE) 


11:00 new sensors 53 

J. Luprano (Neuchatel, CH) 

11:22 new information processing 54 

N. Maglaveras (Thessaloniki, GR) 

11:45 Developing clinical services 55 

D. Barrett (Hull, GB) 

12:07 Patient empowerment and data quality 56 

B. Celler (Sydney, AU) 

20



Major co-morbidities in heart failure: diagnosis and treatment 

Chairperson(s): K. Dickstein (Stavanger, NO); J. Nanas (Athens, GR) 



- Identify additional risk and challenges related to co-morbidities in heart failure 

- Participants should be able to appreciate to characterize and diagnose the most frequent comorbidities 

in heart failure 

- Appropriately implement guidelines for treating co-morbidities in heart failure into clinical 

practice 

11:00 Depression 57 

J. T. Parissis (Athens, GR) 

11:18 anaemia 58 

K. Swedberg (Goteborg, SE) 

11:36 ischaemia 59 

I. S. Anand (Edina, US) 

11:54 Hypertension 60 


12:12 CoPD 61 

H. Krum (Melbourne, AU) 


Predicting and monitoring of cardiotoxicity? 

Chairperson(s): V. Adams (Leipzig, DE); M. Pfeffer (Boston, US) 



- How to identify a cancer patient at risk for cardiotoxicity 

- How to prevent life threatening arrhythmias in cancer patients 

11:00 Biology of relevant receptors in the heart and cancer 62 

G. W. A. De Keulenaer (Wilrijk, BE) 

11:18 Predicting the pro-arrhythmic potential of drugs 63 

L. Hondeghem (Ostend, BE) 

11:36 testing pro-arrhythmic drugs on engineered heart tissues 64 

A. Hansen (Hamburg, DE) 

11:54 Pre-clinical prediction of cardiotoxicity 65 

T. Force (Philadelphia, US) 

12:12 Cardiac side effects of pro- arrhythmic cancer therapy 66 


21 

SUnDaY

SUnDaY 



Quality of life in heart failure: how do the available measurement tools 

perform in practice? 

Chairperson(s): A.P. Maggioni (Florence, IT); I. Ekman (Goteborg, SE) 



- Able to identify the usefulness of quality of life instruments when assessing individual patients´ 

wellbeing 

- Able to identify the usefulness of quality of life instruments when evaluating care and treatment 

in clinical practice 

11:00 minnesota living with heart failure questionnaire 67 

I. Ekman (Goteburg, SE) 

11:18 functional status questionnaire 68 

D. Castagno (Torino, IT) 

11:36 Short-form 36 69 

F. D. R. Hobbs (Birmingham, GB) 

11:54 Kansas city cardiomyopathy questionnaire 70 


12:12 How should we assess sexual function/satisfaction 71 

T. Jaarsma (Norrkoping, SE) 

11:00 - 12:30 YIA Abstracts Stuttgart 

The Philip Poole-Wilson Young Investigator Award for Clinical Research 

Chairperson(s): P. Ponikowski (Wroclaw, PL); J.J.V. McMurray (Glasgow, GB) 

Judge(s): S.D. Anker (Berlin, DE); D.J. van Veldhuisen (Groningen, NL); 

S. Adamopoulos (Athens, GR); D. Mann (St. Louis, US) 

11:00 metformin in insulin resistant lV Dysfunction, a Double-blind, placebo 

controlled trial 72 

A.K.F. Wong, R.S. Symon, M.A. Alzadjali, D.S.C. Ang, A.M. Choy, J. Petrie, 

A.D. Struthers, C.C. Lang (Dundee, GB) 

11:15 Pressure-volume loop evaluation of Crt in end-stage heart failure. a 

comparison of patients with a narrow, intermediate and broad QrS complex 73 

G.J. De Roest, C.P. Allaart, S.A. Kleijn, M.L. Hendriks, J.G.F. Bronzwaer, 

A.C. Van Rossum, C.C. De Cock (Amsterdam, NL) 

11:30 Beta blockers and pulmonary function in elderly patients with heart failure: 

insight from CiBiS-elD 74 

M. Lainscak, G. Gelbrich, S. Inkrot, E. Tahirovic, F. Edelmann, W. Doehner, 

A. Neskovic, S. Apostolovic, S.D. Anker, H.D. Duengen (Golnik, SI; Leipzig, Berlin 

and Goettingen, DE; Zemun and Nis, RS) 

22


11:00 - 12:30 YIA Abstracts Stuttgart 

11:45 novel cardiac pacemaker-based human model of periodic breathing to 

develop real-time, pre-emptive technology for respiratory stabilisation 75 

R. Baruah, A. Giannoni, C.H. Manisty, K. Willson, A.A. Kyriacou, P. Pabari, 

B. Unsworth, S. Sen, J. Mayet, D.P. Francis (London, GB; Pisa, IT) 

12:00 Pra is an independent prognostic factor across the entire spectrum of heart 

failure clinical status 76 

G. Vergaro, A. Giannoni, A. Valleggi, R. Poletti, M. Fontana, A. Iervasi, L. Zyw, 

A. Gabutti, C. Passino, M. Emdin (Pisa, IT) 

12:15 Parvovirus B19 persists in normal and diseased hearts, but reactivates in failing 

hearts 77 

R. Dennert, S. Velthuis, P. Wolffs, V. Goossens, C. Bruggeman, J. Waltenberger, 

J. Maessen, R.J. Van Suylen, H.J. Crijns, S. Heymans (Maastricht, NL) 

11:00 - 12:30 Special Session Leipzig 

Aus dem Labor ans Krankenbett – Klinische Anwendung 

grundlagenwissenschaftlicher Erkenntnisse 



Chairperson(s): A. Auricchio (Lugano, CH); F.J.G.H. Just (Freiburg, DE) 



- Forschungsentwicklungen, die heute eine relevante klinische Bedeutung haben. 

11:00 therapien die 2009/2010 in die realität angekommen sind 78 

E. Erdmann (Koeln, DE) 

11:18 neue molekulare mechanismen bei infarkt und Herzinsuffizienz 79 

K. C. Wollert (Hannover, DE) 

11:36 Warum sind Chemotherapeutika kardiotoxisch? 80 

M. Rauchhaus (Rostock, DE) 

11:54 genetische ansätze in der Diagnostik der Herzinsuffizienz 81 

H. Schunkert (Lubeck, DE) 

12:12 neuigkeiten zu Stammzellen und mirna’s 82 

A. M. Zeiher (Frankfurt, DE) 

23 

SUnDaY

SUnDaY 

SUnDaY 30 maY 2010 - afternoon 

12:45 - 13:30 Mini-Satellite Session Hannover 

New hope, new life. The era of mechanical circulatory support is upon us 

mini-Satellite Symposium organised by thoratec europe ltd 

Chairperson(s): P.J. Mohacsi (Bern, CH); R. Hetzer (Berlin, DE) 

12:45 introduction. 83 

P. J. Mohacsi (Bern, CH) 

12:50 What does the new Hmii destination therapy trial data really tell us in europe? 84 

J.-N. Trochu (Nantes, FR) 

13:10 How should we select the right patient for mechanical circulatory support? 85 


13:25 Conclusion. 86 


12:45 - 13:30 Mini-Satellite Session Leipzig 

Biomarkers: optimising treatment guidance in heart failure 

mini-Satellite Symposium organised by Pfizer ltd. 

Chairperson(s): M. Boehm (Homburg/Saar, DE); F. Zannad (Nancy, FR) 

12:45 introduction: heart failure biomarkers in clinical practice. 87 


13:00 novel cardio-renal biomarkers in heart failure. 88 


13:10 extracellular matrix remodelling in ePHeSUS. 89 


13:20 Questions and answers. 90 


12:45 - 14:00 Satellite Session Hamburg 

Managing heart failure by slowing heart rate with ivabradine 

Satellite Symposium organised by Servier 

Chairperson(s): K. Swedberg (Goteborg, SE); L. Tavazzi (Cotignola, IT) 

12:45 introduction. 

K. Swedberg (Goteborg, SE) 

12:50 Unmet needs and management in heart failure. 91 


13:10 Benefits of slowing heart rate in heart failure: evidences and questions. 92 

M. R. Cowie (London, GB) 

13:35 Clinical perspectives with ivabradine: the SHift study. 93 


12:55 Conclusion. 

L. Tavazzi (Cotignola, IT) 

24


12:45 - 14:00 Satellite Session Munich 

Device therapy for heart failure: current and new indications 

Satellite Symposium organised by medtronic 

Chairperson(s): J.G.F. Cleland (Kingston Upon Hull, GB); D.J. van Veldhuisen 

(Groningen, NL) 



12:50 established indications for Crt: evidence and clinical practice. 95 


13:10 Crt in mild Heart failure. 96 

C. Hassager (Copenhagen, DK) 

13:30 innovative solutions for optimal device and patient management. 97 

G. Klein (Hannover, DE) 

13:50 Panel discussion. 98 

D. J. van Veldhuisen (Groningen, NL) 

12:45 - 14:00 Satellite Session Frankfurt 

Emerging treatment opportunities in the management of heart failure: 

exploring novel strategies to optimize outcomes 

Satellite Symposium organised by novartis Pharma ag 

Chairperson(s): A.P. Maggioni (Florence, IT); L. Kober (Gentofte, DK) 

12:45 Welcome and introduction. 99 

A.P. Maggioni (Florence, IT) 

12:50 the state of the art: modern management of heart failure. 100 


13:05 acknowledging the challenge of managing acute heart failure: what have we 

learnt from randomized controlled trials and what are the future directions? 101 

G.S. Filippatos (Athens, GR) 

13:25 targeting the renin-angiotensin-aldosterone system (raaS) and beyond in 

chronic heart failure - investigating new opportunities. 102 


13:45 Questions and panel discussion. 103 

G.S. Filippatos (Athens, GR); H. Krum (Melbourne, AU); A.P. Maggioni (Florence, IT) 

13:55 Summary and close. 104 


25 

SUnDaY

SUnDaY 


12:45 - 14:00 Satellite Session Stuttgart 

Die erweiterte nutzung kardialer marker von der akutversorgung bis 

in die arztpraxis 

Satellite Symposium organised by alere (formerly inverness medical) 

Chairperson(s): S.D. Anker (Berlin, DE); C. Mueller (Basel, CH) 

12:45 einführung. 105 


12:50 Die wachsende rolle von Biomarkern in der kardialen Diagnostik und therapie. 106 

C. Wrede (Regensburg, DE) 

13:10 Die zunehmende Bedeutung natriuretischer Peptide bei akuter und 

chronischer Herzinsuffizienz. 107 

A. Luchner (Regensburg, DE) 

13:30 natriuretische peptide: neue wege in der ärztlichen grundversorgung. 108 


13:50 Zusammenfassung. 109 


26



Late Breaking Trials - Session I 

Chairperson(s): J.J.V. McMurray (Glasgow, GB); S.D. Anker (Berlin, DE) 

14:15 triDent-1 110 

W. T. Abraham (Columbus, US) 

14:30 BenefiCial 111 


14:45 CUPiD trial 112 

B. H. Greenberg (San Diego, US) 

15:00 rfa-Hf 113 

M.A. McDonald (Edmonton, CA) 

15:15 fair-Hf renal function analysis 114 


15:30 maDit-Crt echocardiography Study 115 

S. Solomon (Boston, US) 


Troubleshooting in heart failure management 

Chairperson(s): H. Krum (Melbourne, AU); M. Petrie (Glasgow, GB) 



- To identify potential hurdles in heart failure management 

- To discuss the whole complex heart failure management process starting from a proper 

diagnosis and ending with end-stage heart failure treatment 

14:15 How to use biomarkers in diagnosis 118 

A. Maisel (Solana Beach, US) 

14:33 How to assess and manage deteriorating renal function 119 


14:51 titrating evidence-based treatment: troubleshooting problems 120 

A. Cohen-Solal (Paris, FR) 

15:09 How to optimise cardiac resynchronisation therapy? 121 

A. Auricchio (Lugano, CH) 

15:27 When to refer for a lVaD and transplantation? 122 

J. R. Teerlink (San Francisco, US) 

27 

SUnDaY

SUnDaY 



Atrial fibrillation and heart failure 

Joint session with the european Heart rhythm association (eHra) 

Chairperson(s): M. Boehm (Homburg/Saar, DE); 

P.E. Vardas (Heraklion, GR) 



- Understand the pathophysiology and epidemiology of atrial fibrillation in heart failure 

- Interpret the results of the recent trials of atrial fibrillation in heart failure. 

- Appropriately implement into clinical practice guidelines for drug treatment and ablation of 

atrial fibrillation in heart failure 

14:15 atrial fibrillation in patients with heart failure: pathophysiology 123 

G. Ertl (Wurzburg, DE) 

14:33 atrial fibrillation in patients with heart failure: impact on the individual and 

the society 124 

P. E. Vardas (Heraklion, GR) 

14:51 treating atrial fibrillation in heart failure with drugs 125 

L. Kober (Gentofte, DK) 

15:09 atrial fibrillation: the impact of statins and arBs 126 

L. Tavazzi (Cotignola, IT) 

15:27 ablation for atrial fibrillation in patients with heart failure 127 

M. Gasparini (Rozzano, IT) 


Cardiology meets oncology: problems beyond cardiotoxicity 

Chairperson(s): M. Rauchhaus (Rostock, DE); M. Ewer (Houston, US) 


14:15 fatigue in cancer - clinical correlate of heart failure? 128 

W. Levy (Seattle, US) 

14:33 Why do patients with cancer die? any evidence for cardiovascular problems? 129 

G. M. C. Rosano (Roma, IT) 

14:51 Pathophysiology of cachexia in cancer and heart failure: all the same? 130 

S. Von Haehling (London, GB) 

15:09 from mice to men: treating cancer with cardiovascular drugs?! 131 

J. Springer (Berlin, DE) 

15:27 managing cardiovascular problems in cancer patients: from hypertension to 

diabetes 132 


28



How to deal with pain in the heart failure patient 

Joint session with the american association of Heart failure nurses (aaHfn) 

Chairperson(s): P. Strachan (Hamilton, CA); A. Stromberg (Linkoping, SE) 



- Pain is a common, but neglected and poorly treated symptom in patients with heart failure. 

This session will provide knowledge on how to deal with pain in heart failure and address 

pathophysiology, methods of assessment and treatment aspect. 

14:15 Prevalence and pathways of pain in heart failure patients 133 

A. L. Clark (Kingston-Upon-Hull, GB) 

14:37 Presentation and assessment of pain in heart failure 134 

I. Ekman (Goteborg, SE) 

15:00 Pharmacological intervention for relief of subjective suffering in heart failure 135 

C. E. Angermann (Wurzburg, DE) 

15:22 non pharmacological interventions 136 

N. Albert (Cleveland, US) 


Advances in hypertrophic signalling 

Chairperson(s): D. Hilfiker-Kleiner (Hannover, DE); S. Janssens (Leuven, BE) 


Learning objectives : 

- A review of the latest research on cellular pathways involved in the development of cardiac 

hypertrophy. 

- Provides information on potential new therapeutic targets to reduce or ameliorate hypertrophy. 

14:15 from hypertrophy to remodelling: state of science in may 2010 137 


14:33 transcriptional pathways regulating hypertrophy 138 

L. J. De Windt (Maastricht, NL) 

14:51 nox4 naDPH oxidase and cardiac hypertrophy 139 

A. M. Shah (London, GB) 

15:09 novel mechanisms of erK activation in hypertrophy 140 

K. Lorenz (Wurzburg, DE) 

15:27 role of PKD signalling 141 

F. Cuello (London, GB) 

29 

SUnDaY

SUnDaY 



Das kardio-renale Syndrom und Ko-Morbiditäten bei Herzinsuffizienz 



Chairperson(s): E. Erdmann (Koeln, DE); H.P. Schultheiss (Berlin, DE) 


- Der herzinsuffiziente Patient und andere Organsysteme mit relevantem Einfluss auf die 

Erkrankung 

14:15 Herz-niere-interaktionen bei chronisch Kranken 142 

J. Bauersachs (Wurzburg, DE) 

14:33 Herzinsuffizienz als folge von Systemerkrankunge 143 

F. Mehrhof (Berlin, DE) 

14:51 Diabetes mellitus und Herzinsuffizienz 144 

C. Tschoepe (Berlin, DE) 

15:09 Schlaganfall und Herzinsuffizienz 145 

W. Doehner (Berlin, DE) 

15:27 therapie von anämie und eisenmangel bei Herzinsuffizienz 146 


30



Atrial fibrillation 


Chairperson(s): M. Boehm (Homburg/Saar, DE); D.J. van Veldhuisen (Groningen, NL) 





presented. 


session. 

16:30 atrial fibrillation and stroke. 147 

G.Y.H. Lip (Birmingham, GB) 

16:48 atrial fibrillation with acute heart failure. 148 

B.M. Pieske (Graz, AT) 

17:06 atrial fibrillation with inadequate rhythm control. 149 

H.-R. Neuberger (Homburg, DE) 

17:24 take home messages - What do the guidelines say? 150 


17:42 Panel. 151 

W. Haverkamp (Berlin, DE), G.Y.H. Lip (Birmingham, GB), H.-R. Neuberger 

(Homburg, DE), B.M. Pieske (Graz, AT) 


Imaging heart failure 

Joint session with the european association of echocardiography (eae) 

Chairperson(s): L. Badano (Udine, IT); K. Dickstein (Stavanger, NO) 


- Gain appreciation of key developments in non-invasive imaging. 

- Understand the advantages and limitations of main non-invasive imaging techniques. 

- Learn how to choose which imaging technique for which patient in clinical practice and 

develop an integrated imaging strategy for patients with heart failure. 

16:30 echocardiographic assessment of diastolic heart failure 152 

B. A. Popescu (Bucharest, RO) 

16:52 three-dimensional echocardiography: why we need it? 153 

L. Badano (Udine, IT) 

17:15 multimodality imaging & mri 154 


17:37 an integrated approach to address patients’ needs 155 


31 

SUnDaY

SUnDaY 



Nutrition for Heart Failure ?! 

Chairperson(s): M.F. Piepoli (Piacenza, IT); M. Gheorghiade (Chicago, US) 



- Understand the biochemistry and energetics of the failing heart 

- Identify opportunities for nutrition supplement in treating heart failure 

- Identify interventions destined to improve skeletal muscle function in heart failure patients 

16:30 the biochemistry of the heart’s work: where does the energy come from and 

how is this altered in heart failure 156 

M. P. Frenneaux (Aberdeen, GB) 

16:48 Pathophysiology of essential amino acids and their application in heart failure 157 


17:06 all a cardiologist needs to know about fat tissue 158 

G. Jondeau (Paris, FR) 

17:24 nutritional supplements for acute and chronic heart failure 159 


17:42 treating skeletal muscle: electrical impulses, anabolics, ghrelin and exercise 160 

E. A. Jankowska (Wroclaw, PL) 


Targeting anaemia and/or iron deficiency in heart failure – ready for prime time?! 

Chairperson(s): J. Comin-Colet (Barcelona, ES); L. Tavazzi (Cotignola, IT) 



- To increase the awareness about anaemia and iron deficiency as important comorbidities in 

heart failure. 

16:30 Setting the stage: epidemiology and pathophysiology of anemia and iron 

deficiency 161 

G. S. Filippatos (Athens, GR) 

16:48 iron metabolism, symptoms and outcome in heart failure: much more than 

just anemia 162 


17:06 epo and darbepoietin alpha for chronic heart failure: status 2010 163 

K. McDonald (Dublin, IE) 

17:24 epo and darbepoietin alpha for chronic renal failure and cancer: a critical 

review of efficacy and safety 164 

M. Pfeffer (Boston, US) 

17:42 Using intravenous iron to treat iron deficiency in heart failure: more than 

taking care of anemia 165 


32


16:30 - 18:00 YIA Abstracts Frankfurt 

Nursing Investigator Award 

Chairperson(s): T. Jaarsma (Norrkoping, SE); N. Albert (Cleveland, US) 

Judge(s): I. Ekman (Goteborg, SE); M. Ryder (Dunlaoghaire, IE); P. Strachan 

(Hamilton, CA); J. Riley (London, GB) 

16:30 Self-rated health in elderly patients with heart failure: influence of betablocker 

titration 166 

S. Inkrot, E. Tahirovic, M. Lainscak, J. Farkas, A. Toepper, H.-H. Radlach, 

F. Edelmann, C. Herrmann-Lingen, T. Dassen, H.-D. Duengen (Berlin and 

Goettingen, DE; Golnik and Ljubljana, SI) 

16:45 Quality of life, functional status and cardiac event-free survival in patients with 

heart failure 167 

J.R. Wu, T.L. Lennie, D.K. Moser (Lexington, US) 

17:00 Short-term follow up of a randomised study evaluating effects of education 

and psychosocial support to patients and their partners 168 

A. Stromberg, S. Agren, C. Hjelm, L. Evangelista (Linkoping, SE; Los Angeles, US) 

17:15 the relationship between self-concept cognitive perception and adherence to 

prescribed therapeutic regimen in patients with heart failure 169 

A. Heidary, S. Ahrari, S. Vaghee (Mashhad and Birjand, IR) 

17:30 Predictors of uncertainty in caregivers of patients with heart failure- a 

longitudinal study 170 

K. Harkness, H.M. Arthur, R.S. Mckelvie (Hamilton and Ontario, CA) 

17:45 factors related to delay in seeking care after symptom onset in heart failure 

patients 171 

M.M.W. Nieuwenhuis, M.H.L. Van Der Wal, T. Jaarsma, D.J. Van Veldhuisen 

(Groningen, NL; Norrkoping, SE) 


State of the art: genomics in heart failure research 

Chairperson(s): D.L. Brutsaert (Kontich, BE); P.A.F.M. Doevendans (Utrecht, NL) 



- Provides an update on the recent revolution in analyzing genetic predisposition to heart disease 

with consideration of the different methodologies being used as well as latest scientific findings 

16:30 genome-wide scans for disease genes in heart disease 172 

H. Schunkert (Lubeck, DE) 

16:48 gWaS analysis of Qt interval 173 

A. Pfeufer (Munich, DE) 

17:06 Screening for determinant of lV mass 174 

S. A. Cook (London, GB) 

33 

SUnDaY

SUnDaY 



17:24 model organisms for genetic studies of cardiovascular traits 175 

J. Bakkers (Utrecht, NL) 

17:42 genetics and individualizing therapy: learning from cancer and gambling 176 

H. Lehrach (Berlin, DE) 


Technologie-basierte Ansätze bei Diagnostik und Therapie der 

Herzinsuffizienz 



Chairperson(s): C. Zugck (Heidelberg, DE); R. Dietz (Berlin, DE) 


- Technische Entwicklungen, die bereits Einzug in die Realität genommen haben 

16:30 Cardiac imaging 177 


16:48 Herzkatheter & Biopsien – update 2010 178 


17:06 telemedizin in der Betreuung herzinsuffizienter Patienten 2010 179 


17:24 iCDs und Crts bei Herzinsuffizienz 180 

B. Maisch (Marburg, DE) 

17:42 Die Zukunft der Device-basierten therapie(steuerung) bei Herzinsuffizienz 181 

S. Stork (Wurzburg, DE) 

34

SUnDaY 30 maY 2010 - eVening 


MADIT-CRT: Impact on clinical practice 

mini-Satellite Symposium organised by Boston Scientific 

Chairperson: K. Dickstein (Stavanger, NO) 

18:15 introduction. 

18:20 intervening before heart failure gets “bad“. 182 

M.R. Cowie (London, GB) 

18:35 Diagnosing worsening of heart failure remotely. 183 

B.M. Pieske (Graz, AT) 

18:55 Conclusion. 


Remote disease management in the heart failure patient 

Satellite Symposium organised by St Jude medical 

Chairperson(s): To be announced 

18:15 remote disease management: Clinical evidence. 184 


18:30 telemedicine: Current state of play. 185 


18:45 implantable diagnostics: new technologies. 186 


19:00 Clinical implications: Key takeaways. 187 


35 

SUnDaY

SUnDaY 

noteS 

36

SUNDAY 

POSTERS SESSIONS 

l ate BreaKing trialS anD reSearCH 

late Breaking research - Basic & translational .............................................................Page 38 

late Breaking trials .............................................................................................................................................Page 39 

morning 

moderated Posters Sessions 1 (10:00 - 11:00) ........................................................Page 40 

Poster Session 1 ...........................................................................................................................Pages 41 to 58 

All Posters will be on display from 08:30 - 12:30 

afternoon 

moderated Posters Sessions 2 (15:45 - 16:30) ........................................................Page 59 

Poster Session 2 ..........................................................................................................................Pages 60 to 77 


Don’t miss! 

Heart Failure Pilot Registry 

presented by Professor A.P. Maggioni 

Moderated Poster Area 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 

late BreaKing reSearCH 

Heart Failure 2010 – Late Breaking Research Posters 

Deficiency of the cardiorenal protective hormone BnP in stage a heart failure defined 

by early hypertension lBr1 

A. Cataliotti, F. Macheret, P. M. McKie, R. J. Rodeheffer, L. C. Costello-Boerrigter, 

G. Boerrigter, K. R. Bailey, J. C. Burnett 

Knockout mice for CamK4 gene display a hypertensive phenotype lBr2 

G. Santulli, D. Sorriento, E. Cipolletta, C. Del Giudice, A. Anastasio, M. Marino, V. Trimarco, 

M. Illario, B. Trimarco, G. Iaccarino 

the brain cortex - mediated effect of thermal response to exercise on 

cardioplumonary capacity lBr3 

R. Skalik, L. Borodulin-Nadzieja 

the synergistic interaction between the heme oxygenase system and atrial natriuretic 

peptide suppress endothelin-1 and kidney lesions in mineralocorticoid-induced 

hypertension lBr4 

J.F. Ndisang, A. Jadhav 

left atrium of adult porcine heart is a better source of progenitor cells than left 

ventricle: a comparative study lBr5 

Li Ping Su, Jing Zhang, Kian Keong P, Lei Ye 

the atoS trial (Coronary venous activation to salvage cells and to transform the 

failing heart into viable myocardium) regenerative potential of Pressure - Controlled 

intermittent Coronary Sinus occlusion (PiCSo) in heart failure patients lBr6 

W. Mohl, C. Khazen, L. Leitner, G. Heinze, D. Milasinovic, A. Mujagic, B. Birkenberg, A. Jusic 

Pulmonary hypertension due to left heart disease in patients is characterized by 

increased serotonin blood and increased myocardium serotonin transporter lBr7 

V. Kirillova 

il-18 stimulates BnP synthesis by cardiomyocytes and its plasma levels correlate with 

bnp in “non-overloaded“ heart failure patients lBr8 

S. Di Somma, M. R. Torrisi, V. Pittoni, S. Raffa, R. Marino 

Short term morbidity and mortality follow up of newly diagnosed systolic heart failure 

patients after their first admission lBr9 

M. A. Alshaikha, B. S. Anany, A. G. Hassanin, A. I. Nassar 

Prevalence of cardiovascular risk factors and their contribution to Heart failure with 

Preserved ejection fraction (HfPef): a comparison of the US-framingham and the 

german-austrian aldo-DHf cohorts lBr10 

E. Kraigher-Krainer, F. Edelmann, A. Schmidt, R. S. Vasan, B. Pieske 

effect of ursodeoxycholic acid on peripheral blood flow, immune function, and 

markers of neurohormonal activation in chronic heart failure: a randomized, placebocontrolled, 

double-blind cross-over study lBr11 

S. von Haehling, E.A Jankowska, A. Vazir, P.R. Kalra, A. Sandek, W. Doehner, H.-D. Volk, 

P.A. Poole-Wilson, S.D. Anker 

effect of melatonin and captopril on continuous light exposure and l-name-induced 

left ventricular remodeling lBr12 

F. Simko, O. Pechanova, V. Pelouch, K. Krajcirovicova, M. Mullerova, K. Bednarova, 

P. Celec, L. Paulis, M. Adamcova 

High sensitive cardiac troponin t as biomarker of cardiotoxicity of the antineoplastic 

agents lBr13 

M. Adamcova, M. Sterba, O. Popelova, E. Jirkovsky, Y. Mazurova, I. Guncova, V. Gersl 

38

late BreaKing trialS 

left ventricular proteomic profiling reveals significantly reduced abundance of 

mitochondrial proteins in tachycardia-induced heart failure lBr14 

C. M. Birner, A. Dietl, R. Deutzmann, G. Riegger, A. Luchner 

Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an 

angiotensin ii-dependent pathway lBr15 

M. Oroszlan, N. Ligeti, H.-P. Marti, B. Meier, P. Mohacsi 

Hemostatic derrangements and inflammation in systolic heart failure: influence of 

endothelial dysfunction and heart failure etiology lBr16 

B. Jug, M. Sebestjen, M. Sabovic, M. Lainscak, I. Keber 

Differential cardiac remodeling in preload versus afterload - remodeling in taC vs. 

Shunt lBr17 

K. Toischer, A.Rokita, B. Unsld, W. Zhu, G. Kararigas, R. Zagrosek, J. Backs, L. J. Field, Lars S. 

Maier, G. Hasenfuss 

assessment of myocardial function with gated SPeCt to predict cardiac 

resynchronization therapy response lBr18 

D. Zizek, M.Cvijic, L. Lezaic, M. Lainscak, I. Zupan 

Heart Failure 2010 – Late Breaking Trials Posters 

Symblock trial lBt1 

left cervico-thoracic sympathetic blockade by video-thoracoscopic clipping: a novel 

surgical treatment for systolic heart failure? - G.E. Conceicao-Souza 

tHeSUS-Hf StUDY lBt2 

Diagnosis, treatment and outcome of acute heart failure in africa -results of the 

thesus-hf study - A. Damasceno 

aHeaD lBt3 

acute Heart failure Datbase - J. Spinar 

maximal ventricular mass-to-power output in advanced heart failure lBt4 

maximal left ventricular mass-to-power output: a novel index to assess left 

ventricular performance and to predict outcome in patients with advanced heart failure 

F. Dini 

nt-ProBnP aCS lBt5 

Have BnP or nt-ProBnP the same discrimination power as risk markers in acute 

Coronary Syndrome patients? - N. Marques 

aDe trial lBt6 

atorvastatin use associated with different effect in patients with systolic and diastolic 

heart failure - E. Kozlova 

Choice of angiotensin receptor blocker affects mortality in heart failure - analysis of lBt7 

5823 patients in the Swedish Heart failure registry - M. Eklind-Cervenka 

treat lBt8 

Predictors of heart failure in patients with diabetes mellitus and chronic kidney disease 

E. Lewis 

Cacao on endothelial function in CHf lBt9 

acute and chronic effects of flavanoid-rich cacao on endothelial function in patients 

with chronic heart failure - R. Corti 

BaSel ii - Private Practice lBt10 

Use of b-type natriuretic peptide to diagnose acute heart failure in private practice: a 

randomized controlled trial - C. Mueller 

39 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 

SUnDaY 30 maY 2010 - morning PoSterS 

08:30 - 12:30 Moderated Posters Moderated Poster Area 

Moderated Poster Session 1 

Diagnosis of heart failure - echocardiography - atrial fibrillation - Cardiomyopathy & 

natriuretic peptides 

Chairperson(s): B. Maisch (Marburg, DE); C. Mueller (Basel, CH) 

These abstracts were chosen for their outstanding quality and will be presented during the 

Moderated Poster Session between 10:00 and 11:00 

Posters must be set up between 08:00 and 08:30 and removed between 12:30 and 13:00 

10:00 Circulating secreted frizzled related protein 3 (sfrP3) predicts outcome in 

patients with chronic heart failure P188 

E.T. Askevold, C.P. Dahl, K. Broch, S. Aakhus, A. Yndestad, L. Gullestad, P. Aukrust, 

T. Ueland (Oslo, NO) 

10:06 Stage of desmin expression in cardiomyocytes as a good predictor of 

development of chronic heart failure P189 

A. Pawlak, A. Nasierowska-Guttmejer, J. Rzezak, E. Czarnowska, R.J. Gil (Warsaw, PL) 

10:12 Degradation of type i collagen is increased in patients with symptomatic heart 

failure following myocardial infarction P190 

C. Manhenke, S. Orn, I. Squire, K. Dickstein (Stavanger, NO; Leicester, GB) 

10:18 the relation between cardiac cachexia and serum adiponectin levels in 

patients with heart failure P191 

V. Polat, E. Bozcali, H. Akbulut, I. Karaca (Elazig and Sanliurfa, TR) 

10:24 Diastolic dysfunction of left ventricle vs desmin expression in cardiomyocytes 

patients with systolic heart failure P192 

A. Pawlak, E. Czarnowska, W. Grajkowska, A.I. Gziut, J. Rzezak, R.J. Gil (Warsaw, PL) 

10:30 abnormal collagen turnover and mmP-9 are the common link between 

increased arterial stiffness, impaired coronary flow reserve and left ventricular 

untwisting in untreated hypertensive patients P193 

I. Ikonomidis, J. Lekakis, I. Paraskevaidis, S. Tzortzis, C. Papadopoulos, 

H. Triantafyllidi, P. Trivilou, K. Venetsanou, M. Anastasiou-Nana, D.T. Kremastinos 

(Athens, GR) 

10:36 Burden of atrial fibrillation in heart failure patients with preserved vs. those 

with reduced left ventricular ejection fraction P194 

G. C. M. Linssen, M. Rienstra, T. Jaarsma, A.A. Voors, I.C. Van Gelder, H.L. Hillege, 

D.J. Van Veldhuisen (Groningen, NL) 

10:42 Differences in parvovirus B19 prevalence and load in the hearts of patients 

with dilated cardiomyopathy and increased autoimmunity P195 

R. Dennert, P. Van Paassen, P. Wolffs, C. Bruggeman, H.J. Crijns, 

R.J. Cohen Tervaert, S. Heymans (Maastricht, NL) 

10:48 Hypertensive and hypertrophic cardiomyopathies have distinctive 

phenotypes of myocardial remodelling and deformation: a magnetic 

resonance imaging study P196 

V. Puntmann, C. Jahnke, B. Schnackenburg, E. Fleck, I. Paetsch (London, GB; Berin, DE) 

10:54 Plasma B-type natriuretic peptide levels in old age and the risk of mortality in 

Chagas disease: 10-year follow-up of the Bambui population-based cohort study P197 

A. L. Ribeiro, S. V. Peixoto, M. F. Lima-Costa (Belo Horizonte and Ouro Preto, BR) 

40


08:30 - 12:30 Poster Session Poster Area 

Poster Session 1 

Posters must be set up between 08:00 - 08:30, removed between 12:30 - 13:00, to be on display 

between 08:30 - 12:30. The presenter should be present during the coffee break (10:00 to 11:00) 

in order to discuss the poster. 

Acute heart failure (diagnosis, pathophysiology, other) 

transient left ventricular apical ballooning syndrome: who are these patients? P198 

J. Guardado, M. Fernandes, O. Azevedo, F. Canario-Almeida, V. Sanfins, A. Pereira, 

J. Almeida (Guimaraes, PT) 

impact of comorbities in acute decompensate heart failure. the role of Chagas and 

non-Chagas Cardiomyopathy etiology P199 

A. Abuhab, F. Bacal, E.M. Trindade, S. Mangini, G.A. Barros, C.V. Gouveia, E.A. Bocchi 

(Sao Paulo, BR) 

Killip classification in patients with acute coronary syndrome: insight from multicenter 

registry from the middle east P200 

A. El-Menyar, M.Z. Zubaid, W.A. Al Mahmeed, K.S. Sulaiman, A.A. Alnabti, R. Singh, 

J. Al Suwaidi (Doha, QA; Kuwait, KW; Abu Dhabi, AE; Muscat, OM) 

Demographic characteristics of patients with heart failure in the southern turkey P201 

N. Yeral, U. Iyigun, F. Yalcin (Antioch, TR) 

the obesity paradox - body mass index and prognosis in patients with acute heart 

failure P202 

R. Faria, E. Correia, B. Rodrigues, L.F. Santos, P. Ferreira, L. Nunes, J.L. Pipa, O. Santos 

(Viseu, PT) 

acute effects of weaning to mechanical ventilation in patients with heart failure 

monitorized by impedance cardiography P203 

S. Chermont, M.P. Quintao, J.M. Linhares, J.C. Pereira, A. Torrao, B. Mota, F. Torres, 

L. Mello, N. Charles, E.T. Mesquita (Niteroi and Teresopolis, BR) 

nt-proBnP and troponin i predict the extent of myocardial necrosis and ventricular 

function in acute myocarditis P204 

J. Silva Marques, A.G. Almeida, M. Gato Varela, M. Pedro, D. Brito, M.G. Lopes 

(Lisbon, PT) 

Differential diagnosis and treatment in neoplastic pericardial effusion causing 

heart failure P205 

B. Maisch, R. Moll, A. Ristic, U. Baandrup, S. Pankuweit (Marburg, DE; Belgrade, RS; 

Hjorring, DK) 

the impact of troponin release in patients with acute heart failure and cardio-renal 

syndrome: analysis from the ProteCt pilot study P206 

C.M. O’connor, C. Lombardi, M. Fiuzat, K. Fujita, G. Jia, M. Metra (Durham, NC and New 

Jersey, Nj, US; Brescia, IT) 

Comparison of invasive and non-invasive assessment of haemodynamic parameters in 

patients with severe, advanced heart failure P207 

M. Sokolski, A. Rydlewska, B. Krakowiak, R. Zymlinski, J. Biegus, W. Banasiak, 

E. A. Jankowska, P. Ponikowski (Wroclaw, PL) 

41 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



tissue Doppler indexes of systolic and diastolic function seem to have prognostic 

significance for the six-minute walking performance in patients with newly-diagnosed 


C. Chrysohoou, J. Kotrogiannis, G. Metallinos, S. Athanassopoulou, G. Tsitsinakis, 

C. Antoniou, P. Arsenos, S. Brilli, C. Pitsavos, C. Stefanadis (Athens, GR) 

independent predictors of acute heart failure in patients with myocardial infarction P209 

R. Faria, B. Rodrigues, C. Emanuel, L.F. Santos, P. Ferreira, L. Nunes, C. Nascimento, 

J.L. Pipa, O. Santos (Viseu, PT) 

a new radiological score for verification of evolving heart failure in the course of acute 

myocardial infarction P210 

M. Shochat, M. Kasatzker, V. Gurovich, Y. Levi, E. Noiman, P. Rabinovich, D. Blondheim, 

A. Shotan, S. Meisel (Hadera and Tel Aviv, IL) 

Acute heart failure (therapy) 

in Hospital use of eplerenone P211 

S. Kadir, C. Christopoulos, S. Foster, S.E.N. Devadathan (Blackpool and Leicester, GB) 

Clinical and echocardiographic characteristics associated with high dose loop diuretics 

in decompensated heart failure patients P212 

J. I. A. Orea-Tejeda, A. Valdespino-Trejo, L. Castillo-Martinez, D. Gonzalez, W. Rodriguez, 

A. Sanchez, C. Santillan, E. Colin, P. Montano (Mexico, MX) 

Heart failure Program in an asian multi-ethnic acute Heart failure Cohort and outcomes P213 

K. T. G. Leong, V.S. Tan, Y. Cao, S. Lim, S. Buhari, Y. Yeo, K. Poh, M. Tan, P.P. Goh 

(Singapore, SG) 

the incremental value of ambulatory BP monitoring in titration of therapies in a 

chronic heart failure population with concomitant renal dysfunction- a single center 

experience P214 

M. Al Qaseer, C. Lewis, A. Khan, B. Mcadam (Dublin, IE) 

Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat (BaY 58-2667) 

in patients with hepatic impairment P215 

R. Frey, W. Mueck, S. Unger, A. Schmidt, G. Wensing (Wuppertal, DE) 

early treatment with high dose steroids and ventricular support in patients with acute 

heart failure and lymphocytic myocarditis improves left ventricular function and shortterm 

prognosis P216 

A. Torrens Oses, J. Gonzalez-Costello, N. Manito, M. Rodriguez, J. Roca, I. Tatjer, 

J.C. Sanchez-Salado, V. Lorente, A. Ariza, E. Esplugas (Barcelona, ES) 

Prognosis (other) 

Dilated versus ischemic cardiomyopathy - are there differences in prognosis? an 

advanced heart failure centre experience P217 

C.N. Lourenco, F. Saraiva, H. Martins, R. Batista, S. Costa, H. Vieira, P. Monteiro, F. Franco, 

L. Goncalves, L.A. Providencia (Coimbra, PT) 

aspirin, clopidogrel and warfarin use and outcomes in a cohort of 580 patients 

discharged after hospitalization for decompensated heart failure P218 

G. Kozdag, M. Yaymaci, G. Ertas, E. Ural, U. Bildirici, T. Kilic, D. Ural (Kocaeli, TR) 

42



evaluation of ventricular remodeling as prognostic predictor in advanced heart failure: 

comparison of chagasic and non-chagasic aetiology P219 

G.E. Conceicao-Souza, J.L. Vieira, L.F.P. Moreira, L.M. Peesoa-De-Melo, E.A. Bocchi, 

J.A.F. Ramires (Sao Paulo, BR) 

Prognostic value of serial mPi studies in patients with CHf after nSt-aCS P220 

D. Dolgushev, V. Soukhov (St Petersburg, RU) 

left ventricular failure, early after St-elevation myocardial infarction P221 

D.-E. Ovricenco, L. Axente, F. Pater, F. Adam, A. Popa, C. Sinescu (Bucharest, RO) 

multiresolution wavelet analysis of heart rate variability predicts total mortality in 

heart failure patients P222 

P. Arsenos, K. Gatzoulis, G. Manis, T. Gialernios, P. Dilaveris, G. Lazaros, E. Karstagoulis, 

S. Archontakis, I. Sotiropoulos, C. Stefanadis (Athens and Ioannina, GR) 

Predictors of in-hospital mortality in a population with advanced heart failure P223 

H. Martins, M.F. Saraiva, R. Baptista, P.L. Mendes, P. Monteiro, S. Costa, F. Franco, 

L.A. Providencia (Coimbra, PT) 

long term prognosis of patients hospitalised with acute myocardial infarction and/or 

acute heart failure and discharged alive home (the Brno registry) P224 

J. Spinar, O. Ludka, M. Sepsi, J. Parenica, R. Miklik, L. Dusek, D. Tomcikova (Brno, CZ) 

Prognostic implications of arterial blood gases in acute decompensated heart failure P225 

P. Merlos, G. Minana, J. Nunez, J. Sanchis, V. Bodi, P. Palau, B. Mascarell, E. Rumiz, 

R. Robles, A. Llacer (Valencia, ES) 

SDnn from heart rate variability analysis risk stratifies heart failure patients for sudden 

cardiac death P226 

P. Arsenos, K. Gatzoulis, G. Manis, T. Gialernios, P. Dilaveris, E. Karstagoulis, G. Lazaros, 

I. Andreou, K. Tsioufis, C. Stefanadis (Athens and Ioannina, GR) 

Predictors in heart failure with normal ejection fraction P227 

T. Damy, A. Kallvikbacka-Bennet, J. Zhang, K. Goode, K. Lewinter, J. Hobkirk, 

J.L. Dubois-Rande, L. Hittinger, J.G.F. Cleland, A.L. Clark (Creteil, FR; Hull, GB) 

Concordant versus discordant left bundle branch block in heart failure patients: novel 

clinical value of an old electrocardiographic diagnosis P228 

A. Valleggi, M. Emdin, G. Vergaro, F. Luca’, C.M. Rao, L. Perrotta, F. Cappelli, A. L’abbate, 

C. Passino, L. Padeletti (Pisa and Florence, IT) 

evaluation of prognosis of the patients with heart failure who suffered aCS 

depending on a genotype of the fibrinogen, apolipoproteinB100 and protein C genes P229 

N. Koziolova, E.A. Polyanskaya (Perm, RU) 

Prognosis (using biomarkers) 

reduced renal function in chronic heart failure: nt-proBnP identifies very high risk 

patients P230 

R. Poletti, T. Prontera, C. Passino, M. Emdin (Pisa, IT) 

nt proBnP can predict the cardiovascular events in patients with dilated CmP P231 

E.-S. Jeon, D.J. Choi, K.H. Ryu, J.J. Kim, M.C. Cho, S.H. Lee, J.O. Choi (Seoul and 

Cheong Ju, KR) 

43 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



Prognostic value of cardiac troponin t in patients with moderate to severe heart 

failure scheduled for cardiac resynchronization therapy P232 

M. Aarones, L. Gullestad, S. Aakhus, T. Ueland, R. Skaardal, H. Aass, H.J. Smith, 

R. Wergeland, P. Aukrust, E. Kongsgaard (Oslo and Tonsberg, NO) 

the width of red blood cell distribution is the only significant prognostic marker of 

poor outcome in advanced heart failure P233 

E. Tseliou, J. Terrovitis, E. Kaldara, S. Vakrou, E. Konstantakis, S. Sventzouri, N. 

Michelinakis, V. Kontopidi, M. Anastasiou-Nana, J. Nanas (Athens, GR) 

Does the severity of lV dysfunction or the extent of myocardial scar explain elevations 

in plasma galectin-3 in patients with heart failure? P234 

N.S. Sherwi, E.L. Lukaschuk, J. Zhang, K.M. Goode, A.L. Clark, A. Yassin, A. Torabi, 

R. Nicholls, O. Khaleva, J.G.F. Cleland (Hull, GB) 

the cardio-hepatic syndrome in chronic heart failure: prevalence and prognostic 

significance P235 

G. Poelzl, M. Ess, C. Mussner-Seeber, M. Frick, H. Ulmer (Innsbruck, AT) 

association between vascular endothelial growth factor B and outcome after 


Y. Devaux, C. Yvorra, F. Azuaje, M. Vausort, D. Kelly, L.L. Ng, I.B. Squire, D.R. Wagner 

(Luxembourg, LU; Leicester, GB) 

Prognostic value of established and novel biomarkers in patients with shortness of 

breath attending an emergency department P237 

B. Dieplinger, A. Gegenhuber, G. Kaar, W. Poelz, M. Haltmayer, T. Mueller (Linz and 

Bad Ischl, AT) 

Arrhythmias and treatment 

the parameteres of ventricle dyssynchrony in patients with selective septum pacing: 1 

year results P238 

A.E. Komlev, O.V. Sapelnikov, R.S. Latypov, I.R. Grishin, R.S. Akchurin (Moscow, RU) 

reduced Deceleration Capacity of heart rate risk stratifies heart failure patients for 

sudden cardiac death (aPret) P239 

P. Arsenos, K. Gatzoulis, P. Dilaveris, C. Chrysohoou, S. Vaina, K. Tsioufis, K. Zissimos, 

K. Aggeli, I. Dima, C. Stefanadis (Athens, GR) 

Beta blockers 

evaluation of cardiac sympathetic nerve activity and ventricular function in patients 

with ischaemic or idiopathic cardiomyopathy before and after beta-blocker therapy P240 

B. Fontanella, M. Metra, T. Bordonali, G. Verzura, C. Villa, M. Adamo, M. Mapelli, F. 

Caobelli, R. Giubbini, L. Dei Cas (Brescia, IT) 

Study of clinical efficacy of nebivolol and carvedilol administration in complex 

therapy of chronic heart failure due to coronary heart disease combined with chronic 

obstructive pulmonary disease P241 

V. Evdokimov, A. Radzevich, A. Evdokimova, E. Kovalenko (Moscow, RU) 

effects of B-blocker therapy on mortality of Chagas disease patients with chronic 

systolic heart failure P242 

R. Bestetti, A. P. Otaviano, A. Cardinalli Neto, B. F. Rocha, T. A. D. Theodoropoulos, 

J. A. Cordeiro (Sao Jose do Rio Preto, BR) 

44



Carvedilol reduces left ventricular dilatation and improves cardiac function in 

postinfarction heart failure rats P243 

M.P. Baldo, D. Zaniqueli, A.P.C. Davel, S.L. Rodrigues, L.V. Rossoni, J.G. Mill (Vitoria and 

Sao Paulo, BR) 

Cardiac resynchronisation therapy 

Do biomarkers predict response to cardiac resynchronization therapy? P244 

M. E. Tettamanti, J. Lopez Diaz, A. Recio Platero, C. Tapia Ballesteros, R. Arnold, A. Revilla 

Orodea, J.A. San Roman, E. Garcia Moran, M.L. Nieto, I. Gomez Salvador (Valladolid, ES) 

Cardiac resynchronization therapy in end-stage heart failure patients P245 

M. Sasov, B. Liska, E. Goncalvesova, P. Margitfalvi, T. Malacky, M. Svetlosak, R. Hatala 

(Bratislava, SK) 

applicability of low cost oximeter-type plethysmography as an alternative to volume 

clamp (finapres-type) plethysmography in biventrivular pacemaker optimization P246 

A. Kyriacou, Z.I. Whinnett, P.A. Pabari, R. Baruah, D. Lefroy, D.W. Davies, N.S. Peters, 

P. Kanagaratnam, J. Mayet, D.P. Francis (London, GB) 

new method of haemodynamic monitoring for determination of the best site for right 

ventricle lead during Crt device implantation P247 

A. Bobrov, M. Didenko, A. Tsyganov, A. Fedyainova, G. Khubulava, S. Shulenin, L. Bobrov 

(St Petersburg, RU) 

Very long term clinical and echocardiographic outcomes of cardiac resynchronization 

therapy: a single center 10 year experience P248 

M. Cipriani, M. Frigerio, M. Lunati, G.B. Magenta, F. Macera, G. Masciocco, A. Garascia, 

S. Bisetti, E. Bancala, F. Oliva (Milan, IT) 

relative Contribution of Heart rate regularization, versus heart rate increase, to 

improved consistency of optimization of pacemakers at higher paced heart rates P249 

A. Kyriacou, P.A. Pabari, Z.I. Whinnett, R. Baruah, D. Lefroy, N.S. Peters, D.W. Davies, 

J. Mayet, P. Kanagartnam, D.P. Francis (London, GB) 

ICD therapy 

Very low rates of inappropriate iCD-therapy by using optimal medical treatment and 

high degree of dual-chamber/biventricular iCD P250 

U. Koepp, F.T. Gjestvang, G. Eivindson, E.S.P. Myhre (Kristiansand, NO) 

Underrepresentation of women with pacemakers and iCDs in heart failure - data from 

the german heart failure network P251 

B. Maisch, G. Gelbrich, C. Angermann, T. Scheffold, T. Mueller-Tasch, V. Regitz-Zagrosek, 

H.D. Duengen, T. Neumann, R. Wachter, R. Dietz (Marburg, Leipzig, Wuerzburg, Witten, 

Heidelberg, Berlin, Essen and Goettingen, DE) 

Drug therapy, other 

influence of antihypertensive drugs with statin on the level of markers of heart failure 

in patients with metabolic syndrome and postinfarction cardiosclerosis. P252 

I.I. Vakalyuk, M.A. Orynchak, I.P. Vakalyuk (Ivano-Frankivsk, UA) 

repetitive dosing of levosimendan is safe and does not increase mortality over 3 years P253 

J. Aulin, I. Lofman, I. Barbici, B. Andren, I. Hagerman, G. Wikstrom (Uppsala and 

Stockholm, SE) 

45 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



influence of statin and beta-blocker on long-term prognosis in patients with chronic 

heart failure and preserved systolic function P254 

L. R. Tumasyan, K.G. Adamyan (Yerevan, AM) 

Changes in chemoreflex characteristics following acetazolamide administration in 

patients with chronic heart failure and Cheyne-Stokes respiration P255 

M. Fontana, G. Iudice, F. Bramanti, R. Poletti, A. Gabutti, A. Giannoni, M. Emdin, 

C. Passino (Pisa, IT) 

is the effect of aspirin on mortality in patients with heart failure modified by aCeinhibitors 

or angiotensin receptor blocker use? a non-experimental study P256 

E.E.S. Van Riet, F.H. Rutten, A.W. Hoes (Utrecht, NL) 

Combined use of aliskiren and telmisartan in overweight hypertensive patients with 


I.G. Alizade, N.T. Karayeva (Baku, AZ) 

Heart transplantation / Assist devices 

later evolution after Cardiac transplantation in Chagas Disease. P258 

O. J.R. Oliveira Jr, A.I. Fiorelli, G.E. Conceicao, D.D.F. Lorenco, E.A. Bocchi, N.A.G. Stolf 


transplantation as an end-stage treatment for ventricular assist device (VaD) 

infections due to multi-drug resistant nosocomial pathogens P259 

A. Gkouziouta, S. Adamopoulos, A. Manginas, E. Manoli, G. Saroglou, P. Sfirakis, 

V. Voudris (Athens, GR) 

economic impact of concomitant diltiazem use in cardiac transplantation patients on 

calcineurin inhibitors P260 

G.E. Conceicao-Souza, F. Figuinha, J.L. Vieira, F.F. Costa, V.S. Issa, P.R. Chizzola, F. Bacal, 

S.M. Ayub-Ferreira, F.D. Cruz, E.A. Bocchi (Sao Paulo, BR) 

Predictors of hospital mortality and survival after heart transplantation according to 

the profile of the donors. P261 

J.L. Oliveira Jr, A.I. Fiorelli, G.E. Conceicao, E.A. Bocchi, N.A.G. Stolf (Sao Paulo, BR) 

Dobutamine induced changes in right ventricle contractility and pulmonary artery 

pressure as pre-operative predictors of right ventricle failure following vontinuous 

flow lVaD implantation P262 

T. Damy, G. Deswarte, M. Kirsch, P.F. Lesault, J.C. Roussel, E. Vermes, D. Loisance, 

J.L. Trochu, D. Duveau, L. Hittinger (Creteil and Nantes, FR) 

Heart transplatation for previously undiagnosed cardiac sarcoidosis P263 

D. Arumugam, M. Brown, D. Platts, G. Javorsky (Brisbane, AU) 

Surgery (CABG, valvular, artificial heart, other) 

early outcomes in patients with left ventricle systolic dysfunction after non-cardiac 

surgery P264 

A. N. Sumin, A.V. Bezdenezhnykh, D.O. Evdokimov, E.V. Korok, S.V. Ivanov, 

O.L. Barbarash, L.S. Barbarash (Kemerovo, RU) 

Comparing addictive and logistic euroscore - a single institution study P265 

M. Paiva, A. Correia, S. Oliveira, A. Goncalves, R. Almeida, M. Pereira, E. Alves, P. Dias, 

P. Pinho (Porto, PT) 

46



reverse remodeling after surgical ventricular reconstruction: does it persist along time? P266 

M. Di Donato, A. Frigiola, S. Castelvecchio, A. Canziani, L. Menicanti (Florence and 

San Donato Milanese, IT) 

influence of left ventricular remodeling pattern on outcome after surgical ventricular 

restoration P267 

M. Di Donato, A. Frigiola, S. Castelvecchio, J. Salvia, P. Gagliardotto, L. Menicanti 

(Florence and San Donato Milanese, IT) 

Diuretics and fluid status management 

results of a prospective trial to assess sensitivity and positive predictive value of 

implantable intrathoracic impedance monitoring in the prediction of heart failure 

hospitalizations: SenSe-Hf trial P268 

V.M. Conraads, L. Tavazzi, M. Santini, F. Oliva, B. Gerritse, C.M. Yu, M.R. Cowie (Edegem, 

BE; Cotignola, Rome and Milan, IT; Maastricht, NL; Hong Kong, CN; London, GB) 

intra-thoracic impedance and ultrasound comet-tail images for the detection of heart 

failure deterioration P269 

M. Maines, D. Catanzariti, C. Angheben, A. Manica, S. Valsecchi, G. Vergara (Rovereto 

and Rome, IT) 

estimation of lung edema level in patients carrying implantable pacemaker via a novel 

bio-impedance approach - a computerized study P270 

S. Abboud, M. Arad, S. Zlochiver (Tel Aviv and Tel Hashomer, IL) 

Renin-angiotensin-aldosterone antagonists and diuretics 

are diuretics inferior to other heart failure drugs in reducing mortality in patients with 

heart failure? Daily practice data from primary care P271 

Y. Van Mourik, L.C.M. Bertens, A.W. Hoes, F.H. Rutten (Utrecht, NL) 


Perindopril and amiodarone as a combined treatment of advanced heart failure and 

atrial fibrillation P272 

S. Grigoryan, L.G. Hazarapetyan, A.A. Stepanyan (Yerevan, AM) 

effects of beta-blocker therapy in elderly patients with heart failure and atrial 

fibrillation: results from the Cardiac insufficiency Bisoprolol Study in elderly P273 

I. Stankovic, A.N. Neskovic, S. Apostolovic, B. Putnikovic, M. Lainscak, F. Edelmann, 

W. Doehner, G. Gelbrich, S.D. Anker, H.D. Dungen (Belgrade and Nis, RS; Golnik, SI; 

Gottingen, Berlin and Leipzig, DE) 

rac1 induced Connective tissue growth factor and lysyl oxidase lead to atrial fibrosis 

in atrial fibrillation P274 

D. Lavall, O. Adam, K. Theobald, M. Grube, H.K. Kroemer, M. Boehm, U. Laufs (Homburg 

and Greifswald, DE) 

Cardiomyopathy 

Detection of viral genomes in endomyocardial biopsies and blood samples from 

patients with inflammatory cardiomyopathy: first results P275 

E. Belyavskiy, K. Zykov, O. Narusov, A. Skvortsov, V. Masenko, A. Schedrina, 

S. Tereschenko (Moscow, RU) 

47 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



asymmetric dimethyl l-arginine(aDma),endogenous inhibitor of nitric oxide synthase 

in congestive heart failure: relation to cardiac function P276 

M.A.G.D.Y. Abdel Hamid, Y. Abdel Hady, D. Sabry, M. Shafik (Cairo and Beni-Suef, EG) 

electrocardiographic pattern of left ventricular noncompaction and its relation with 

left ventricular function. P277 

C. E. Correia, B. Rodrigues, L. Santos, R. Faria, P. Gama, C. Nascimento, L. Nunes, 

O. Dionisio, C. Cabral, O. Santos (Viseu, PT) 

transthyretin mutations in a st.petersburg cohort of cardiomyopathies, complicated 

by chronic heart failure. P278 

A. Goodkova, E.N. Semernin, P.A. Chekanov, A.A. Kostareva, Y.A. Gudkov, E.V. Shlyakhto 


enhanced external Counterpulsation (eeCP) as an optional modality in ischemic 

cardiomyopathy P279 

D. Y. Nassar, S. H. Omar (Cairo and Giza, EG) 

Serum sCD40ligand in patients with ischaemic cardiomyopathy: relationship with 

risk factors P280 

D. Tousoulis, S. Metaxa, L. Kormali, E. Toli, A. Miliou, N. Papageorgiou, C. Tsioufis, S. Brili, 

E. Vavuranakis, C. Stefanadis (Athens, GR) 

myocardial hypertrophy localization and hypertrophic cardiomyopathy clinical course P281 

V.I. Tseluyko, O.O. Bilostotska, K.U. Kinoshenko, O.V. Radchenko (Kharkov, UA) 

implications of depression on the functional capacity of patients with heart failure P282 

B. Lobao, J.F. Santos, L. Mendes, P. Amador, C. Miranda, S. Goncalves, S. Correia, 

L. Soares (Setubal, PT) 

adiponectin expression in patients with inflammatory cardiomyopathy indicates 

favourable outcome and inflammation control. P283 

C. Skurk, P. Bobbert, A. Jenke, S. Wilk, W. Poller, U. Eriksson, H.P. Schultheiss, 

C. Scheibenbogen (Berlin, DE; Zuerich, CH) 

Beneficial effects of low-dose benidipine in acute autoimmune myocarditis P284 

C. Kishimoto, Z. Yuan, K. Shioji (Kyoto, JP) 

the genetic polymorphisms of the renin-angiotensin-aldosterone system in patient 

with hypertrophic cardiomyopathy P285 

E.V. Privalova, Y.N. Belenkov, V.Y. Kaplunova, D.V. Stambolsky, A.A. Fomin (Moscow, RU) 

epitope mapping of conformational cardio-stimulatory antibodies by ala-scannig with 

fret-microscopy P286 

A. Schlipp, A. Zuern, V.O. Nikolaev, N. Deubner, D. Berliner, J. Ullrich, V. Boivin, 

M.J. Lohse, R. Jahns (Wuerzburg, DE) 

the prostacyclin agonist iloprost induces enhanced cardiac damage and fibrosis in 

enteroviral myocarditis by increasing inoS expression P287 

S. Gruhle, M. Sauter, G. Szalay, R. Kandolf, K. Klingel (Tuebingen, DE) 

Hypertension / LV hypertrophy 

tissue-type plasminogen activator plasma levels are related with systolic blood 

pressure and left ventricular mass in patients with essential hypertension P288 

M. Rivera Otero, E. Rosello, F. Garcia De Burgos, P. Morillas, J.R. Gonzalez Juanatey, 

R. Paya, C. Lauwers, J.R. Calabuig, M. Portoles, V. Bertomeu (Valencia, Elche, Alicante 

and Santiago, ES) 

48



aldosterone levels are related with diastolic and pulse pressure in patients with 

essential hypertension P289 

M. Rivera Otero, E. Rosello, T. Lozano, P. Morillas, B. De Rivas, C. Lauwers, A. Salvador, 

R. Cortes, M. Portoles, V. Bertomeu (Valencia, Villajoyosa, Madrid and San Juan De 

Alicante, ES) 

interleukin-6 plasma levels are related with systolic and pulse pressure in patients with 


M. Rivera Otero, E. Rosello, A. Jordan, R. Paya, A. Salvador, F. Soria, T. Lozano, R. Cortes, 

M. Portoles, V. Bertomeu (Valencia, Elche, Murcia, Villajoyosa and Alicante, ES) 

the effects of melatonin on fibrosis and hypertrophy in experimental hypertension 

are dissociated and no-independent P291 

L. Paulis, O. Pechanova, P. Celec, M. Adamcova, J. Zicha, F. Simko (Berlin, DE; Bratislava, 

SK; Hradec Kralove and Prague, CZ) 

activation of gata-4 by mechanical stretch-induced cardiac hypertrophy is regulated 

via p38 maPK- and erK-mediated phosphorylation P292 

L. Kaikkonen, H. Tokola, L. Karkkola, R. Kerkela, H. Ruskoaho (Oulu, FI) 

Pulmonary hypertension 

accuracy of doppler echocardiography in measuring right-heart pressure in patients 

with pulmonary hypertension P293 

C. Falletta, C. Cascio, F. Tuzzolino, C. Mina’, R. Baglini, C.M. Hernandez Baravoglia, 

C. Scardulla, P. Vitulo, F. Clemenza (Palermo, IT) 

the muscle status and exercise capacity in patients with pulmonary hypertension P294 

A. N. Sumin, O.G. Arhipov, N.A. Snitskaya (Kemerovo and Mysky, RU) 

a not so rare form of heart failure in urban black africans: right heart failure in the 

Heart of Soweto cohort P295 

S. Stewart, M. Carrington, S. Pretorius, P. Methusi, K. Sliwa-Hahnle (Melbourne, AU; 

Johannesburg and Cape Town, ZA) 

Determinants of pulmonary venous hypertension in patients with chronic systolic 

heart failure with and without functional mitral valve regurgitation P296 

W. L. Miller, D. W. Mahoney, M. E. Sarano (Rochester, MN, US) 

Diagnosis of heart failure and biomarkers 

High cardiovascular morbidity in Vojvodina: is homocysteine the cause? P297 

M. Milosevic-Tosic, J. Borota, K. Pavlovic, N. Cemerlic-Adjic, G. Prtenjak, V. Cabarkapa, 

J. Stojcevic-Maletin, Z. Stosic (Novi Sad, RS) 

left and right Ventricular tissue Doppler tei index in Patients with Heart failure P298 

M. Tsverava, D. Tsverava (Tbilisi, GE) 

Clinical, echocardiographic, neurohormonal and inflammatory Differences Between 

Chagas Cardiomyopathy Patients with and without Preserved left Ventricular Systolic 

function. P299 

F.E.R.N.A.N.D.O. Botoni, P.P.W. Poole-Wilson, B.M.R. Oliveira, W.C. Tavares Junior, 

M.M. Teixeira, A.L.A. Teixeira Junior, A.M. Reis, A.L.P. Ribeiro, E.R.P. Pedroso, M.O.C. Rocha 

(Belo Horizonte, BR; London, GB) 

49 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



role of cadiac troponins in pathogenesis of chronic heart failure P300 

E.N. Golovenko, A.S. Panferov, D.A. Napalkov, V.A. Sulimov (Moscow, RU) 

Serum uric acid levels in patients with recent decompensated heart failure - a new 

biomarker? P301 

A. Campeanu, A. Iliesiu, D. Nistorescu, B. Strajean, G. Uscoiu, D. Dusceac, T. Nanea 

(Bucharest, RO) 

Simultaneous evaluation of hemodynamic parameters with thoracic electric 

bioimpedance (teB) cardiography and pulumonary artery catheter in patients with 

heart failure. P302 

M. Watanabe, K. Hashimura, H. Takahama, M. Amaki, T. Hasegawa, H. Kanzaki, 

M. Kitakaze (Suita, Osaka, JP) 

red cell distribution width (rDW) as a novel biomarker in heart failure - what is behind? P303 

E. Kalicinska, W. Banasiak, E. A. Jankowska, P. Ponikowski (Wroclaw, PL) 

Clinical value of circulating cystatin-c levels in elderly chronic heart failure patients 

without advanced renal impairment P304 

Y. Mitsuke, A. Nakano, H. Uzui, T. Geshi, T. Satoh, J.D. Lee (Fukui, JP) 

elevated B-type natriuretic peptide is a useful screening tool for asymptomatic left 

ventricular systolic dysfunction in an at-risk community population: the Screening to 

Prevent Heart failure Study P305 

H.C. Cooney, I. Dawkins, M. Ledwidge, K. Mcdonald (Dublin, IE) 

Pulmonary “Comet tail“ artefact in patients with Heart failure and preserved systolic 

function P306 

M. Tsverava, D. Tsverava (Tbilisi, GE) 

Circulating mirnas as potential biomarkers in cardiovascular disease P307 

M.F. Corsten, R. Dennert, T. Kouznetsova, Y. Devaux, J.A. Staessen, L. Hofstra, 

S. Heymans, B. Schroen (Maastricht, NL; Leuven, BE; Luxembourg, LU) 

Animal models and experimentation 

induction of heart failure in porcine models P308 

D. Ladage, K. Ishikawa, A. Garcia-Lopez, M. Garcia, Y. Kawase, R.J. Hajjar (New York, US) 

effects of parasympatthetic preservation on noninvasive myocardial function in Wistar 

rats with myocardial infarction P309 

R. Sirvente, R.N. Fuente, L.E. Souza, I.C.M. Silva, G.O. Candido, S. Lacchini, M.C. Irigoyen, 

C. Mady, V.M.C. Salemi (Sao Paulo, BR) 

impaired control of Ca current following SerCa knockout; arrhythmogenic implications P310 

H.K. Mork, S. Richard, I. Sjaastad, K.B. Andersson, G. Christensen, O.M. Sejersted, 

W. Louch (Oslo, NO; Montpellier, FR) 

Significance of mitochondrial function in Coxsackievirus B3-induced myocarditis P311 

L. Ebermann, S. Wika, I. Vogelpohl, H.P. Schultheiss, A. Doerner (Berlin, DE) 

Natriuretic peptides 

the levels of nt-proBnP and CrP as predictors of the left ventricle systolic function 

following nStemi P312 

E. Karapatsoudi, A. Ioannidis, K. Oikonomou, I. Karantoumanis, K. Karali, M. Ntalapascha, 

M. Papitsas, K. Koskinas, C. Makridis, P. Makridis (Edessa, GR) 

50



elevated natriuretic peptide levels in stable heart failure patients are associated with 

heightened collagen turnover; implications for management P313 

A. Jan, C. Watson, I. Dawkins, N.F. Murphy, P. Collier, J. Baugh, M. Ledwidge, 

K. Mcdonald (Dublin, IE) 

increased adrenomedullin and noradrenaline levels in patients with dilated 

cardiomyopathy without overt heart failure and left bundle branch block: an effect of 

asynchrony? P314 

S. Del Ry, M. Cabiati, M. Maltinti, M. Piacenti, C. Prontera, D. Giannessi, D. Neglia, 

M.A. Morales (Pisa, IT) 

Echocardiography 

right ventricular diastolic parameters assessed by tissue Doppler as predictors of the 

maximal functional capacity P315 

D. Popovic, I. Nedeljkovic, M. Petrovic, A. Kocijancic, B. Vujisic-Tesic, S. Damjanovic, 

M.C. Ostojic (Belgrade, RS) 

left ventricular end-ejection and not end-systolic indexes predict postoperative left 

ventricular function after mitral valve repair P316 

D. Miani, R. Onut, D. Muraru, D. Ermacora, M.T. Grillo, P. Gianfagna, L. Badano (Udine, 

IT; Bucarest, RO) 

interrelation of mitral regurgitation degree with indices of electromechanical 

myocardial dyssynchrony for patients with chronic heart failure P317 

N. Yakush, Y. Ostrovskiy, E. Atroschenko, D. Romanovskiy, O. Pashuk, E. Kurlyanskaya 

(Minsk, BY) 

Combined prognostic value of tissue Doppler right ventricular systolic and diastolic 

function indices and plasma B-type natriuretic peptide in patients with advanced 


V. Bistola, J. T. Parissis, F. Panou, D. Farmakis, P. Psarogiannakopoulos, I. Paraskevaidis, 

E. Iliodromitis, G. Filippatos, M. Anastasiou-Nana, D. Kremastinos (Athens, GR) 

tricuspid plane systolic excursion in patients with suspected chronic heart failure and 

its value as a predictor of outcome P319 

T. Damy, A. Kallvikbacka-Bennet, K. Goode, K. Lewinter, J. Hobkirk, N.P. Nikitin, 

J.L. Dubois-Rande, L. Hittinger, J.G.F. Cleland, A.L. Clark (Creteil, FR; Hull, GB) 

isovolumic myocardial acceleration, new index of right ventricular function after 

percutaneous mitral valvuloplasty P320 

E. A. Khalifa, W. Alnagar, Z. Ashour (Cairo, EG) 

impaired apical and basal rotation lead to a reduction in twist on exercise in patients 

with heart failure with normal ejection fraction (Hfnef) P321 

Y. T. Tan, F.W.G. Wenzelburger, E.S.P. Lee, G. Heatlie, F. Leyva, J.E. Sanderson 

(Birmingham and Stoke-On-Trent, GB) 

greater relative impairment in circumferential over radial strain differentiates chronic 

from acute ischemic myocardial injury P322 

D. Ladage, K. Ishikawa, A. Garcia-Lopez, S. Shapiro, L. Fernandez-Friera, M. Garcia, 

R.J. Hajjar, Y. Kawase (New York, US) 

51 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



MRI, nuclear cardiology and CT (imaging) 

Uptake of 123i-miBg myocardial scintigraphy predicts exercise capacity in patients 

with chronic heart failure P323 

Y. Akashi, K. Ashikaga, K. Mizukoshi, S. Koh, M. Izumo, Y. Ishibashi, K. Kida, K. Suzuki, 

K. Omiya, F. Miyake (Kawasaki and Yokohama, JP) 

myocardial fibrosis in patients with a history of idiopathic inflammatory myopathies 

evaluated by contrast-enhanced cardiovascular magnetic resonance P324 

S. Mavrogeni, M.N. Manoussakis, M. Douskou, H.M. Moutsopoulos (Athens, GR) 

myocarditis in greece: assessment by cardiovascular magnetic resonance, 

immunohistology and real time polymerase chain reaction P325 

S. Mavrogeni, K. Spargias, E. Demerouti, E. Papadopoulou, P. Constandoulakis, 

V. Markussis, A. Magoutas, A. Dimopoulos, S. Papamentzelopoulos, D.V. Cokkinos 

(Athens, GR) 

Cancer/Cardiotoxicity 

Common cardiac symptoms in chronic diseases: a comparison between patients with 

heart failure and colorectal cancer concerning heart rate variability, cardiac function 

and exercise capacity P326 

L. C. Brandao, T. Kung, B. Hildebrandt, A. Nicolaou, W. Doehner, S. Anker, 

S. Von Haehling (Berlin, DE) 

the duration of the use of imatinib mesylate is only weakly related to elevated BnP 

levels in chronic myeloid leukemia patients P327 

M. S. Marcolino, E. Boesma, M.C.P. Nunes, M.M. Barbosa, N.C.D. Clementino, 

M.H.C.R. Silva, M.L. Geleijnse, A.L.P. Riveiro (Belo Horizonte, BR; Rotterdam, NL) 

Cardio-renal syndrome 

St elevation acute myocardial infarction and primary angioplasty: prognostic impact 

of admission creatinine P328 

J. Delgado Silva, L. Seca, R. Providencia, S. Barra, F. Caetano, P. Gomes, J.R. Pais, 

A. Leitao-Marques (Coimbra, PT) 

advanced glycation end products: new marker of renal dysfunction in patients with 

chronic heart failure P329 

S. Raposeiras Roubin, B. Rodino Janeiro, L. Grigorian Shamagian, M. Moure Gonzalez, 

A. Seoane Blanco, A. Varela Roman, E. Alvarez, J.R. Gonzalez Juanatey (Santiago de 

Compostela and Vigo, ES) 

Cellular biology 

apoptosis and aging, the study of peripheral blood lymphocytes P330 

V. Mantini, W.G. Gianni, C.P. Paci, T.C. Cassina, E.P. Pasotti, T.M. Moccetti (Rome and 

San Benedetto Del Tronto, IT; Lugano, CH) 

Cell Signalling 

effects of JtV519 (K201)on na+- and Ca2+ overload - induced arrhythmogenic Ca2+ 

release in mouse cardiac myocytes and the role of CamKii P331 

M. Sacherer, S. Sedej, P. Gronau, M.A. Vos, J. Kockskamper, B. Pieske, F.R. Heinzel 

(Graz, AT; Gottingen, DE; Maastricht, NL) 

52



Co-morbidities (inc COPD,anaemia,cachexia) 

Correction of mild anemia with erythropoietin and quality of life in patients with 

severe chronic heart failure P332 

K. Kaloudis, K.M. Lampropoulos, N. Kouvelas, T.I. Iliopoulos (Athens, GR) 

ischemic stroke history predicts increased cardiovascular mortality in chronic heart failure P333 

G. Kozdag, M. Yaymaci, G. Ertas, E. Ural, U. Bildirici, T. Kilic, D. Ural (Kocaeli, TR) 

Clostridium difficile in frequently hospitalaized chronic heart failure patients P334 

N. Bylova, G. P. Arutyuno, L. I. Kafarskay, N. A. Savelov, Y. A. Pokrovskiy, 

M. I. Korsunskaya, N. V. Kokosadze, A. B. Risnenko (Moscow, RU) 

age-related differences in cardiovascular risk factors among ambulatory heart failure 

patients referred to outpatient heart failure clinics of the Canadian Heart failure 

network (CHfn) 1999 - 2008 P335 

M. Arnold, A. Ignaszewski, J. Howlett, H. Haddad, M.-H. Leblanc, M. Chan, P. Liu, 

A.M. Kaan, G. Marchiori (London, Vancouver, Calgary, Ottawa, Quebec City, Edmonton 

and Toronto, CA) 

adipose tissue catabolism, insulin resistance and chronic heart failure P336 

T. Szabo, E. Postrach, A. Maehler, S.D. Anker, M. Boschmann, W. Doehner (Berlin, DE) 

failing human heart myocardial iron hemeostasis and load and their association to 

iron serum markers P337 

P. Leszek, B. Sochanowicz, M. Szperl, P. Kolsut, T. Rywik, W. Piotrowski, J. Rozanski, 

B. Danko, M. Kruszewski (Warsaw, PL) 

Cytokines and inflammation 

lipopolysaccharide responsiveness is an independent predictor of death in chronic 


T. Kung, A. Sandek, J. Springer, E. Jankowska, S. Genth-Zotz, W. Doehner, S.D. Anker, 

S. Von Haehling (Berlin and Mainz, DE; Wroclaw, PL) 

inflammatory chemokines CCl3 and CCl4 are activated in aortic stenosis P340 

P. J. Ohukainen, P. Taskinen, J. Napankangas, T. Peltonen, T. Juvonen, J. Satta, 

H. Ruskoaho, J. Rysa (Oulu, FI) 

Cardiac inflammation induces transdifferentiation of myofibroblasts and triggers 

diastolic dysfunction in patients with Hfnef P341 

D. Westermann, M. Kasner, D. Lindner, H.-P. Schultheiss, C. Tschoepe (Berlin, DE) 

Gene and cell therapy 

the effect of long-term physical training on cytokine activation in chronic heart failure P342 

E. Besaga, N. Tkach (Kyiv, UA) 

monocyte chemotactic protein 3 is a new homing factor of endothelial progenitor cells P343 

M. Bousquenaud, C. Schwartz, F. Leonard, M. Rolland-Turner, B. Leners, C. Nicolas, 

Y. Devaux, D.R. Wagner (Luxembourg, LU) 

Haemodynamics / Coronary and peripheral circulation 

effects of coronary revascularization in patients with heart failure and preserved 

ejection fraction: 1-year data P344 

Y. Yegorova, O. V. Kuryata (Dnepropetrovsk, UA) 

53 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



Central aortic pressure estimated by radial applanation tonometry in heart failure P345 

E.-R. Mustafa, O. Istratoaie, E. Belu, D.-D. Ionescu (Craiova, RO) 

Hormones / neurohumoral regulation 

Does the recognized hypofunction of the thyroid have the influence on the surgical 

course at ill older subjected cardiosurgical operations ? P346 

A. Kowalczuk, J. Foremny, M. Herdynska, M. Zembala (Zabrze, PL) 

Left ventricular function 

Congestive heart failure and narrow QrS: is myocardial dyssynchrony significant and 

rhythm dependent? P347 

M. Trukshina, M. Sitnikova, D. Lebedev, E. Shlyakhto (St.Petersburg, RU) 

Postinfarction changes of left ventricle in patients with Q-wave myocardial infarction 

with impaired global contractility P348 

N. Vinogradova, L. Ushakova, L. Polonetsky, T. Sevruc (Minsk, BY) 

Clinical signs of heart failure in patients with Q-wave myocardial infarction with 

preserved systolic function of left ventricle P349 

N. Vinogradova, L. Ushakova, L. Polonetsky, T. Sevruc (Minsk, BY) 

Sleep related breathing disorders and left-heart dysfunction in patients with chronic 


B. Pencic, V. Celic, A. Sljivic, A. Majstorovic, M. Kleut (Belgrade, RS) 

Poor systolic function is tied to high Hba1C in patients with diabetes after suffered 


I. Burazor, Z. Burazor, M. Burazor, M. Pesic, M. Lazovic, V. Stojanovic, J. Djordjevic, 

M. Krstic, N. Burazor (Nis, RS) 

Serum uric acid as a predictor of the six months left ventricle systolic function of 

patients with acute non-St-elevation acute coronary syndromes P352 

A. Jovelic, S. Bugarski, T. Miljevic, B. Radisic, R. Jung, T. Popov, M. Kovacevic, K. Pavlovic, 

N. Cemerlic-Adjic (Sremska Kamenica, RS) 

Does early interventricular dyssynchrony after right ventricular pacemaker 

implantation predict late decrease of left ventricular function in patients with initially 

preserved lV systolic function ? P353 

M. Petrovic, G. Milasinovic, B. Vujisic-Tesic, D. Trifunovic-Zamaklar, V. Jovanovic, 

M. Banovic, I. Nedeljkovic, M. Boricic, O. Petrovic, I. Petrovic (Belgrade, RS) 

the influence of left bundle branch-block on 2D-strain parameters in patients with 

heart failure with reduced ejection fraction P354 

C. Mornos, L. Petrescu, R. Dan, D. Cozma, A. Ionac, S. Pescariu (Timisoara, RO) 

Dynamic correction for parallel conductance and gain factor alpha in invasive murine 

lV volume measurements P355 

A. Kottam, M.D. Feldman, J.E. Porterfield (London, CA; San Antonio and Austin, US) 

54



Metabolism / Diabetes mellitus 

the relationship between body composition and heart failure disease severity in 

patients with or without type 2 diabetes P356 

Y.U. Sazonova, M. Sitnikova, M. Budanova, A. Babenko (St Petersburg, RU) 

echocardiographic right ventricular strain and strain rate assessment in typ 2 diabetic 

patients P357 

A. Stevanovic, A. Toncev, S. Dimkovic, N. Paunovic, D. Toncev, N. Sekularac (Belgrade, RS) 

tg/HDl ratio as a surrogate marker of insulin resistance in Hf P358 

G. Borelli, L. Rondinini, F. Bellini, F. Calicchio, E. Minuti, I. Morelli, V. Srebot, R. Mariotti 

(Pisa, IT) 

Ischemia / Reperfusion / Preconditioning 

Percutaneous intramyocardial injection of bone marrow cells in patients early after 

acute myocardial infarction: echocardiography analysis of strain rate imaging and 

speckle tracking P359 

K. Krause, K. Jaquet, J. Von Wedel, K.H. Kuck, C. Schneider (Hamburg, DE) 

altered substrate handling is not responsible for the cardioprotective deficit of delayed 

preconditioning in mouse models of the metabolic syndrome. P360 

A. Vanderper (Leuven, BE) 

Molecular biology / Genetics 

endothelial nitric oxide synthase glu298asp gene polymorphism in a multi-ethnical 

heart failure population and controls P361 

M.W.M. Velloso, S. Bernardez, L. Gouveia, S. Chermont, O. Tardin, M. Quintao, T. Oliveira, 

G.S. Ribeiro, E.T. Mesquita (Niteroi, Rj, BR) 

the expression of the polymorphisms m235t and t174m of the angiotensinogen gene 

in patients with heart failure P362 

L. Kormali, D. Tousoulis, A. Miliou, E. Toli, S. Metaxa, E. Oikonomou, I. Vlaseros, E. Tsiamis, 

N. Papageorgiou, C. Stefanadis (Athens, GR) 

the g5665t polymorphism on endothelin-1 gene is associated with plasma 

endothelin-1 levels in patients with ischemic heart disease P363 

D. Tousoulis, E. Toli, C. Antoniades, A. Miliou, N. Papageorgiou, G. Hatzis, L. Kormali, 

S. Metaxa, I. Paroutoglou, C. Stefanadis (Athens, GR) 

Pathophysiology 

Heart failure with preserved systolic function may be associated with interatrial 

dyssynchrony P364 

J.-C. Eicher, G. Laurent, O. Barthez, G. Bertaux, J.-L. Philip, A. Mathe, J.-E. Wolf (Dijon, FR) 

Cardiomyocyte remodeling in heart failure P365 

O. Barnett, Y. Kyyak (Lviv, UA) 

Proteomic analysis of myocardial remodeling in experimental model of chronic heart 

failure using itraQ chemistry and ief-lC/malDi-mS P366 

J. Petrak, J. Pospisilova, L. Lorkova, M. Sedinova, P. Jedelsky, H. Strnad, M. Kolar, J. Benes, 

V. Melenovsky (Prague, CZ) 

55 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



Vascular biology, other 

impaired vascular function is related to left ventricular diastolic dysfunction in chronic 

kidney disease P367 

E. Hamodraka, I. Paraskevaidis, C. Michalakeas, K. Tsitlakidis, G. Vlachakos, J. Lekakis, 

D. Kremastinos, M. Anastasiou-Nana (Athens, GR) 

Telemedecine and E-Health 

Home telemonitoring in congestive heart failure: patients perspective P368 

N. Knotter, P. G. Meregalli, W.E. Kok, W.G. De Voogt, M. De Beurs, C. Cherpanath-Paes, 

P.M. Donk, A.H.M. Veelenturf, R. Zwart, J.M. Schroeder-Tanka (Amsterdam, NL) 

results from a systematic review and meta-analysis of remote (non-invasive) 

monitoring in 8,323 heart failure patients on length of stay, quality of life, knowledge, 

compliance and satisfaction. P369 

R.A. Clark, S.C. Inglis, F.A. Mcalister, J. Ball, C. Lewinter, D. Cullington, S. Stewart, 

J.G.F. Cleland (Adelaide and Melbourne, AU; Edmonton, CA; Cottingham, GB) 

Population studies / Epidemiology 

Characterization of a heart failure population P370 

F. Saraiva, H. Martins, R. Baptista, P. Mendes, S. Costa, F. Franco, P. Monteiro, 


Can heart failure diagnosis at a rapid access heart function clinic be predicted from 

pre-assessment screening? P371 

P. M. Haydock, H. F. Mcintyre (London and Hastings, GB) 

incidence of heart failure in young adults in Sweden 1987 to 2007 P372 

A. Barasa, A. Rosengren, K. Swedberg, M. Schaufelberger (Gothenburg, SE) 

Hydroxychloroquine is a safe drug for heart in the rheumatic diseases: a case 

control study P373 

S. Jimenez, V. Hernandez, T. Alberca, J. Saavedra, A. Gallego (Madrid, ES) 

Exercise testing and training 

the effect of exercise training on the left ventricular function and nt-proBnP levels in 

heart failure patients with low ejection fraction P374 

N. Santos, R.M. Soares, A. Abreu, L.M. Branco, S. Silva, M.T. Alves, S. Alves, E. Oliveira, 

F. Miranda, R.C. Ferreira (Lisbon, PT) 

Screening patients for early exercise training after decompensation of severe heart 

failure P375 

A. V. Snytnikova, A. A. Doletsky, A. V. Svet, M. D. Kuklina, D. A. Andreev, A. L. Syrkin 

(Moscow, RU) 

effects of beta-blockers on ventilation efficiency in heart failure P376 

P. Agostoni, A. Apostolo, E. Salvioni, L. Antonioli, C. Vignati, M. Contini, A. Magini, 

G. Cattadori, P. Palermo, C. Fiorentini (Milan, IT) 

muscular counterpulsation in patients with chronic heart failure: acute effects on 

cardiac output P377 

D. Ostojic, I. Seifert, V. Puetz, S. Bartsch, T. Bitter, D. Horstkotte, O. Oldenburg 

(Bad Oeynhausen, DE) 

56



Controlled deep slow breathing induces favorable large vessel compliance changes in 

patients with congestive heart failure P378 

D. Karia, S. Gupta, N. Verma, M. Afiniwala, K. Murthy, C. Kilgallon (Philadelphia, US) 

thoracic fluid content - a possible determinant of ventilatory efficiency in patients with 


B.T. Valente, J. Feliciano, R.M. Soares, A. Toste, F. Ferreira, H. Hamad, N. Santos, S. Silva, 

A. Abreu, R. Cruz Ferreira (Lisbon, PT) 

the effect of long-term physical training on cytokine activation in chronic heart failure P380 

E. Besaga, N. Tkach (Kyiv, UA) 

Nursing 

Cardiomobile home care for congestive heart failure patients P382 

L. Hinterbuchner, M.F. Fritsch (Salzburg, AT) 

exploration of readmitting process in patients with congestive heart failure: a 

grounded theory study P383 

D. Hekmatpou, E. Mohammadi, F. Ahmadi, S. H. Arefi (Arak and Tehran, IR) 

role of Cystatin C and nt-proBnP levels predicting mortality in elderly heart failure 

patients P384 

M. Mendez, N. Munoz Rivas, J. Ortiz Alonso, C. Romero Roman, S. Nieto, J. Solis Villa, 

L. Audibert Mena (Madrid, ES) 

Quality of life in age- and gender-matched patients with preserved and reduced 

ejection fraction P385 

T. Hoekstra, I. Lesman, T. Jaarsma, R. Sanderman, D.J. Van Veldhuisen (Groningen, NL; 

Linkoping, SE) 

Disease management and patient education 

Patient education significantly improves quality of life, exercise capacity and BnP level 

in stable heart failure patients P386 

E. Lycholip, J. Celutkiene, A. Rudys, R. Steponeniene, A. Laucevicius (Vilnius, LT) 

indices of collagen type i turnover correlate with quality of life in chronic heart failure 

patients in long term follow up P387 

S. Chatzikyriakou, D. Tziakas, G. Chalikias, D. Stakos, A. Thomaidi, S. Konstantinidis 

(Alexandroupolis, GR) 

reduction of consultations to the emergency department and readmissions in 

patients with heart failure after implementation of a multidisciplinary heart failure unit P388 

I. Tatjer Hernanz, J. Gonzalez Costello, M. Nebot, D. Chivite, A. Torrens, N. Manito, 

J. Rodriguez, J. Roca, C. Capdevila, E. Esplugas (Barcelona, ES) 

the disease management and telemonitoring program CorDiVa for patients with 

heart failure reduces hospitalizations and costs: 2 years experience P389 

S. Sonntag, H.Y. Sohn, V. Klauss, M. Ziegler, H. Moehlmann, F.X. Kleber (Potsdam, Munich 

and Berlin, DE) 

Psychosocial / Ethical concepts / Education 

the level of depression of patients with left ventricle hypertrophy P390 

A. Ibatov (Moscow, RU) 

57 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



rates and predictors of incident major and minor depression in patients with chronic 


N. Lossnitzer, W. Herzog, G. Gelbrich, S. Stoerk, T. Mueller-Tasch, R. Dietz, C. Zugck, 

V. Regitz-Zagrosek, S. Pankuweit, C.E. Angermann (Heidelberg, Leipzig, Wuerzburg, 

Berlin and Marburg, DE) 

Other 

Detection of preclinical body fluid retention by a digital weight scale incorporating a 

bioelectrical impedance analyzer during follow-up of established heart failure patients P392 

H. Kataoka (Oita, JP) 

microcirculation changes in the oral mucosa in patiens with chronic heart failure P393 

A. Barmasheva, L.Y.U. Orekhova, E.V. Shlyachto, A.I.A. Goodkova (St Petersburg, RU) 

muscular counterpulsation is safe in pacemaker and iCD-patients P394 

B. Lamp, G. Kersting, S. Peschl, C. Lenz (Bad Driburg, DE; Winterthur, CH) 

Vascular endothelial growth factor and tumor-necrosis-factor-alpha in malignant 

pericardial effusion P395 

K. Karatolios, S. Pankuweit, A. Richter, R. Moosdorf, B. Maisch (Marburg, DE) 

neurohormonal and functional correlates of linear and poincare’ plot indexes of heart 

rate variability in heart failure patients P396 

G. D’addio, G.D. Pinna, M. Cesarelli, R. Maestri, M.T. La Rovere, M. Romano, G. Corbi, 

N. Ferrara, F. Rengo (Telese Terme, Montescano, Naples and Campobasso, IT) 

night-to-night variability of indexes of nocturnal breathing disorders in heart failure 

patients P397 

G.D. Pinna, R. Maestri, E. Robbi, M.T. La Rovere (Montescano, IT) 

58

SUnDaY 30 maY 2010 - afternoon PoSterS 



Cardiac resynchronisation - Diagnosis - gene & cell therapy - Surgery 

Chairperson: A. Auricchio (Lugano, CH) 




15:45 gln27glu beta-2 adrenergic receptor gene polymorphism influences left 

ventricular reverse remodelling after cardiac resynchronization therapy P398 

N. Pezzali, M. Metra, C. Maiandi, E. Pezzotti, A. Monti, A. Lipari, M. Cerini, 

L. Bontempi, A. Curnis, L. Dei Cas (Brescia, IT) 

15:50 Prognostic value of ischemic and non-ischemic type patterns of late 

gadolinium enhancement cardiovascular magnetic resonance in patients with 

cardiac resynchronization therapy P399 

A. Valle, J. Estornell, M. Corbi, A. Pirola, O. Fabregat, J. Perez-Bosca, N. Martinez, 

A. Quesada, R. Paya, F. Ridocci Soriano (Valencia, ES) 

15:56 Combined resynchronization and implantable cardioverter defibrillator 

therapy: meta-analysis of randomized controlled trials P400 

C. Bonanno, F. Mistrorigo, M. Morato, R. Ometto, A. Fontanelli (Vicenza, IT) 

16:01 echocardiographically-guided VV and aV optimisation of lVot Vti improves 

parameters of ventricular dyssynchrony in Crt non-responders P401 

M. J. Daly, K. Morisson, K. Ashfield, R. Kirkpatrick, L. Hill, L. J. Dixon (Belfast, GB) 

16:07 influence of heart failure aetiology on long-term effects of cardiac 

resynchronization therapy on left ventricular structure and function in 

patients treated with beta-blockers P402 

V. Zaca’, C. Baiocchi, R. Gaddi, R. Gentilini, S. Lunghetti, M. Padeletti, F. Furiozzi, 

S. Mondillo, R. Favilli (Siena, IT) 

16:13 non-invasive lung impedance monitoring in the outpatient clinic facilitates the 

prediction of hospitalization of patients with decompensated heart failure and 

enables early therapy to prevent hospital P403 

M. Shochat, M. Kasatzker, V. Gurovich, Y. Levi, A. Asif, H. Sabax, P. Rabinovich, 

D. Blondheim, A. Shotan, S. Meisel (Hadera and Tel Aviv, IL) 

16:18 efficiency of intramyocardial injections of autologous bone marrow 

mononuclear cells in patients with ischemic heart failure: a randomized study P404 

A. Romanov, E. Pokushalov, A. Cherniavskiy, P. Larionov, I. Terehov, E. Kliver, 

S. Artemenko, N. Shirokova, A. Karaskov, N. Dib (Novosibirsk, RU; San Diego, US) 

16:24 Diastolic heart failure - efficacy assessment of a new device-based approach P405 

L.L. Lak, E.A. Elami, S.R. Shofti, S.A. Sherman, F.Y. Feld, R.L. Rosen, B.Y. 

Benshabat, L.M. Lipperman, D.S. Dubi, C.S. Carasso (Herzelia, Jerusalem, Haifa 

and Tel Aviv, IL) 

59 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 








Small increases of nt-probnp in patients with acute congestive heart failure and 

normal ejection fraction P406 

R. Ciomag, M. Dasoveanu, A. Popa, F. Adam, C. Sinescu (Bucharest, RO) 

Slovak acute heart failure survey - predictors of in-hospital mortality P407 

P. Lesny, I. Varga, M. Luknar, P. Solik, B. Liska, S. Babej, E. Goncalvesova (Bratislava, SK) 

Primary and secondary cardiac tumors cause heart failure P408 

B. Maisch, R. Moosdorf, R. Moll, U. Baandrup, S. Pankuweit, R. Funck, H. Bechtold, 

A. Ristic (Marburg, Bad Hersfeld and Crailsheim, DE; Hjorring, DK; Belgrade, RS) 

Precipitants of acute heart failure in a multi-ethnic asian urban known heart failure 

cohort study P409 

G.E.R.A.R.D. Leong, Y. Cao, P.P. Goh (Singapore, SG) 

the differences in characteristic of patients hospitalizated with acute heart failure in 

hospital with cath lab and without cath lab P410 

L. Pohludkova, K. Zeman, L. Dusek, D. Tomcikova, J. Spinar, J. Parenica (Frydek-Mistek and 

Brno, CZ) 

is persistent hyponatremia associated with increased mortality in heart failure patients 

in the community? P411 

S. Ghosh, J. Dexter, C. Caroll-Hawkins, J. Smith, N. Okelly (Leicester, GB) 

acute heart failure: prognosis value of renal failure P412 

L. Abid, R. Hammami, M. Ellouz, I. Trabelsi, S. Kammoun (Sfax, TN) 

exclusive olive oil consumption is associated with lower likelihood of developing left 

ventricular systolic dysfunction in acute coronary syndrome patients P413 

C. Chrysohoou, P. Aggelopoulos, C. Kastorini, D. Tsiachris, K. Liontou, G. Tsitsinakis, 

E. Christoforatou, D.B. Panagiotakos, C. Pitsavos, C. Stefanadis (Athens, GR) 

in-hospital mortality of patients with left ventricle dysfunction admitted with acute 

decompensated heart failure: the role of renal function during hospitalization P414 

S. Mangini, A. Abuhab, A.G. Correa, P.K.O. Yokota, L.F. Lisboa, M.R. Makdisse, F. Bacal 


level of ltC4 in Patients with acute Heart failure at the Background of treatment of 

Water-soluble form of flavonoid Qurcetin. P415 

V. Zolotaikina (Kharkiv, UA) 

acute heart failure: Does it predict cardiovascular risk at 24 months? P416 

S. N. C. Barra, J. Silva, P. Gomes, R. Providencia, L. Seca, A. Leitao Marques (Coimbra, PT) 

Hemodynamic Predictors of Heart failure morbidity and mortality: fluid or flow? P417 

J. Rogers, M. Fiuzat, C. Lombardi, L.K. Shaw, G.M. Felker, C.M. O’connor 

(Durham, NC, US; Brescia, IT) 

60



Clinical profile, in-hospital management and outcome in patients with acute 

pulmonary edema according to systolic blood pressure: the acute Heart failure 

global Survey of Standard treatment (alarm-Hf) P418 

D. Farmakis, J.T. Parissis, M. Nikolaou, I. Ikonomidis, A. Mebazaa, J. Delgado, F. Vilas-Boas, 

A. Mc Lean, D.T. Kremastinos, F. Follath (Athens, GR; Paris, FR; Madrid, ES; Salvador, BR; 

Sydney, AU; Zurich, CH) 


atrial fibrillation and heart failure in pregnancy P419 

O. Londono Sanchez, S. Pacreu (Barcelona, ES) 

is there a role to levosimendan therapy in critical care patients? P420 

J.M. Guardado, A. Alves, F. Canario-Almeida, G. Campello, C. Granja (Guimaraes and 

Matosinhos, PT) 

Vasoactive drugs or diuretic perfusions with elastomeric pump at home.nursing 

education work P421 

A.M. Torres, A.M. Tella, E.B. Villegas, J.F. Pajares (Barcelona, ES) 

anemia natural history in patients with advanced heart failure P422 

A. C. Pereira Barretto, M.E. Ochiai, J.N. Cardoso, C.H. Del Carlo, P.C. Morgado, 

R.T. Munhoz, A.R. Scipioni, J.A.F. Ramires (Sao Paulo, BR) 

Domicilary intravenous drug infusions in the management of advanded chronic heart 

failure in elderly population P423 

E.B. Villegas, A.M. Torres, M. Camprecios, R. Freixa (Barcelona, ES) 

the age-BnP Survival model: prediction of survival in elderly (75 years and older) 

patients with heart failure, observed by general practitioners P424 

E. Shlyakhto, M. Sitnikova, T. Lelyavina (St Petersburg, RU) 

Use of intravenous morphine for acute decompensated heart failure P425 

Z. Iakobishvili, E. Cohen, M. Garty, T. Ben Gal, S. Behar, A. Shotan, A. Sandach, 

M. Mittelman, A. Battler, D. Hasdai (Petah Tikva, Ramat Gan, Hadera and Tel Aviv, IL) 


is mortality of congestive heart failure still that bad? P426 

O. Ludka, L. Galkova, Z. Gregorova, M. Sablaturova, Z. Pozdisek, M. Musil, J. Spinar 

(Brno, CZ) 

Diabetes: a poor prognosis predictor in advanced heart failure P427 



Percutaneous aortic valve implantation for severe aortic stenosis using the third 

generation CoreValve revalving System: impact on clinical and valve-related outcomes P428 

A.J. Munoz Garcia, M.F. Jimenez-Navarro, A.J. Dominguez-Franco, J.H. Alonso-Briales, 

I. Rodriguez-Bailon, P. Hernandez, E. Olalla-Mercade, J.M. Hernandez-Garcia, 

E. De Teresa Galvan (Malaga, ES) 

moderate consumption of protein seems to lower the risk for cardiovascular events, in 

patients with newly diagnosed heart failure, during a 12 months follow-up period P429 

C. Chrysohoou, G. Pounis, J. Kotrogiannis, C. Kastorini, S. Athanassopoulou, P. Arsenos, 

C. Pitsavos, C. Stefanadis (Athens, GR) 

61 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



Detrended fluctuation analysis (Dfa) of Heartbeat time series and a1 exponent 

predicts total mortality in heart failure patients P430 

P. Arsenos, K. Gatzoulis, T. Papaioannou, T. Gialernios, P. Dilaveris, C. Aggeli, G. Manis, 

D. Tsiahris, K. Dimitriadis, C. Stefanadis (Athens and Ioannina, GR) 

Serial echocardiography and measurement of B-type natriuretic peptide during 

admission for prediction of outcome in patients with acute de novo heart failure P431 

S.-E. Kim, D.G. Park, J.Y. Hong, S.Y. Cheon, S.J. Lim, J.H. Lee, K.R. Han, D.J. Oh, K.S. Hong 

(Seoul and Chuncheon, KR) 

Prognosis of chagas’ cardiomyopathy versus non-chagas’ cardiomyopathy in betablockers 

era: 24 month follow-up P432 

G.E. Conceicao-Souza, L.M. Pessoa-De-Melo, J.L. Vieira, V. Batistela, E. Gorobets, 

L.R. Valim, A.C.P. Barretto, E.A. Bocchi, J.A.F. Ramires (Sao Paulo, BR) 

Predicting prognosis in heart failure patients: can heart rate do it? P433 



risk stratification and mortality of acute heart failure patients with hypertension as 

underlying disease P434 

M. Felsoci, R. Miklik, J. Parenica, D. Tomcikova, J. Spinar (Brno, CZ) 

renal dysfunction, left ventricular filling pattern and mortality risk in patients admitted 

with heart failure: a 7-year follow-up study P435 

M. Schou, J. Kjaergaard, C. Torp-Pedersen, C. Hassager, F. Gustafsson, D. Akkan, 

J.E. Moller, L. Kober (Hillerod, Copenhagen and Hellerup, DK) 

Chronotropic incompetence and survival in chronic heart failure P436 

Y. Al-Najjar, K.K. Witte, A.L. Clark (Hull and Leeds, GB) 

respiratory pattern during cardiopulmonary exercise test and risk assessment in 

elderly patient with chronic heart failure P437 

A.B.S. Scardovi, R.D.M. De Maria, A.F. Ferraironi, A.C. Celestini, S.F. Forte, M.P. Parolini, 

L.G. Gatto, S.S. Sciarretta, R.R. Ricci, M.G. Guazzi (Rome and Milano, IT) 

Comparison between creatinine clearance calculated by Cockroft and mDrD_4 

formulas in an outpatient heart failure population P438 

E. Zamora, J. Lupon, A. Urrutia, B. Gonzalez, G. Bickham, L. Cano, S. Altimir, R. Cabanes, 

C. Diez, J. Ara (Badalona, ES) 


gamma-glutamyltransferase (ggt) rather than bilirubin is of prognostic significance in 


M. Ess, C. Mussner-Seeber, H. Ulmer, M. Frick, G. Poelzl (Innsbruck, AT) 

Problems with the use of Bmi and egfr in prognostic models of heart failure P440 

J. Zhang, A.S. Rigby, R. Silva, D. Cullington, D. Ahmed, A. Crundall, J.G.F. Cleland, 

K.M. Goode (Hull, GB) 

incremental prognostic potential of n-terminal-proBnP, high sensitive c-reactive 

protein und tumour necrosis factor alpha in patients with suspected heart failure P441 

C. Morbach, D. Berliner, S. Stoerk, K. Boldt, G. Gelbrich, S.H. Peter, S. Guenther, 

V. Holzendorf, G. Ertl, C.E. Angermann (Würzburg and Leipzig, DE) 

osteoprotegerin levels predict mortality in symptomatic aortic stenosis P442 

T. Ueland, P. Aukrust, C.P. Dahl, O.G. Solberg, S. Aakhus, L. Gullestad (Oslo, NO) 

62



treatment with vitamin e in chronic heart failure: is there contribution to the 

conventional therapy? P443 

K. Vitlianova, T.I. Donova, M.D. Apostolova (Sofia, BG) 

Prognostic value of Ca 125 in mild to moderate heart failure patients P444 

E. Vizzardi, N. Pezzali, G. Faden, A. D’aloia, M. Metra, L. Dei Cas (Brescia, IT) 

Copeptin as predictor of clinical events and mortality in patients with chronic heart 

failure: relationship with renal insufficientcy, iron deficiency and inflammation P445 

Z. Prohaszka, Z. Pozsonyi, Z. Forhecz, T. Gombos, J. Kunde, G. Borgulya, L. Janoskuti 

(Budapest, HU; Hennigsdorf, DE) 

echocardiographic and laboratory indicators of in-hospital and all-cause mortality in 

end-stage rneal disease patients P446 

S. Lee, S.R. Lee, K. Rhee, K. Chae, W. Kim, J. Ko (Jeonju, KR) 


ivabradine improves time-domain heart rate variability in patients with stable chronic 


I. Donoiu, O.-D. Dracea, R.-I. Radu, A. Giuca, R.-E. Mustafa, D.-D. Ionescu (Craiova, RO) 

rapid improvement of lV systolic function after curative ablation of idiopathic PVe/Vt 

in children P448 

D. Goncharik, A. Mrochek, A. Chasnoits, O. Kovalenko, V. Golenischa, E. Protsenko, 

J. Persidskich (Minsk, BY) 

Beta blockers 

Physical well-being in elderly patient with heart failure under beta blocker therapy P449 

E. Tahirovic, A. Toepper, S. Inkrot, F. Mehrhof, B. Gusy, D. Jahandar Lashki, M. Filter, 

H.-D. Duengen (Berlin, DE) 

relationship of Beta-blocker therapy, Serial measures of Bilirubin, and outcomes: 

Data from the Beta-blocker evaluation of Survival trial (BeSt) P450 

L. Allen, M. Fiuzat, G. Davis, G.M. Felker, M.R. Bristow (Denver, CO, Durham, NC and 

Broomfiled, CO, US) 

Heart failure with preserved ejection fraction: influence on sympathetic activity and 

interaction with betablockers compared to patients with low ejection fraction P451 

G. Gonzalez-Robledo, J. Comin-Colet, D. Silva-Cantillo, S. Ruiz, M. Rizzo, A. Herranz, 

M. Cladellas, J. Bruguera-Cortada (Barcelona, ES) 

Determinants of change in quality of life in the randomized controlled cardiac 

insufficiency bisoprolol study in elderly (CiBiS-elD) P452 

C. Herrmann-Lingen, M. Scherer, S. Inkrot, E. Tahirovic, M. Lainscak, W. Doehner, 

F. Edelmann, S. Apostolovic, G. Gelbrich, H.D. Duengen (Gottingen, Luebeck, Berlin 

and Leipzig, DE; Golnik, SI; Nis, RS) 


optimal pharmacotherapy in cardiac resynchronization therapy candidates, single 

centre experience P453 

F. Malek, D. Vondrakova, L. Sediva, J. Kupec, J. Petru, M. Taborsky, P. Neuzil (Prague, CZ) 

63 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



Usefullness of echocardiographically assessed baseline left ventricular lateral 

wall postsystolic displacement in prediction of reverse remodeling by cardiac 

resynchronization therapy P454 

S. Salinger, Z. Perisic, T. Kostic, D. Milic, S. Obradovic, S. Apostolovic, T. Stanojlovic, 

D. Djordjevic-Radojkovic, R. Jankovic, M. Damjanovic (Nis and Belgrade, RS) 

Beta-blocker therapy uptitration enhances reverse remodeling and improves outcome 

after Crt P455 

G. Borelli, L. Rondinini, F. Bellini, L. Conte, P. Giordano, E. Soldati, M.G. Bongiorni, 

R. Mariotti (Pisa, IT) 

Utility of intraclass Correlation Coefficient to quantify efficiency of optimization markers P456 

A. Kyriacou, Z.I. Whinnett, P.A. Pabari, R. Baruah, D. Lefroy, N.S. Peters, D.W. Davies, 

P. Kanagaratnam, J. Mayet, D.P. Francis (London, GB) 

the renal function expressed by parameter creatinine clearance is an independent 

predictor of mortality in patients receiving cardiac resynchronization therapy P457 

G. De Masi De Luca, S. Iacopino, M. Accogli, C. Sacra, A. Galati (Tricase and Catanzaro, IT) 

temporal patterns of atrial fibrillation occurrences and heart failure hospitalizations in 

patients wearing implantable biventricular defibrillators. P458 

F. Oliva, M. Gasparini, M. Landolina, S. Ghio, M. Santini, A. Proclemer, D. Miani, S. Bisetti, 

G. Visconti, M. Lunati (Milano, Rozzano, Pavia, Rome and Udine, IT) 

ICD therapy 

is there an association between implantable cardioversor-defibrillators and anxiety or 

depression? P459 

C.N. Lourenco, F. Saraiva, N. Antonio, J. Cerejeira, M. Ventura, J. Cristovao, L. Elvas, 


incidence of implantable cardioverter-defibrillator interventions depending on 

reduced left ventricular ejection fraction in patients with hypertrophic cardiomyopathy P460 

C. Schukro, L. Leitner, T. Pezawas, G. Stix, J. Kastner, M. Wolzt, H. Schmidinger 

(Vienna, AT) 


3 year aggresive lipid lowering therapy of patients with chronic heart failure due to 

coronary heart disease P461 

T. Vakhtangadze, F. Todua, M. Akhvlediani (Tbilisi, GE) 

Vascular remodeling with ivabradine-induced change in collagenous matrix in 


N. Koziolova, A. Chernyavina, M. Surovtseva (Perm, RU) 

Down regulation of the very first players of local raS in human stenotic aortic valves 

are not affected by statin treatment P463 

T. O. A. Peltonen, J. Napankangas, J. Aro, P. Taskinen, H. Ruskoaho (Oulu, FI) 

effect of levosimendan treatment on cardiac troponin release in patients with acute 

heart failure syndrome who have coronary artery disease P464 

Y. Cavusoglu, E. Gencer, M. Tek, C. Demirustu, A. Birdane, B. Gorenek, A. Unalir, 

O. Goktekin, N. Ata (Eskisehir, TR) 

64



reduced breathlessness by device-guided slow breathing in patients with chronic 

heart failure (CHf): a randomized controlled trial P465 

I. Ekman, J. Norman, K. Falk, D. Morales-Martinez, K. Swedberg (Gothenburg, SE) 

Dose-dependent effects of omega-3 fatty acids on systolic left ventricular function, 

endothelial dysfunction, and interleukin-6 in patients with severe chronic heart failure 

of non-ischemic origin P466 

D. Moertl, A. Hammer, R. Hutuleac, S. Steiner, R. Berger (Vienna, AT) 


Survival of patients with ischaemic versus non-ischaemic heart failure after 

transplantation in a south brazilian hospital: a 25 years longitudinal study P467 

I. Kohler, L.C. Petersen, S. Bordignon, L.C. Danzmann, M.A. Maldonado, M.A. Torres, 

G.C. Stich, M. Garcia, C.F. Saldanha, I. Nesralla (Porto Alegre - RS, BR) 

Predictors of mortality after heart transplantation P468 

J. Ljubas, B. Skoric, J. Samardzic, D. Milicic (Zagreb, HR) 

Heart rate recovery following repeated peak exercise testing during the early stages 

of mechanical device assist support P469 

G. C. Donovan, R.S. George, D.J. Jakovljevic, D. Nunan, R.S. Bougard, M.H. Yacoub, 

E.J. Birks, D.A. Brodie (Uxbridge and London, GB) 

Prognostic performance of heart failure survival score across wide range of body mass 

index in patients referred for heart transplantation P470 

P. Rozentryt, J.U. Nowak, S. Von Haehling, J. Niedziela, K. Myrda, J. Iwinski, J. Korewicki, 

L. Polonski, S.D. Anker (Zabrze and Warsaw, PL; Berlin, DE) 

one-year intravascular ultrasound (iVUS) follow-up after heart transplant: correlation 

with risk factor for cardiac allograft vasculopathy P471 

A. Verde, I. Bossi, F. Macera, G. Masciocco, F. Oliva, F. De Marco, I. Oreglia, S. Klugman, 

L. Martinelli, M. Frigerio (Milan, IT) 

early steroid withdrawal has no impact on diabetes mellitus (Dm), renal function, late 

cellular rejection or development of transplanted heart coronary vasculopathy (CaV). P472 

M. K. Lizak, M. Zakliczynski, A. Jarosz, M. Zembala, Z. Kalarus (Zabrze, PL) 


failing heart predicts serious gastrointestinal complications after cardiopulmonary 

bypass operations P473 

P. Soos, B. Schmack, M. Karck, G. Szabo (Budapest, HU; Heidelberg, DE) 

effects of long waiting of coronary bypass grafting on quality of life, depression and 

anxiety in patients with congestive heart failure P474 

E. Averin, V. Delaru, U. Lopatin (Volgograd, RU) 

long-term survival and quality of life of the elderly patients undergoing aortic valve 

replacement P475 

S. M. Oliveira, A.S. Correia, M. Paiva, A. Goncalves, R. Almeida, M. Pereira, E. Alves, 

P. Dias, P. Pinho (Porto, PT) 

outcomes following surgical ventricular reconstruction for patients with clinically 

advanced congestive heart failure P476 

M. Di Donato, S. Castelvecchio, J. Salvia, V. Montericcio, L. Menicanti (Florence and 


65 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 




incidence and risk factors for worsening renal function during hospitalization in 

decompensated heart failure patients P477 

A. Valdespino Trejo, L. Castillo Martinez, J. I. A. Orea-Tejeda, D. Gonzalez, W. Rodriguez, 

A. Sanchez, C. Santillan, E. Colin (Mexico, MX) 

Bed-side bioimpedenzometry monitoring for fluid balance management in acute 


M. Milli, S. Spini, L. Goedecke, L. Fratoni, N. Aspromonte, R. Valle (Florence, Rome and 

Chioggia, IT) 

Determinants and consequences of dysnatraemias in heart failure P479 

N. Deubner, S. Brenner, D. Berliner, R. Jahns, G. Gueder, W. Fenske, B. Allolio, G. Ertl, 

C. Angermann, S. Stoerk (Wuerzburg, DE) 


antialdosterone therapy: tolerability and efficacy in clinical practice P480 

D. Nassiacos, S. Rogiani, S. Meloni, P. Antognini (Saronno, IT) 


rate-control therapy in exercise tolerance and quality of life in patients with chronic 

atrial fibrillation and chronic heart failure with preserved systolic function P481 

A. V. Kolchurina, A. A. Doletsky, D. A. Andreev, M. D. Kuklina, A. V. Svet, A. L. Syrkin 

(Moscow, RU) 

rate-control vs rhythm-control control for atrial fibrillation in heart failure patients: a 

meta-analysis P482 

D. Caldeira, C. David (Lisbon, PT) 

Detection of malignant ventricular arrhythmias in permanent forms of atrial fibrillation P483 

T.A. Abdullaev, R.D. Kurbanov, N.U. Zakirov, S.H. Khusanov (Tashkent, UZ) 


alfa galactosidase a activity in whole blood spots in patients with hypertrophic 


C. E. Correia, B. Rodrigues, L. Santos, R. Faria, P. Gama, P. Ferreira, C. Cabral, O. Santos 

(Viseu, PT) 

a comprehensive approach combined pathological features with genome-wide 

analysis to clarify the pathogenesis of HCm subset progressing to the dilated phase P485 

T. Toyo-Oka, M. Kobayashi, T. Tanaka, K. Takazawa, Y. Nakamura, S. Kostin, T. Izumi, 

J. Schaper, K. Tokunaga (Tokyo and Sagamihara, JP; Bad Nauheim, DE) 

medium-term follow up of population with left ventricular noncompaction P486 

C. E. Correia, L. Santos, B. Rodrigues, R. Faria, P. Gama, L. Antunes, J. Pipa, O. Dionisio, 

C. Cabral, O. Santos (Viseu, PT) 

Dobutamine stress echocardiography in patients with Chagas’ disease and normal left 

ventricular systolic function P487 

V. M. C. Salemi, A.Y. Matsumoto, J.L.B. Pena, C.B.C. Oliveira, B.M. Ianni, L.V. Rosa, 

C.A. Ferreira, A.L. Dabarian, R. Sirvente, C. Mady (Sao Paulo, BR) 

66



genomes of viruses and borrelia burgdorferi in endomyocardial biopsies of patients 

with recent-onset dilated cardiomyopathy P488 

M. Kubanek, M. Sramko, J. Maluskova, H. Hrbackova, D. Hulinska, L. Hoskova, I. Malek 

(Prague, CZ) 

the role of inflammation and infectious agents in dilated cardiomyopathy: a 

comparison with normal hearts P489 

S. Mangini, M.L. Higuchi, M.M. Reis, S. Palomino, A.I. Fiorelli, J.L. Oliveira Jr, S.M. Ferreira, 

M.L. Vieira, F. Bacal, E.A. Bocchi (Sao Paulo, BR) 

european multicentre diagnostic study on the etiology, titre-course, and impact on 

survival of cardiac autoantibodies: rationale and design of the prospective etiCS-study P490 

N. Deubner, D. Berliner, A. Schlipp, S. Brenner, C.E. Angermann, M.J. Lohse, G. Ertl, 

S. Stoerk, R. Jahns (Wuerzburg, DE) 

Clinical polymorphism and long-term natural history in hypertrophic cardiomyopathy: 

the trieste heart muscle disease experience P491 

G. Finocchiaro, M. Merlo, B. Pinamonti, G. Barbati, A. Di Lenarda, G. Sinagra (Trieste, IT) 

focus on cardiac amyloidosis: analysis of baseline clinical and instrumental features 

and predictors of short-medium term prognosis. P492 

G. Finocchiaro, M. Merlo, F. Giannini, B. Pinamonti, G. Barbati, A. Depellegrin, R. Bussani, 

A. Di Lenarda, G. Sinagra (Trieste, IT) 

Carvedilol at patients with hypertrophic cardiomyopathy: changes of the 

electrocardiographic parameters P493 

T.A. Abdullaev, B.U. Mardanov, O.K.H. Allaberganov, R.D. Kurbanov (Tashkent, UZ) 

a functional promotor polymorphism in CCn2 encoding connective tissue growth 

factor (Ctgf) in patients with cardiac recovery during mechanical circulatory support P494 

M. G. Posch, A.N. Panek, S. Hussein, G. Schmidt, N. Hiemann, A. Perrot, R. Hetzer, 

H.B. Lehmkuhl, C. Ozcelik (Berlin, DE) 

Differences in genetic background influence the functionality of natural killer cells and 

determine the outcome of enteroviral myocarditis P495 

K. Kotsch, K. Goeldner, D. Stauch, M. Sauter, R. Kandolf, K. Klingel (Berlin and 

Tuebingen, DE) 

mutation screening of sarcomere genes mYH7, mYBPC3, lDB3, and tnnt2 in a large 

cohort of dilated cardiomyopathy families P496 

M. Merlo, E. Carniel, D. Slavov, E. Salcedo, J. Cavanaugh, A. Di Lenarda, G. Sinagra, 

X. Zhu, L. Mestroni, M. Taylor (Trieste, IT; Denver, US) 


interleukin-1 receptor antagonist plasma levels are related with central adiposity in 

patients with essential hypertension P497 

M. Rivera Otero, E. Rosello, C. Lauwers, F. Garcia De Burgos, J.R. Calabuig, P. Morillas, 

L. Mainar, A. Salvador, R. Cortes, V. Bertomeu (Valencia, Elche, Alicante and Requena, ES) 

ambulatory blood pressure monitoring is useful for evaluating of white coat 

hypertension in children P498 

A. Jurko, A. Jurko Jr, P. Durdik (Martin, SK) 

67 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



Procollagen type iii amino-terminal peptide and diastolic dysfunction in asymptomatic 

patients with essential hypertension P499 

M. Rivera Otero, E. Rosello, R. Cortes, F. Garcia De Burgos, V. Miro, J.L. Perez Bosca, 

L. Grigorian, T. Lozano, M. Portoles, V. Bertomeu (Valencia, Elche, Santiago and 

Villajoyosa, ES) 

Serum markers of tissue fibro-inflammation - painting a new picture of the 

biochemical natural history of hypertension P500 

P. Collier, C. Watson, V. Voon, D. Phelan, A. Jan, G. Mak, R. Martos, J. Baugh, 

M. Ledwidge, K. Mcdonald (Dublin, IE) 

overexpression of apolipoprotein B attenuates cardiac hypertropic response P501 

T. Ramunddal, M. Lindbom, M. Scharin-Tang, J. Boren, E. Omerovic (Gothenburg, SE) 


inferior vena cava respiratory variation and right atrial function are predictors of ntproBnP 

in pulmonary arterial hypertension patients P502 

J. Silva Marques, S. Martins, A.G. Almeida, A. Nunes Diogo, S. Ribeiro, A. Feijao, 

M.G. Lopes (Lisbon, PT) 

long-term prognostic impact of heart failure in patients with acute pulmonary 

embolism P503 

S. R. N. Leal, H. Dores, I. Rosario, M. J. Carvalho, J. Monge, I. Arroja, A. Leitao, 

C. Fonseca, A. Aleixo, A. Silva (Lisbon, PT) 

Passive physycal training in patients with pulmonary hypertension: influence on 

muscle and arrhythmic status P504 

A. N. Sumin, N.A. Snitskaya, O.G. Arhipov (Kemerovo and Mysky, RU) 

Does pulmonary hypertension in systemic sclerosis impact global function of the right 

ventricle? P505 

B. Ivanovic, M.T. Tadic, D.S. Simic (Belgrade, RS) 


abdominal obesity, nt-proBnP and diastolic function of left ventricle P506 

E. Bazhenova, O.L.G.A. Belyaeva, A. Berezina, E. Nikolaychyk, T. Lozovaya, V. Kirmos, 

A. Kozlenok, T. Karonova, O. Berkovich, E. Baranova (St Petersburg, RU) 

Prognostic value of QrS duration to predict mortality in patients with heart failure P507 

V. Chioncel, C. Calin Andrei, D. Mincu, M. Anastasiu, R. Ciomag, C. Sinescu 


nt-proBnP levels in patients with decreased ejection fraction after first St-elevation 

myocardial infarction treated with primary coronary angioplasty P508 

I. Szadkowska, L. Pawlicki, J. Kowalski, K. Chizynski (Lodz, PL) 

new implications for Soluble receptor for advanced glycation end products (srage): 

relation with ischemia in patients with chronic heart failure P509 

S. Raposeiras Roubin, B.R.U.N.O. Rodino Janeiro, L.I.L.I.A.N. Grigorian Shamagian, 

A. Seoane Blanco, M. Moure Gonzalez, A.F.O.N.S.O. Varela Roman, E.Z.E.Q.U.I. Alvarez, 

J.R. Gonzalez-Juanatey (Santiago de Compostela and Vigo, ES) 

68



Utility of nt-proBnP to identify left ventricular dysfunction and adverse prognosis in 

patients with a remote myocardial infarction P510 

A. Torabi, J.G.F. Cleland, A.S. Rigby, K. Goode, N. Sherwi, O. Khaleva, J. Zhang, A. Yassin 

(Hull, GB) 

nt-proBnP concentration, nYHa class, and left ventricular dysfunction six months 

after myocardial infarction treated with primary angioplasty with complete coronary 

revascularization. P511 

I. Szadkowska, L. Pawlicki, J. Kowalski, K. Chizynski (Lodz, PL) 

Serum neopterin levels predict worsening of renal function in acute decompensated 


A. Dominguez Rodriguez, P. Abreu Gonzalez, S. Samimi Fard, E. Arroyo Ucar, 

R. Juarez Prera, G. Blanco Palacios, I.F. Hernandez Baldomero, C. Enjuanes Grau, 

A. Lara Padron, J.C. Kaski (Tenerife, ES; London, GB) 

Diagnosing heart failure in geriatric patients: derivation of a diagnostic rule P513 

I. Oudejans, A. Mosterd, J.A.M. Bloemen, F.H. Rutten, M. Valk, E. Van Velzen, 

J.P.M. Wielders, N.P.A. Zuithoff, A.W. Hoes (Helmond, Amersfoort and Utrecht, NL) 

leucine-rich alpha-2-glycoprotein: a potential novel biomarker of ventricular 

dysfunction and heart failure P514 

C.J. Watson, M. Ledwidge, D. Phelan, P. Collier, J. Byrne, M. Dunn, K. Mcdonald, 

J. Baugh (Dublin, IE) 


outflow tract pacing sites result in better acute cardiac performance over apical 

pacing sites in a range of different aV delays measured by thoracic impedance P515 

C.H. Steinberg, J.F. Roux, F. Ayala Paredes (Sherbrooke, CA) 

Post-infarction mechanical changes of cardiomyocytes in mice P516 

A. Balogh, D. Czuriga, D. Santer, B. Podesser, Z. Papp (Debrecen, HU; Vienna, AT) 

t-tubule proliferation in cardiomyocytes following conditional Serca2 knockout P517 

F. Swift, G.F. Jolle, K.B. Andersson, G. Christensen, O.M. Sejersted, W.E. Louch (Oslo, NO) 

endothelial overexpression of beta-3 adrenergic receptor in rat, a relevant model of 

heart failure with preserved ejection fraction P518 

N. Piriou, G. Toumaniantz, B. Rozec, M. Erfanian, S. Erbibou, S. Menoret, I. Anegon, 

J.N. Trochu, C. Gauthier (Nantes, FR) 


relation between nt-proBnP plasma level changes and early re-hospitalization in 

patients with acute or decompensated heart failure P519 

F. A. Gabrielli, M. Savino, R. Natali, E. De Marco, G. Bencardino, G. Comerci, 

B. Garramone, M. Lotrionte, A. Sonaglioni, F. Loperfido (Rome, IT) 

Defining cut-offs in natriuretic peptide screening: factors for consideration. P520 

C.M. Conlon, I. Dawkins, C. O Loughlin, C. Kelleher, M. Ledwidge, K. Mc Donald 

(Dublin, IE) 

BnP is markedly elevated in early stage of decompensating aortic stenosis P521 

A. Gackowski, E. Konduracka, A. Chrustowicz, J. Sadowski, J. Nessler, W. Piwowarska 

(Krakow, PL) 

69 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



B-type natriuretic peptide attenuation of monocyte chemotaxis suggests potential 

beneficial role in diastolic heart failure P522 

N. Glezeva, P. Collier, C. Watson, M. Ledwidge, K. Mcdonald, J. Baugh (Dublin, IE) 


analysis of duration of ea component of reflected high intensity motion signals in 

detection of mild diastolic dysfunction P523 

A. Kastanayan, N. Nelassov, S. Zatonsky, M. Nagaplev, O. Eroshenko, J. Biswas, F. Charaf, 

M. Morgunov (Rostov-on-Don, RU) 

e/vp ratio in hypertensive patients with acute myocardial infarction P524 

D. Toader, R. Radu, M. Popescu, R. Musetescu, D.-D. Ionescu (Craiova, RO) 

Cardiac dysfunction after continuous right ventricular apical pacing in patients with 

bradycardia. P525 

T. Yamada (Osaka, JP) 

tissue e velocity is diastolic parameters correlated with PWV at rest or pre-load 

augmention by leg elevation P526 

S.J. Rhee, S.J. Kim, C.O. Choi, J.J. Choi, K.H. Yun, N.J. Yoo, N.H. Kim, S.K. Oh, J.W. Jeong, 

H.U. Song (Iksan, KR) 

age-adjusted algorithm to diagnosis and grading of diastolic dysfunction in adults: a 

systematic review. P527 

L.C. Danzmann, M.R.N. Pontes, L.H. Canani (Porto Alegre, BR) 

lateral, medial, average or maximal tissue doppler velocities for the estimation of left 

ventricular filling pressure in patients with intermediate e/ea? P528 

C. Mornos, L. Petrescu, R. Dan, A. Ionac, D. Cozma, S. Pescariu (Timisoara, RO) 

assessment of ventricular dyssynchrony in patients with heart failure: comparison 

among triplane tissue Doppler echocardiography, speckle tracking imaging and 

radionuclide angiocardiography P529 

A. Vitarelli, P. Franciosa, B.L. Nguyien, G. De Curtis, V. Padella, D. Battaglia, O. Dettori, 

L. Capotosto, M. Cortes Morichetti, S. Rosanio (Rome, IT; Paris, FR; Galveston, US) 

evaluation of diastolic function: comparing transesophageal with transthoracic 

echocardiography P530 

P. Amador, L. Mendes, I. Silvestre, C. Miranda, S. Goncalves, T. Pestana, M.J. Lopes, 

L. Bernardino, L. Soares (Setubal, PT) 


left ventricular systolic dysfunction in myocarditis: relation with cardiac magnetic 

resonance imaging findings P531 

S. M. Oliveira, T. Pinho, A.J. Madureira, I. Ramos, M.J. Maciel (Porto, PT) 

the cardiac function improvement with carvedilol in heart failure patients is 

associated with left ventricular contraction ressynchronization P532 

M.V. Simoes, F. Marques, F. Caligaris, B.C. Maciel (Ribeirao Preto, BR) 

Prognostic value of myocardial fibrosis in nonischaemic dilated cardiomyopathy 

patients with no or mild symptoms of heart failure P533 

A. Barison, P.G. Masci, G.D. Aquaro, A. Pingitore, G. Vergaro, M. Fontana, A. Valleggi, 

C. Passino, M. Lombardi, M. Emdin (Pisa, IT) 

70




Similar patterns of exercise capacity, autonomic dysfunction and inflammation in 

patients with chronic heart failure and pancreatic cancer P534 

T. Kung, C. Misgeld, C. Heinz, Y. Mori, W. Doehner, S.D. Anker, M. Rauchhaus, 

S. Von Haehling (Berlin and Rostock, DE) 


the cardiorenal connection in acute heart failure: two organs, one syndrome... 

Preliminary results of riCa (acute heart failure registry) P535 

B. Rodrigues, L.F. Santos, E. Correia, R. Faria, P. Gama, P. Ferreira, C. Nascimento, 

L. Nunes, J. Pipa, O. Santos (Viseu, PT) 

is it possible to predict the development of cardiorenal syndrome in heart failure 

patients? P536 

E. Azenha Balhau Jorge, R. Baptista, F. Saraiva, H. Martins, P. Mendes, C. Lourenco, 

S. Costa, P. Monteiro, F. Franco, L.A. Providencia (Coimbra, PT) 

renal function in heart failure: serum creatinine, egfr or cystatin C? P537 

R. Jarai, M. Djurkovic, D. Cilesiz, J. Cup, I. Kozanli, M. Schwarz, G. Jakl, K. Huber 

(Vienna, AT) 


interleukin-18 (il-18), endothline-1 and aldosterone induce smooth muscle senescence 

via rho/rho-kinase- and PPar-dependent pathways P538 

T. Akagami, M. Ohyanagi, T. Sakoda, T. Naka, T. Doi (Nishinomiya, JP) 

Co-morbidities (inc COPD, anaemia, cachexia) 

Prognosis of heart failure patients: does anemia matters? P539 



Chronic obstructive pulmonary disease in heart failure: prevalence and therapeutic 

implications P540 

F. Cecaro, A. Fucili, E. Faragasso, S. Biscaglia, A. Ferri, A. Potena, L.M. Fabbri, P. Boschetto, 

C. Ceconi, F. Ferrari (Ferrara and Modena, IT) 

Prevalence and influence of non-cardiac complications of heart failure on the duration 

of hospitalization P541 

C.L. Andrei, V.P. Chioncel, D.E. Mincu, C.J. Sinescu, O. Dina, M. Dasoveanu 


Chronic heart failure in patients hospitalized for chronic obstructive pulmonary 

disease: prevalence, treatment and mortality P542 

I. Sarc, T. Jeric, K. Ziherl, S. Suskovic, M. Kosnik, W. Doehner, S. Von Haehling, S.D. Anker, 

M. Lainscak (Golnik, SI; Berlin, DE) 

Complex sleep apnoea in congestive heart failure P543 

T. Bitter, N. Westerheide, C. Prinz, C. Langer, D. Horstkotte, O. Oldenburg 

(Bad Oeynhausen and Bielefeld, DE) 

71 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



Xanthine oxidase inhibition improves cardiac function and reduces wasting in 

experimental cancer cachexia P544 

A. Tschirner, K. Hartman, S. Palus, R. Von Harsdorf, S.D. Anker, W. Doehner, J. Springer 

(Berlin, DE; Toronto, CA) 


High adiponectin levels are associated with reduced muscle mass and impaired 

function in patients with chronic heart failure P545 

A. M. Van Berendoncks, P. Beckers, V. Y. Hoymans, N. Possemiers, C. J. Vrints, J. Gielen, 

V. M. Conraads (Antwerp, BE) 

monocyte chemoattractant protein-1: a dichotomous role in cardiac remodelling 

following acute myocardial infarction in man? P546 

R. A. P. Weir, C.A. Murphy, C.J. Petrie, S. Clements, T. Steedman, L.L. Ng, I.B. Squire, 

H.J. Dargie, J.J.V. Mcmurray (Glasgow and Leicester, GB) 

myocardial infarction activates the expression of cardiometabolic biomarkers in the 

heart: study in a swine model. P547 

C. Caselli, O. Melaiu, T. Prescimone, M. Cabiati, M. Campan, V. Lionetti, S. Del Ry, 

D. Giannessi (Pisa, IT) 

PPar agonists attenuated leptin induces endothelin-1-rho/rho-kinase-interleukin -18 

pathway in cardiomyocytes P548 

T. Doi, T. Sakoda, T. Akagami, T. Naka, T. Tsujino, T. Masuyama, M. Ohyanagi 

(Nishinomiya, JP) 

Cardiotrophin-1 is a determinant of arterial stiffness and thickness in rodents P549 

N. Lopez, L. Calvier, M.A. Fortuno, C. Labat, N. Sloboda, G. Simon, J. Diez, F. Zannad, 

P. Lacolley, P. Rossignol (Vandoeuvre-les-Nancy and Domartin-Les-Toul, FR; Pamplona, ES) 


Bone marrow cell transplantation in patients after acute myocardial infarction and left 

ventricular dysfunction: long term effects on heart function and remodeling P550 

A. Malagoli, M.F. Piepoli, C. Armentano, D. Vallisa, M.C. Arbasi, A. Rossi, L. Cavanna, 

G.Q. Villani (Piacenza, IT) 

thymosin beta 4 protects cardiomyocytes from the hypoxic injury P551 

M. C. Cho, E.J. Choi, J.W. Bae, D.J. Choi, J.J. Kim, E.S. Jeon, K.H. Ryu (Cheongju and 

Seoul, KR) 


Hypotensive effects of positive airway pressure ventilation in heart failure patients 

with sleep-disordered breathing P552 

O. Oldenburg, T. Bitter, D. Horstkotte (Bad Oeynhausen, DE) 


Clinical and neurohormonal correlates of serum prolactin levels in chronic heart failure 

patients with depressive symptoms P553 

J. T. Parissis, D. Farmakis, M. Nikolaou, K. Fountoulaki, D. Karatzas, V. Bistola, 

K. Venetsanou, G. Filippatos, M. Anastasiou-Nana, D. Kremastinos (Athens, GR) 

72



Cardiac effects of neuronostatin, a novel peptide encoded by somatostatin gene P554 

L. Hekkala, A. Natynki, J. Piuhola, A. Perjes, H. Ruskoaho, I. Szokodi, R. Kerkela (Oulu, FI; 

Pecs, HU) 


the risk factors for isolated diastolic heart failure among patients with heart failure P555 

B. Ivanovic, M.T. Tadic, D.S. Simic, S.M. Matic (Belgrade, RS) 

aortic valve replacement and depressed left ventricular function: left ventricular 

function recovery and physical activity of patients P556 

A. Zhadan, V. Tseluyko, O. Romanenko (Kharkiv, UA) 

failure of left ventricular remodeling despite progressive myocardial injury P557 

I. P. Clements, D.O. Hodge, C.G. Scott (Rochester, US) 

Development of left ventricular systolic function of premature infant. By use of new 

echocardiographic tissue doppler imaging of strain and strain rate. P558 

Y. Kikuchi (Tochigi, JP) 

left ventricular diastolic dysfunction (lVDD) in impaired glucose intolerance (igt) patients. P559 

P. Karmakar, M. Bhuiyan (Dhaka, BD) 

Beta-blockers improve left ventricular filling pressure in patients with heart failure and 

systolic dysfunction P560 

H. Haouala, O. Salah, D. Lahidheb, N. Hajlaoui, I. Saadi, A. Haggui, T.H. Filali, 

M. Ghommidh, N. Barakett, W. Fehri (Tunis, TN) 

Prognostic effect of partial and complete left ventricular reverse remodeling in chronic 

heart failure with ischemic and nonischemic etiology P561 

B. Szabo, N. Nyolczas, M. Dekany, B. Ancsin, T. Borsanyi, E. Marosi, R.G. Kiss 

(Budapest, HU) 

myocardial stiffness increased in heart failure regardless of left ventricular ejection fraction P562 

M.S. Shin, B.R. Kim, W.-J. Chung, W.C. Kang, C.I. Moon, T.H. Ahn, I.S. Choi (Incheon and 

Seoul, KR) 

Diastolic dysfunction, but not ejection fraction, is a major predictor of exercise 

capacity after myocardial infarction P563 

R. Fontes-Carvalho, D. Caeiro, N. Ferreira, O. Sousa, G. Silva, F. Sampaio, N. Bettencourt, 

M. Teixeira, L. Simoes, V. Gama (Vila Nova de Gaia, PT) 


Has the hdl- cholesterol a cardiovascular protector effect in patients with chronic 

heart failure? P564 

L.C. Danzmann, C.B.R. Dreschler, D.K. Ferreira, A. Faistauer, A.V. Azevedo, D.A. Cardoso, 

M.A.R. Torres, I. Kohler, S. Bordignon, L.C. Bodanese (Porto Alegre, BR) 

Hyperuricemia in heart failure P565 

E.-R. Mustafa, O. Istratoaie (Craiova, RO) 

the omega-3 index in heart failure: associations with clinical data and comorbidities P566 

D. Berliner, S. Mattern, M. Rost, N. Deubner, S. Brenner, R. Jahns, G. Ertl, 

C.E. Angermann, C. Von Schacky, S. Stoerk (Würzburg and Munich, DE) 

73 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 




is there need for preprocedural echocardiography in prediction of in-hospital heart 

failure in patients successfully treated with primary percutaneous coronary 

intervention? P567 

I. Nedeljkovic, M. Ostojic, B. Vujisic-Tesic, M. Petrovic, M. Boricic-Kostic, D. Trifunovic, 

V. Giga, M. Banovic, M. Nedeljkovic, B. Beleslin (Belgrade, RS) 

a role for Hsp70 in ischemic heart failure? P568 

I. Portig, F. Kliebe, C. Kliebe, B. Maisch (Marburg, DE) 


Beta adrenergic receptors polymorphisms: susceptibility, response therapy and 

prognosis in chronic heart failure. P569 

S. Bernardez-Pereira, S. Chermont, B. Nascimento, F. Pena, O. Tardin, T. Alves, C. Giro, 

M. Quintao, G.S. Ribeiro, E.T. Mesquita (Niterói, Rj, BR) 

endothelial system polymorphisms and ventricular remodeling in heart failure P570 

M.J. Ruiz Olgado, R. Gonzalez, C. Martin Luengo, I. Santos, M. Clemente, M. Gallego, 

T. Gonzalez (Salamanca, ES) 

Heat shock remodeling of endocardial and epicardial localization for nucleophosmin, 

thr34 - phosphorylated BirC5 and htert in spontaneously hypertensive rats a 

possible synergy ? P571 

V. Salpeas, I. Rizos, A. Rigopoulos, E. Sakadakis, A. Papathanasiou, A. Kalogeropoulos, 

E. Patsouris, M.I. Anastasiou-Nana (Athens, GR) 


Central Co2-receptor sensitivity in patients with chronic heart failure and nocturnal 

Cheyne-Stokes respiration is dependent of left ventricular filling pressures P572 

O. Oldenburg, T. Bitter, C. Piper, D. Horstkotte (Bad Oeynhausen, DE) 

thermometabolic index is a new reliable determinant of cardiopulmonary capacity in 

health and chronic heart failure P573 

R. Skalik, W. Wozniak, L. Borodulin - Nadzieja (Wroclaw, PL) 


Comparison of endothelial dysfunction in patients with chronic heart failure and 

acute ischemic stroke P574 

N. Scherbakov, T. Szabo, T. Kung, G. Turhan, S. Von Haehling, S.D. Anker, W. Doehner 

(Berlin, DE) 


the value of innovative iCt guided disease management combined with 

telemonitoring in outpatient clinics for chronic heart failure patients (in toUCH trial) P575 

A. E. De Vries, I. H. Kraai, R. M. Otten, R. M. De Jong, R. B. Van Dijk, 

D. J. Van Veldhuisen, T. Jaarsma, H. L. Hillege (Groningen, NL; Norrkoping, SE) 

telemedicine in clinical practice (motiva-Philips): feasibility, acceptance rate, 

confidence, and satisfaction: the Carme study (Catalan remote management 

evaluation) P576 

M. Domingo, J. Lupon, B. Gonzalez, A. Ramos, R. Lopez, E. Crespo, A. Urrutia, 

J. Valenzuela, S. Altimir, T. Pascual (Badalona and Barcelona, ES) 

74




epidemiology Study of Heart failure in Chinese Population in Barcelona P577 

O. Londono Sanchez, S. Pacreu, L.U.I.S. Paredes (Barcelona, ES) 

Short term prognosis of patients hospitalised with acute myocardial infarction and/or 

acute heart failure (the Brno registry) P578 

J. Spinar, O. Ludka, M. Sepsi, J. Parenica, R. Miklik, L. Dusek, D. Tomcikova (Brno, CZ) 

Chronic heart failure treatment - major factor of declining coronary heart disease 

mortality. P579 

J. Bruthans, R. Cifkova, V. Lanska, M. Flaherty, J. Critchley, S. Capewell (Prague, CZ; 

Liverpool and Newcastle, GB) 

evolution of quality of life assessed with the minnesota living with heart failure 

questionnaire during follow-up in a multidisciplinary heart failure unit P580 

G. Bickham, J. Lupon, B. Gonzalez, L. Cano, R. Cabanes, A. Urrutia, C. Diez, R. Coll, 

T. Pascual, S. Altimir (Badalona, ES) 

gender modifies the effect of heart failure on survival in patients with CoPD P581 

L. C. M. Bertens, Y. Van Mourik, G. Guder, A.W. Hoes, F.H. Rutten (Utrecht, NL) 


improvement of physical performance and quality of life in patients with heart failure P582 

J.P. Poles, H.B. Hizar, P.L. Lebar (Topolsica, SI) 

Prediction of ongoing myocardial damage by neurohormonal evaluation and non 

invasive estimation of frank-Starling curve during effort stress in systolic heart failure. P583 

L. E. Pastormerlo, C. Passino, A. Giannoni, C. Prontera, A. Agazio, C. Ciurli, C. Mammini, 

M. Fontana, A. Gabutti, M. Emdin (Pisa, IT) 

Polymorphism asp298glu in the six-minute walk test in patients with heart failure with 

lower left ventricular ejection fraction P584 

S. Chermont, M.M.P. Quintao, S. Lindemberg, S. Bernardez, B. Mota, L. Mello, 

M.W.M. Velloso, G.S. Ribeiro, W.A. Martins, E.T. Mesquita (Niteroi and Teresopolis, BR) 

exercise training normalizes the ventilatory response to hypoxia in patients with 


G. Guimaraes, J.F.C. Belli, V.O. Carvalho, S.A. Ferreira, V.S. Issa, L.G. Cruz, G.E. Souza, 

E.G. Ciolac, E.A. Bocchi, J.A. Neder (Sao Paulo, BR) 

left ventricular stiffness is associated with the degree of cardiac exercise capacity in 

patients with heart failure despite normal ejection fraction P586 

D. Sinning, M. Kasner, W. Westermann, K. Schulze, H.P. Schultheiss, C. Tschoepe 

(Berlin, DE) 

Diabetes is a predictor of effort tolerance and ventilatory efficiency in patients with 

moderate systolic dysfunction on beta-blocker therapy P587 

L. E. Pastormerlo, M. Emdin, A. Giannoni, R. Poletti, M. Fontana, C. Prontera, C. Passino 

(Pisa, IT) 

mens sana in corpore sano: psychological factors do really influence functional status P588 

S. M. Oliveira, A. Rocha, A.S. Correia, M. Paiva, A. Sousa, A.M. Lebreiro, A.I. Silva, 

V. Araujo, F. Parada-Pereira, M.J. Maciel (Porto, PT) 

75 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 



Swimming reduces the severity of atherosclerosis in apolipoprotein e-deficient mice by 

antioxidant effects P589 

C. Kishimoto, T. Okabe, K. Shimada, M. Hattori, T. Murayama, M. Yokode, T. Kita 

(Kyoto, JP) 

Nursing 

Heart failure patient: teaching strategies P590 

A.C. Cavalcanti, C.S. Arruda, G.C. Queluci, D.M.S. Correia, E.T. Mesquita (Niteroi, BR) 

Brain natriuretic Peptide nurse determined in a heart failure clinics: a practical and 

important tool to determine death from progressive heart failure but not sudden death P591 

F.D.C. Cruz, V.S.I. Issa, F.B. Bacal, P.V. Vieira, E.B. Bocchi (Sao Paulo, BR) 

a closer look at a hospitalization for heart failure P592 

P. A. Ninaber, M. Rolfes- Peters (Arnhem, NL) 

Use of telemedicine (motiva-Philips) in an heart failure unit: changes in patient’s 

behaviour and impact on quality of life: the Carme study (Catalan remote 

management evaluation) P593 

B. Gonzalez, M. Domingo, J. Lupon, R. Lopez, A. Ramos, E. Crespo, A. Urrutia, 

J. Valenzuela, L. Cano, C. Diez (Badalona and Barcelona, ES) 


assessment of the Quality of life (Sf36) after optimized Cardiovascular therapy in 

Chagas Cardiomyopathy P594 

F.E.R.N.A.N.D.O. Botoni, P.P.W. Poole-Wilson, A.L.P. Ribeiro, V.C. Guedes, B.M.R. Oliveira, 

M.M. Teixeira, A.L. Teixeira Junior, A.M. Reis, A.L.A. Silva, M.O.C. Rocha (Belo Horizonte, 

BR; London, GB) 

a heart failure disease management programme with both a hospital based and a 

home based element provides optimal care for heart failure patients P595 

M. Ryder, N.F. Murphy, M. Ledwidge, K. Mcdonald (Dublin, IE) 

implantable cardioverter defibrillator in the early phase of acute myocardial infarction P596 

C. Bonanno, M. Morato, M. Paccanaro, R. Ometto, A. Fontanelli (Vicenza, IT) 

Heart failure hospital management among very elderly patients. the national 

cardiovascular disease prevention and treatment program, PolKarD 2005 P597 

B. Wizner, M. Fedyk-Lukasik, P. Matusik, J.S. Dubiel, T. Zdrojewski, G. Opolski, M. Dubiel, 

M. Stompor, M. Czech, T. Grodzicki (Krakow, Gdansk and Warsaw, PL) 


the impact of anxiety and depression symptoms, perception of life style and health 

perception in the quality of life in heart failure hospitalized patients P598 

C. Figueroa, S. Rincon, L. Alcocer, B. Ramos, V. Flores (Mexico City, MX) 

Other 

Prevalence of acute heart failure after myocardial infarction in the community P599 

G. Gheorghe, I.T. Nanea, A. Cristea (Bucharest, RO) 

76



low circulating n-3 polyunsaturated fatty acid and high monosaturated n-7 fatty acid 

are associated with disease severity and predict mortality in heart failure P600 

E. H. Oie, T. Ueland, C. P. Dahl, P. Bohov, C. Berge, A. Yndestad, L. Gullestad, P. Aukrust, 

R. K. Berge (Oslo and Bergen, NO) 

Hypoxia-recovery of cardiovascular function in the zebrafish embryo P601 

K. M. Hamilton-Smith, A. Kotwica, C.S. Tucker, A.G. Japp, D.E. Newby, M.A. Denvir 

(Edinburgh, GB) 

non-St-elevation myocardial infarction with preserved left ventricular systolic function P602 

H. Dores, S. Leal, I. Rosario, L. Bronze, M. J. Correia, J. Monge, I. Arroja, C. Fonseca, 

A. Aleixo, A. Silva (Lisbon, PT) 

Uric acid and myocardial injury in stable non-ischemic heart failure P603 

R. Wojnicz, B. Spinczyk, B. Szygula-Jurkiewicz, K. Wilczek, J. Nowak, K. Helewski, M. 

Ploch, M. Zembala, L. Polonski (Zabrze, PL) 

assessment of latent coronary artery disease in psychosomatic disorders P604 

G. B. Ramteke, P. Joshi, V.S. Pal, U. Sardesai, P. Rastogi, A. Bajpai (Indore, IN) 

77 

SUnDaY 

PoSterS

SUnDaY 

PoSterS 

noteS 

78

monDaY

monDaY 

monDaY 31 maY 2010 - morning 


Devices 


Chairperson: J.G.F. Cleland (Kingston Upon Hull, GB) 





presented. 


session. 

Case presentations and panel discussions 605 

W. T. Abraham (Columbus, US), K. Dickstein (Stavanger, NO), 

M. Gasparini (Rozzano, IT), R. Lipicky (North Potomac, US) 


Biomarkers in heart failure: what is their value compared to clinical 

assessments and routine laboratory values? 

Chairperson(s): L. Kober (Gentofte, DK); W.F. Peacock (Cleveland, US) 



- To discuss clinical usefulness of routine biomarker assessment for heart failure management. 

08:30 natriuretic peptides for acute and chronic heart failure 606 

A. Maisel (Solana Beach, US) 

08:45 other peptides instead of or in addition to nP for acute and chronic heart failure 607 


09:00 Prognostic scores 608 

T. A. McDonagh (London, GB) 

09:15 the alternative: assessing heart failure patients from cardiac biopsies 609 

H. P. Schultheiss (Berlin, DE) 

09:30 Panel 610 


80


08:30 - 10:00 Special Session Munich 

New solutions for acute and chronic heart failure: update from industry 

Chairperson(s): J.J.V. McMurray (Glasgow, GB); S.D. Anker (Berlin, DE) 


- Industry representatives will present highlights of their current programme of research in heart 

failure and their views about the field more generally . They will inform the audience about 

projects in the pipeline and phase II/III trials. 

- Each presentation will be concluded by panel discussion. Questions from the audience are 

encouraged. 

novartis heart failure development portfolio: from relaxin to angiotensin 

receptor neprilysin inhibition and beyond 611 

A. Nathwani (Basel, CH) 

Bg medicine: novel markers of cardiovascular risk prediction and patient 

segmentation 612 

P. Gardiner (Groton, US) 

relypsa: innovative therapeutic in heart failure and CKD to enable use of 

current life-saving drugs 613 

G. Klaerner (Santa Clara, US) 

Update from Cytokinetics 614 

A. Wolff (South San Francisco, US) 

Several more companies have been contacted 615 

Panel 618 

G.S. Filippatos (Athens, GR), G.M.C. Rosano (Roma, IT), A.M. Shah (London, GB) 


Heart failure and diabetes 

Chairperson(s): M.R. Cowie (London, GB); U.G. Dahlstrom (Linkoping, SE) 

Diabetes 


- Participant should be able to identify the special needs of patients with heart failure and diabetes. 

08:30 acute heart failure in diabetes mellitus 619 

J. T. Parissis (Athens, GR) 

08:48 Silent ischemia in diabetic patients with heart failure 620 

E. Van Belle (Lille, FR) 

09:06 Diabetic cardiomyopathy: the disease searching for its identity 621 

W. J. Paulus (Amsterdam, NL) 

09:24 Diabetes and inflammation: bad getting worse?! 622 

D. Mann (St. Louis, US) 

09:42 aldosterone blockade in patients with heart failure and diabetes mellitus 623 

B. Pitt (Ann Arbor, US) 

81 

monDaY

monDaY 



Heart failure management 2010 and beyond - what are the key issues for nursing? 

Chairperson(s): M.H.L. Van Der Wal (Groningen, NL); N. Albert (Cleveland, US) 



- Participants should get an update on the latest evidence on care issues related to heart failure 

management including strategies for follow-up, patient education, self-care and palliation. 

08:30 Palliative care 624 

P. Strachan (Hamilton, CA) 

08:48 Self-care and care from carers 625 

A. Stromberg (Linkoping, SE) 

09:06 Co-morbidities in heart failure: what nurses need to know 626 


09:24 Heart failure management programmes 627 

J.-N. Trochu (Nantes, FR) 

09:42 the heart failure nurse specialist/practitioner 628 

M. Ryder (Dunlaoghaire, IE) 


The sarcoplasmic calcium pump as a therapeutic target in heart failure 

Chairperson(s): S.E. Harding (London, GB); D.L. Brutsaert (Kontich, BE) 



- Participants should understand the physiological and pathophysiological role of the muscle 

SERCA pump 

- They will also understand potential therapeutic options related to SERCA 

08:30 lessons from human cardiac myocytes 629 

S. E. Harding (London, GB) 

08:48 transgenic manipulation of SerCa levels 630 

O. M. Sejersted (Oslo, NO) 

09:06 SerCa and arrhythmias 631 

A. Zaza (Milan, IT) 

09:24 expression of skeletal muscle SerCa 632 

G. Hasenfuss (Goettingen, DE) 

09:42 Boosting SerCa function by gene therapy 633 

R. J. Hajjar (New York, US) 

82

monD aY 31 maY 2010 - morning 

08:30 - 10:00 YIA Abstracts Leipzig 

The Helmut Drexler Young Investigator Award for Basic Science 

Chairperson(s): R. Fischmeister (Chatenay-Malabry, FR); J. Bauersachs (Wurzburg, DE) 

Judge(s): T. Force (Philadelphia, US); J. Bakkers (Utrecht, NL); S.A. Cook 

(London, GB) 

08:30 Hypophosphorylation of the stiff n2B titin isoform raises cardiomyocyte 

resting tension in failing human myocardium 634 

A. Borbely, I. Pires, N. Hamdani, L. Van Heerebeek, A.F. Leite-Moreira, I. Edes, 

Z. Papp, J. Van Der Velden, G.J.M. Stienen, W.J. Paulus (Debrecen, HU; Porto, PT; 

Amsterdam, NL) 

08:45 microrna-199 plays a key role in cardiac muscle growth and atrophy 635 

A. Haghikia, M. Scherr, L. Venturini, M. Mayr, E. Missol-Kolka, A. Haghikia, 

S.D. Anker, J. Springer, G. Condorelli, D. Hilfiker-Kleiner (Hannover, Bochum and 

Berlin, DE; London, GB; Milan, IT) 

09:00 myocardial phosphodiesterase 5 is increased in patients with severe aortic 

stenosis and contributes to left ventricular dysfunction in pressure-overloaded mice 636 

S. Vandenwijngaert, P. Pokreisz, M. Pellens, H. Gillijns, H. Hermans, T. Dresselaers, 

P. Herijgers, J. D’hooge, K.D. Bloch, S. Janssens (Leuven, BE; Boston, US) 

09:15 Phosphorylation of syndecan-4 regulates activation of the pro-hypertrophic 

calcineurin-nfat signalling pathway in the myocardium 637 

I. G. Lunde, A. V. Finsen, H. O. Jarstadmarken, I. Sjaastad, A. Hasic, H. Kvaloy, 

T. Tonnesen, S. A. Wilcox-Adelman, C. R. Carlson, G. Christensen (Oslo, NO; 

Watertown, Massachusetts, US) 

09:30 modelling cardiac diseases with engineered heart tissue 638 

A. Stoehr, A. Eder, A. Hansen, M.N. Hirt, S. Schlossarek, L. Carrier, T. 

Eschenhagen (Hamburg, DE) 

09:45 Cardiotoxicity of bortezomib - the anticancer therapeutic agent 639 

J. Bil, M. Maczewski, U. Mackiewicz, M. Kujawa, A. Ratajska, M. Wieckowski, 

G. Wilczynski, D. Nowis, J. Golab (Warsaw, PL) 

HFA General Assembly 

10:00 - 11:00 

Room Leipzig 

83 

monDaY

monDaY 



Hypertension 


Chairperson(s): F. Zannad (Nancy, FR); F. Follath (Zurich, CH) 





presented. 


session. 

Case presentation. 640 


Hypertension and acute heart failure in iCU 641 

A. Mebazaa (Paris, FR) 

Panel 642 

I.S. Anand (Edina, US), V. Mareev (Moscow, RU), B. Pitt (Ann Arbor, US), 

V. Regitz-Zagrosek (Berlin, DE) 


New biomarkers in heart failure: ready for prime time? 

Chairperson(s): D. Logeart (Paris, FR); A. Maisel (Solana Beach, US) 



- To present what novel biomarkers can offer for the management of heart failure. 

11:00 mid regional peptides 643 

E. A. Jankowska (Wroclaw, PL) 

11:18 markers of renal dysfunction 644 

H. Hillege (Groningen, NL) 

11:36 inflammatory - stress markers (gDf-15, St-2) 645 

K. C. Wollert (Hannover, DE) 

11:54 markers of cell death 646 

W.F. Peacock (Cleveland, US) 

12:12 markers of infection 647 

B. Mueller (Aarau, CH) 

84



The adenosine antagonists story of targeting the kidney in heart failure: status 

May 2010 

Chairperson(s): G. Jondeau (Paris, FR); P. Ponikowski (Wroclaw, PL) 



- To overview problems in the management of patients with heart failure and impaired renal function. 

- To update the audience with the recent clinical experience with adenosine antagonists. 

11:00 Studies before ProteCt 648 

S. Gottlieb (Baltimore, US) 

11:15 the ProteCt study: update on results 649 


11:30 Seizure: just an inconvenience?! 650 

R. Lipicky (North Potomac, US) 

11:45 Comparing different adenosine antagonists 651 

U. Laufs (Homburg, DE) 

12:00 Panel discussion 652 

M. Komajda (Paris, FR), B.M. Massie (San Francisco, US), S. Solomon (Boston, US) 


Heart failure and Diabetes: a challenge for the 21st century 

Chairperson(s): E. Van Belle (Lille, FR); J. Nanas (Athens, GR) 

Diabetes 


- Specificities of the management of diabetes in patients with heart failure and the management 

of heart failure in diabetic patients. 

- Diabetes-related changes in cardiac structure and function leading to heart failure. 

- Prevention strategies for heart failure in diabetic patients. 

- Recommendations for the use of thiazolidinediones in patients with diabetes mellitus and heart failure. 

11:00 epidemiology: heart failure in diabetic populations and diabetes in heart 

failure populations 653 


11:18 What is the cause of diabetes in heart failure? 654 

F. Ruschitzka (Zurich, CH) 

11:36 managing body weight in diabetic patients with and without heart failure 655 

W. Doehner (Berlin, DE) 

11:54 is treatment of heart failure different in diabetic patients? 656 

M. Petrie (Glasgow, GB) 

12:12 Heart failure and thiazolidinediones: lessons from clinical trials and registries 657 


85 

monDaY

monDaY 



What do we need to know about the indication for surgery in heart failure patient? 

Chairperson(s): A. Pitsis (Thessaloniki, GR); F. Oliva (Milan, IT) 



- Be updated on latest developments in surgical techniques for heart failure. 

- Understand the current place of cardiac transplantation in the overall management of heart 

failure. 

11:00 indications for CaBg - Coronary artery Bypass grafting 658 

M.R. Cowie (London, GB) 

11:18 assessing the indications for mitral valve surgery 659 

B. Maisch (Marburg, DE) 

11:36 reshaping the ventricle: what is new? 660 


11:54 minimally invasive surgery: what is new? 661 

F. W. Mohr (Leipzig, DE) 

12:12 Cardiac transplantation in 2010 662 

F. Oliva (Milan, IT) 


New drugs for heart failure: update 2010 

Chairperson(s): K. Dickstein (Stavanger, NO); G.S. Filippatos (Athens, GR) 



This session will review 5 novel pharmacological approaches that have shown promise in the 

management of heart failure. 

The faculty will discuss the mechanisms of action, review the currently available data and present 

an overview of currently ongoing clinical research with these agents. 

11:00 Vasopressin antagonists 663 


11:18 Calcium modulators 664 

R. J. Hajjar (New York, US) 

11:36 Cardiac myosin activators 665 


11:54 guanylate-cyclase activators 666 

M. Gheorghiade (Chicago, US) 

12:12 arni – angiotensin receptor blocker neprilysin inhibitor 667 


86

monD aY 31 maY 2010 - morning 

11:00 - 12:30 Oral Abstracts Leipzig 

Judges choice: Basic Science 

oral abstract session 

Chairperson(s): T. Eschenhagen (Hamburg, DE); S. Janssens (Leuven, BE) 

11:00 Carabin is a new inhibitor of prohypertrophic signalling pathways in cardiac 

myocytes 668 

M. Breckler, M. Berthouze, A. Varin, A. Lucas, F. Lezoualc’h (Chatenay-Malabry, FR) 

11:18 accerelated transition of pressure overload-induced cardiac hypertrophy 

to heart failure in mice with a human ryanodine receptor mutation for 

catecholaminergic polymorphic ventricular tachycardia 669 

S. Sedej, A. Schmidt, S. Walther, E. Bisping, F.R. Heinzel, S.G. Priori, 

J. Kockskamper, B. Pieske (Graz, AT; Pavia, IT) 

11:36 metformin induces adiponectin expression in Hl-1 cardiomyocytes. Protective 

effect on oxidative stress 670 

M.C. Asensio-Lopez, A. Lax, D. Saura, M. Valdes, D.A. Pascual-Figal, 

J. Sanchez-Mas (Murcia, ES) 

11:54 novel renal Specific Chimeric natriuretic Peptide with renal enhancing 

actions in the absence of Hypotension. 671 

H. Chen, J. Burnett (Rochester Mn, US) 

12:12 fibroblast-activation-Protein alpha and wound healing after myocardial 

infarction 672 

J. Tillmanns, D. Hoffmann, D. Fraccarollo, P. Galuppo, G. Ertl, J. Bauersachs 

(Wurzburg, DE) 

Award Ceremony 

14:15 - 14:30 

Room Berlin 

87 

monDaY

monDaY 

monDaY 31 maY 2010 - afternoon 

12:45 - 13:30 Mini-Satellite Session Hannover 

Which patients should be considered for cardiac resynchronization therapy? 

mini-Satellite Symposium organised by BiotroniK 

Chairperson(s): K. Dickstein (Stavanger, NO); J.G.F. Cleland (Kingston Upon Hull, GB) 



12:50 Patients with mild symptoms of heart failure? 674 

W.T. Abraham (Columbus, US) 

13:05 Patients with narrow QrS? 675 

F. Ruschitzka (Zurich, CH) 

13:20 Summary. 676 

J.G.F. Cleland (Kingston Upon Hull, GB) 


Galectin-3: a novel biomarker of fibrosis in heart failure 

mini-Satellite Symposium organised by Bg medicine, inc 

Chairperson(s): D.J. van Veldhuisen (Groningen, NL); M. Boehm (Homburg/Saar, DE) 

12:45 Welcome and introduction. 677 


12:55 galectin-3 biology: remodelling and progression in heart failure. 678 


13:05 galectin-3 in heart failure: clinical evidence. 679 

L. Gullestad (Oslo, NO) 

13:15 role of galectin-3 in the management of heart failure. 680 

D.J. van Veldhuisen (Groningen, NL) 

13:25 Questions and closing remarks. 681 

M. Boehm (Homburg/Saar, DE), D.J. van Veldhuisen (Groningen, NL) 

12:45 - 14:00 Satellite Session Berlin 

Helping patients with chronic heart failure: time to think again? 

Satellite Symposium organised by Vifor Pharma 

Chairperson(s): J.J.V. McMurray (Glasgow, GB); E. Erdmann (Koeln, DE) 



12:50 iron deficiency anaemia: more than just a heart failure risk factor? 683 

P. Van Der Meer (Groningen, NL) 

13:10 living with chronic heart failure: if not longer, then better? 684 


13:30 intravenous iron for symptomatic patients with heart failure: the trial evidence. 685 

S.D. Anker (Berlin, DE) 

13:50 Discussion. 686 

J.J.V. McMurray (Glasgow, GB) 

88



Changing heart failure risk assessment 

Satellite Symposium organised by ge Healthcare 

Chairperson: J.J. Bax (Leiden, NL) 


J.J. Bax (Leiden, NL) 

12:50 Heart failure challenges in 2010. 688 


13:10 Cardiac sympathetic innervation imaging. 689 

I. Carrio (Barcelona, ES) 

13:30 impact of new clinical studies on patient management. 690 


13:55 Conclusion. 691 


12:45 - 14:00 Satellite Session Stuttgart 

The dynamic clinical utility of biomarkers across the spectrum of cardiovascular 

diseases 

Satellite Symposium organised by alere (formerly inverness medical) 

Chairperson(s): M. Komajda (Paris, FR); M.A. Alonso Garcia (Madrid, ES) 

12:45 introduction of the symposium. 692 


12:50 enhanced utilization of natriuretic peptides testing in heart failure throughout 

the clinical spectrum. 693 

A. Cohen-Solal (Paris, FR) 

13:10 the value of a multimarker approach in the diagnosis and prognosis of 

cardiovascular disease. 694 

W.F. Peacock (Cleveland, US) 

13:30 the role of neutrophil gelatinase-associated lipocalin (ngal) as a promising 

biomarker for early detection of acute Kidney injury (aKi) in Cardio-renal 

Syndrome. 695 

C. Ronco (Vicenza, IT) 

13:50 Closure of the symposium. 696 

M.A. Alonso Garcia (Madrid, ES) 

89 

monDaY

monDaY 


14:15 - 15:45 Debate Berlin 

Award Ceremony followed by a Debate Session 

Chairperson(s): S.D. Anker (Berlin, DE); P. Ponikowski (Wroclaw, PL) 

14:15 the Philip Poole-Wilson Young investigator award Presentation. 


14:20 the Helmut Drexler Young investigator award for Basic Science Presentation. 

A. M. Shah (London, GB) 

14:25 Hfa research grant Presentation. 


Does diastolic heart failure exist? 

14:30 Pro. 697 


14:45 Contra. 698 



Lifestyle debate 

15:05 Pro. 699 


15:20 Contra. 700 




Fancy new devices for heart failure 

Chairperson(s): M. Gasparini (Rozzano, IT); J.R. Teerlink (San Francisco, US) 



- Diagnostic devices may improve the management of heart failure patients 

- A lot of data will be collected but using and interpreting these data is complex and timeconsuming 

- Over-treatment as a result of acting early on signals must be avoided 

14:15 What do we need to monitor? Defining the right signals which would prompt 

action. a review of the existing monitoring devices 701 


14:33 new invasive devices to measure congestion and pressures 702 

D. J. van Veldhuisen (Groningen, NL) 

14:51 How to manage all this information: from telemedical centers to artificial 

intelligence 703 


15:09 much simpler: devices to improve medication adherence 704 

M. H. L. Van Der Wal (Groningen, NL) 

15:27 lVaDs 705 

A. Pitsis (Thessaloniki, GR) 

90



HFPEF – all you need to know on Heart Failure with Preserved Ejection Fraction 

Chairperson(s): B.M. Pieske (Graz, AT); M.S. Nieminen (Helsinki, FI) 



- Understand the current state of the art of risk factors for diastolic heart failure and how to 

adequately treat those 

14:15 Setting the stage: an update on diagnosis, epidemiology, and pathophysiolgy 706 

J. R. Gonzalez Juanatey (Santiago De Compostela, ES) 

14:33 is diastolic heart failure always the same? Comparing continents 707 

K. Harada (Tokyo, JP) 

14:51 all just hypertension – how to diagnose and manage hypertensive patients 

with diastolic heart failure 708 

M. Lainscak (Golnik, SI) 

15:09 all just ageing – how to prevent and treat diabetic patients with diastolic 

heart failure 709 

H. Persson (Stockholm, SE) 

15:27 all just diabetes – how to diagnose and manage diabetic patients with 

diastolic heart failure 710 


14:15 - 15:45 Oral Abstracts Cologne 

Judges choice: Clinical Research 

oral abstract session 

Chairperson(s): L. Gullestad (Oslo, NO); J. Comin-Colet (Barcelona, ES) 

14:15 Does response to therapy differ between preserved and reduced lV systolic 

function in heart failure? results from time-CHf 712 

H. P. Brunner-La Rocca, M.T. Maeder, S. Muzzarelli, P. Rickenbacher, M. Gutmann, 

U. Jeker, B. Julius, M. Peter, R. Schindler, M.E. Pfisterer (Maastricht, NL; St. Gallen, 

Basel, Bruderholz, Liestal, Lucerne, Baden and Wolhusen, CH) 

14:33 Pulmonary hypertension predicts the development of heart failure in patients 

with acute myocardial infarction 713 

D. Aronson, D. Mutlak, H. Hammerman, Y. Agmon (Haifa, IL) 

14:51 framingham risk score, b-type natriuretic peptide, c-reactive protein, urinary 

albumin, and glomerular filtration rate: which is the best predictor for onset of 

heart failure in the general population 714 

T. Segawa, M. Nakamura, F. Tanaka, Y. Koeda, K. Sato, S. Makita, T. Onoda, 

K. Itai, K. Sakata, A. Okayama (Morioka, Kamaishi and Tokyo, JP) 

15:09 Coronary artery bypass grafting with concomitant cardiac resynchronization 

therapy in patients with ischemic heart failure: results from a multicenter study 715 

A. Romanov, E. Pokushalov, A. Cherniavskiy, D. Prohorova, K. Goscinska-Bis, 

J. Bis, A. Bochenek, A. Karaskov (Novosibirsk, RU; Katowice, PL) 

91 

monDaY

monDaY 



15:27 atrial fibrillation in heart failure does not increase the risk of death in patients 

without underlying ischemic heart disease 716 

J. Raunsoe, H. Dominguez, M. L. Hansen, O. D. Pedersen, J. Kjaergaard, 

C. Hassager, J. E. Moller, C. Torp-Pedersen, L. Kober (Hellerup, Herlev and 

Copenhagen, DK) 


Pregnancy associated heart disease 

Chairperson(s): I.L. Pina (Cleveland Heights, US); D.S.-F. Yu (Hong Kong, HK) 


14:15 Peripartum cardiomyopathy: definition, presentation and prognosis 717 

K. Sliwa-Hahnle (Cape Town, ZA) 

14:33 new insights into pathophysiology of peripartum cardiomyopathy and 

options for therapy 718 

D. Hilfiker-Kleiner (Hannover, DE) 

14:51 Preeclampsia and pregnancy associated hypertension 719 

V. Regitz-Zagrosek (Berlin, DE) 

15:09 Pregnancy associated heart disease: using biomarkers?! 720 

S. Stork (Wurzburg, DE) 

15:27 Pregnancy associated heart disease: european perspective 721 

G. M. C. Rosano (Roma, IT) 


Embryonic stem cells or iPS: what is the future? 

Chairperson(s): C. Denning (Nottingham, GB); T. Eschenhagen (Hamburg, DE) 


14:15 mass production of cardiac myocytes 722 

C. Denning (Nottingham, GB) 

14:33 eS cell derived vascular cells 723 

Q. Xu (London, GB) 

14:51 Disease modelling with iPS 724 

U. Martin (Hannover, DE) 

15:09 Disease modelling wih adult cardiac stem cells 725 

P. A. F. M. Doevendans (Utrecht, NL) 

15:27 Update 2010 on using stem cells in human cardiovascular medicine 726 

A. M. Zeiher (Frankfurt, DE) 

92



Targeting fibrosis in the heart: the forgotten problem 

Chairperson(s): S.A. Cook (London, GB); F. Zannad (Nancy, FR) 



- Understand what is the extracellualr matrix in the heart. 

- Identify fibrosis as a mecahnism of cardiac remodelling and a target for intervention. 

- Appreciate the role of Micro RNAs in cardiac matrix remodelling. 

14:15 regulation of fibrosis by specific micro rnas 727 

T. Thum (Hannover, DE) 

14:33 mir423-5p as a circulating biomarker for heart failure 728 

E. Creemers (Amsterdam, NL) 

14:51 roS, inflammation and fibrosis 729 

C.E. Murdoch (London, GB) 

15:09 matricellular proteins and fibrosis 730 

S. Heymans (Maastricht, NL) 

15:27 lessons from human studies 731 

J. Diez Martinez (Pamplona, ES) 

93 

monDaY

monDaY 



Late Breaking Trials - Session II 

Chairperson(s): P. Ponikowski (Wroclaw, PL); G.S. Filippatos (Athens, GR) 

16:30 observational study on acute and chronic heart failure 732 


16:45 mUSiC 733 

I.S. Anand (Edina, US) 

17:00 Handheld-BnP-Study 734 

C.E. Angermann (Wurzburg, DE) 

17:15 SCreen-Hf 735 

M. McGrady (Melbourne, AU) 

17:30 Phrenic nerve stimulation 736 

W.T. Abraham (Columbus, US) 

17:45 DUel 737 

V. Mareev (Moscow, RU) 


Devices in heart failure: Update 2010 

Chairperson(s): P.E. Vardas (Heraklion, GR); B. Pitt (Ann Arbor, US) 


16:30 renal replacement therapies 740 


16:48 enhanced external counterpulsation 741 


17:06 extra systolic monitoring devices 742 


17:24 non-invasive ventilation 743 

M. R. Costanzo (Naperville, US) 

17:42 Ventricular assist devices 744 

B. Meyns (Leuven, BE) 

94



Acute heart failure – what you need to know to take care of your patient 

Chairperson(s): K. McDonald (Dublin, IE); J.-N. Trochu (Nantes, FR) 



- Participants should be able to have a better understanding of the epidemiology and 

pathophysiology behind acute heart failure 

16:30 Setting the stage: trends in epidemiology and pathophysiolgy update 745 

U. G. Dahlstrom (Linkoping, SE) 

16:48 Using diuretics – all the same? all different? 746 


17:06 Which inotrope and when – dobutamine or levosimendan or PDeis? 747 


17:24 Which vasodilator and when – gtn, SnP or nesiritide? 748 

I. S. Anand (Edina, US) 

17:42 When to use a balloon pump? or assist devices? 749 

M. Petrie (Glasgow, GB) 


Judges choice: Treatment Research 

oral abstract Session 

Chairperson(s): P. Van Der Meer (Groningen, NL); F. Ruschitzka (Zurich, CH) 


16:30 Direct involvement of bortezomib in the occurrence of heart failure 750 

B. Honton, N. Dumonteil, C. Rouvellat, M. Roussel, F. Despas, J.L. Montastruc, 

D. Carrie, M. Galinier, A. Pathak (Toulouse, FR) 

16:45 is there a mortality risk amongst heart failure patients with use of inhaled 

beta-2 agonists? 751 

M. Bermingham, E. O’callaghan, S. Miwa, I. Dawkins, S. Samsuddin, 

K. Mcdonald, M. Ledwidge (Dublin, IE) 

17:00 association of beta-adrenergic receptor polymorphisms and mortality in 

carvedilol-treated chronic heart failure patients 752 

M. Petersen, J.T.A. Andersen, B.R.H. Hjelvang, K.B. Broedbaek, S.A. Afzal, 

M.N. Nyegaard, A.B. Borglum, L.K. Kober, C.T.P. Torp-Pedersen, H.E.P. Poulsen 

(Copenhagen, Aalborg and Aarhus, DK) 

17:15 Skeletal muscle waisting in chronic heart failure: age-related effects of exercise 

training 753 

S. Gielen, M. Sandri, V. Adams, N. Mangner, R. Hambrecht, G. Schuler (Leipzig, DE) 

95 

monDaY

monDaY 



17:30 influence of intravenous ferric carboxymaltose on health-related quality of life 

measures in patients with chronic heart failure and iron deficiency: an analysis 

from the fair-Hf study 754 

J. Comin-Colet, M. Lainscak, K. Dickstein, G. Filippatos, P. Johnson, T.F. Luscher, 

C. Mori, R. Willenheimer, P. Ponikowski, S.D. Anker (Barcelona, ES; Golnik, SI; 

Stavanger and Bergen, NO; Athens, GR; Glattbrugg and Zurich, CH; Malmo, SE; 

Wroclaw, PL; Berlin, DE) 

17:45 Cardiac resynchronization therapy and bone marrow cell transplantation in 

patients with ischemic heart failure and electro-mechanical dyssynchrony. a 

randomized study. 755 

A. Romanov, E. Pokushalov, A. Cherniavskiy, P. Larionov, I. Terehov, S. Artemenko, 

E. Kliver, N. Shirokova, G. Corbucci, D. Prohorova (Novosibirsk, RU; Maastricht, NL) 


Heart failure from a primary care perspective 

Joint session with WonCa (World organization of family Doctors) 

Chairperson(s): F.D.R. Hobbs (Birmingham, GB); I. Ekman (Goteborg, SE) 


16:30 out patient Heart failure management programmes - what works and what 

doesn’t? examples from disadvantaged and privileged populations 756 


16:48 Devices: what the primary care physician should know 757 


17:06 Comorbidities in heart failure and improving treatment compliance 758 

A. W. Hoes (Utrecht, NL) 

17:24 Diagnosing heart failure - update on the best pathway 759 

F. D. R. Hobbs (Birmingham, GB) 

17:42 gPs and nurses: complementary or competitive? 760 

M. Ryder (Dunlaoghaire, IE) 

96



Targeting integrins and arterial stiffness in heart failure 

Chairperson(s): M.P. Frenneaux (Aberdeen, GB); G. Hasenfuss (Goettingen, DE) 


16:30 integrins and cardiovascular stiffnening 761 

P. Lacolley (Vandoeuvre-Les-Nancy Cedex, FR) 

16:52 Ventricular-vascular coupling in heart failure 762 


17:15 role of endothelial mechanisms in arterial stiffness 763 

P. Chowienczyk (London, GB) 

17:37 Destiffening agents: any future for heart failure therapy 764 

G. Ertl (Wurzburg, DE) 

16:30 - 18:00 Oral Abstracts Leipzig 

Oral abstract session: Basic Science 

Chairperson(s): B.M. Pieske (Graz, AT); Z. Papp (Debrecen, HU) 

16:30 Spontaneous cardiac hypertrophy and identification of novel hypertrophic 

pathways in a genetic mouse model that emulates human diabetes 765 

S. Gibbons, Z. Hegab, M. Zi, S. Prehar, T. Mohammed, D. Oceandy, R.D. Cox, 

E. Cartwright, L. Neyses, M.A. Mamas (Manchester and Oxford, GB) 

16:45 intravenous iron modulates favourably nitrosative stress and heat shock 

proteins (Hsp27/Hsp70) expression in heart of iron-deficient rats. 766 

J. Toblli, F.G. Giani, M.C. Munoz, G. Cao, C. Rivas, F.P. Dominici (Buenos Aires, AR) 

17:00 epac- induced cardiac myocyte hypertrophy involves H-raS, CamKii and 

HDaC4 nuclear export 767 

E. Morel, M. Metrich, A.C. Laurent, M. Breckler, N. Duquesnes, B. Crozatier, 

f. lezoualc’h (Chatenay-malabry, fr) 

17:15 effect of the fc(gamma)-receptor-iia polymorphism H/r-131 on cardaic 

function of DCm patients after immunoadsorption therapy 768 

L. R. Herda, L. G. Eckerle, A. Hummel, C. Mueller, W. Hoffmann, R. Kandolf, 

H. K. Kroemer, A. Greinacher, S. B. Felix, A. Staudt (Greifswald and Tuebingen, DE) 

17:30 targeted inhibition of myocardin gene expression in ventricular myocardium 

in vivo augments systolic function: an experimental large animal study 769 

M. Torrado, A. Centeno, E. Lopez, A. Mikhailov (La Coruna, ES) 

17:45 mechanical stretch up-regulates BnP and nPra in human cardiac fibroblast 

cells: a possible protective mechanism against tgf-beta induced myocardial 

fibrosis. 770 

C.J. Watson, D. Phelan, M. Xu, P. Collier, N. Glezeva, A. Smolenski, M. Ledwidge, 

K. Mcdonald, J. Baugh (Dublin, IE) 

97 

monDaY

monDaY 

monDaY 31 maY 2010 - eVening 


Biomarkers as an aid in cardio-pulmonary acute diseases 

Satellite Symposium organised by B.r.a.H.m.S 

Chairperson(s): S.D. Anker (Berlin, DE); J.J.V. McMurray (Glasgow, GB) 

18:15 mr-proaDm in risk stratification of acute dyspnea. 771 

M. Noveanu (Basel, CH) 

18:35 What information do we get from natriuretic peptides and Procalcitonin in 

patients with shortness of breath? 772 

S. Di Somma (Roma, IT) 

18:55 Prognostic value of mr-proaDm in acute myocardial infarction. 773 

L. Ng (Leicester, GB) 

19:15 How do troponins and Copeptin fit in diagnosing myocardial infarction? 774 

E. Giannitsis (Heidelberg, DE) 

19:35 Panel Discussion. 775 

98

MONDAY 





morning 

moderated Posters Sessions 3 (10:00 - 11:00) ....................................................Page 100 

Poster Session 3 ....................................................................................................................Pages 101 to 118 


afternoon 

moderated Posters Sessions 4 (15:45 - 16:30) .....................................................Page 119 

Poster Session 4 ....................................................................................................................Pages 120 to 137 


Don’t miss! 

Heart Failure Pilot Registry 

presented by Professor A.P. Maggioni 

Moderated Poster Area 

monDaY 

PoSterS

monDaY 

PoSterS 

monDaY 31 maY 2010 - morning PoSterS 



acute heart failure & Prognosis 

Chairperson(s): I.S. Anand (Edina, US); E. Erdmann (Koeln, DE) 




10:00 impact of tni-autoantibodies in chronic dilated and ischemic cardiomyopathy P776 

S. Mueller, A. Doesch, S. Celik, M. Konstandin, A. Kristen, L. Frankenstein, 

S. Goeser, Z. Kaya, C. Zugck, H.A. Katus (Heidelberg, DE) 

10:06 obesity and heart failure: the paradox continues in the long-term follow-up P777 

E. Zamora, J. Lupon, A. Urrutia, B. Gonzalez, L. Cano, R. Cabanes, G. Bickham, 

T. Pascual, S. Altimir, C. Diez (Badalona, ES) 

10:12 iron deficiency: an ominous sign in patients with systolic chronic heart failure P778 

E. A. Jankowska, P. Rozentryt, A. Witkowska, J. Nowak, O. Hartmann, 

W. Banasiak, L. Polonski, G. Filippatos, S. D. Anker, P. Ponikowski (Wroclaw and 

Zabrze, PL; Berlin, DE; Athens, GR) 

10:18 mode of death and rehospitalization from the fUSion ii trial: concordance of 

CeC adjudicated versus investigator reported outcomes P779 

M. Fiuzat, C.M. O’connor, C. Lombardi, P. Carson, J. Lindenfeld, A. Miller, 

L.K. Shaw, L.J. Wang, C. Yancy, K.W. Mahaffey (Durham, NC, Washington DC, 

Denver, CO, Jacksonville, FL, New Jersey, NJ and Dallas, TX, US) 

10:24 the effect of the acetylation status on the hemodynamics after intravenous 

administration of levosimendan P780 

M. Kivikko, S. Sundberg, P. Pohjanjousi (Helsinki and Espoo, FI) 

10:30 glycaemic control and the development of heart failure and its importance in 

diabetic patients with established heart failure P781 

C.C. Lang, L. Donnely, A. Doney, A.F. Wong, M. Pauriah, M. Jabir, R. Libianto, 

E.D.H. Elder, A.M. Choy, A.D. Struthers (Dundee, GB) 

10:36 increased 90 day mortality in patients with elevated copeptin and low 

sodium: secondary results from the Biomarkers in acute Heart failure (BaCH) 

study P782 

P. Gabbai-Saldate, Y. Xue, K. Shah, A. Maisel (San Diego, US) 

10:42 Serial ultra-sensitive troponin i predicts outcomes in patients with acute 


P. Gabbai-Saldate, Y. Xue, A. Maisel (San Diego, US) 

10:54 Prognostic value of cystatin C on admission in heart failure with preserved 


F.J. Carrasco Sanchez, L. Galisteo Almeda, I. Paez Rubio, C. Ruiz Frutos, 

R. Lopez Aguilar, C. Camacho Vazquez, E. Pujol De La Llave, 

A. Tobaruela Gonzalez (Huelva, ES) 

100








Predictor for readmission of heart failure at our national Cardiovascular Center. P786 

B.-B. Siswanto, T.R.I. Mawartinah Msc, P.A.N.D.U. Riono P, R.A.T.N.A. Djuwita (Jakarta 

and Depok, ID) 

acute heart failure: predictive factors of immediat and mid term mortality P787 

L. Abid, R. Hammami, M. Ellouz, I. Trabelsi, S. Kammoun (Sfax, TN) 

High frequency electrography in patients suffering congestive heart failure P788 

G. Shafieian (Tehran, IR) 

recovery of the faction of ejection after a hospital income with acute systolic heart 

failure: prevalence, outcome predictors and prognosis P789 

J. G. Sanchez Ramos, P. Martin De La Fuente, S. Martinez Huertas, E. Moreno Escobar, 

G. Moreno Terribas, L. Lozano Herrera, A. Gonzalez Ramirez, C. Correa Vilchez 

(Granada, ES) 

in acute decompensated heart failure long-term outcome is not predicted by mitral 

regurgitation severity at admission. a single-center 3-years follow-up. P790 

R. Natali, E. De Marco, B. Garramone, N. Marchese, F.A. Gabrielli, G. Comerci, 

M. Lotrionte, M. Savino, F. Loperfido (Rome, IT) 

Hypoalbuminemia as a prognostic factor reflecting malnutrition, inflammation, and 

fluid volume expansion in patients with acute decompensated heart failure P791 

Y. Kinugasa, M. Kato, S. Sugihara, M. Hirai, K. Ishida, K. Yanagihara, Y. Kato, K. Ogino, 

I. Hisatome, C. Shigemasa (Yonago, JP) 

Clinical characteristics and predictors of in-hospital mortality in 270 consecutive 

patients admitted due to acute heart failure during one year P792 

J. Biegus, R. Zymlinski, J. Szachniewicz, P. Siwolowski, W. Banasiak, E. A. Jankowska, 


time from the symptoms onset, risk profile and extension of coronary artery disease: 

is there association with the severity of heart failure during a myocardial infarction? P793 

N. Cabanelas, D.D. Durao, M.A. Alves, M.P. Peres, V.M. Martins, G.F.S. Silva 

(Santarem, PT) 

risk stratification in acute pulmonary embolism: shock index as an effective predictor 

of right ventricular dysfunction determined by Ct Scan P794 

L.F. Seca, J. Silva, R. Providencia, P. Gomes, G. Costa, S. Barra, F. Caetano, A. Faustino, 

M. Costa, A.M. Leitao Marques (Coimbra, PT) 

elevation of liver enzyme levels predicts early cardiac events in patients with acute 

decompensated heart failure P795 

S. Sugihara, K. Yanagihara, K. Ishida, Y. Kinugasa, M. Kato, I. Hisatome, C. Shigemasa 

(Yonago, JP) 

101 

monDaY 

PoSterS

monDaY 

PoSterS 



Predictors of cardiac death due to congestive heart failure in patients treated with 

primary coronary intervention for acute myocardial infarction: 30-day follow up period P796 

I. Nedeljkovic, M.C. Ostojic, B. Vujisic-Tesic, M. Petrovic, M. Boricic-Kostic, M. Nedeljkovic, 

D. Trifunovic, O. Petrovic, M. Banovic, M. Tesic (Belgrade, RS) 

Sex-related differences in mortality among patients with incident heart failure. the 

danish national indicator project P797 

A. Nakano, S.P. Johnsen, A.B. Vind, A.M.S.H. Hansen, K. Egstrup (Aarhus, Glostrup and 

Svendborg, DK) 

Hemodynamic assessment of impedance cardiography compared with clinical 

evaluation in patients with acute heart failure P798 

M.W. Montera, S. Bernardez, Y.M. Pereira, R.K. Osugi, M. Barbosa, A.L.S. Silva, M.S. Diniz, 

A. Volchan (Rio de Janeiro, BR) 


Differences in admission and discharge medications between patients with acute 

pulmonary edema and those with acute decompensated chronic heart failure in the 

alarm-Hf registry P799 

D. Farmakis, J.T. Parissis, M. Nikolaou, I. Ikonomidis, A. Mebazaa, J. Delgado, F. Vilas-Boas, 

A. Mc Lean, M. Anastasiou-Nana, F. Follath (Athens, GR; Paris, FR; Madrid, ES; Salvador, 

BR; Sydney, AU; Zurich, CH) 

Comparison of combined intermittent inotropic and ultrafiltration versus ultrafiltration 

in treatment of refractory heart failure in eldery with impaired renal function P800 

I. Samuil, S. Hana, F. Saiko (Kanagawa, JP) 

levosimendan vs. conventional inotropic therapy in decompensate heart failure. 

24 months clinical follow-up. P801 

L. Sargento, D. Brito, H. Madeira (Lisbon, PT) 

early implementation of continuous venovenous hemodiafiltration in acute renal 

failure in severe cardiac diseases: is this a way for better prognosis? P802 

A. Konopka, M. Banaszewski, M. Marona, I. Wojtkowska, J. Stepinska (Warsaw, PL) 

Single-centre experience with short-term ventricular assist devices as a bridge to 

recovery or heart transplantation in acute heart failure P803 

C. Plata, M.A. Castel, A. Sionis, R. Cartana, M. Castella, J.L. Pomar, E. Roig, A. Garcia, 

F. Perez-Villa (Barcelona, ES) 

renal effects of levosimendan in patients admitted with acute decompensated heart 

failure P804 

M. Mancone, C. Caira, B. Brasolin, N. Bruno, S. Mennuni, A. D’ambrosi, F. Fedele 

(Rome, IT) 


renal failure: a nightmare in patients with advanced heart failure P805 



independent prognostic value of serum albumin in chronic heart failure P806 

Y. Tanada, Y. Sato, E. Yamamoto, T. Sawa, S. Noge, Y. Nakai, A. Matsumoto, T. Fujiwara, 

H. Fujiwara, Y. Takatsu (Amagasaki and Kyoto, JP) 

102



Brain natriuretic peptide in acute heart failure: reflecting the present, predicting 

the future P807 

P. Mendes, F. Saraiva, E. Jorge, H. Martins, R. Batista, R. Teixeira, S. Costa, F. Franco, 

P. Monteiro, L. A. Providencia (Coimbra, PT) 

long-term prognosis assessment in acute decompensated heart failure: the role of 

neurohormonal score P808 

F. Moscoso Costa, J. Ferreira, C. Aguiar, R. Couto, J. Figueira, A. Silva (Lisbon, PT) 

adrenomedullin and endothelin-1 are novel prognostic markers in chronic heart failure P809 

T. Gombos, Z. Forhecz, Z. Pozsonyi, J. Kunde, L. Janoskuti, Z. Prohaszka (Budapest, HU; 

Hennigsdorf, DE) 

Changes of red cell distribution width (rDW) values are related to long-term mortality 

in chronic heart failure P810 

Z.S. Forhecz, T. Gombos, Z. Pozsonyi, Z. Prohaszka, L. Janoskuti (Budapest, HU) 

Clinical observations on plasma Ct-proaVP in patients with suspected heart failure 

(a Hull-lifelab analysis) P811 

K. Goode, J.G. Cleland, R. Nicholls, J. Struck, A. Bergmann, A.L. Clark (Hull, GB; 

Hennigsdorf, DE) 

Serum sodium concentration in heart failure - determinants and prognostic significance P812 

J. Zhang, K.M. Goode, L. Buga, Y. Najjar, N. Sherwi, A. Yassin, O. Khaleva, A. Torabi, 

A.L. Clark, J.G.F. Cleland (Hull, GB) 


Prognostic factors of chronic systolic heart failure in different ages P813 

B. Ancsin, B. Szabo, N. Nyolczas, M. Dekany, T. Borsanyi, E. Marosi, A. Kosztin, R.G. Kiss 


the ambulatory lung ultrasound can reduce congestive heart failure hospital 

readmission? P814 

M.E. Antoniucci, A. Lancia, A. Giorgi (Rome, IT) 

a new prognostic score for event prediction after hospitalization for advanced heart 

failure P815 



Prognostic importance of microalbuminuria in acute myocardial infarction P816 

S. Apostolovic, D. Stanojevic, R. Jankovic Tomasevic, D. Djordjevic Radojkovic, S. Salinger 

Martinovic, M. Pavlovic, V. Djordjevic, M. Damjanovic, I. Ilic (Nis, RS) 

Previous heart failure episode as a prognosis factor in a contemporary chronic 

ischaemic heart disease cohort in a primary care setting. the Barbanza ischaemic 

Cardiomyopathy (BariC) study P817 

R. C. Vidal Perez, F. Otero Ravina, L. Gonzalez Rodriguez, A. Vizcaya Ramos, 

R. Lafuente Taboada, J. Vidal Sampedro, A. Perez Fernandez, A. Carvajal De La Torre, 

L. Vazquez Fernandez, J.R. Gonzalez-Juanatey (Santiago de Compostela, ES) 

mortality in heart failure with preserved vs. reduced systolic function; the same 

outcome but different causes P818 

B. Zafrir, H. Paz, R. Wolff, N. Salman, D. Merhavi, A. Antebi, N. Yaniv, R. Ammar, 

B.S. Lewis, O. Amir (Haifa, IL) 

103 

monDaY 

PoSterS

monDaY 

PoSterS 



elevated resting heart rate and bad prognosis in heart failure P819 

A. Varela Roman, A. Roman Rego, S. Raposeiras Proupin, I. Gomez Otero, 

L. Grigorian Shamagian, A. Seoane Blanco, M. Moure Gonzalez, R. De La Fuente Cid, 

F. Lado Lado, J.R. Gonzalez Juanatey (Santiago de Compostela, ES) 

acute coronary syndrome: long-term impact of heart failure at admission P820 

H. Dores, S. Leal, I. Rosario, L. Bronze, J. Monge, M.J. Correia, I. Arroja, C. Fonseca, 


Prognostic value of nt-proBnP, cardiopulmonary exercise testing and impedance 

cardiography in patients with chronic heart failure P821 

A. Toste, R.M. Soares, J. Feliciano, F. Miranda, R. Ramos, A. Lousinha, H. Hamad, S. Silva, 

A. Abreu, R.C. Ferreira (Lisbon, PT) 

Quality of life in chronic heart failure predicts subsequent hospitalisation and 

mortality: a longitudinal study P822 

J. Iqbal, L. Francis, J. Reid, S. Murray, M.A. Denvir (Edinburgh, GB) 

restriction in lung function tests predicts survival in chronic heart failure patients with 

peak oxygen consumption above the cut-off point for heart transplantation listing P823 

M.K. Lizak, M.W. Zakliczynski, A. Jarosz, M. Zembala, Z. Kalarus (Zabrze, PL) 

the comparative prognostic significance of exercise test variables in patients with 

suspected heart failure: understanding the non-linearity in their relationship to 

mortality. P824 

R. Sloan, A.L. Clark, K.K. Witte, S. Carroll, L. Ingle, Y. Al-Najjar, J.G. Cleland, K.M. Goode 

(Hull and Leeds, GB) 

the CoaCH risk engine: a simulation model for predicting survival and duration of 

hospitalization in patients with heart failure P825 

D. Postmus, A. A. Abdul Pari, T. Jaarsma, M.-L. Luttik, D. J. Van Veldhuisen, E. Buskens, 

H. Hillege (Groningen, NL) 

alpha-defensins: a novel biomarker in heart failure? P826 

H. Christensen, J. Frystyk, J. Faber, A. Flyvbjerg, P. Hillebrandt, C. Kistorp (Herlev, Aarhus, 

Glostrup and Frederiksberg, DK) 


non-sustained ventricular tachycardia episodes from 24 hours holter recordings risk 

stratify heart failure patients for sudden cardiac death P827 

P. Arsenos, K. Gatzoulis, T. Gialernios, P. Dilaveris, E. Karstagoulis, K. Zissimos, P. Pietri, 

I. Dima, S. Sideris, C. Stefanadis (Athens, GR) 

Power spectral analysis of heart rate variability can be important to predict risk of 

ventricular life-threatening arrhythmias in patients with acute myocardial infarction 

and heart failure P828 

M.O. Harbar, R.Y. Dutka, H.V. Svitlyk, A.Y. Fainyk, S.S. Pavlyk (Lviv, UA) 

acute decompensated heart failure and potassium: is it time to review the normality 

range? P829 

E. Azenha Balhau Jorge, R. Baptista, F. Saraiva, H. Martins, P. Mendes, R. Teixeira, 

S. Costa, P. Monteiro, F. Franco, L.A. Providencia (Coimbra, PT) 

104



Beta blockers 

nebivolol therapy improves Qtc and Qtcd parameters in heart failure patients P830 

S. Cay, S.M. Aksoy, G. Cagirci, N. Sen (Ankara, TR) 

are beta-blockers a therapeutic option in patients with advanced chronic heart failure 

and associated chronic obstructive pulmonary disease? P831 

E. Badila, M. Bazac, C.M. Tirziu, F. Mehic, D. Bartos, M. Dorobantu (Bucharest, RO) 

left ventricular reverse remodeling by beta-blocker therapy is accompanied by the 

improvement of histopathological findings P832 

N. Sasaki, Y. Yasumura, M. Watanabe, Y. Ikeda, H. Ishibashi-Ueda (Osaka and Suita, 

Osaka, JP) 

no more target dose, long live target heart rate? - a suggestion from the CiBiS-elD trial P833 

G. Gelbrich, F. Edelmann, S. Inkrot, E. Tahirovic, A. Toepper, S. Apostolovic, M. Lainscak, 

T. Rau, T. Eschenhagen, H.-D. Duengen (Leipzig, Goettingen, Berlin and Hamburg, DE; 

Nis, RS; Golnik, SI) 


efficiency of mitral valve annuloplasty and simultaneous implantation of 

cardioresynchronization devices in patients suffered from severe heart failure P834 

N. Yakush, Y. Ostrovskiy, E. Atroschenko, D. Romanovskiy, O. Pashuk, E. Kurlyanskaya, 

I. Sidorenko (Minsk, BY) 

right ventricular function as a predictor of response to cardiac resynchronization therapy P835 

M. Edner, M. R. Ring, P. H. Henriksson (Danderyd and Solna, SE) 

echocardiographic hyper-responders in cardiac resynchronization therapy P836 

F. Cabrera Bueno, J. Alzueta, M.J. Molina Mora, J. Fernandez Pastor, A. Barrera, J. Pena, 

E. De Teresa (Malaga, ES) 

High rate of successful left ventricle lead placement in the target wall region in 

standard Crt- implantation P837 


Heart failure monitoring in patients with cardiac resynchronization devices: value 

of physiological parameters in association with transthoracic electrical impedance 

monitoring P838 

N. Cortez-Dias, D. Silva, M. Valente, S. Martins, L. Sargento, L. Carpinteiro, J. Sousa, 

M.G. Lopes (Lisbon, PT) 

ICD therapy 

the value of implantable Cardioverter Defibrillator in an unselected advanced heart 

failure clinic: a safe and very efficient therapy. P839 

R. Baptista, E. Jorge, F. Saraiva, H. Martins, P. Mendes, C. Lourenco, S. Costa, P. Monteiro, 

F. Franco, L.A. Providencia (Coimbra, PT) 

Beta-2 gln27glu adrenergic receptor gene polymorphisms and risk of malignant 

arrhythmias in patients with implantable cardioverter defibrillator P840 

N. Pezzali, M. Metra, C. Maiandi, E. Pezzotti, M. Adamo, A. Lipari, M. Cerini, L. Bontempi, 

A. Curnis, L. Dei Cas (Brescia, IT) 

105 

monDaY 

PoSterS

monDaY 

PoSterS 




Cardiac transplantation: emotional aspects of patients on the waiting list P841 

S. Bordignon, I.A. Nesralla, P. Ruschel, M.A. Maldonado, C. Avila, F. Ribas, S. Fonseca, 

D. Loureiro, L.L. Lima, P. Cordeiro (Porto Alegre, BR) 

Basiliximab utilization as induction therapy in cardiac transplantation in real life: 

analysis of 101 patients P842 

G.E. Conceicao-Souza, F.S. Feitosa, M.S. Avila, S.M. Ayub-Ferreira, V.S. Issa, J.L. Vieira, 

F. Bacal, P.R. Chizzola, G.V. Guimaraes, E.A. Bocchi (Sao Paulo, BR) 

is vasculopathy connected with Quilty effect ? P843 

M. Sobieszczanska-Malek, T. Zielinski, M. Piotrowska, A. Browarek, K. Komuda, 

J. Korewicki (Warszawa, PL) 

Dental health of patients after heart transplantation - epidemiology, diagnosis and 

impact on survival P844 

M. A. Engelen, H. Welp, E. Schaefer, J. Stypmann (Muenster, DE) 

arterial hypertension and heart rate variability in pediatric heart transplant recipients P845 

G. Grutter, S. Volpe, U. Giordano, F. Esu, F. Parisi (Rome, IT) 

antibody-mediated rejection in pediatric and adolescent haert transplant recipients: 

incidence, diagnosis, and treatment P846 

G. Grutter, S. Volpe, F. Esu, F. Parisi (Rome, IT) 


the clinical and instrumentation estimation of the efficiency of the conservative and 

surgical treatment at various terms of the coronary artery bypass grafting in patients 

with Q-wave myocardial infa P847 

E. Medvedeva, L. Gelis, Y. Ostrovskiy, N. Shibeko, I. Lazareva (Minsk, BY) 

early outcome after cardiac surgery in the elderly: what can we rely on to predict 

survival? P848 

S. M. Oliveira, A.S. Sofia, M. Paiva, A. Goncalves, R. Almeida, M. Pereira, E. Alves, P. Dias, 

P. Pinho (Porto, PT) 

Changes in left ventricle surgical restoration: computer assisted left ventricle 

engineering P849 

I. Hartyanszky, J. Pepper, A. Toth, G. Veres, B. Berta, M. Polos, K. Vida, Z. Szabolcs, 

F. Horkay (Budapest, HU; London, GB) 


ten-year survival of medically treated patients with dilated cardiomyopathy in Serbia P850 

P. Otasevic, S. Boskovic, N. Tasic (Belgrade, RS) 

levosimendan in patients with advanCed heart failure (laiCa study): rationale and 

design P851 

M. J. Garcia Gonzalez, A. Lara Padron, F. Marrero Rodriguez, A. Barragan Acea, 

J. Lacalzada Almeida, I. Laynez Cerdena, F. Bosa Ojeda, M.M. Garcia Saiz, T. Virgos Aller, 

I. Rodriguez Pedrosa (San Cristobal de La Laguna, Tenerife, SP) 

106



the effect of micronutrient supplementation on quality of life and left ventricular 

function in elderly patients with chronic failure and ischaemic heart disease P852 

T. Momcilov-Popin, T. Momcilov Popin, A. Stojsic Milosavljvic, A. Stojsic Milosavljvic, 

N. Cemerlic Adjic, G. Bojic Kolarski, S. Popin (Sremska Kamenica and Novi Sad, RS) 

Uptake of evidence-based medical therapy for patients with heart failure caused by 

left ventricular systolic dysfunction, through a new heart failure service P853 

A. Al-Mohammad, L. O’toole, C. West, A. Birchall, D. Barnett, J. Laing, N. Buckley 

(Sheffield, GB) 

effect of nebivolol in comparison with bisoprolol on myocardial collagen turnover 

in patients with chronic heart failure P854 

E.S. Zhubrina, A.G. Ovchinnikov, E.M. Seredenina, V.P. Masenko, F.T. Ageev (Moscow, RU) 

effects of rosuvastatin and allopurinol on endothelial progenitor cells in patients with 

chronic heart failure: the role of inflammation and oxidative stress P855 

I. Andreou, D. Tousoulis, C.A. Papadimitriou, C. Tentolouris, M. Tsiatas, I. Kotrogiannis, 

G. Siasos, K. Zisimos, M.A. Dimopoulos, C. Stefanadis (Athens, GR) 


Peritoneal dialysis as an alternative approach to end stage refractory heart failure 

contraindicated for heart transplantation: a retrospective cohort study P856 

G.E. Conceicao-Souza, E.S. Oliveira, E. Osawa, A.S. Oliveira, J.L. Vieira, V.S. Issa, 

S.M. Ayub-Ferreira, F. Bacal, P.R. Chizzola, E.A. Bocchi (Sao Paulo, BR) 

the role of peritoneal ultrafiltration in the treatment of refractory congestive heart 

failure P857 

J.E. Sanchez, C. Rodriguez, T. Ortega, B. Diaz-Molina, M. Martin, C. Garcia-Cueto, 

P. Vidau, E. Gago (Oviedo, ES) 

monitoring of body hydration by bioimpedance vector analysis and brain natriuretic 

peptide helps optimizing the management of patients with acute decompensated 


N. Aspromonte, C. Ronco, M. Santini, L. Milani, D. Cruz, M. Tubaro, F. Colivicchi, 

G. Vianello, A. Anzoletti Boscolo, R. Valle (Rome, Vicenza, and Venice, IT) 


is there a role for spironolactone in atrial fibrillation prevention? P859 

R. Lopes, P. Lourenco, C. Paulo, A. Sousa, A. Lebreiro, J. Mascarenhas, S. Silva, M. Santos, 

H. Silva, P. Bettencourt (Porto, PT) 


overdrive ventricular pacing in pacemaker recipients with permanent atrial 

arrhythmia and sleep apnea P860 

P. Bordier, S. Maurice-Tison (Pessac and Bordeaux, FR) 

atrial fibrillation in elderly heart failure patients before and after biventricular implantation P861 

S. De Feo, A. Fusco, F. Leonardo, O. Spadaro, G. Cannizzaro, I. Sheiban, L. Pederzoli, 

A. Vicentini (Peschiera del Garda, IT) 

107 

monDaY 

PoSterS

monDaY 

PoSterS 



association between frequency of recurrence of atrial fibrillation and functional class 

of chronic heart failure P862 

T.A. Abdullaev, R.D. Kurbanov, N.U. Zakirov, O.B. Klicheva, S.H. Khusanov (Tashkent, UZ) 


Cardiac i-123-mibg scintigraphy and arrhytmic risk in isolated left ventricle noncompaction P863 

S. M. Oliveira, E. Martins, A. Oliveira, T. Pinho, C. Gavina, J.C. Silva-Cardoso, J. Pereira, 

M.J. Maciel (Porto, PT) 

Hypertrophic cardiomyopathy in older patients: are there differences? P864 

C. E. Correia, R. Faria, B. Rodrigues, L. Santos, P. Gama, L. Nunes, J. Pipa, C. Cabral, 

O. Santos (Viseu, PT) 

myocardial performance index in dilated cardiomyopathy in childhood P865 

A. Jurko, A. Jurko Jr (Martin, SK) 

Sympathetic reserve during orthostatic stress is associated with exercise capacity in 

patients with dilated cardiomyopathy P866 

W. Grander, B. Koller, M. Duenser (Hall in Tyrol, AT; Bern, CH) 

role of tissue Doppler imaging in exposure of systolic dysfunction in patients with 

hypertrophic cardiomyopathy and normal ejection fraction of left ventricle P867 

Z. Oko-Sarnowska, H. Wachowiak-Baszynska, A. Katarzynska-Szymanska, 

E. Straburzynska-Migaj, O. Trojnarska, S. Grajek (Poznan, PL) 

relationship between oxidative stress and echocardiographic and clinical assessment 

in stable dilated cardiomyopathy patients P868 

C.A. Wojciechowska, W. Jachec, E. Romuk, B. Skrzep-Poloczek, A. Gala, A. Tomasik, 

E. Nowalany-Kozielska, E. Birkner (Zabrze, PL) 

overdiagnosis of coronary heart disease and chronic obstructive pulmonary disease 

among patients predominant diastolic congestive heart failure, caused by various 

forms of systemic amyloidosis. P869 

A. Goodkova, I.A. Kuznetzova, E.N. Semernin, A.V. Kozlenok, A.Y.A. Gudkov, 

A.A. Barmasheva, L.Y.U. Orekhova, M.G. Rybakova, E.V. Shlyakhto (St Petersburg, RU) 

the extent of cardiac sympathetic denervation correlates with changes of ventricular 

repolarization in chronic Chagas cardiomiopathy P870 

M.V. Simoes, C.H. Miranda, A.B. Figueiredo, E. Arfeli, B.C. Maciel, J.A. Marin-Neto 

(Ribeirao Preto, BR) 

Stress-induced cardiomyopathy in Sweden, evidence for different ethnic/genetic 

predisposition P871 

E. Omerovic, Y. Bergmann Sverrisdottir, T. Schultz, T. Ramunndal, P. Albertsson, 

G. Matejka (Gothenburg, SE) 

anemia at patients with dilated cardiomyopathy: prevalence and importance P872 

T.A. Abdullaev, I.A. Tsoy, B.U. Mardanov, R.D. Kurbanov (Tashkent, UZ) 

association between nutritive and androgen statuses of dilated cardiomyopathy patients. P873 

T.A. Abdullaev, B.U. Mardanov, R.D. Kurbanov (Tashkent, UZ) 

ina,late block by ranolazine atttenuates intracellular na+ and Ca2+ dysregulation in 

myocytes from Scn5a-1798insD/+ mice P874 

A. Baartscheer, C.A. Remme, A.O. Verkerk, A.A.M. Wilde, D. Zeng, L. Belardinelli, 

H.V. Van Rijen, J.M.T. De Bakker, C.R. Bezzina (Amsterdam and Utrecht, NL; Palo Alto, US) 

108



the -308g/a polymorphism in the promoter of the tnf-alpha gene is associated with 

dilated cardiomyopathy P875 

V. Ruppert, T. Meyer, D. Pietz, A. Perrot, M. Posch, A. Richter, C. Oezcelik, B. Maisch, 

S. Pankuweit (Marburg and Berlin, DE) 


stnf-r1 and stnf-r2 in ageing patients with essential hypertension and increased risk 

of coronary heart disease P876 

M. Rivera Otero, E. Rosello, V. Miro, L. Martinez Dolz, P. Morillas, A. Jordan, L. Grigorian, 

P. Orosa, F. Soria, V. Bertomeu (Valencia, Alicante, Santiago de Compostela, Gandia and 

Murcia, ES) 

evaluation of global left ventricular function and its association with brain natriuretic 

peptide levels in hypertensive patients P877 

D. Mytas, M. Papavasileiou, A. Anastasopoulou, A. Kitsiou, G. Papadimitriou, 

K. Giannakopoulos, M. Seferou, I. Vasiliadis, G. Lampropoulou, S. Karas (Athens, GR) 

Plasma glycogen phosphorylase bb is associated with pulmonary artery wedge 

pressure, left ventricle mass index in patients with hypertrophic cardiomyopathy P878 

R. Pudil, M. Vasatova, J. Lenco, M. Tichy, J.M. Horacek, J. Vojacek, V. Palicka 

(Hradec Kralove, CZ) 

Heart function influenced by selective mid-cervical right vagus nerve stimulation in man P879 

P. Peclin, J. Rozman, I. Knezevic, T. Mirkovic, B. Gersak, M. Podbregar (Ljubljana, SI) 

erythropoietin receptor deficient mice have impaired cardiac adaptation during 

voluntary exercise P880 

W.T. Ruifrok, L.M.G. Meems, B.D. Westenbrink, A.H. Maass, H.H.W. Sillje, 

D.J. Van Veldhuisen, W.H. Van Gilst (Groningen, NL) 


the role of tissue doppler imaging in the evaluation of pulmonary hypertension in 

hemodialysis patients P881 

N. Papagiannis, E. Kavouria, P. Tsouni, N. Smyrnioudis, A. Kartalis, P. Sgourakis, 

P. Moschouris, I. Malakos, G. Georgiopoulos, J. Kyriazis (Chios, GR) 

eprosartan and bisoprolol efficacy in patients with chronic heart failure and 

secondary pulmonary hypertension syndrome P882 

O. Pashuk (Minsk, BY) 

Pulmonary hypertension in severe heart failure - the pre-capillary component 

reversibility testing P883 

J. Krejci, P. Hude, E. Ozabalova, H. Poloczkova, L. Spinarova, J. Vitovec (Brno, CZ) 


interleukin 6 might predict response to cardiac resynchronization therapy P884 

M. E. Tettamanti, J. Lopez Diaz, J.A. San Roman, R. Arnold, A. Revilla Orodea, C. Tapia 

Ballesteros, E. Garcia Moran, J. Rubio, M.L. Nieto, I. Gomez Salvador (Valladolid, ES) 

109 

monDaY 

PoSterS

monDaY 

PoSterS 



Human heart type fatty acid binding protein is elevated in the serum of heart failure 

patients but does not predict the occurrence of events. P885 

M. E. Tettamanti, J. Lopez Diaz, C. Tapia Ballesteros, J.A. San Roman, M.L. Nieto, E. Garcia 

Moran, L. De La Fuente Galan, J. Rubio, P. Mota Gomez, I. Gomez Salvador 

(Valladolid, ES) 

Prevalence and predictors of diastolic heart failure in a cardiovascular risk cohort P886 

A. Kockskaemper, H. Post, G. Gelbrich, S. Kleta, L. Binder, R. Wachter, F. Edelmann, B. 

Pieske (Graz, AT; Leipzig and Goettingen, DE) 

Carboxy - terminal propeptide of procollagen type i serum levels are associated with 

the ocurrence of events in heart failure patients and performs better than heart type 

fatty acid binding protein. P887 

M. E. Tettamanti, M.L. Nieto, J.A. San Roman Calvar, J. Lopez Diaz, A. Revilla Orodea, 

R. Arnold, E. Garcia Moran, C. Tapia Ballesteros, L. De La Fuente Galan, I. Gomez Salvador 

(Valladolid, ES) 

ggt measurement in primary care: a coherent indicator of cardiovascular risk? P888 

C.M. Conlon, C. Kelleher, I. Dawkins, M. Ledwidge, K. Mc Donald (Dublin, IE) 

are physiological perfusion-ventilation parameters by non-invasive lung 

measurements associated to heart failure (Hf) P889 

C. Lewinter, T.D. Damy, A.B. Bennett, K.M.G. Goode, L.K. Kober, E.T. Toft, A.L.C. Clark, 

J.G.F.C. Cleland (Hull, GB; Copenhagen and Aalborg, DK) 

Cardiac markers validity in detecting mortality in arDS in patients without structural 

heart disease P890 

Y. S. Nassar, D. Monsef, G. Hamed, S. Abdelshafy (Cairo, EG) 

Prevalence and predictors of asymptomatic left ventricular systolic dysfuntion in a 

population with high cardiovascular risk: preliminary results of DaViD-Berg study P891 

A. Grosu, M. Gori, A. Iacovoni, S. Guideri, P. Ferrari, P. Rocca, M. Senni, A. Filippi, 

R. De Maria, A. Gavazzi (Bergamo, Seriate and Milano, IT) 

the level of circulating matrix metalloproteinase-3 as a marker of early cardiac 

remodeling after Q-wave myocardial infarction P892 

A. Berezin, T.A. Panasenko (Zaporozhye, UA) 

regional cardiac expression of biomarkers involved in apoptotic process in an 

experimental model of left ventricular pacing-induced heart failure. P893 

T. Prescimone, C. Colotti, S. Del Ry, V. Lionetti, C. Caselli, M. Cabiati, M. Emdin, F. Recchia, 

D. Giannessi (Siena and Pisa, IT) 


angiotensin ii-induced diastolic dysfunction in conscious pigs: a novel approach for 

investigating left diastolic heart failure P894 

M. Rienzo, D. Pongas, A. Bize, L. Sambin, J.B. Su, L. Hittinger, A. Berdeaux, B. Ghaleh 

(Creteil, FR) 

Differences in extracellular matrix production between right and left ventricles in rats 

with heart failure post myocardial infarction. P895 

V. Cachofeiro Ramos, A.A. Fernandes, M. Valero-Munoz, R.F. Ribeiro Jr, M. Martinez, 

C. Rodriguez, D.V. Vassallo, J. Martinez-Gonzalez, V. Lahera, I. Stefanon (Madrid and 

Barcelona, ES; Vitoria, BR) 

110



Cardiac lesions induced by testosterone: protective effects of dexrazoxane and 

trimetazidine P896 

Q. Timour Chah, D. Belhani, F. Vaillant, L. Dehina, A. Jacquet, J. Descotes (Lyon and 

Courbevoie, FR) 


grey zone of left ventricular ejection fraction in acute coronary syndrome P897 

H. Dores, S. Leal, I. Rosario, L. Bronze, M.J. Correia, J. Monge, I. Arroja, C. Fonseca, 


right ventricular echocardiographic parameters in patients with pulmonary arterial 

hypertension P898 

L. Agoston Coldea, T. Mocan, S. Lupu (Cluj-Napoca, RO) 

the longitudinal systolic function of the left ventricle in patients with heart failure 

with preserved ejection fraction caused by arterial hypertension P899 

I. Daskalov (Sofia, BG) 

left ventricular dyssynchrony, assessed by real-time 3-D echocardiography, relates 

to functional status, mitral regurgitation and biomarkers increase in pts with 

symptomatic dilated cardiomyopathy P900 

E. De Marco, R. Natali, F.A. Gabrielli, B. Garramone, M. Savino, G. Comerci, M. Lotrionte, 

A. Sonaglioni, F. Loperfido (Rome, IT) 

the relation between the mitral annular motion and the ejection fraction in patients 

with reduced global systolic function P901 


Systolic and diastolic parameters of heart failure changes from the very early stage of 

hypertension in non-dippers P902 

C.S. Park, M.J. Kim, S.H. Ihm, H.Y. Kim, E.J. Cho, H.O. Jung, H.K. Jeon, H.J. Youn, J.H. Kim 

(Seoul, KR) 

2D Ste-based strain imaging is superior to tDi-based strain imaging in 

differentiation of transmural from non-transmural chronic scar in post-mi patients 

with lV systolic dysfunction P903 

O. Khaleva, O. Onyshchenko, E. Lukaschuk, N. Sherwi, A. Torabi, J. Zhang, N. Nikitin, 

J.G. Cleland (Hull, GB; Linköping, SE) 

improvement in left atrial volume as assessed by 3D and 2D echocardiography in 

obstructive sleep apnoea: effects of continuous positive airway pressure therapy P904 

M. Butt, G. Dwivedi, O.A. Khair, R. Haynes, G.Y.H. Lip (Birmingham, GB) 

three-dimensional echocardiography to assess right ventricular size and function. 

Validation against magnetic resonance, two-dimensional and m-mode measurements P905 

D. Miani, D. Muraru, M.T. Grillo, R. Onut, D. Ermacora, P. Gianfagna, L. Badano (Udine, 

IT; Bucarest, RO) 


left ventricle diastolic function and myocardial coronary calcium index in the patients 

with coronary artery disease, arterial hypertension combined with nonalcoholic 

steatohepatitis P906 

M.N. Dolzhenko, A.Y. Bazilevich, M.I. Sarbash, O.A. Sharaevskiy (Kiev and Lviv, UA) 

111 

monDaY 

PoSterS

monDaY 

PoSterS 



Cardiac involvement in chronic fatigue syndrome as assessed by combined cardiac 

magnetic resonance imaging P907 

M. Olimulder, M.A. Galjee, J. Van Es, J. Van Der Palen, F.C. Visser, R.C.W. Vermeulen, 

C. Von Birgelen (Enschede and Amsterdam, NL) 

microvascular myocardial ischemia correlates to improvement of left ventricular systolic 

function in non-ischemic cardiomyopathy patients with heart failure after long-term 

oral dipyridamole P908 

M.V. Simoes, P.V. Schwartzmann, A.B. Figueiredo, A.O. Pintya, F. Marques, B.C. Maciel 

(Ribeirao Preto, BR) 


multiple biomarkers in the evaluation of cardiac toxicity associated with anthracycline 

chemotherapy P909 

J.M. Horacek, R. Pudil, M. Vasatova, M. Tichy, L. Jebavy, J. Maly (Hradec Kralove, CZ) 


Diastolic dysfunction in children and adults with familial hypertrophic cardiomyopathy P910 

A. Goodkova, M.V. Yuschenko, A.V. Kozlenok, A.N. Krutikov, G.A. Novik, E.V. Shlyakhto 


low-dose dopamine prevents worsening of renal function in elderly patients 

hospitalized for acute decompensated heart failure P911 

G. Karayannis, G. Giamouzis, C. Parisis, D. Rovithis, J. Nastas, J. Butler, R.C. Starling, 

T. Tsaknakis, J. Skoularigis, F. Triposkiadis (Larissa and Volos, GR; Atlanta, Georgia and 

Cleveland, US) 

High central venous pressure and left ventricular filling pressure are associated with 

renal function worsening P912 

M. Iacoviello, A. Puzzovivo, P. Guida, D. Saulle, C. Forleo, M.M. Ciccone, S. Favale (Bari, IT) 


adenosine up-regulates chemotaxis of endothelial progenitor cells through enhanced 

expression of CXCr4 P913 

F. Leonard, M. Rolland-Turner, C. Nicolas, Y. Devaux, D.R. Wagner (Luxembourg, LU) 


mechanical stress induces nfat activity and a hypertrophic response in isolated 

cardiomyocytes from neonatal mice P914 

G. Florholmen, I.G. Lunde, C.R. Carlson, G. Christensen (Oslo, NO) 


the difficulties of functional class heart failure assessment in the patients with 

concomitant chronic obstructive pulmonary disease P915 

P.A. Fedotov, M.Y. Sinikova, E.V. Shlyakhto, N.L. Shaporova, V.V. Dorofeykov 


112



Chronic obstructive pulmonary disease in heart failure: prognostic implications P916 

F. Cecaro, A. Fucili, E. Faragasso, S. Biscaglia, A. Ferri, A. Potena, L.M. Fabbri, P. Boschetto, 

C. Ceconi, R. Ferrari (Ferrara and Modena, IT) 

Do value of the ejection fraction and BnP concentration have relationship with 

apnea/hypopnea index in heart failure patients? P917 

M. Dobosiewicz, W. Sinkiewicz, D. Karasek (Bydgoszcz, PL) 

osteoporosis is highly prevalent in heart failure and is associated with its severity and 

prognosis P918 

P. Zotos, J. Terrovitis, E. Tseliou, N. Diakos, I. Pozios, A. Tassoulis, L. Vlahakis, 

A. Chalazonitis, M. Anastasiou-Nana, J. Nanas (Athens, GR) 

Prevalence estimates of anaemia in patients with suspected and confirmed chronic 

heart failure (CHf) are highly sensitive to differences in haemoglobin threshold P919 

K. Goode, A.L. Clark, S. Ghosh, J. Kim, J.G. Cleland (Hull and Cambridge, GB) 

in vitro cell studies investigating co-morbidities aggravating heart failure P920 

A.Y. Goodkova, A.Y. Zaritskey, S.V. Anisimov, A.A. Kostareva, I.R. Minullina, R.I. Dmitrieva, 

I.A. Meln, A.A. Bilibina, O.V. Tarasova, E. V. Shlyakhto (St Petersburg, RU) 


markers of inflammation under combination therapy with telmisartan and statin in 

hypertensives with heart failure P921 

O.M. Sheremeta, M. A. Orynchak, V. E. Neyko (Ivano-Frankivsk, UA) 

inflammatory status and coronary collaterals development in acute myocardial infarction P922 

R. Glowczynska, A. Budaj-Fidecka, M. Grabowski, J. Wilczynska, W. Kukwa, A. Kondracka, 

K.J. Filipiak, G. Opolski (Warsaw, PL) 

Plasma levels of Wnt inhibitory factor-1 (Wif-1) are elevated and predict mortality in 

symptomatic aortic stenosis P923 

E.T. Askevold, L. Gullestad, S. Aakhus, O.G. Solberg, P. Aukrust, T. Ueland (Oslo, NO) 

association of increased fractalkine levels and impaired clopidogrel responsiveness in 

human and experimental heart failure P924 

A. Schaefer, D. Fraccarollo, U. Flierl, J. Pfrang, G. Ertl, J. Bauersachs (Wuerzburg, DE) 

Pentraxin 3 causes ventricular dysfunction after pressure-overload P925 

Y. Takeishi, S. Suzuki, I. Kubota (Fukushima and Yamagata, JP) 


assessment of the impact of intracoronary infusion of bone marrow mononuclear cells 

(BmmCs) on left ventricular remodeling of patient with moderate chronic heart failure P926 

S.S. Bazhan, A.V. Sychev, V.I.U. Mareev, A. Samko, O.V. Stukalova, Y.A. Romanov, 

A.N. Sokolov, Y.F. Osmolovskaya, I.U.N. Belenkov (Moscow, RU) 

Characterization and defining a new subset of hematopoietic stem cells for myocardial 

regeneration after ami by its intracellular reactive oxygene species level (roS) P927 

C. Rueder, N. Langwieser, J. Peter, J. Schwarz, H.P. Schultheiss, D. Zohlnhoefer 

(Berlin, DE) 

113 

monDaY 

PoSterS

monDaY 

PoSterS 




Prevalence of and clinical associations with the 3rd heart sound according to acoustic 

intensity grade in out-patients with heart failure P928 

D. Cullington, C. Lewinter, K.M. Goode, J.G.F. Cleland (Kingston-Upon-Hull, GB) 


reference change values and determinants of variability of ntproanP and gDf15 in 

stable chronic heart failure P929 

L. Frankenstein, S. Gut, G. Hess, J. Franke, T. Taeger, D. Zdunek, H. Katus, C. Zugck 

(Heidelberg and Mannheim, DE) 

analysis of the effects of sexual hormone estrogen on cardiomyocyte hypertrophy (CmH) P930 

S. Mahmoodzadeh, E. Dworatzek, E. Eva Brozova, K. Nawrath, A. Kuehne, 

V. Regitz- Zagrosek (Berlin, DE) 


Heart failure with preserved systolic function: a forgotten threat? P931 

A. C. Faustino, F. Caetano, S. Barra, P. Gomes, J. Silva, R. Providencia, L. Seca, G. Costa, 

M. Costa, A. Leitao-Marques (Coimbra, PT) 

analysis of left ventricle diastolic indices compared to the functional classes in a 

population with left ventricle ejection fraction ranging from 40 to 60% P932 

L.C. Danzmann, D.C. Roso, C. Cyrre, C.M. Stefani, E.L. Garcia, M.G. Menezes, 

A.C.G. Schaidauer, S. Bordignon, M.A.R. Torres, I. Kohler (Porto Alegre, BR) 

Value of tei index and e/e ratio determination in patients with heart failure with 

preserved systolic function. P933 

D. Karasek, J. Blazejewski, W. Sinkiewicz, J. Dudziak (Bydgoszcz, PL) 

Parameters of diastolic left ventricle function and polysomnographic parameters in 

acute myocardial infarction P934 

R. Glowczynska, A. Budaj-Fidecka, M. Grabowski, W. Kukwa, J. Wilczynska, A. Kondracka, 

J. Kochanowski, K.J. Filipiak, G. Opolski (Warsaw, PL) 

Hospitalized congestive heart failure patients with preserved vesrus reduced left 

ventricular systolic function. P935 

T. Livieratos, A.R. Tziovas, K.Y.R. Grammatikopoulos, G.E. Agrafiotis, K.Y.R. Perdikouris, 

G.E. Kordosis (Agrinio, GR) 

esterase and homocysteine thiolactonase activities of paraoxonase -1 (Pon-1) in heart 

failure patients with preserved left ventricular fraction P936 

E. Moldoveanu, D.S. Marta, M. Serban, I. Serban, G. Catalin, G. Manole, V.G. Dinca, 

R. Huica, M. Lazar, T. Kosaka (Bucharest, RO; Osaka, JP) 

assessment of lV diastolic functions in HCV patients using tissue doppler imaging and 

ntproBnP P937 

A. Saleh, A. Matsumori, H. Negm, H. Fouad, A. Onsy (Cairo, EG; Kyoto, JP) 

a comparison of left atrial volumes evaluated by 3D &2D echocardiography in 

obstructive sleep apnoea with hypertensive and healthy controls P938 


114



arterial stiffness and coronary flow reserve are independent determinants of left 

ventricular untwisting in untreated patients with essential hypertension: a speckle 

tracking echocardiography study P939 

I. Ikonomidis, J. Lekakis, I. Parskevaidis, H. Triantafyllidi, S. Tzortzis, C. Papadopoulos, 

P. Trivilou, M. Anastasiou-Nana, D.T. Kremastinos (Athens, GR) 


Patient with ischemic heart disease and obesity and left ventricle remodeling P940 

A. Ibatov (Moscow, RU) 

myocardial structure in type 2 diabetes and the metabolic syndrome P941 

D. J. Campbell, D.L. Prior, A.J. Jenkins, M. Yii, J.F. Kenny, A.N. Newcomb, M.J. Black, 

D.J. Kelly (Fitzroy and Clayton, AU) 

neurohormonal and prognostic weight of type 2 diabetes mellitus in chronic heart failure P942 

L.E. Pastormerlo, M. Emdin, G. Vergaro, A. Valleggi, A. Gabutti, G. Mirizzi, C. Mammini, 

C. Passino (Pisa, IT) 


oleuropein induced cardioprotection but not cardiac preconditioning in rats P943 

M. Esmailidehaj, B. Rasoulian, M. Mosadeghmehrjerdi, S. Moshtaghion, A. Morshedi 

(Yazd and Khoramabad, IR) 


impact of genetic polymorphisms of beta-adrenergic and raaS on progression left 

ventricular systolic dysfunction and remodelling in patients with chronic heart failure. P944 

C. Bergamini, M. Cicoira, A. Rossi, M. Rigolli, D. Cassater, L. Zanolla, C. Vassanelli 

(Verona, IT) 

a2a and a3, adenosine receptors mrna are overexpressed in an experimental animal 

model of myocardial infarction P945 

S. Del Ry, M. Cabiati, M. Campan, C. Caselli, T. Prescimone, D. Giannessi (Pisa, IT) 

mimecan is an essential regulator of cardiac extracellular matrix integrity after 


N.L.C. Van Aelst, M. Swinnen, S.A. Cook, F. Van De Werf, P. Carmeliet, B. Schroen, 

D. Vanhoutte, S. Heymans (Leuven, BE; London, GB; Maastricht, NL) 


relation of exercise capacity and nt-proBnP levels in patients with chronic severe 


M.S. Shin, B.R. Kim, W.-J. Chung, W.C. Kang, K.H. Lee, T.H. Ahn, E.K. Shin (Incheon and 

Seoul, KR) 

Correlation between serum nt-proBnP levels and hemodynamic parameters obtained 

by thoracic electrical bioimpedance in patients with chronic heart failure P948 

H. Hamad, J. Feliciano, R.M. Soares, A. Lousinha, N. Santos, F. Ferreira, B.T. Valente, 

S. Silva, F. Miranda, R.C. Ferreira (Lisbon, PT) 

Plasma and urinary cgmP in heart failure in relation to natriuretic peptides P949 

A. Jovanovic, S. Lehinant, W.G. Forssmann, C. Hamm, V. Mitrovic (Bad Nauheim and 

Hannover, DE) 

115 

monDaY 

PoSterS

monDaY 

PoSterS 



Sequencing and cardiac expression of natriuretic peptide receptors a and C in normal 

and heart failure pigs P950 

M. Cabiati, M. Campan, C. Caselli, T. Prescimone, D. Giannessi, S. Del Ry (Pisa, IT) 


the efficiency of carbon dioxide output and ventilatory response while 

cardiopulmonary exercise test is related to cognitive performance irrespective of left 

ventricular contractile function P951 

R. Skalik, W. Wozniak, L. Borodulin-Nadzieja (Wroclaw, PL) 

Potential pathophysiological role of chronic fc(gamma)-ii receptor stimulation in DCm P952 

L. R. Herda, C. Mueller, L. G. Eckerle, Y. Reinke, S. B. Felix, A. Staudt (Greifswald, DE) 


Different controll of angiotensine converting enzyme (aCe) expression in the sera and 

in vascular tissue P953 

A. Darago, M. Fagyas, Z. Galajda, T. Szerafin, J. Harsfalvi, I. Edes, Z. Papp, A. Toth, 

J. Szentmiklosi (Debrecen, HU) 


Simple telecardiology Programme in Severe Heart failure Patients. P954 

C. Armentano, M. F. Piepoli, A. Malagoli, M. Villani, G.Q. Villani (Piacenza, IT) 

telemedicine reduces hospitalisation rates in patients with chronic heart failure - 

results of the randomized Hitel trial P955 

C. Zugck, R. Cebola, L. Frankenstein, M. Nelles, T. Taeger, R. Pribe, R. Pribe, P. Ehlermann, 

D. Schellberg, H.A. Katus (Heidelberg, DE) 


Heart failure in women P956 

F. Adam, A. Popa, R. Ciomag, E. Ovricenco, C. Sinescu (Bucharest, RO) 

moderate coffee consumption lowers the likelihood of developing left ventricular 

systolic dysfunction in post acute Coronary Syndrome normotensive patients P957 

C. Chrysohoou, C. Kastorini, P. Aggelopoulos, G. Metallinos, A. Aggelis, C. Antoniou, 

P. Arsenos, D. Panagiotakos, C. Pitsavos, C. Stefanadis (Athens, GR) 

management of acute heart failure in 2009: the ofiCa study P958 

D. Logeart, R. Isnard, F. Bauer, F. Delahaye, E. Donal, J.C. Eicher, M. Galinier, P. Gibelin, 

P. Jourdain, G. Mulak (Paris, Rouen, Lyon, Rennes, Dijon, Toulouse, Nice and Pontoise, FR) 

low socioeconomic status predicts increased risk of heart failure P959 

E. Prescott, M. Heitmann, S. Christensen, R. Mogelvang (Copenhagen and Holbaek, DK) 

Premature ventricular complexes are associated with risk of new-onset heart failure: 

results from the ariC study P960 

S. Agarwal, G. Heiss, R. Simpson, P. Rautaharju, E. Shahar, M. Massing, S. Saba (Chapel 

Hill, Winston-Salem, Tucson and Pittsburgh, US) 

116




myocardial contractility and muscular reserve of sportsmen during the two week 

trainings P961 

A. Bobrov, N. Hyshova, L. Bobrov (St Petersburg, RU) 

effect of bisoprolol and carvedilol on glycemic control and exercise intolerance in 


T. Naka, C. Yoshida, T. Akagami, T. Doi, K. Takahashi, M. Masutani, T. Sakoda, T. Tsujino, 

T. Masuyama, M. Ohyanagi (Nishinomiya, JP) 

effect of different intensities of physical training on cardiopulmonary exercising test 

principal prognostic parameters in a population of chronic heart failure patients P963 

F. Cecaro, A. Fucili, E. Faragasso, L. Pirani, S. Biscaglia, A. Ferri, M. Malagu, C. Ceconi, 


Haemodynamic response to exercise in men with heart failure with impaired and 

preserved left ventricle ejection fraction P964 

B. Krakowiak, W. Banasiak, E. A. Jankowska, P. Ponikowski (Wroclaw, PL) 

functional electrical stimulation is more effective in severe symptomatic heart failure 

patients and improves their adherence to rehabilitation programs P965 

V. Matzaraki, A. Karavidas, J. T. Parissis, S. Arapi, C. Varounis, P. Grillias, V. Pirgakis, 

G. Filippatos, M. Anastasiou-Nana, D. Kremastinos (Athens, GR) 

right heart hemodynamics in heart failure: relation to exercise capacity. P966 

M. T. La Rovere, R. Maestri, G.D. Pinna, J. Baccheschi, A. Caporotondi, G.P. Guazzotti, 

O. Febo (Montescano, IT) 

Clinical efficiency of electrical stimulation of skeletal muscles in aged patients with 

postinfarction heart failure P967 

A.V. Bezdenezhnykh, A. N. Sumin, O.M. Baydina, T.A. Popova, O.P. Hayredinova 

(Kemerovo and Leninsk-Kuznetsky, RU) 

effects of differents physical training methodologies on cardiac function and 

baroreflex sensibility in dilated cardiopathy P968 

G. Masson, C. Espindula, L. Marafoni, G. Oliveira, A. Lucena, E. Tibirica, M.A. Lessa 

(Rio de Janeiro, BR) 

Nursing 

Components of life Quality evaluation in Heart failure Clinic P970 

F.D.C. Cruz, V.S. Issa, S.A.M. Ayub, F.B. Bacal, E.B. Bocchi (Sao Paulo, BR) 

there is no correlation between heart failure patients knowledge and their reactions P971 

A. Boireau, P. Jourdain, C. Antoniazzi (Pontoise and Paris, FR) 

long term medical art therapy: influence on quality of life, functional capacity and 

compliance in advanced heart failure patients. P972 

N. Sela, N. Baruch, R. Stein, V. Yaari, A. Pinchas, A. Battler, T. Ben Gal (Petah Tikva, IL) 


results of the implementation of a nursing program intervention in Heart failure Unit P973 

M.G. Lopez Moyano, M.M. Martinez Quesada, C. Rus Mansilla, D. Duran Torralbo, 

G. Cotez Quiroga, C. Recuerda Casado, M. Delgado Moreno Andujar, ES) 

117 

monDaY 

PoSterS

monDaY 

PoSterS 



influence of uptitration of carvedilol and trandolapril on hemodynamics in severe 


P. Lesny, M. Luknar, E. Goncalvesova (Bratislava, SK) 

risk factors may be different on short term re-hospitalization and on long term rehospitalization 

in patients with chronic heart failure P975 

G. Kozdag, M. Yaymaci, G. Ertas, U. Bildirici, T. Kilic, E. Ural, D. Ural (Kocaeli, TR) 

management of heart failure: a comparison of general practitioners and cardiologists P976 

M.J.M. Valk, F.H. Rutten, A. Mosterd, A.W. Hoes (Utrecht, NL) 


anxiety predicts Quality of life in patients with Chronic Heart failure independently 

of the severity of disease. P977 

L. Samartzis, C. Manetos, S. Dimopoulos, V. Agapitou, A. Mpouchla, E. Tseliou, I. Pozios, 

E. Kaldara, J. Terrovitis, S. Nanas (Athens, GR) 

Other 

Value of left atrial function in predicting effort capacity in patients with left ventricular 

systolic dysfunction P978 

S. Mansy, M. Madkour, M. Abo Elmagd, M. Ezzat, W. Attia, S. Hozayen (Cairo, EG) 

Heart failure in patients with HiV infection: an evolving clinical condition P979 

S.R. Devarapally, S. Hoskote, E. Herzog (New York, US) 

Determinants of aortoventricular coupling in the presence and absence of post-infarct 

lV remodelling P980 

V.O. Puntmann, J. Mirelis, R. Gebker, C. Jahnke, B. Schnackenburg, K.F. Fox, E. Fleck, 

I. Paetsch (London, GB; Berin, DE) 

Heart failure and depression - chicken and egg, or interacting evils? P981 

G. Gelbrich, H. Faller, F. Kendel, S. Stoerk, A. Broda, M. Loeffler, G. Ertl, C. E. Angermann 

(Leipzig, Wuerzburg and Berlin, DE) 

Prevalence of diastolic dysfunction and associated predictors of heart failure in dialysis 

patients with preserved ejection fraction P982 

E. Joyce, M. O’shaughnessy, A. Khan, D. Reddan, D. Lappin, B. Mcneill, J. Crowley, 

K. Daly, P. Nash (Galway, IE) 

are there right ventricular dysfunction predictors after tetralogy of fallot repair? P983 

C.N. Lourenco, H. Andrade, N. Antonio, D. Rodrigues, G. Castro, M. Silva, M.J. Ferreira, 


118

monDaY 31 maY 2010 - afternoon PoSterS 



Population studies - telemedicine - Psychosocial / ethical concept & education - 

exercise testing & training - 

Chairperson(s): I.L. Pina (Cleveland Heights, US); F.M. Fruhwald (Graz, AT) 




15:45 How much longer do you want to live?: end of life issues associated with 

implantable cardioverter defibrillators P984 

P.H. Strachan, S.L. Carroll, L. Schwartz, S. De Laat, H.M. Arthur (Hamilton, CA) 

15:50 the burden of heart failure: excess mortality and life years lost P985 

P. Engelfriet, R.T. Hoogenveen, H.C. Boshuizen, P.H.M. Van Baal (Bilthoven, NL) 

15:56 addictional beneficts of tai chi and endurance training in elderly patients with 

chronic heart failure: a randomized pilot study. P986 

G. Caminiti, M. Volterrani, A. Cerrito, G. Marazzi, B. Sposato, A. Franchini, 

M.E. Lippi, G. Rosano (Rome, IT) 

16:01 Short-stay units as an alternative to internal medicine for elderly patients with 


D. Chivite Guillen, R. Pujol, A. Salazar, J. Alonso (L’Hospitalet de Llobregat, ES) 

16:07 long term follow up of left ventricular dysfunction in an urban population P988 

T. A. Mcdonagh, I. Ford, H.J. Dargie (London and Glasgow, GB) 

16:13 guideline based remote monitoring and 24/7 telephone support for people 

with heart failure: an opportunity to improve outcomes in germany P989 

F. Zucca, D. Baden, B. Neukirch, W. Urbaszek (Dusseldorf, Krefeld and Rostock, DE) 

16:18 the Canadian Cardiovascular Society Heart failure guidelines: results of the 

5-year closed loop implementation program P990 

G. W. Moe, J.G. Howlett, R.S. Mckelvie, C. Pullen (Toronto, Calgary, Hamilton and 

Ottawa, CA) 

16:24 a meta-analysis of 8,323 heart failure patients receiving structured 

telephone support or non-invasive telemonitoring to reduce mortality, 

hospitalisation and cost P991 

S.C. Inglis, R.A. Clark, F.A. Mcalister, J. Ball, C. Lewinter, D. Cullington, S. Stewart, 

J.G.F. Cleland (Melbourne and Adelaide, AU; Edmonton, CA; Cottingham, GB) 

119 

monDaY 

PoSterS

monDaY 

PoSterS 








Heart failure in Chagas Desease P992 

O. Londono, S.U.S.A.N.A. Pacreu (Barcelona, ES) 

the occurrence and prognostic significance of permanent atrial fibrillation in acutely 


S. Kozhukhov, A. Parkhomenko (Kiev, UA) 

risk factors for the development of cardiogenic shock after primary percutaneous 

coronary intervention P994 

I. Mrdovic, L. Savic, G. Krljanac, J. Perunicic, M. Asanin, Z. Vasiljevic, M. Ostojic, R. Lasica 

(Beograd, RS) 

Clinical Predictors of mortality in Heart failure in the real World P995 

M. Manankil, C. Mahr, M. Chandrasekaran, E.J. Jorge, G. Rossell, V. Eranki, M. Niaki, 

S.C. Danciu (Chicago, US) 

Changes in autonomic balance in patients with decompensated chronic heart failure P996 

A. Rydlewska, E. A. Jankowska, B. Ponikowska, L. Borodulin-Nadzieja, W. Banasiak, 


recovery of the left ventricular ejection fraction after a hospital income with acute 

systolic heart failure: prevalence, outcome predictors and prognosis P997 

J. G. Sanchez Ramos, P. Martin De La Fuente, S. Martinez Huertas, E.D. Moreno Escobar, 

G. Moreno Terribas, J.M. Lozano Herrera, A. Gonzalez Ramirez, C. Correa Vilchez 

(Granada, ES) 

mode of death in advanced heart failure: impact of race, etiology and hemodynamics 

in the evaluation Study of Congestive Heart failure and Pulmonary artery 

Catheterization effectiveness (eSCaPe) trial P998 

J. Rogers, C. Lombardi, M. Fiuzat, G. Tassisa, C. O’connor (Durham, US; Brescia, IT) 

Cardiogenic shock complicating acute coronary syndrome in octogenarians: outcome 

following percutaneous intervention P999 

J. Delgado Silva, S. Barra, L. Seca, F. Caetano, R. Providencia, P. Gomes, J.R. Pais, 

A. Leitao-Marques (Coimbra, PT) 

estimated glomerular filtration rate as an indicator of outcome in elderly patients 

admitted with acute decompensated heart failure. is occult renal insufficiency 

something to take care with? P1000 

F. Bacal, A. Abuhab, S. Mangini, A.G. Correa, P.K.O. Yokota, B.F. Santos, M. Makdisse 


Predictors of ventricular septal defect in patients after acute myocardial infarction 

treated with successful primary percutaneous coronary intervention P1001 

A. Ledakowicz-Polak, L. Polak, M. Zielinska (Lodz, PL) 

120



the t-786C promoter gene polymorphism of endothelial nitric oxide synthase: 

relationship with acute heart failure in patients with acute myocardial infarction P1002 

S. Kozhukhov, A. Parkhomenko, Y. Lutay, O. Irkin, A. Moibenko, V. Dosenko (Kiev, UA) 

impact of human immunideficiency virus(HiV)/aiDS on the manifestation of newly 

diagnosed heart failure in an urban african community: insights from the Heart of 

Soweto Study P1003 

K. Sliwa, M. Carrington, A. Becker, M. Ntsekhe, S. Stewart (Cape Town and 

Johannesburg, ZA; Melbourne, AU) 


intermediate follow-up results of therapy with intravenous milrinone for low output 

acute decompensated heart failure in patients with nYHa class iV P1004 

R. Martos, C. Lewis, B. Mcadam (Dublin, IE) 

Single centre obserational studysuggest that 1st line intravenous diuretic therapy 

is superior to oral diuretics in advanced heart failure with an episode of decompensation 

in an ambulatory setting P1005 

C.C. Lewis, M. Alqaseer, R. Conroy, B. Mcadam (Dublin, IE) 

interim analysis of the alster Stem cell trial: percutaneous, intramyocardial injection of 

unselected bone marrow cells via noga-XP after acute myocardial infarction P1006 

M. W. Bergmann, C. Schneider, K. Jaquet, K. Krause, K.H. Kuck (Hamburg, DE) 

is it really necessary to withdraw betablockers in patients with acute heart failure with 

signs of low output? P1007 

M.V. Lima, J.N. Cardoso, M.E. Ochiai, P.C. Morgado, R.T. Munhoz, P.S. Grativvol, 

K.M. Grativvol, E.C.O. Brancalhao, A.R. Scipione, A.C. Pereira-Barreto (Sao Paulo, BR) 

Beta-blocker pretreatment does not affect the renoprotective effects of low-dose 

dopamine in patients admitted for acute decompensated heart failure. P1008 

G. Giamouzis, D. Rovithis, C. Parisis, J. Nastas, G. Karayannis, J. Skoularigis, T. Tsaknakis, 

J. Butler, R.C. Starling, F. Triposkiadis (Larissa and Volos, GR; Atlanta, Georgia and 

Cleveland, US) 

renal impairment does not alter the pharmacokinetics of the soluble guanylate 

cyclase activator cinaciguat (BaY 58-2667) P1009 

J.T. Lettieri, A. Mazzu, R. Frey, W. Mueck, R. Silang, W. Smith, T. Marbury, C. Cannon, 

K. Lasseter, P.R. Sundaresan (Pine Brook, NJ, Knoxville, TN, Orlando, FL, Minneapolis and 

Miami, US; Wuppertal, DE) 


left ventricular reverse remodeling due to cardiac resynchronization therapy, in 

patients with dilated cardiomyopathy and heart failure P1010 

M. Petrovic, B. Vujisic-Tesic, M. Petrovic, G. Milasinovic, D. Trifunovic-Zamaklar, I. 

Nedeljkovic, Z. Calovic, V. Jelic, I. Petrovic, M. Banovic (Belgrade, RS) 

gender-related differences in response to cardiac resynchronization therapy: are 

women the superior sex? P1011 

R. Dierckx, M. Goethals, S. Verstreken, M. De Proft, C. Keppens, M. Vanderheyden 

(Aalst, BE) 

121 

monDaY 

PoSterS

monDaY 

PoSterS 



early and delayed effects of resynchronization therapy in elderly patients with severe 

heart failure patients P1012 

S. De Feo, A. Fusco, F. Leonardo, O. Spadaro, G. Cannizzaro, I. Sheiban, L. Pederzoli, 

A. Vicentini (Peschiera del Garda, IT) 

over 10 years of cardiac resynchronization therapy: a single center experience very 

long term all cause mortality data P1013 

F. Oliva, M. Cipriani, M. Lunati, G. Cattafi, G. Masciocco, F. Macera, F. Turazza, D. Fanelli, 

S. Bisetti, M. Frigerio (Milan, IT) 

echocardiography in cardiac resynchronization therapy: is it possible to anticipate 

responders? P1014 

M.Z. Petrovic, M. Petrovic, G. Milasinovic, B. Vujisic-Tesic, I. Nedeljkovic, 

D. Trifunovic-Zamaklar, Z. Calovic, V. Jelic, I. Petrovic, M. Banovic (Belgrade, RS) 

righ ventricular versus biventricular pacing in patients with preserved lV function - 

tUgenDHat study P1015 

M. Taborsky, J. Kupec, J. Vlasinova, J. Spinar, M. Novak, J. Vitovec (Prague and Brno, CZ) 


risk factors associated with development of microalbuminuria in acute myocardial 

infarction P1016 

D. Stanojevic, S. Apostolovic, R. Jankovic Tomasevic, D. Djordjevic Radojkovic, 

S. Salinger Martinovic, M. Pavlovic, V. Djordjevic, M. Damjanovic, G. Koracevic (Nis, RS) 

Prevalence and prognostic evaluation of left bundle branch block in patients with 

chronic heart failure. P1017 

T. Livieratos, K.Y.R. Grammatikopoulos, A.R. Tziovas, G.E. Agrafiotis, K.Y.R. Perdikouris, 

G.E. Kordosis (Agrinio, GR) 

minnesota life score predicts 3-year survival in nYHa iii chronic heart failure patients P1018 

L. Voronkov, L. Parashchenjuk, P. Babich (Kyiv, UA) 

Six years mortality in older adults with heart failure in an outpatient setting P1019 

V. S. Engin, M. Ozturk, C. Kaymaz, M. Sarac (Istanbul and Isparta, TR) 

Beck depression inventory scale and marital mtatus: two novel prognostic predictors 

in chronic heart failure? data from the national institutes of mental health (nimH) 

heart failure survey P1020 

C. Lombardi, M. Fiuzat, W. Jang, M. Kuchibhatla, S. Ladd, R. Krishnan, C. O’connor 

(Brescia, IT; Durham, US) 

turbulence onset of heart rate predicts total mortality in heart failure patients P1021 

P. Arsenos, K. Gatzoulis, T. Gialernios, P. Dilaveris, S. Archontakis, K. Masoura, 

V. Antonakis, I. Dima, K. Zissimos, C. Stefanadis (Athens, GR) 

the prognostic value of blood pressure response to exercise in patients with heart 

failure. a simple cost effective non invasive marker P1022 

M. S. Kallistratos, A. Dritsas, I. D. Laoutaris, L.E. Poulimenos, A. Pittaras, A. J. Manolis, 

D. V. Cokkinos (Athens, GR) 

Proportional pulse pressure, a non-invasive parameter with high prognostic power in 

advanced heart failure P1023 

M. Dekany, B. Szabo, N. Nyolczas, B. Ancsin, T. Borsanyi, E. Marosi, R.G. Kiss 


122



risk Stratification in men and Women With Chronic Heart failure - Do nt-proBnP, 

mUStt mortality Score and HfSS Score equally Perform? P1024 

J. Franke, L. Frankenstein, M. Hochadel, P. Ehlermann, A. Schmitt, M. Nelles, R. Zahn, 

H.A. Katus, J. Senges, C. Zugck (Heidelberg and Ludwigshafen am Rhein, DE) 

How can decompensated heart failure be predicted following discharge for acute 

myocardial infarction? P1025 

S. N. C. Barra, P. Gomes, J. Silva, R. Providencia, L. Seca, A. Leitao Marques (Coimbra, PT) 

Prognostic implications of citomegalovirus infection in patients with acute heart failure P1026 

J. Nunez, D. Navarro, J. Sanchis, V. Bodi, G. Minana, M. Pellicer, M. Chilet, P. Merlos, 

E. Nunez, A. Llacer (Valencia, ES) 

is left ventricular ejection fraction the best predictor of the efficacy of ace inhibitors, 

angiotensin receptor blockers, beta-blockers and aldosterone antagonists? the 

galichus study P1027 

L. Grigorian, F. Otero Ravina, A. Varela Roman, L. Zuniga, C. Pineiro Diaz, C. Iglesias Diaz, 

J.R. Gonzalez-Juanatey (Santiago De Compostela, A Coruña and La Coruña, ES) 

Pulmonary systolic pressure as a major risk factor in patients with severe heart failureresults 

of PolKarD-Hf-registry. P1028 

J. Wisniewska, A. Browarek, T. Zielinski, K. Kozar-Kaminska, J. Korewicki (Warsaw, PL) 


acute myocardial infarction with 3 vessel disease, what really matters to the prognosis? P1029 

P. Gomes, S. Barra, R. Providencia, L. Seca, G. Costa, F. Caetano, A. Faustino, L. Paiva, 

I. Almeida, A.M. Leitao Marques (Coimbra, PT) 

Blood urea nitrogen as a marker of in-hospital prognosis in acute myocardial infarction P1030 

D. Stanojevic, S. Apostolovic, R. Jankovic Tomasevic, D. Djordjevic Radojkovic, S. Salinger 

Martinovic, M. Pavlovic, V. Djordjevic, M. Damjanovic, G. Koracevic, I. Ilic (Nis, RS) 

Ventricular arrhythmias in patients with congestive heart failure: impact of low 

tryptophan P1031 

E.V. Zukhovitskaya, V.A. Snezhitsky, E.M. Doroshenko, V.M. Pyrochkin, M.S. Deshko, 

T.P. Stempen, A.V. Naumov (Grodno, BY) 

the prognostic value of serial ntproBnP-measurements in patients with chronic heart 

failure under optimized therapy with beta-blockers and aCe-inhibitors P1032 

J. Franke, L. Frankenstein, M. Nelles, D. Schellberg, D. Schmahl, J.S. Wolter, J. Fischer, 

A. Remppis, H.A. Katus, C. Zugck (Heidelberg and Mannheim, DE) 

Predicting long-term outcome in acute heart failure patients: is sodium the answer? P1033 

R. Baptista, E. Jorge, F. Saraiva, H. Martins, P. Mendes, R. Teixeira, S. Costa, P. Monteiro, 

F. Franco, L.A. Providencia (Coimbra, PT) 

Serum YKl-40 predicts adverse clinical outcomes in patients with chronic heart failure P1034 

Y. Takeishi, S. Suzuki, O. Bilim, I. Kubota (Fukushima and Yamagata, JP) 

nt-ProBnP variation 24 and 96h after levosimendan infusion in decompensate 

congestive heart failure as a mid-term prognostic marker. 24 months follow-up. P1035 

L. Sargento, D. Brito, H. Madeira (Lisbon, PT) 

Von Willebrand factor, flow mediated dilatation and evolution with heart failure 

readmission in acute coronary syndromes P1036 

M. Donea, M. Radoi, G. Datcu, E. Bobescu, H. Rus, M. Anghel (Brasov and Iasi, RO) 

123 

monDaY 

PoSterS

monDaY 

PoSterS 




Predictors of left ventricular systolic dysfunction after permanent right ventricular 

apical pacing in patients with complete atrioventricular block and normal left 

ventricular function P1037 

E. Belu, C. Bataiosu, R. Musetescu, D.-D. Ionescu, M. Cosulschi, N. Florescu (Craiova, RO) 

Programmed ventricular stimulation as compared to the non invasive risk stratifiers for 

sudden cardiac death prediction among heart failure patients. P1038 

P. Arsenos, K. Gatzoulis, P. Dilaveris, S. Sideris, I. Sotiropoulos, G. Lazaros, C. Chrysohoou, 

S. Archontakis, L. Raftopoulos, C. Stefanadis (Athens, GR) 

mechanism of heart failure progression in patients with frequent premature 

ventricular contractions P1039 

D. C. Cozma, L. Petrescu, C. Mornos, D. Gaita, M. Rosu, S. I. Dragulescu (Timisoara, RO) 

Beta blockers 

the uptake of betablockers and acei in elderly patients with lvsd P1040 

A.L.I. Mehrzad, J. Curry, P. Cawley, A. Williams, A. Hetherington, K. Naylor (Bishop 

Auckland.Co Durham, GB) 

Beneficial effects of betablockers on left ventricular function and cellular energy 

reserve in patients with heart failure P1041 

R. Spoladore, G. Fragasso, G. Perseghin, G. Lattuada, G. Calori, F. Decobelli, 

A. Del Maschio, A. Margonato (Milan, IT) 

Beta blockers reduce mortality in heart failure patients with concurrent CoPD as 

much as in those without CoPD P1043 

F. H. Rutten, G. Guder, E. Van Riet, A.W. Hoes (Utrecht, NL; Wurzburg, DE) 

ICD therapy 

newly diagnosed non-ischemic cardiomyopathy patients bridged with the wearable 

cardioverter defibrillator P1044 

D. Karia, N. Bianco, S. Szymkiewicz (Philadelphia and Pittsburgh, US) 


Bridge to “transplantability“: normalization of high pulmonary pressure and 

pulmonary vascular resistance with axial flow pump left ventricular assist device 

support P1045 

B. Medalion, M. Abuhazira, Z. Iakobishvili, V. Yaari, E. Porath, T. Ben Gal (Petah Tikva, IL) 

Changes of matrix metalloproteinases and their inhibitor serum levels in heart 

transplant patients with acute rejection P1046 

P. Hude, J. Tomandl, J. Krejci, L. Spinarova, E. Ozabalova, P. Nemec, A. Sirotkova 

(Brno, CZ) 

Patients with low socio-economic status undergoing ventricular assist device implant 

do not have increased occurrence of adverse events P1047 

G. Ashrith, J. Franzwa, E. Mathews, J. Goerbig-Campbell, Y. Suzuki, F. Johnson (Iowa, US) 

10-years Doppler-echocardiographic follow-up after orthotopic heart transplantation - 

a single center experience P1048 

M. A. Engelen, H. Welp, J. Stypmann (Muenster, DE) 

124



temporary mechanical circulatory support for acute cardiogenic shock P1049 

A. Loforte, A. Montalto, F. Ranocchi, P. Lilla Della Monica, F. Sbaraglia, V. Polizzi, 

G. Distefano, F. Musumeci (Rome, IT) 

reduced myocardial mmP-2, mmP-9 and glutathione peroxidase activities and 

elevated cytokine levels in patients supported by left ventricular assist device P1050 

R. Caruso, J. Campolo, S. Trunfio, R. De Maria, C. Boroni, F. Milazzo, M. Parolini, 

L. Martinelli, C. Russo, O. Parodi (Milan, IT) 


Balloon aortic valvuloplasty (BaV) for end-stage calcified aortic stenosis in patients 

with heart failure and high operative risk - immediate and mid-term results - single 

center initial experience P1051 

K. Wilczek, P. Chodor, T. Niklewski, J. Glowacki, T. Podolecki, R. Przybylski, 

P. Nadziakiewicz, M. Zembala, Z. Kalarus, L. Polonski (Zabrze, PL) 

left cervico-thoracic sympathetic blockade by video-thoracoscopic clipping: a new 

surgical treatment for systolic heart failure? P1052 

G.E. Conceicao-Souza, P.M. Pego-Fernandes, L.F.P. Moreira, M.L.C. Vieira, C.J. Grupi, 

F. Bacal, M.C.P. Giorgi, G.V. Guimaraes, F.D. Cruz, E.A. Bocchi (Sao Paulo, BR) 

Severe aortic stenosis rejected for surgical valve replacement: characteristics, mortality 

and the importance of left ventricular ejection fraction and previous heart failure 

admissions. P1053 

J. Ocampo-Miguez, I. Gonzalez-Bermudez, E. Paredes-Galan, C. Rodriguez Pascual 

(Vigo, ES) 

Comparison of the development of corrected and non-corrected mild to moderate 

functional tricuspid regurgitation in a near term post-operative period P1054 

M. Smid, J. Cech, R. Rokyta, P. Roucka, T. Hajek (Pilsen, CZ) 


long term results with outpatient inotropic therapy in refractory heart failure P1055 

F. Oliva, F. M. Turazza, M. Cipriani, G. Foti, A. Garascia, F. Macera, G. Masciocco, 

M. Frigerio (Milan, IT) 

long term suppression of circulating free fatty acids in chronic heart failure patients 

changes whole body metabolism but does not affect cardiac and circulatory function P1056 

R. Nielsen, M.H. Halbirk, H.N. Norrelund, N.M. Moller, L.G. Gotzsche, 

J.E.K. Nielsen-Kudsk, S.N. Nielsen, H.E. Eiskjaer, H.E.B. Botker, H.W. Wiggers (Aarhus and 

Viborg, DK) 

effects of levosimendan in patients with decompensated advanced heart failure and 

severe renal impairment P1057 

A. N. Kitsiou, G. Papadimitriou, K. Giannakopoulos, E. Antoniou, I. Vasileiadis, M. Seferou, 

S. Karas (Athens, GR) 

effects of therapy with purine (adenosine) receptors activator on endothelial 

dysfunction in patients with heart failure P1058 

A.N. Bilovol, I. Knyazkova, V.A. Kozlovskiy (Kharkov, UA) 

acetazolamide improves severity of chronic heart failure in patients with obstructive 

sleep apnea syndrome P1059 

E. Belyavskiy, A. Kalinkin, V. Mareev (Moscow, RU) 

125 

monDaY 

PoSterS

monDaY 

PoSterS 



intravenous levosimendan in heart failure patients treated with digoxin provides no 

significant further improvement in left ventricular systolic functions: a radionuclide 

ventriculographic study P1060 

Y. Cavusoglu, A. Beyaztas, E. Entok, C. Demirustu, M. Tek, I. Uslu, A. Birdane, N. Ata 

(Eskisehir, TR) 

long-term therapy with rosuvastatin normalizes mrna and protein expression of 

nitric oxide synthase in myocardium of dogs with heart failure P1061 

S. Rastogi, S. Mishra, M. Wang, V. Zaca, M.S. Sabbah, R. Gupta, H.N. Sabbah (Detroit, US) 


intravenous intensive diuretic treatment and risk of renal deterioration in CHf pts with 

normal versus impaired lVef:new insights P1062 

R. De Vecchis, A. Ciccarelli, C. Ariano, C. Cioppa, A. Giasi, S. Cantatrione (Naples and 

Somma Vesuviana (Napoli), IT) 

Ultrafiltration: ultima ratio therapy for patients with refractory heart failure nYHa 

class iV P1063 

L. Mircheva, A. Angelov, V. Sirakova, D. Paskalev, K. Nenov (Varna, BG) 

effects of single dose administration of lixivaptan, a selective V2 receptor antagonist, 

or furosemide in healthy volunteers P1064 

W. Abraham, J. Ghali, V. Braman, A. Nirula, N. Wisniacki, C. Orlandi (Columbus, Detroit, 

Philadelphia and Cambridge, US) 


Structural and functional heart remodeling in patients with paroxysmal atrial fibrillation P1065 

D. Pilant (Vitebsk, BY) 

left atrial asynchrony: electrical and mechanical parameters in patients with persistent 

atrial fibrillation undergoing electrical cardioversion P1066 

A. Degiovanni, G. Dell’era, M. Bortnik, E. Rondano, E. Occhetta, P. Marino (Novara and 

Vercelli, IT) 

Changes in haemodynamic parameters at dilated cardiomyopathy patients with atrial 

fibrillation P1067 

T.A. Abdullaev, B.U. Mardanov, R.D. Kurbanov, Y.A.R. Akhmatov (Tashkent, UZ) 


Stress cardiomyopathy (takotsubo syndrome): analysis of 15 cases P1068 

F. Moscoso Costa, R. Gomes, P. Santos, G. Cardoso, J. Brito, R. Cale, M. Trabulo, C. Aguiar, 

J. Ferreira, A. Silva (Lisbon, PT) 

inflammatory heart disease: myopericarditis versus infection-associated cardiomyopathy P1069 

D.-G. Park, S.-Y. Chun, S.-J. Lim, S.-E. Kim, M.-K. Kim, J.-H. Lee, K.-R. Han, D.-J. Oh, 

K.-S. Hong (Seoul, KR) 

endomyocardial biopsy in takotsubo cardiomyopathy P1070 

B. Maisch, U. Baandrup, R. Moll, S. Pankuweit (Marburg, DE; Hjorring, DK) 

alcohol cardiomyopathy and heart failure. Should we yet be concerned about 

anything in 2010? 2-year follow-up. P1071 

P. Kycina, Z. Lazikova, Z. Pogranova, J. Murin (Lipt.Mikulas,Bratislava and Bratislava, SK) 

126



myocardial biopsies in greek adults with idiopathic left ventricular dysfunction is 

asociated frequently with viral and chlamydia genomes P1072 

A. Gkouziouta, S. Adamopoulos, G. Karavolias, D. Tsiapras, D. Degiannis, G. Saroglou, 

V. Voudris (Athens, GR) 

Secondary cardiomyopathy in patients with beta-thalassemia major: a model of 

reverse cardiomyopathy P1073 

S. Biscaglia, F. Cecaro, A. Ferri, A. Fucili, E. Faragasso, L. Pirani, M. Malagu, C. Ceconi, 


Safety and efficacy of ivabridine in patients with idiopathic dilated cardiomyopathy 

using echocardiography P1074 

M. M. Rayan, H. Zeidan, N. Elmahallawy, Y. Mahmoud (Cairo, EG) 

arrhytmogenic right ventricular cardiomyopathy: prognostic role of left ventricular 

function normalization under tailored tratment - preliminary results P1075 

M. Merlo, S. Pyxaras, B. Pinamonti, M. Russo, A. Draagos, G. Sinagra (Trieste, IT) 

left ventricular systolic function and myocardial iron load in transfusion-dependent 

thalassemia major patients on modern therapy P1076 

D. Farmakis, E. Polymeropoulos, E. Gotsis, A. Aessopos (Athens, GR) 

embryonic heart specific myomesin isoform as a novel marker for dilated 


R. Schoenauer, M.Y. Emmert, A. Felley, E. Ehler, T. Pedrazzini, V. Falk, S.P. Hoerstrup, 

I. Agarkova (Zurich and Lausanne, CH; London, GB) 

genetic loss of the plasma membrane calcium atPase 1 (PmCa1) leads to dilated 

cardiomyopathy and heart failure P1078 

M.A. Shaheen, M. Zi, S. Prehar, T.M.A. Mohamed, Z. Hegab, C. Schelcher, L. Neyses, 

E.J. Cartwright (Manchester, GB) 

Diversity of cardiomyopathy phenotypes regarding lamin a/C: a novel lmna 

mutation in hypertrophic cardiomyopathy P1079 

A. Perrot, M. Neubert, R. Dietz, M.G. Posch, C. Oezcelik (Berlin, DE) 


Heart and carotid arteries remodeling, moxonidine therapy in hypertensive 

postmenopausal women with metabolic syndrome P1080 

E. Chubenko, O. Belyaeva, O. Bolshakova, O. Berkovich, S. Nifontov, A. Kozlenok, 

E. Baranova, E. Shlyakhto (St Petersburg, RU) 

impedance cardiography diastolic parameters in hypertensive patients with acute 


R. Musetescu, D. Toader, A.E. Musetescu, M. Popescu, R. Radu, A. Belu, D.D. Ionescu 

(Craiova, RO) 

non-dipping pattern is associated to left ventricular hypertrophic remodeling in 


J. Silva Marques, A.G. Almeida, M.J. Correia, M.G. Lopes (Lisbon, PT) 

tissue Doppler global function index in patients with hypertensive heart diseasse, 

three years follow up P1083 

A. Stevanovic, M. Dekleva, M. Krotin, S. Trajic, A. Grdinic, A. Simic, D. Kosevic 

(Belgrade, RS) 

127 

monDaY 

PoSterS

monDaY 

PoSterS 



Hypertensive ren2 rats have mild anemia and severe bone marrow dysfunction, 

which cannot be corrected by erythropoietin administration P1084 

W.T. Ruifrok, C. Qian, H.H.W. Sillje, D.J. Van Veldhuisen, W.H. Van Gilst, R.A. De Boer 

(Groningen, NL) 


impact of long-term PDe5i (sildenafil) treatment on incidence of sudden cardiac 

death and ventricular tachyarrhytmias in patients with pulmonary hypertension and 

advanced heart failure P1085 

A. Reichenbach, H. Al-Hiti, J. Kautzner, I. Malek, V. Melenovsky (Prague, CZ) 

ratio of B-type natriuretic Peptide to fibrinogen Degeneration Product in Blood 

Could imply Chronic thromboembolic origin in de novo exposed Pulmonary 

embolism. P1086 

R. Kosugi, T. Inomata, T. Izumi (kanagawa, JP) 

Prevalence of pulmonary arterial hypertension and its relationship with BnP in heart 

failure with normal ejection fraction. P1087 

A.J. Lagoeiro Jorge, E.T. Mesquita, L.C.M. Fernandes, M.L. Ribeiro, F.V. Licio (Niterói and 

Rio De Janeiro, BR) 


the beneficial effect of n-3 polyunsaturated fatty acids on adriamycin-induced chronic 

heart failure in rats P1088 

L.L. Teng, Z. Zhang, S. Shao (Shanghai, CN) 

ankyrin B regulates na/K-atPase activity in mouse ventricular cardiomyocytes P1089 

N. Tovsrud, C.R. Carlsson, P. Wanichawan, I. Sjaastad, O.M. Sejersted, F. Swift (Oslo, NO) 

Cancer cachexia therapy: a matter of treating the heart P1090 

J. Springer, A. Tschirner, S. Palus, A. Grzesiak, E. Kaschina, J.M. Argiles, S. Von Haehling, 

S.D. Anker (Berlin, DE; Barcelona, ES) 


nt-pro-bnp over 10.000: clinical evolution in Heart failure P1091 

A. De Bernardi, M.T. Spinnler, G. Miotto, M. Balagna, F. Rabaioli, B. Parodi, D. Scotta, 

S. Cambursano, R. Orsi (Moncalieri, IT) 

expectance chronic heart failure after anterior myocardial infarction P1092 

A. Galyavich, A. Shaidullina, R. Minnetdinov, I. Yakupov, R. Galyavi (Kazan, RU) 

level of nt -pro Brain natriuretic Peptide and risk of death in patients with chronic 

heart failure. P1093 

K. Zahidova (Baku, AZ) 

elevated stress nt-proBnP levels can predict an early stage of diastolic heart failure in 

asymptomatic hypertensives with microvascular disease P1094 

A. Kisko, J. Kmec, M. Babcak, N. Kishko (Presov, SK; Uzhgorod, UA) 

evaluation of proBnP levels for the diagnosis of destabilized heart failure in patients 

admitted to emergency department. P1095 

D. Gruson, F. Thys, F. Verschuren (Brussels, BE) 

128



Correlation of nt-proBnP with metabolic liver function as assessed with 

13C-methacetin breath test in patients with acute decompensated heart failure P1096 

M. Hendrichova, F. Malek, P. Ostadal, J. Vranova, J. Horak (Prague, CZ) 

the body temperature and the extent of myocardium damage in patients with first 

acute myocardial infarction treated with successful primary percutaneous coronary 

intervention P1097 

M. Kacprzak, K. Stokfisz, M. Szyda, M. Zielinska (Lodz, PL) 

independent predictors of elevated D-dimer level in patients with chronic heart failure P1098 

N. M. Vorobyeva, A. B. Dobrovolsky, E. V. Titaeva, E. P. Panchenko (Moscow, RU) 

early diastolic dysfunction is not associated with systemic renin-angiotensin activation 

or oxidative stress P1099 

S.I. Negi, I. Shukrullah, R.R. Reddy, E. Veladar, T.M. Fan, D.P. Jones, S.C. Dudley Jr 

(Chicago and Atlanta, US) 

Biomarkers in treated patients with heart failure P1100 

E.V. Privalova, Y.N. Belenkov, L.V. Knyazeva, E.A. Zheleznyh, Y.A. Danilogorskaya 

(Moscow, RU) 

Potential new biomarkers for congestive heart failure: evaluation of apelin and 

kisspeptin in an animal model of hypertension-induced heart failure P1101 

S. Meili-Butz, K. Buehler, P. Buser, M. Brink, T. Dieterle (Basel, CH) 


left ventricular filling pressure and diastolic function evaluated with 2d speckle tracking P1102 

L. Donato, L. Perez De Isla, C. Torromeo, A. Calicchia, G. Giura, P.M. Alberca, C. Almeria, 

J.L. Rodrigo, C. Macaya, J.L. Zamorano (Rome, IT; Madrid, ES) 

three important parameters of left atrial function:atrial depolarization time, volumes 

and electromechanical activity in normal subjects;are they correlated? P1103 

I. Kulcsar, I. Stoian, I. Tepes Piser, O. Chioncel, A. Carp, E. Stoica, C. Macarie 


echocardiographyc parameters of diastolic heart failure in diabetic patients: impact of 

the evolution time, glycosylated hemoglobin and treatment. P1104 

B. Rodrigues, E. Correia, L.F. Santos, R. Faria, P. Gama, C. Cabral, J. Pipa, O. Santos 

(Viseu, PT) 

Correlation between the levels of B-type natriuretic peptide and 2D strain values in 

patients with heart failure P1105 

P. Amador, L. Mendes, J.F. Santos, S. Goncalves, C. Miranda, S. Correia, L. Bernardino, 

L. Soares (Setubal, PT) 

assessment of right ventricular function by two-dimensional strain in patients with left 

ventricular dysfunction and normal right ventricle by standard echocardiography P1106 

M. F. Oliveira Caetano, H. Almeida, L. Santos, O. Barroso, E. Guerreiro, J. Tavares 

(Barreiro, PT) 

Prothrombotic risk prediction in af: is left atrial dysfunction assessment better than 

CHaDS? P1107 

R. A. Providencia, A. Botelho, J. Silva, L. Seca, P. L. Gomes, S. Barra, A. C. Faustino, 

F. Caetano, N. Quintal, A. M. Leitao-Marques (Coimbra, PT) 

129 

monDaY 

PoSterS

monDaY 

PoSterS 



the role of speckle tracking echocardiography in the estimation of left ventricular 

filling pressure in patients with heart failure due to idiopathic dilated cardiomyopathy P1108 

L. Spinarova, J. Meluzin, P. Hude, J. Krejci, H. Podrouzkova, R. Panovsky, M. Orban, 

L. Dusek, M. Pesl, J. Korinek (Brno and Prague, CZ) 

left atrial strain, new parameter of left atrial function, is not totally volume-independent P1109 

C.S. Park, W.B. Chung, E.J. Cho, S.H. Ihm, H.O. Jung, H.K. Jeon, H.Y. Kim, H.J. Youn, 

J.H. Kim (Seoul, KR) 

long-term prognostic value of coronary flow velocity reserve in patients without 

significant left anterior descending coronary artery disease P1110 

A. Nemes, E. Balazs, A. Egyed, S. Pinter, M. Csanady, T. Forster (Szeged, HU) 

mitral regurgitant volume is a main predictor of death and hospitalization in patients 

with non-ischemic dilated cardiomyopathy P1111 

C. Bergamini, A. Rossi, M. Cicoira, L. Zanolla, C. Vassanelli (Verona, IT) 


Dobutamine-induced myocardial perfusion improvement in ischemic patients with 

late post infarction remodeling and severe heart failure P1112 

N. Maroz-Vadalazhskaya, L. Rachok, T. Dubovik (Minsk, BY) 

myocardial miBg tomoscintigraphy in a geriatric day clinic of heart failure P1113 

N. Ngo Mandag, B. Peperstraete, I. Chouchane, P.H. Martin, P. Bergmann, P. Decoodt 

(Brussels, BE) 

Does the patient with lV ischemic cardiomyopathy with absent myocardial viability by 

low dose dobutamine echocardiography still have a chance for functional recovery 

after coronary revascularization? P1114 

O. A. Rifaie, S.H. Demerdash, T. M. Abdel Dayem, Z. M. Abdelsalam, M. A. Eisa 

(Cairo, EG) 


Similar patterns of autonomic dysfunction and exercise capacity in patients with 

chronic heart failure and lung cancer P1115 

T. Kung, C. Misgeld, M. Paland, W. Doehner, S.D. Anker, M. Rauchhaus, S. Von Haehling 

(Berlin and Rostock, DE) 


Statins may be effective for the prevention of worsening of renal function in patients 


M. Kawasaki, T. Yamada, Y. Okuyama, T. Morita, Y. Furukawa, K. Tanaka, Y. Iwasaki, 

H. Ueda, T. Okada, M. Fukunami (Osaka, JP) 

global longitudinal strain and chamber stiffness correlate with plasma volume in 

chronic renal failure P1117 

F. W. G. Wenzelburger, B. John, E.S.P. Lee, Y.T. Tan, K.B. Tan, G. Heatlie, S.J. Davies, 

J.E. Sanderson (Birmingham and Stoke On Trent, GB) 

the impact of transient and persistent worsening renal function in patients with acute 


D. Aronson, A.J. Burger (Haifa, IL; Cincinnati, US) 

130




Comparable potential of BnP and nt-proBnP to predict long-term outcome in 

diagnostically naive patients with suspected heart failure P1119 

D. Berliner, C. Morbach, K. Boldt, G. Gelbrich, N. Deubner, S. Brenner, V. Holzendorf, 

G. Ertl, S. Stoerk, C.E. Angermann (Würzburg and Leipzig, DE) 

Variability of nt-proBnP in stable chronic heart failure and its relation to changes in 

clinical variables P1120 

H. Froehlich, L. Frankenstein, J. Franke, M. Nelles, G. Hess, D. Zdunek, H. Katus, C. Zugck 

(Heidelberg and Mannheim, DE) 

expression of B-type natriuretic peptide forms in ischemic human hearts P1121 

M. Rivera Otero, R. Cortes, E. Rosello, R. Sirera, I. Azorin, A. Montero, A. Salvador, T. Pla, 

L. Martinez Dolz, M. Portoles (Valencia, ES) 


regulation of the extracellular matrix proteins in human cardiac fibroblasts derived 

from endomyocardial biopsies of patients with dilated cardiomyopathy P1122 

D. Lindner, D. Westermann, C. Zietsch, H.-P. Schultheiss, C. Tschoepe (Berlin, DE) 


p38 maPK isoform -dependent regulation of cardiomyocyte hypertrophy P1123 

E. Isopoussu, L. Kaikkonen, H. Tokola, S. Pikkarainen, R. Kerkela, H. Ruskoaho (Oulu, FI) 


in CHf patients the reduction in serum hemoglobin concentration is associated with 

renal impairment and appears to be favoured or promoted by aCe-inhibition therapy. P1124 

R. De Vecchis, A. Ciccarelli, C. Ariano, A. Giasi, C. Cioppa, S. Cantatrione (Naples and 

Somma Vesuviana (Napoli), IT) 

natural history of anemia in patients with advanced heart failure P1125 

A. C. Pereira Barretto, M.E. Ochiai, J.N. Cardoso, C.H. Del Carlo, P.C. Morgado, 

R.T. Munhoz, A.R. Scipioni, J.A.F. Ramires (Sao Paulo, BR) 

the impact of the anemic state on symptoms and hospital admissions rate in patients 


V. Larina, B. Bart (Moscow, RU) 

nocturnal cardiac symptoms in patients with chronic heart failure: indicators for sleep 

disordered breathing P1127 

S. Brenner, T. Rockel, P.P. Zavaglia, S. Baron, N. Deubner, G. Guder, R. Jahns, G. Ertl, 

C.E. Angermann, S. Stork (Wurzburg, DE) 

anemia in heart failure: the role of inflammation P1128 

A.M.S. Belonje, A.A. Voors, T. Jaarsma, S. Ghosh, J. Kim, D.J. Van Veldhuisen (Groningen, 

NL; Uxbridge, GB) 

Clinical associations with anemia in patients with suspected and confirmed heart 

failure (a Hull-lifelab analysis) P1129 

K. Goode, A.L. Clark, L. Tin, S. Ghosh, R. Kilpatrick, J. Kim, J.G. Cleland (Hull and 

Cambridge, GB) 

131 

monDaY 

PoSterS

monDaY 

PoSterS 




Pro-thrombotic and pro-inflamatory factors in advanced Chagas cardiomyopathy P1130 

L.M. Pessoa-De-Melo, G.E. Conceicao-Souza, E.A. Damico, T.R.F. Rocha, C.S. Soares-Silva, 

C.M. Strunz, A.C.P. Barretto, E.A. Bocchi, J.A.F. Ramires (Sao Paulo, BR) 

the homeostatic chemokine CCl21 predicts mortality and may play a pathogenic role 

in heart failure P1131 

A. Yndestad, A.V. Finsen, T. Ueland, C. Husberg, K. Dickstein, D. Hilfiker-Kleiner, M. Lipp, 

L. Gullestad, G. Christensen, P. Aukrust (Oslo and Stavanger, NO; Hannover and 

Berlin, DE) 

effects of pro-inflammatory cytokines and oxidative stress on matrix 

metalloproteinases in congestive heart failure P1132 

I. Andreou, D. Tousoulis, C. Tentolouris, G. Siasos, K. Zisimos, A. Miliou, I. Kotrogiannis, 

C. Chrysohoou, C. Stefanadis (Athens, GR) 

Cytokine-associated paracrine effects of cardiac progenitor cells P1133 

S. Wenzel, S. Mufti, N. Krehbiehl, S. Scheufen, H. Maxeiner, K.-D. Schlueter (Giessen, DE) 


mesenchymal stem cells have direct anti-viral features P1134 

S. Van Linthout, J. Peng, K. Miteva, J. Ringe, C. Schmidt-Lucke, M. Sittinger, 

H.-P. Schultheiss, C. Tschoepe (Berlin, DE) 

Beta-catenin regulates left ventricular resident precursor cell proliferation and 

differentiation P1135 

M.P. Zafiriou, L. Zelarayan, M. W. Bergmann (Berlin and Hamburg, DE) 


Carotid intima-media thickness as a predictor for ischemic etiology in patients 

presented as end stage lV systolic dysfunction P1136 

S.W. Han, K.H. Ryu, H.J. Kim, S.Y. Seo, M.M. Lee (Seoul and Ilsan, KR) 

impact of anemia on hemodynamics in patients with diastolic heart failure P1137 

D. Karia, H. Ra, M. Hoque, N. Huda, M. Afiniwala, N. Verma (Philadelphia, US) 


arginine vasopressin inversely correlates to anaemia in systolic heart failure patients P1138 

J. Silva Marques, H. Luz Rodrigues, A.G. Almeida, M.G. Lopes (Lisbon, PT) 


left ventricular systolic function in patients with acute coronary syndrome and 

advanced Killip class P1139 

H. Dores, S. Leal, I. Rosario, L. Bronze, M.J. Correia, J. Monge, I. Arroja, C. Fonseca, 


effectiveness of treatment with irbesartan in patients with essential hypertension and 

reduced left ventricular systolic function taking enalapril P1140 

S. Vatinian, S. Gurgenyan, K. Nikoghosyan (Yerevan, AM) 

132



Subclinical left ventricular dysfunction in rheumatic mitral stenosis: correlation with 

high sensitivity c-reactive protein levels P1141 

E. Khalifa, W. Alnagar, Z. Ashour (Cairo, EG) 

Heart failuire with preserved ejection fraction in hypertensive and non-hypertensive 

patients is related to family history of hypertension P1142 

I. Burazor, M. Burazor, S. Stefanovic, V. Stefanovic, M. Krstic, M. Lazovic (Nis and 

Knjazevac, RS) 

end-tidal Co2 pressure, the forgotten parameter: correlation with cardiac output and 

stroke volume in patients with heart failure P1143 

A. Toste, R. Soares, J. Feliciano, B. Valente, S. Silva, R. C. Ferreira (Lisbon, PT) 

How we can increase myocardial reserve in patients with DDDr pacemaker? P1144 

A. Bobrov, M. Didenko, A. Tsyganov, A. Fedyainova, G. Khubulava, S. Shulenin, L. Bobrov 


low peripheral hyperemic response is associated with left ventricular diastolic 

dysfunction in patients with rheumatoid arthritis in the absence of overt 

cardiovascular disease P1145 

E. Myasoedova, S. Obzherina, N. Svyatova, S. Myasoedova (Ivanovo, RU) 

Prognostic factors in acute and sub-acute congestive heart failure with preserved 


L. Ferreira Santos, E. Correia, B. Rodrigues, R. Faria, R. Silverio, P. Gama, L. Nunes, 

C. Henriques, A. Matos, J. Oliveira Santos (Viseu, PT) 

a role for cardiotrophin-1 in myocardial fibrosis and left ventricular dysfunction P1147 

N. Lopez, C. Inigo, J.J. Gavira, G. Abizanda, P. Lacolley, F. Zannad, P. Rossignol, 

M.A. Fortuno, J. Diez (Vandoeuvre-les-Nancy and Domartin-Les-Toul, FR; Pamplona, ES) 


essential amino acid supplementation and heart rate in chronic heart failure P1148 

A. Macchi, I. Franzoni, F. Buzzetti, I. Rosa, M.C. Pedrigi, G.V. Gaudio, A. Margonato 

(Milan, IT) 

influence of type 2 diabetes mellitus on the early outcomes coronary bypass surgery 

in patients with left ventricular systolic dysfunction P1149 

N.A. Bezdenezhnykh, A. N. Sumin, A.V. Bezdenezhnykh, S.V. Ivanov, O.L. Barbarash, 

L.S. Barbarash (Kemerovo, RU) 

lung-Heart Uptake of aminoacids in Chronic Heart failure P1150 

R. Aquilani, F. Boschi, M. Verri, S. Viglio, M. Bruni, D. Corbellini, O. Febo, M.T. La Rovere 

(Montescano and Pavia, IT) 


Characteristics and hospital outcomes of patients with acute heart failure complicating 

acute myocardial infarction treated with primary percutaneous coronary intervention P1151 

D. Matic, I. Mrdovic, M. Asanin, G. Stankovic, N. Antonijevic, D. Rajic, M. Srdic, N. Brdar, 

T. Ivosevic, Z. Vasiljevic (Belgrade, RS) 

the role of altered mPtP characteristics in failing delayed preconditioning in mouse 

models of the metabolic syndrome. P1152 

A. Vanderper (Leuven, BE) 

133 

monDaY 

PoSterS

monDaY 

PoSterS 




the influence of i/D aCe gene polymorphism on the efficacy of treatment with 

aCe inhibitors in patients after myocardial infarction treated with primary coronary 

angioplasty. P1153 

L. Polak, A. Ledakowicz-Polak, M. Zielinska, J. Drozdz, K. Chizynski (Lodz, PL) 

adenosine receptors mrna expression in normal and failing minipig heart P1154 

S. Del Ry, M. Cabiati, E. Belcastro, A. Simioniuc, C. Caselli, T. Prescimone, D. Giannessi 

(Pisa, IT) 

the pro-inflammatory adipocytokine visfatin might play a role regulating cardiac 

metabolism in human and experimental aortic stenosis P1155 

J. L. Bjornstad, I. Sjaastad, S. Nygard, A.V. Finsen, A. Hasic, G. Christensen, T. Tonnessen 

(Oslo, NO) 


impaired myocardial blood flow reserve in obstructive sleep apnoea as assessed by 

myocardial contrast echocardiography: effects of continuous positive airway pressure 

therapy P1156 


Decreased matricellular protein thrombospondin (tSP) -4 expression in human 

calcified aortic valves P1157 

E. Mustonen, V. Pohjolainen, P. Taskinen, J. Napankangas, T. Peltonen, H. Leskinen, 

T. Juvonen, J. Satta, H. Ruskoaho, J. Rysa (Oulu, FI) 


n-acetylcysteine reduces the severity of atherosclerosis in apolipoprotein e-deficient 

mice by reducing superoxide production P1158 

C. Kishimoto, K. Shimada, T. Murayama, M. Yokode, T. Kita, H. Uzui, T. Ueda, J.D. Lee 

(Kyoto and Fukui, JP) 


telemedicine in heart failure: heart failure service support for south west Queensland P1159 

D. Korczyk, B. Mcpherson, A. Hickey, R. Peters, C. Cook (Brisbane, AU) 

Homecare telesurveillance program in patients with CHf: evaluation of clinical 

changes over time P1160 

S. Scalvini, E. Zanelli, F. De Giuli, F. Vigliani, F. Rivadossi, A. Cinelli, E. Trussardi, C. Scotti, 

A. Giordano (Lumezzane, IT) 


electrocardiography, chest radiology, and echocardiography data of hospitalized 

heart failure patients, an egyptian study P1161 

S. Hozien, N. Farag, S. Sabet, R. Raymond, A. Hassan, M. El Ramly, W. El Naggar (Giza 

and Cairo, EG) 

fish consumption is associated with lower likelihood of developing left ventricular 

systolic dysfunction, in acute Coronary Syndrome patients: P1162 

C. Chrysohoou, C. Kastorini, P. Aggelopoulos, C. Antoniou, G. Tsitsinakis, G. Metallinos, 

C. Liontou, D.B. Panagiotakos, C. Pitsavos, C. Stefanadis (Athens, GR) 

134



long-term enrolment to a physical active lifestyle seems to preserve left ventricular 

systolic function by reducing inflammatory response in patients with an acute 

coronary syndrome P1163 

C. Chrysohoou, P. Aggelopoulos, D.B. Panagiotakos, G. Tsitsinakis, C. Antoniou, 

D. Tsiachris, L. Raftopoulos, K. Liontou, C. Pitsavos, C. Stefanadis (Athens, GR) 

is the hemodynamic profile a useful device in acute heart failure syndrome patients 

with preserved systolic function. a report from the attenD registry Database P1164 

K. Murai, N. Sato, K. Kajimoto, R. Munakata, M. Aokage, K. Asai, Y. Minami, T. Mizuno, 

T. Takano, K. Mizuno (Chiba, Tokyo and Saitama, JP) 

gender differences in the prevalence of left ventricular dysfunction and heart failure 

in a general elderly population in italy: the PreDiCtor study P1165 

V. Rizzello, G.F. Mureddu, N. Agabiti, G. Cesaroni, C. Perucci, F. Forastiere, G. Cacciatore, 

A. Boccanelli (Rome, IT) 


Cardiac rehabilitation in patients with left ventricular systolic dysfunction - the initial 

results in the parameters of the effort P1166 

N. Santos, R.M. Soares, A. Abreu, J. Feliciano, S. Silva, M.T. Alves, S. Alves, E. Oliveira, 

R.C. Ferreira (Lisbon, PT) 

Six-minute walk test combined with measurement of cardiac contractility for 

evaluation of cardiac function P1167 

M. Xie, T. Liu, S. Xiao, H. Zeng, Z. Xiao (Chongqing and Chengdu, CN) 

Chronotropic response to exercise in subjects with lv hypertrophy and diastolic 

dysfunction: elite ex-athletes and hypertensive patients P1168 

N. Sharashidze, Z. Pgava, G. Saatashvili, G. Nikolaishvili (Tbilisi, GE) 

the effects of Cardiac rehabilitation on anxiety and Depression in patients with Heart 

failure and Systolic Dysfunction P1169 

C. J. Boos, L. Everett, F. Keen, D. Speck, S. Orr, J. Hardy, K. Knopps, V. Tite (Poole, GB) 

aerobic training decreases aortic stiffness in patients with heart failure P1170 

C. Passino, R.M. Bruno, S. Severino, L. Masi, S. Taddei, M. Emdin, L. Ghiadoni (Pisa, IT) 

Prognostic value of cardiopulmonary exercise test in patients with heart failure treated 

with beta blockers P1171 

C. Bougon Dufay, A. Belin, R. Sabatier, J.P. Mabire, A. Pellissier, L. Champ-Rigot, P. Scanu, 

P. Milliez, G. Grollier (Caen and Trouville sur Mer, FR) 

iron deficiency but not anaemia is related to impaired exercise capacity in patients 

with systolic chronic heart failure P1172 

E. A. Jankowska, P. Rozentryt, A. Witkowska, J. Nowak, O. Hartman, W. Banasiak, 

L. Polonski, G. Filippatos, S. D. Anker, P. Ponikowski (Wroclaw and Zabrze, PL; Berlin, DE; 

Athens, GR) 

attenuated fatigue in slow twitch skeletal muscle during isotonic compared to 

isometric contractions in rats with chronic heart failure P1173 

M. Munvkik, P.K. Lunde, J.M. Aronsen, J.A.K. Birkeland, I. Sjaastad, O.M. Sejersted 

(Oslo, NO) 

135 

monDaY 

PoSterS

monDaY 

PoSterS 



Nursing 

nursing diagnoses for hospitalized clients with cardiovascular diseases P1174 

A. C. Cavalcanti, J.M.V. Pereira, K.M. Cassiano, G.C. Queluci, D.M.S. Correia, 

T.C.F. Guimaraes, R.F. Santana (Niteroi, BR) 

interest of a specific care for the patients carrying a implanted cardiovecter 

defibrillator and/or a multisite pacemaker P1175 

A. Boireau, P. Jourdain, C. Antoniazzi, A. Khemache, F. Funck (Pontoise, Paris and 

Neuilly sur seine, FR) 

modifying self-care behavior in patients with heart failure: impact of the heart failure 

dedicated nurse intervention P1176 

V. Yaari, N. Baruch, T. Jaarsma, R. Stein, A. Battler, T. Ben Gal (Petah Tikva, IL; 

Linkoping, SE) 


implementation of a quality sistem in treatment and control of patients with heart 

failure P1177 

A. Flamarique, M.J. Callejo, C. Gomez Del Valle, B. Sierra, F.J. Ruiz, F. Ruiz (Zaragoza, ES) 

Vaccinal status against influenza, pneumococcal and tetanus in heart failure patients 

admitted to a heart failure clinic: neglected recommendations P1178 

W.A. Martins, M.G. Oliveira, M.A.R. Manhaes, L.S.N. Barros, L.B. Oliveira, 

G.A.C.M. Pereira, E.P. Campos, S.L.S.M.C. Chermont, M.M.P. Quintao, E.T. Mesquita 

(Niteroi and Teresópolis, RJ, BR) 

lack of gender differences in mortality outcome among heart failure patients within a 

chronic disease management program P1179 

R. C. C. Wong, S.C. Seow, S. Aziz, P.T. Tan, Y.H. Seow, P. Chai (Singapore, SG) 

management of patients with heart failure with preserved ejection fraction in hospital 

settings: a french observational cohort survey P1180 

P. De Groote, O. Hanon, F. Dievart, G. Pisica-Donose (Lille, Paris, Dunkerque and 

Rueil Malmaison, FR) 

is simple educational intervention sufficient to improve effectivness of management of 

heart failure patients? P1181 

T. Rywik, P. Kolodziej, R. Targonski, M. Fedyk-Lukasik, A. Nowicka, B. Zbyszynski, 

P. Achremczyk, J. Gorski, P. Leszek, J. Korewicki (Warsaw, siedlce, Olsztyn, Krakow, 

Poznan, Ciechanow, Radom and Gdansk, PL) 

Other 

thermoregulatory efficiency and cognitive performance are strong determinants of 

cardiopulmonary capacity in health and chronic heart failure P1182 

R. Skalik, W. Wozniak, L. Borodulin - Nadzieja (Wroclaw, PL) 

Cardiac involvement in churg-strauss syndrome P1183 

R. Dennert, P. Van Paassen, S. Schalla, T. Kuznetsova, J. Staessen, H.J. Crijns, 

J.W. Cohen Tervaert, S. Heymans (Maastricht, NL; Leuven, BE) 

136



intracoronary transplantation of autologous bone marrow mononuclear cells in 

patients with non-acute coronary artery disease and severe heart failure (6 year 

experience). P1184 

A. Nemkov, V. Sedov, B. Afanasyev, S. Beliy, S. Burnos, N. Petrov, V. Lukashenko, 

Y.U. Nesteruk (St Petersburg, RU) 

Collagen type i and iii in Hfref and HfPref myocardium P1185 

N. Solomakhina, D. Shchekochikhin (Moscow, RU) 

Percutaneous implantation of the left ventricular partitioning device for chronic heart 

failure: a pilot study with 1-year follow-up P1186 

P. Otasevic, D. Sagic, H. Sievert, V. Mitrovic, A. Elsasser, S. Gradinac (Belgrade, RS; 

Frankfurt am Main and Bad Nauheim, DE) 

the breathing pattern and exercise capacity profile in Chronic Heart failure patients 

with Chronic obstructive Pulmonary Disease P1187 

A. Tasoulis, S. Dimopoulos, A. Mpouchla, G. Tzanis, M. Kravari, N. Diakos, L. Katsaros, 

E. Repasos, C. Pantsios, S. Nanas (Athens, GR) 

electrocardiographic localization of inflammation in patients with acute myocarditis P1188 

R. Dennert, S. Velthuis, B. Alzand, J.M. Senden, H.J. Crijns, S. Heymans (Maastricht and 

Amersfoort, NL) 

etiologic diagnostic evaluation of patients with new-onset systolic heart failure P1189 

A. N. Kitsiou, K. Giannakopoulos, G. Papadimitriou, M. Seferou, E. Antoniou, I. Vasileiadis, 

S. Karas (Athens, GR) 


Spanish language version of the Kansas City cardiomiopathy questionnaire to measure 

health related quality of life in heart failure patients: psychometric properties P1190 

C. Figueroa, S. Rincon, L. Alcocer, B. Ramos, V. Flores (Mexico City, MX) 

137 

monDaY 

PoSterS

monDaY 

PoSterS 

noteS 

138

HIGHLIGHTS FROM 

HeaRT FaILuRe 2010 

Updates from the Heart failure association Winter and Summer meetings 

and the european Journal of Heart failure 

tuesday, 31 august 2010 

11:00 - 12:30 - Copenhagen - Zone a 

Chairpersons: 

T. Jaarsma (Norrkoping, SE) & K. Dickstein (Stavanger, NO) 

11:00 

new science 


11:22 

new diagnostic and prognostic 

insights 

U.g. Dahlstrom (linkoping, Se) 

11:45 

therapeutic news 

a.P. maggioni (florence, it) 

12:07 

my top ten papers from the european 

Journal of Heart failure 2008/9 

D.J. van Veldhuisen (groningen, nl) 

tUeSDaY

tUeSDaY 

tUeSDaY 1 JUne 2010 - morning 


Device therapy for heart failure with normal ejection fraction: why should we try? 

Chairperson(s): A. Auricchio (Lugano, CH); K. Harada (Tokyo, JP) 



- Understand the rationale of innovative, device based treatment strategies in diastolic heart failure 

08:30 treatment in the absence of evidence 1191 


08:48 exercise pacing 1192 


09:06 resynchronisation therapy 1193 

P. E. Vardas (Heraklion, GR) 

09:24 aiCD 1194 

S. Solomon (Boston, US) 

09:42 Devices, drugs or exercise 1195 

B. M. Pieske (Graz, AT) 


The cardio-renal syndrome in heart failure today 

Chairperson(s): M. Lainscak (Golnik, SI); D.J. van Veldhuisen (Groningen, NL) 



- Renal dysfunction is one of the most powerful predictors of prognosis in heart failure 

- Selective improvement of renal function by drugs is difficult 

- Newer markers of early renal dysfunction are needed 

08:30 Cardio-renal syndrome: definition, classification, epidemiology, pathophysiology 1196 


08:48 Difficulties in assessing kidney function in acute and chronic heart failure 1197 


09:06 treating the cardio renal syndrome in heart failure: is there a realistic 

approach in sight? 1198 


09:24 Diuretic resistance: scope of the problem and solutions 1199 

S. Gottlieb (Baltimore, US) 

09:42 management of cardio renal syndrome: focus on anaemia 1200 


140



Blocking the RAAS in heart failure – past, present and future 

Chairperson(s): J.L. Lopez-Sendon (Madrid, ES); E.V. Shlyakhto (St Petersburg, RU) 



- Understand the role of drugs interferring with the RAAS in cardiovascular therapy. 

- Identify newer pathways and targets for drugs directedd toward the RAAS 

- Review the preliminary results and the ongoing trials with new RAAS modulating drugs. 

08:30 Blocking the raaS: what we have achieved so far 1201 

M. Pfeffer (Boston, US) 

08:52 the future: renin inhibitors? 1202 


09:15 the future: aldosterone synthase inhibitors? 1203 


09:37 the future: dual neurohumoral modulation with an arni? 1204 



cGMP signaling in the failing heart: beyond NO? 

Chairperson(s): G.W.A. De Keulenaer (Wilrijk, BE); K.C. Wollert (Hannover, DE) 


08:30 new insights in regulation of cgmP – camP balance in cardiomyocytes 1205 

R. Fischmeister (Chatenay-Malabry, FR) 

08:52 cgmP and PDe5 signaling in cardiac hypertrophy 1206 

S. Janssens (Leuven, BE) 

09:15 the role of cgmP and PKg in cardioprotection 1207 

A. Papapetropoulos (Patras, GR) 

09:37 cgmP elevating drugs in the failing heart: rescue when no fails? 1208 


141 

tUeSDaY

tUeSDaY 


11:00 - 12:30 Special Session Hamburg 

Highlights of the congress 

Closing session 

Chairperson(s): S.D. Anker (Berlin, DE); K. Swedberg (Goteborg, SE) 


11:00 Basic Science 1209 


11:15 Diagnosis, imaging, pathophysiology 1210 


11:30 Patient care 1211 


11:45 HfPef: heart failure with preserved ejection fraction 1212 


12:00 Drug treatment 1213 

A. P. Maggioni (Florence, IT) 

12:15 Devices 1214 



Ageing and heart failure: difficult issues 

Joint session with the russian national Society of heart failure 

Chairperson(s): V. Mareev (Moscow, RU); P. Ponikowski (Wroclaw, PL) 


11:00 the age-BnP survival model: prediction of survival in elderly (75 years and 

older) patients with heart failure 1215 

E. V. Shlyakhto (St Petersburg, RU) 

11:18 Diastole in the elderly 1216 

K. Harada (Tokyo, JP) 

11:36 Pharmacology for the elderly 1217 


11:54 management of chronic heart failure in the elderly: comprehensive approach 1218 

Y. Vechersky (Tomsk, RU) 

12:12 Care at the end of life 1219 

V. Conraads (Edegem, BE) 

142



Exercise in chronic heart failure: translation in progress 

Joint Session with the heart failure Working group of the Brazilian Society 

of Cardiology 

Chairperson(s): A. Cohen-Solal (Paris, FR); J.P. Ribeiro (Porto Alegre, BR) 


Learning objectives 

- Mechanisms of exercise intolerance in CHF. 

- Beneficial effect of exercise training on the centre (heart, Lung), periphery (circulation, skeletal 

muscle), and the controlling systems (immune system). 

- How to implement current exercise training recommendation in the clinical management of 

heart failure patients. 

11:00 mechanisms behind exercise training: heart and vasculature 1220 

M. F. Piepoli (Piacenza, IT) 

11:18 mechanisms behind exercise training: lungs and respiratory muscle 1221 

J. P. Ribeiro (Porto Alegre, BR) 

11:36 mechanisms behind exercise training: the skeletal muscle 1222 

V. Adams (Leipzig, DE) 

11:54 mechanisms behind exercise training: the immune system 1223 

E. A. Bocchi (Sao Paulo, BR) 

12:12 How to implement exercise training 1224 

S. Adamopoulos (Athens, GR) 

11:00 - 12:30 Special Session Stuttgart 

Highlights of the congress: Basic Science translated for the clinician 

Chairperson(s): M.P. Frenneaux (Aberdeen, GB); T. Eschenhagen (Hamburg, DE) 


11:00 gene therapy 1225 

R.J. Hajjar (New York, US) 

11:22 late Breaking research: myocardial microrna profile in pressure-overloaded 

mice with cardiac-specific phosphodiesterase 5 overexpression 1226 

P. Pokreisz (Leuven, BE) 

11:37 late Breaking research: generation of patient-specific induced pluripotent 

stem cells from bone marrow-derived mesenchymal stem cells 1227 

K. Guan (Goettingen, DE) 

11:52 late Breaking research: aDma, micrornas and regenerative dysfunction 1228 


12:07 Cells and mirnas at al 1229 

L.J. De Windt (Maastricht, NL) 

143 

tUeSDaY

tUeSDaY 

noteS 

144

TUESDAY 





morning 

moderated Posters Sessions 5 (10:00 - 11:00) .............................Pages 146 & 147 

Poster Session 5 ...................................................................................................................Pages 148 to 165 


A coffee break will be served in the Exhibition area 

from 10:00 to 11:00 

Come, share and network! 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 

tUeSDaY 1 JUne 2010 - morning PoSterS 



Basic Science related topics 

Chairperson(s): F. Cuello (London, GB); To be announced 




10:00 Clinical characteristics and in-hospital outcomes of diabetic versus nondiabetic 

patients with acute heart failure: a sub-analysis from the alarm-Hf 

survey P1230 

J. T. Parissis, V. Bistola, I. Ikonomidis, A. Mebazaa, J. Delgado, F. Vilas-Boas, 

M. Anastasiou-Nana, D. Kremastinos, F. Follath (Athens, GR; Paris, FR; Madrid, ES; 

Bahia, BR; Zurich, CH) 

10:06 Pericardial fat and visceral abdominal adipose tissue, but not subcutaneous 

fat, are associated with early diastolic dysfunction P1231 

R. Fontes Carvalho, D. Caeiro, F. Sampaio, N. Bettencourt, N. Ferreira, G. Silva, 

O. Sousa, E. Pereira, M. Teixeira, V. Gama (Vila Nova de Gaia, PT) 

10:12 Different hemodynamic responses during exercise in patients with heart 

failure despite normal ef and suspected diastolic dysfunction P1232 

M. Kasner, D. Westermann, D. Sinning, J. Lober, D. Milicic, H.P. Schultheiss, 

C. Tschoepe (Berlin, DE; Zagreb, HR) 

10:18 anti-obstructive therapy in chronic heart failure: treatment often unjustified P1233 

S. Brenner, G. Guder, K. Frohlich, D. Berliner, N. Deubner, R. Jahns, B. Jany, 

G. Ertl, C.E. Angermann, S. Stork (Wurzburg, DE) 

10:24 Kruppel-like factor 15 (Klf15) represses beta-catenin-dependent gene 

transcription in cardiac progenitor cells resulting in enhanced differentiation P1234 

C. Noack, L. Zelarayan, M. W. Bergmann (Berlin and Hamburg, DE) 

10:30 Cardiac periostin gene expression in the advanced experimental renal 

insufficiency P1235 

V. Pohjolainen, J. Rysa, P. Koobi, A. Eraranta, I. Porsti, H. Ruskoaho (Oulu and 

Tampere, FI) 

10:36 functional impairment of cardiac inducible proteasome subunit lmP2 protects 

mice from acute and chronic myocarditis P1236 

A. Voigt, E. Opitz, K. Klingel, K. Savvatis, C. Tschoepe, K. Stangl, P.M. Kloetzel 

(Berlin and Tubingen, DE) 

10:42 the arrhythmogenic effect of beta-adrenergic stimulation is potentiated in 

ventricular myocytes with decreased SerCa2 abundance. P1237 

M. K. Stokke, S.J. Briston, G.F. Joelle, W.E. Louch, K.B. Andersson, G. Christensen, 

D.A. Eisner, O.M. Sejersted, A.W. Trafford, I. Sjaastad (Oslo, NO; Manchester, GB) 

10:48 oxidative damage at the titin-actin overlap region contributes to elevated 

resting tension of failing human cardiomyocytes P1238 

D. Czuriga, A. Borbely, S.J.P. Bogaards, I. Falcao-Pires, I. Edes, Z. Papp, 

J. Van Der Velden, G.J.M. Stienen, R.J.P. Musters, W.J. Paulus (Debrecen, HU; 

Amsterdam, NL; Porto, PT) 

146



10:54 endothelial progenitor cells represent a novel target in parvovirus B19associated 

endothelial dysfunction P1239 

C. Schmidt-Lucke, T. Zobel, T. Pozzuto, S. Van Linthout, T. Groessl, H. Fechner, 

H.P. Schultheiss, C. Tschope (Berlin, DE) 

147 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 








Clinical significance of the release of serum troponin levels in patients with acute heart 

failure P1240 

L. Bettari, M. Metra, S. Bugatti, V. Carubelli, F. Del Magro, V. Lazzarini, C. Lombardi, 

B. Piovanelli, A. Vaccari, L. Dei Cas (Brescia, IT) 

Baseline characteristics and outcomes of patients who do not desire resuscitation: an 

analysis of the eSCaPe trial population P1241 

D. Sandesh, C. Lombardi, M. Fiuzat, C. O’connor, D. Tassisa, J. Rogers (Durham, US; 

Brescia, IT) 

Clinical significance of increased serum troponin levels in patients with acute heart 

failure P1242 

L. Bettari, M. Metra, S. Bugatti, B. Fontanella, V. Lazzarini, C. Lombardi, B. Piovanelli, 

A. Romeo, G. Verzura, L. Dei Cas (Brescia and Rome, IT) 

left bundle branch block is independent marker of prognosis in acute heart failure P1243 

I. Donoiu, A. Giuca, D.-D. Ionescu (Craiova, RO) 

low incidence of acute heart failure in adults with acute myopericarditis P1244 

R. C. Vidal Perez, E. Abu Assi, C. Pena Gil, J.M. Garcia Acuna, M. Jaquet Herter, 

A. Varela Roman, P. Rigueiro Veloso, J.R. Gonzalez-Juanatey (Santiago de Compostela, ES) 

Serum glucose level at hospital admission correlates with left ventricular systolic 

dysfunction in non-diabetic, acute coronary patients P1245 

C. Chrysohoou, P. Aggelopoulos, A. Aggelis, C. Antoniou, G. Tsitsinakis, G. Lazaros, 

E. Tsiamis, D. Panagiotakos, C. Pitsavos, C. Stefanadis (Athens, GR) 

the prevalence of anemia and its impact on hospitalization mortality in patients with 

acute heart failure. P1246 

R. Miklik, M. Felsoci, J. Parenica, J. Spinar, D. Tomcikova (Brno, CZ) 

releasing of unprocessed natriuretic peptides in heart failure P1247 

F. Sibellas, A. Mebazaa, A. Cohen Solal, D. Logeart (Lyon and Paris, FR) 

Slovak acute heart failure survey - characteristics and outcomes of patients P1248 

I. Varga, P. Lesny, P. Solik, M. Luknar, S. Babej, B. Liska, E. Goncalvsova (Bratislava, SK) 

impacts of warm & wet and cold & wet on clinical evaluations in the real-world acute 

heart failure syndromes patients: Data from attenD registry P1249 

K. Murai, N. Sato, K. Kajimoto, R. Munakata, M. Aokage, K. Asai, M. Mizuno, Y. Minami, 

T. Takano, K. Mizuno (Chiba, Tokyo and Saitama, JP) 

Prognostic evaluation of patients admitted for acute heart failure: retrospective study 

on 729 patients hospitalized in our hospital P1250 

S. Bugatti, M. Metra, L. Bettari, A. Foresti, V. Lazzarini, C. Lombardi, B. Piovanelli, 

A. Romeo, A. Vaccari, L. Dei Cas (Brescia and Rome, IT) 

148



Usefulness of Beta-trace Protein and Cystatin C to Predict outcomes in Patients with 

acute Heart failure P1251 

S. Manzano Fernandez, J.C. Bonaque-Gonzalez, C. Munoz-Esparza, F.J. Pastor-Perez, 

M. Boronat-Garcia, M.D. Martinez Martinez-Espejo, R. Garcia-Rodenas, I.P. Garrido-Bravo, 

M. Valdes, D.A. Pascual-Figal (Murcia, ES) 


Chronic ambulatory ultrafiltration does not correct hyponatremia in heart failure P1252 

A. Kazory, M. Goldstein, A. Enkeshafi, J. Insel (Gainesville, Baltimore and Cumberland, US) 

Dobutamine-induced changes of left atrial deformation predict response to 

levosimendan treatment in acutely decompensated heart failure patients: a speckle 

tracking echocardiography study P1253 

I. Paraskevaidis, I. Ikonomidis, J. Parissis, C. Papadopoulos, V. Stasinos, V. Bistola, 

M. Anastasiou-Nana (Athens, GR) 

antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase 

activator cinaciguat (BaY 58-2667) P1254 

R. Frey, W. Mueck, M. Becka, U. Artmeier-Brandt, J. Kraetzschmar, G. Wensing 

(Wuppertal, DE) 

Serial measurement of high sensitive cardiac troponin i in patients with acutely 

decompensated heart failure treated with carperitide versus nitrates P1255 

S. Saijo, Y. Sato, T. Sawa, Y. Tanada, E. Yamamoto, K. Nishi, T. Miyamoto, H. Fujiwara, 

Y. Takatsu (Hyogo, JP) 

intravenous gP531, an adenosine regulating agent, improves left ventricular function 

in dogs with chronic heart failure P1256 

H.N. Sabbah, M. Wang, I. Ilsar, M.S. Sabbah, R.C. Gupta (Detroit, US) 

Using lung impedance as a surrogate endpoint for prediction and beginning of 

preventive treatment acute Heart failure in the Course of acute myocardial infarction. P1257 

M. Shochat, M. Kasatzker, V. Gurovich, Y. Levi, E. Noiman, P. Rabinovich, D. Blondheim, 

A. Shotan, S. Meisel (Hadera and Tel Aviv, IL) 


left atrial enlargement and nt-probnp as bad prognostic factors for rehospitlisation in 

patients with heart failure of ischaemic origin P1258 

M. Dasoveanu, R. Ciomag, A. Popa, C. Sinescu (Bucharest, RO) 

impact of n-terminal pro-brain natriuretic peptide on prognosis of myocardial infarction P1259 

E. Tavlueva, O. Barbarash, E. Usoltseva, V. Kashtalap, M. Zykov, V. Karetnikova, 

L. Barbarash (Kemerovo, RU) 

the prognostic potential of nt-proBnP in diagnostically naive patients with suspected 


K. Boldt, C. Morbach, S. Stoerk, D. Berliner, G. Gelbrich, S. Peter, S. Guenther, 

V. Holzendorf, G. Ertl, C.E. Angermann (Wuerzburg and Leipzig, DE) 

red blood cell distribution with in acute heart failure: clinical, laboratory and 

echocardiographic implications P1261 

R. Faria, L.F. Santos, C. Emanuel, B. Rodrigues, P. Gama, P. Ferreira, L. Nunes, J.L. Pipa, 

O. Santos (Viseu, PT) 

149 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 



relation of biogenous amines level to mortality of patients with congestive heart failure P1262 

E.V. Zukhovitskaya, V.A. Snezhitsky, E.M. Doroshenko, V.M. Pyrochkin, M.S. Deshko, 

T.P. Stempen, A.V. Naumov (Grodno, BY) 


the manchester triage system in acute myocardial infarction, the importance in the 24 

months prognosis P1263 

P. Gomes, S. Barra, R. Providencia, L. Paiva, I. Almeida, A. Antunes, A.M. Leitao Marques 

(Coimbra, PT) 

Hemoglobin levels in the intensive care unit for acute coronary syndrome prognosis 

assessment P1264 

C. Portillo Requena, A. Garrido Servant, V. Bertomeu Gonzalez, S. Guillen Garcia, 

R. Lopez Palop, V. Bertomeu Martinez, F. Colomina Climent (San Juan De Alicante, ES) 

SDnn from heart rate variability analysis predicts total mortality in heart failure patients P1265 

P. Arsenos, K. Gatzoulis, G. Manis, T. Gialernios, P. Dilaveris, E. Karstagoulis, C. Kavouras, 

M. Vavouranakis, K. Dimitriadis, C. Stefanadis (Athens and Ioannina, GR) 

functional assessment tests and mortality in heart failure: Which one is the best 

predictor? P1266 

B. Zafrir, H. Paz, R. Wolff, N. Salman, D. Merhavi, A. Antebi, N. Yaniv, R. Ammar, 

B.S. Lewis, O. Amir (Haifa, IL) 

Clinical characteristics and 1-year outcome of patients aged 75 years or older 

hospitalized for heart failure P1267 

C. Weytjens, A.M. Willems, N. De Laet, H. ‘T Kindt, G. Van Camp, J. De Sutter (Brussels 

and Gent, BE) 

the prognostic significance of chronic kidney disease in patients with left ventricular 

systolic dysfunction after primary percutaneous coronary intervention P1268 

L. Savic, I. Mrdovic, G. Krljanac, D. Rajic, J. Perunicic, M. Asanin, M. Matic, Z. Vasiljevic, 

M. Ostojic (Belgrade, RS) 

influence of precipitating factors about decompensation of chronic heart failure on 

in-hospital evolution P1269 

C.L. Andrei, R. Ciomag, A.L. Mischie, C.J. Sinescu, I. Teodorescu-Gabor (Bucharest, RO) 

Prognostic value of blood urea nitrogen and its changes in patients with chronic 


C. Lombardi, A. Manerba, E. Vizzardi, C. Maiandi, G. Milesi, S. Bugatti, L. Bettari, 

A. Romeo, M. Metra, L. Dei Cas (Brescia and Rome, IT) 

left ventricular end diastolic diameter and Qtc are important and independent 

predicors of sudden cardiac death in heart failure patients P1271 

P. Arsenos, K. Gatzoulis, T. Gialernios, P. Dilaveris, S. Archontakis, L. Raftopoulos, 

K. Masoura, K. Zissimos, I. Andreou, C. Stefanadis (Athens, GR) 

the change in mitral regurgitation and its correlation with left ventricular reverse 

remodeling and survival in chronic heart failure P1272 

N. Nyolczas, B. Szabo, A. Kosztin, M. Dekany, B. Ancsin, T. Borsanyi, E. Marosi, R. Markus, 

B. Polgar, R.G. Kiss (Budapest, HU) 

150



acute heart failure in older old patients: profile and prediction of mortality P1273 

C. Rodriguez Pascual, A. Vilches-Moraga, E. Paredes-Galan, M.J. Lopez-Sanchez, 

A. Ferrero-Martinez, M. Torrente (Vigo, ES) 

Prediction of heart failure re-admission to a regional university based health sciences 

center P1274 

M. Arnold, G. Marchiori (London, CA) 


multiresolution wavelet analysis of heart rate variability predicts sudden cardiac death 

in heart failure patients P1275 

P. Arsenos, K. Gatzoulis, G. Manis, T. Gialernios, P. Dilaveris, E. Karstagoulis, S. Sideris, 

K. Zissimos, I. Andreou, C. Stefanadis (Athens and Ioannina, GR) 

atrial fibrillation begets heart failure and heart failure begets atrial fibrillation: two 

sides of the same story P1276 

R. A. Providencia, A. Botelho, J. Silva, L. Seca, P. L. Gomes, S. Barra, G. Costa, F. Caetano, 

A. C. Faustino, A. M. Leitao-Marques (Coimbra, PT) 

Beta blockers 

oxidative stress and immune inflammatory responses in chronic heart failure and 

beta-adrenoblockers possibilities P1277 

E.V. Privalova, Y.N. Belenkov, L.V. Knyazeva, E.A. Zheleznyh, Y.A. Danilogorskaya 

(Moscow, RU) 

Differential long term effects of carvedilol on pro- and anti-inflammatory cytokines, 

asymmetric dimethylarginine and left ventricular function in patients with heart failure P1278 

R. Spoladore, A.B. Alfieri, L. Briceno, G. Fragasso, A. Palloshi, G. Bassanelli, F. Arioli, 

A. Cuko, G. Ruotolo, A. Margonato (Milan, IT) 

Heart rate turbulence and heart rate variability in elderly patients with heart failure 

receiving beta-blockers: results from the CiBiS-elD trial. P1279 

A. Toepper, H.-Z. Joo, S. Inkrot, M. Mende, W. Haverkamp, H.-D. Duengen (Berlin and 

Leipzig, DE) 

Differential effects of beta-blockade in elderly patients with systolic vs. diastolic heart 

failure: P1280 

F. Edelmann, R. Wachter, S. Inkrot, E. Tahirovic, A. Toepper, W. Doehner, S. Apostolovic, 

M. Lainscak, H.-D. Duengen (Gottingen and Berlin, DE; Nis, RS; Golnik, SI) 


low rates of left ventricle lead failure by adequate lead selection in Crt-implantation P1281 


Cardiac resynchronization therapy and diastolic function P1282 

G. De Masi De Luca, M. Accogli, A. Galati, C. Sacra, S. Iacopino (Tricase and Catanzaro, IT) 

efficiency of different approaches of cardioresynchronization therapy P1283 

N. Yakush, Y. Ostrovskiy, E. Atroschenko, D. Romanovskiy, O. Pashuk, E. Kurlyanskaya, 

I. Sidorenko (Minsk, BY) 

151 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 



Should a Crt-iCD implanted in all patients with permanent rigtht ventricular 

stimulation and reduced left ventricular ejection fraction? P1284 

K. Sonne, S. Raffa, A. Grosse, M. Brunelli, S. Hamid, J.-C. Geller (Landshut and 

Bad Berka, DE) 

Prevalence of potential Crt candidates and actual use of Crt in patients admitted 

with heart failure: results from a real-life registry. P1285 

C. Weytjens, A.M. Willems, N. De Laet, F. Provenier, G. Van Camp, J. De Sutter (Brussels 

and Gent, BE) 

outcomes of cardiac resynchronization therapy in heart failure patients with valvular 


M.A. Castel, A. Martin, C. Plata, J.M. Tolosana, A. Berruezo, B. Vidal, M. Sitges, L. Mont 

(Barcelona, ES) 

ICD therapy 

is muscular counterpulsation safe in patients with implantable cardiac rhythm 

devices? observations in the first 15 patients P1287 

V. Puetz, I. Seifert, J. Heintze, J. Vogt, D. Ostojic, K.J. Gutleben, G. Noelker, D. Horstkotte, 

O. Oldenburg (Bad Oeynhausen, DE) 


the effect of preoperative mild renal dysfunction on the prognosis of cardiac valve 

surgery P1288 

M.S. Shin, B.R. Kim, W.-J. Chung, W.C. Kang, K.H. Lee, T.H. Ahn, I.S. Choi, E.K. Shin 

(Incheon and Seoul, KR) 

aortic valve replacement in the elderly: does concomitant coronary artery bypass 

grafting predict a worse short-term outcome? P1289 

A.S. Correia, S.M. Oliveira, M. Paiva, A. Goncalves, R. Almeida, M. Pereira, E. Alves, P. Dias, 

A. Abreu, P. Pinho (Porto, PT) 

acute effects of left ventricular reconstruction with circumferential mid-ventricular 

intramyocardial injections of alginate hydrogel in dogs with chronic heart failure P1290 

H.N. Sabbah, I. Ilsar, M. Wang, M.S. Sabbah, S. Helgerson, N. Tarazona, R. Lee (Detroit, 

Laguna Hills and San Francisco, US) 

influence of end systolic volume on outcome after surgical ventricular reconstruction 

in end stage heart failure P1291 

M. Di Donato, S. Castelvecchio, A. Frigiola, A. Raweh, C. Ricci, L. Menicanti (Florence and 



Chronic mechanical circulatory support induces reverse remodeling early post 

implantation in end stage heart failure patients P1292 

D. Koudoumas, S. Drakos, N. Diakos, K. Malliaras, E. Tseliou, J. Terrovitis, 

S. Theodoropoulos, S. Nanas, M.H. Yacoub, J. Nanas (Athens, GR; Harefield, GB) 

first use of a new catheter pump to bridge a heart failure patient to heart 

transplantation P1293 

O. Reitan, B. Kornhall, H. Ohlin, J. Harnek, T. Keeble, M. Rothman (Lund, SE; London, GB) 

152



acute sildenafil effects on reverse cardiac remodeling in patients with pulmonary 

hypertension and chronic heart failure P1294 

A. F. Freitas Jr, F. Bacal, J. L. Oliveira Jr, R. Honorato, A. I. Fiorelli, S. Mangini, C. P. Silva, 

E. A. Bocchi (Sao Paulo, BR) 

outcomes in cardiac transplant recipients using allografts from older donors P1295 

V. Martinez Mateo, C. Plata Mosquera, C. Tomas Querol, I. Vallejo, M.A. Castel, 

F. Perez Villa, E. Roig Minguell (Toledo and Barcelona, ES) 

Single center long term follow up of cellular rejection after heart transplantation: 

reliability of echocardiographic assessment P1296 

M. A. Engelen, H. Kubitz, H. Welp, T. Spieker, N. Osada, J. Stypmann (Muenster, DE) 

evaluation of nitric oxyde inhalation as a single pharmacological test for the 

assessment of secondary pulmonary hypertension reversibility in advanced heart 

failure patients P1297 

J. Roy-Giocosa, N. Piriou, J.P. Gueffet, F. Valleix, F. Floch, J.N. Trochu (Nantes, FR) 


the treatment adherence in patient with chronic heart failure after myocardial 

infarction P1298 

O.V. Soya, O.V. Kuryata, N. Bardachenko (Dnipropetrovsk, UA) 

effects of levosimendan infusion on plasma Brain natriuretic Peptide and 

echocardiographic parameters in patients with refractory congestive heart failure. P1299 

M. Feola, C. Taglieri, E. Lombardo, S. Piccolo, E. Nervo, E. Menditto, R. Valle (Fossano and 

Chioggia, IT) 

Value of medical therapy in patients older than 75 years of age with heart failure and 

preserved ejection fraction P1300 

R. C. Vidal Perez, E. Abu Assi, M. Pazo Nunez, C. Lopez Seijas, P. Cabanas Grandio, 

J. Elices Teja, A. Varela Roman, J.R. Gonzalez-Juanatey (Santiago de Compostela, ES) 

evaluation of hemodynamic effects of ivabradine in patients with chronic heart failure P1301 

I. Donoiu, O.-D. Dracea, A. Giuca, O. Istratoaie, D.-D. Ionescu (Craiova, RO) 

Complex therapy of decompensated heart failure by direct renin inhibitor aliskiren: 

changes in renal hemodynamics. P1302 

A. L. Volkova, G. P. Arutyunov, N. A. Bylova, I. I. Dayter (Moscow, RU) 

immediate and follow-up results of extracorporeal shock wave therapy in patients 

with ischemic heart failure P1303 

Y. Vasyuk, A. Hadzegova, E. Shkolnik, M. Kopeleva, O. Krikunova, E. Iouchtchouk, 

E. Aronova (Moscow, RU) 


renal dose dopamine in the treatment of refractory heart failure P1304 

B. Sekar, F. Leyva, J. J. Murphy (Darlington and Sutton Coldfield, GB) 

intra-thoracic impedance alert: clinical usefulness in patients with heart failure and no 

indication to resynchronization therapy. P1305 

G. Molon, M. Santini, W. Rahue, D. Miani, L. Leoni, L. Tomasi, V. Calvi, M. Maines, 

L. Zago, A. Varbaro (Negrar, Rome, Bolzano, Udine, Padova, Verona, Catania, Rovereto 

and Milano, IT) 

153 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 



external wireless monitoring of bioimpedance in heart failure patients: results from 

the aCUte study P1306 

R.P. Katra, W.H.W. Tang, V.K. Chopra, N. Chakravarthy, I. Libbus (St. Paul and 

Cleveland, US; New Delhi, IN) 


Consequences and possible causes of ineffective aCe inhibition in 20% of patients P1307 

M. Fagyas, A. Darago, D. Sipos, I. Siket Manyine, I. Edes, Z. Papp, A. Toth (Debrecen, HU) 


Chronic heart failure with preserved ejection fraction in elderly with persistent nonvalvular 

atrial fibrillation P1308 

G. Gheorghe, I.T. Nanea, S. Almarichi (Bucharest, RO) 

e/(ea*Sa) in prediction of atrial fibrillation in patients with left ventricular 

dysfunction: a prospective study. P1309 

C. Mornos, L. Petrescu, R. Dan, D. Cozma, A. Ionac, S.I. Dragulescu (Timisoara, RO) 


association of plasma retinol binding protein 4 levels and diabetes mellitus in patients 

with inflammatory cardiomyopathy P1310 

P. Bobbert, U. Kuehl, U. Rauch, H.P. Schultheiss, C. Skurk (Berlin, DE) 

the long-term prognostic role of age at diagnosis in hypertrophic cardiomyopathy: 

the trieste heart muscle disease experience P1311 

G. Finocchiaro, M. Merlo, B. Pinamonti, G. Barbati, A. Di Lenarda, G. Sinagra (Trieste, IT) 

Preclinical diagnosis of fabry cardiomyopathy by tissue Doppler imaging velocities P1312 

A. Pavlidis, A. Tsoukas, I. Zisimopoulos, G. Antonakoudis, A.J. Manolis (Athens, GR) 

Structural and functional heart abnormalities are related with severity of end-stage 

liver disease P1313 

F. Bacal, O. M. Silvestre, A.Q. Farias, V. Pugliese, P. Nespoli, M. Furtado, J.L. Andrade, 

L.A.C. D’albuquerque, F.J. Carrillo (Sao Paulo, BR) 

Clinical predictors of left ventricular outflow tract obstruction in hypertrophic 


A. Sousa, A. Lebreiro, E. Martins, M. Campelo, S. Amorim, B. Moura, J. Silva-Cardoso, 

M.J. Maciel (Porto, PT) 

Cardiac amyloidosis: a single centre experience P1315 

J. Doerler, M. Frick, T. Trieb, D. Hoefer, H. Antretter, M. Steurer, G. Poelzl (Innsbruck, AT) 

functional variants of angiotensin-converting enzyme gene and phenotype 

expression in hypertrophic cardiomyopathy P1316 

D. Brito, A. Fernandes, M. Bicho, H.C. Madeira (Lisbon, PT) 

is fibrosis an early marker of hemodynamic deterioration in hypertrophic 

cardiomyopathy? P1317 

A. Lebreiro, A. Sousa, E. Martins, T. Pinho, A.J. Madureira, M. Campelo, S. Amorim, 

I. Ramos, J. Silva-Cardoso, M.J. Maciel (Porto, PT) 

154



Clinical, electrocardiographic and echocardiographic characteristics of tachycardiainduced 


A. Chin, B.N. Ntusi, M. Badri (Cape Town, ZA) 

erythromycin treatment suppressed myocardial injury in autoimmune myocarditis P1319 

C. Kishimoto, K. Shimada, E. Hirano, T. Komiyama, M. Fujita (Kyoto, JP) 

a specific inhibitor for the plasma membrane calcium pump 4 (PmCa4) as a potential 

anti-hypertrophic agent P1320 

T. M. A. Mohamed, D. Oceandy, S. Prehar, M. Zi, F. Baudoin, R. Abou-Leisa, P. Stanley, 

E. Cartwright, L. Neyses (Manchester, GB) 

Sequential cardiac protein analysis in anti-beta1 antibody-induced cardiomyopathy 

reveals endoplasmic reticulum (er)-stress as a key mediator of increased myocyte 

apoptosis P1321 

S. Hartmann, V. Boivin, A. Schlipp, C. Zechmeister, J. Ullrich, V. Schwarzbach, M.J. Lohse, 

R. Jahns (Wuerzburg, DE) 


treatment of hypertensive patients with moderate heart failure with combination of 

calcium antagonists and aCe-inhibitors P1322 

K. Nikoghosyan, S. Gurgenyan, S. Vatinian (Yerevan, AM) 

Serum uric acid is related with central adiposity in patients with essential hypertension P1323 

M. Rivera Otero, R. Cortes, V. Miro, L. Martinez Dolz, L. Grigorian, G. Baron, P. Orosa, 

R. Paya, F. Garcia De Burgos, F. Soria (Valencia, Santiago de Compostela, Sevilla, Gandia, 

Elche and Murcia, ES) 

importance of oxidative stress for development of remodeling and dysfunction in 

hypertensive patients P1324 

M.N. Dekleva, J. Suzic Lazic, D. Begovic, A. Stevanovic (Belgrade, RS) 

Ventricle-specific effects of nitric oxide deficiency on extracellular matrix formation P1325 

R. Schreckenberg, M. Rebelo, S. Wenzel, K.-D. Schlueter (Giessen, DE) 


Peripheral muscle microcirculatory alterations in patients with pulmonary arterial 

hypertension P1326 

S. Dimopoulos, G. Tzanis, C. Manetos, A. Tasoulis, A. Mpouchla, I. Pozios, M. Bonios, 

E. Tseliou, Z. Margari, S. Nanas (Athens, GR) 

BnP monitoring of patients with chronic heart failure treated with sildenafil. P1327 

I. Malek, H. Al-Hiti, V. Melenovsky, A. Reichenbach, M. Hegarova (Prague, CZ) 

iron deficiency is common in pulmonary arterial hypertensive patients P1328 

G. Ruiter, Y.Y. Wong, I. Schalij, P.E. Postmus, W.J. Van Der Laarse, A. Vonk-Noordegraaf 

(Amsterdam, NL) 


Human heart type fatty acid binding protein is elevated in the serum of heart failure 

patients but does not predict the occurrence of events. P1329 

M. E. Tettamanti, J. Lopez Diaz, J.A. San Roman, M.L. Nieto, C. Tapia Ballesteros, 

E. Garcia Moran, J. Rubio, L. De La Fuente Galan, I. Gomez Salvador (Valladolid, ES) 

155 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 



Kidney function evaluation and significance of kidney disorders in ischaemic heart 


E. Nikolaychuk, O. Berkovich, E. Shlyakhto, M. Borodzulia, E. Bazhenova, A. Berezina 


Heart rate turbulence is a diagnostic marker of autonomous dysfunction in severe 

ischemic heart failure P1331 

O.A. Koval, S. V. Romanenko (Dnipropetrovsk, UA) 

Determination of circulating chromogranin a levels in patients with heart failure P1332 

D. Gruson, S.A. Ahn, M.F. Rousseau (Brussels, BE) 

the relation between roCK activity and heart failure P1333 

C. H. Hsu, P.-Y. Liu, P.-S. Cheng, J.-H. Cheng (Tainan, TW) 

red cell distribution width; a new marker of poor exercise tolerance in patients with 


E. Van Craenenbroeck, P. Beckers, N. Possemiers, C. Vrints, V. Conraads (Edegem, BE) 

expression of ubiquitin in patient with heart failure depending on desmin expression. P1335 

A. Pawlak, E. Czarnowska, M. Pronicki, H. Rdzanek, A. Slysz, R.J. Gil (Warsaw, PL) 

the relationship between the time interval difference of isovolumic relaxation and 

ntproBnP levels in patients with intermediate e/ea ratio P1336 

C. Mornos, I. Zacharopoulou, N. Kouremenos, D. Dragulescu, S. Pescariu, S.I. Dragulescu 

(Timisoara, RO) 

Daily variations in diastolic pulmonary arterial pressure P1337 

M. C. Brandt, Y. Rozenman, M. Vanderheyden, H. Sievert, C. Keller, D. Menachemi, 

J. Peterson, N. Wartski, B. D. Schubert, U. C. Hoppe (Cologne and Frankfurt am Main, 

DE; Tel-Aviv, IL; Aalst and Diegem, BE; St. Paul, Minnesota, US) 

factors associated with moderate elevation of B-type natriuretic peptide in subjects 

without heart failure P1338 

Y. D. Kim, T. H. Park, M. H. Kim, S. E. Lee, J. H. Kim, S. E. Park (Busan, KR) 

Secretoneurin is increased in the myocardium and circulation in heart failure, induces 

cardiomyocyte erk1/2 and Stat3 phosphorylation, and protects against cardiomyocyte 

apoptosis P1339 

H. Rosjo, M. Stridsberg, G. Florholmen, K.O. Stenslokken, I. Sjaastad, C. Husberg, 

M.B. Dahl, E. Oie, T. Omland, G. Christensen (Lorenskog and Oslo, NO; Uppsala, SE) 


expression of aromatase, androgen and estrogen alpha receptor mrna is 

downregulated in left ventricle of male porcine myocardium with tachycardia-induced 


M. Zacharski, L. Kiczak, A. Tomaszek, U. Paslawska, A. Noszczyk-Nowak, D. Zysko, 

J. Bania, M. Ugorski, E. A. Jankowska, P. Ponikowski (Wroclaw, PL) 

neutrophil gelatinase-associated lipocalin - pro-matrix metalloproteinase 9 complex is 

upregulated in porcine myocardium with tachycardia-induced cardiomyopathy P1341 

A. Tomaszek, L. Kiczak, M. Zacharski, U. Paslawska, A. Noszczyk-Nowak, P. Skrzypczak, 

J. Bania, M. Ugorski, E. A. Jankowska, P. Ponikowski (Wroclaw, PL) 

156



Cell to cell inhomogeneity in beta-adrenergic signaling in a pig model of pacing 

induced heart failure P1342 

D. Czuriga, A. Balogh, E.T. Pasztor, A. Bodnar, E. Nizsaloczki, V. Lionetti, I. Czuriga, 

A. Toth, I. Edes, Z. Papp (Debrecen, HU; Pisa, IT) 


relation to left bundle branch block and levels of n-terminal pro brain natriuretic 

peptide of patients with chronic heart failure P1343 

K. Zahidova, F.A. Guliyev (Baku, AZ) 

association between brain natriuretic peptide and n-terminal pro brain natriuretic 

peptide levels: effect of renal function P1344 

H. Takase, Y. Dohi, T. Toriyama, T. Okado, H. Sonoda, A. Hagikura, G. Kimura 

(Hamamatsu and Nagoya, JP) 

Differences in nt-proBnP levels in eSrD patients according to whether or not on 

dialysis, dialysis modality, and clinical manifestation P1345 

S. Lee, S.R. Lee, K. Rhee, J. Chae, W. Kim, J. Ko (Jeonju, KR) 

abnormal 24 hour blood pressure variation is associated with increased left atrial 

volume and elevated BnP levels P1346 

D. Phelan, E. Omar, M. Ledwidge, B. Hennigan, D. O’shea, K. Mcdonald (Dublin, IE) 


the non-invasive differentiation between the ischaemic and idiopathic dilated 

cardiomyopathies using lv long axis m-mode echocardiography P1347 

N.V. Nranyan (Yerevan, AM) 

Correlations between noninvasively estimated left ventricular filling pressure and 

invasively measured pulmonary capillary wedge pressure in patients with reduced 

systolic function P1348 


Doppler echocardiography in the screening of systemic sclerosis P1349 

F. Cecaro, R. Revel Chion, A. Fucili, E. Faragasso, L. Pirani, S. Biscaglia, A. Ferri, M. Malagu, 

C. Ceconi, R. Ferrari (Ferrara, IT) 

right ventricular systolic parameters assessed by tissue doppler as predictors of the 

maximal functional capacity P1350 

D. Popovic, I. Nedeljkovic, M. Petrovic, A. Kocijancic, B. Vujisic-Tesic, S. Damjanovic, 

M.C. Ostojic (Belgrade, RS) 

assessment of left ventricular mechanical dyssynchrony in patients with heart failure 

using real-time three-dimensional echocardiography: a comparative study to doppler 

tissue imaging P1351 

A.M.A.B.I.S. Elmissiri, M. Tawfik, R. Samir, G.S. El Shahed, M. Aboel Maaty, M.H. El Sayed 

(Cairo, EG) 

157 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 




role of multislice computed tomography angiography in master athletes with eCg 

repolarization abnormalities during exercise stress test P1352 

E. D’elia, S. Celada, C. Auguadro, M. Manfredi, T. Khouri, E. Vanoli, G. Specchia 

(Monza, IT) 

nucelar Cardiology in follow-up of CHf patients after nSteaCS P1353 

V. Soukhov, D. Dolgushev, P. Bovtyushko, S. Grishaev, A. Svistov (St Petersburg, RU) 

Comparative estimation the results of gated blood-pool SPeCt and echocardiography 

with tissue doppler imaging in assessment of heart global systolic function and 

ventricular mechanical dyssynchrony P1354 

D.V. Ryzhkova, M.A. Trukshina, O.S. Borodina, T.V. Kuzmina (St Petersburg, RU) 


the use of imatinib mesylate has no adverse effects on the heart function. results of a 

pilot study in patients with chronic myeloid leukemia P1355 

M. S. Marcolino, A.L.P. Ribeiro, M.C.P. Nunes, M.M. Barbosa, N.C.D. Clementino, 

M.H.C.R. Silva, H.N.S. Bittencourt, M.L. Geleijnse, E. Boersma (Belo Horizonte, BR; 

Rotterdam, NL) 


Cardiorenal syndrome-problems of definition P1356 

A. Shutov, V. Serov (Ulyanovsk, RU) 

Cardiorenal syndrome in acute heart failure: an inevitable side effect? P1357 

A. F. Simoes Marques Assuncao Caetano, S. Barra, C. Faustino, A. Botelho, P. Mota, 

M. Costa, A. Leitao Marques (Coimbra, PT) 

Peritoneal dialysis in patients with refractory heart failure (stage D): therapeutic 

implications from a longitudinal cohort study P1358 

C. Zugck, R. Cebola, L. Kihm, M. Zeier, A. Remppis, H. Katus, V. Schwenger 

(Heidelberg, DE) 


remodelling of the atrioventricular node, right atrioventricular ring and working 

myocardium in left ventricular heart failure P1359 

J. Yanni, S. Siew, A. Atkinson, O. Fedorenco, H. Zhang, U. Mackiewicz, M. Maczewski, 

A. Beresewicz, M. Boyett, H. Dobrzynski (Manchester, GB; Warsaw, PL) 


molecular analysis of cardiac remodeling following changes in intracellular calcium 

metabolism P1360 

F. Matthes, J.H. Steinbrecher, G. Salinas-Riester, L. Opitz, G. Hasenfuss, S.E. Lehnart 

(Goettingen, DE) 

158




Symptom-based questionnaires for identifying chronic obstructive pulmonary 

disease in Japanese patients with chronic heart failure P1361 

K. Kida, Y.J. Akashi, K. Ashikaga, K. Suzuki, K. Omiya, F. Miyake (Kawasaki, JP) 

reversal of nocturnal Cheyne-Stokes respiration after cardiac transplantation P1362 

O. Oldenburg, T. Bitter, U. Schulz, D. Horstkotte (Bad Oeynhausen, DE) 

Different methods in analyzing of body composition in patients with chronic heart 

failure P1363 

K. B. Shavgulidze, G. P. Arutyunov, N. Bylova (Moscow, RU) 

anemia correction improves the prognosis of end-stage inotrope-dependent heart 


E. Kaldara, J. Terrovitis, M. Bonios, S. Drakos, V. Kontopidi, C. Pantsios, Z. Margari, 

J. Kanakakis, M. Anastasiou-Nana, J. Nanas (Athens, GR) 

Cheyne-Stokes respiration in heart failure: cycle length is dependent on left ventricular 


O. Oldenburg, J. Wedewardt, T. Bitter, C. Prinz, L. Faber, D. Horstkotte 

(Bad Oeynhausen, DE) 

iron deficiency in chronic heart failure with and without anaemia: impact on 

sympathetic activation and prognostic biomarkers P1366 

D.M. Silva, J. Comin-Colet, G. Gonzalez, S. Ruiz, M. Rizzo, A. Herranz, M. Cladellas, 

R. Elosua, R. Serrat, J. Bruguera (Barcelona, ES) 


lack of cytokine response to post-infarction heart failure and exercise P1367 

T.A. Rehn, G. Slettalokken, M. Munkvik, B. Rud, M. Sokjer-Pedersen, I. Sjaastad, J. Hallen, 

O.M. Sejersted, P.K. Lunde (Oslo, NO) 

inflammatory activation during maximal physical effort predicts specific cardiomyocite 

membrane damage in systolic heart failure P1368 

L.E. Pastormerlo, M. Cabiati, C. Caselli, A. Agazio, C. Ciurli, S. Del Ry, D. Giannessi, 

C. Passino, M. Emdin (Pisa, IT) 

il-stimulates BnP synthesis and release by cardiomyocytes:an in vitro model for il-18induced 

BnP production in heart failure patients P1369 

V. Pittoni, V. Nobili, S. Raffa, E. Salvatori, E. Soluri, R. Marino, M.R. Torrisi, S. Di Somma 

(Rome, IT) 

the deficiency of protease activated receptor 2 (Par2) impairs the genesis of coxsackie 

virus B3 (CVB3) induced myocarditis P1370 

A. Weithaeuser, U. Boltzen, H.P. Schultheiss, U. Rauch (Berlin, DE) 


transplantation of cardiac-committed human embryonic stem cells improves 

overloaded right ventricular function in a large animal model P1371 

V. Lambert, A. Capderou, E. Gouadon, E. Le Bret, C. Rucker-Martin, S. Dinanian, B. Stos, 

M. Puceat, A. Serraf, J.F. Renaud (le Plessis Robinson, Clamart and Evry, FR) 

159 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 



gene therapy with manganese superoxide dismutase reduces cardiomyocyte 

remodeling with pre-existing advanced hypertrophy caused by pressure overload P1372 

H. Zhang, D.F. Zhang, L. Shao, Y.T. Zhao, L.L. Teng (Shanghai, CN) 


relationship between oxidative stress and pulmonary hemodynamic parameters in 

stable dilated cardiomyopathy patients P1373 

W. Jachec, C. Wojciechowska, B. Skrzep-Poloczek, E. Romuk, A. Tomasik, A. Gala, 

E. Nowalany Kozielska, E. Birkner (Zabrze, PL) 

relationship between pulmonary wedge pressure, plasma BnP levels and 

transthoracic bioimpedance in patients with decompensated heart failure P1374 

G. Malfatto, S. Blengino, A. Giglio, G. Branzi, G.B. Perego, M. Facchini, G. Parati 

(Milan, IT) 


metabolic imbalance in chronic heart failure, the role of adiponectin in disease 

progression and symptomatic status P1375 

T. Szabo, M. Bauer, A. Sandek, A. Pfeiffer, A. Flyvbjerg, S.D. Anker, W. Doehner 

(Berlin, DE; Aarhus, DK) 


functional mitral regurgitation - impact on chronic heart failure course and structure- 

functional heart state P1376 

V. Larina, B. Bart (Moscow, RU) 

Systolic and isolated diastolic heart failure: comparation of risk factors P1377 

M. Tadic, B.I. Ivanovic, D.C. Cvijanovic, D.S. Simic (Belgrade, RS) 

Diastolic heart failure and diabetic kidney: the value of microalbuminuria and the 

creatinine clearance. P1378 

B. Rodrigues, L.F. Santos, E. Correia, R. Faria, P. Gama, C. Cabral, J. Pipa, O. Santos 

(Viseu, PT) 

Parameters of cardio-pulmonary exercise test as prognostic factors in patients 

with stable coronary disease and asymptomatic heart dysfunction during 2-years 

observation. P1379 

A. Skrzypek (Krakow, PL) 

t-wave alternans in patients with early stages of heart failure with preserved left 

ventricular systolic function P1380 

N. M. Seidova, D.A. Napalkov, V.A. Sulimov (Moscow, RU) 

reflected high-intensity motion signals: determination of normal values in different 

pediatric age groups P1381 

A. Savisko, N. Nelassov, S. Parmon, E. Tepljakova, K. Niranjan (Rostov-on-Don, RU) 

the level of circulating stromelysin-1 as a marker of early cardiac remodeling after 

Q-wave myocardial infarction P1382 

A. Berezin, T.A. Panasenko (Zaporozhye, UA) 

160



inhibition of interleukin-1 activity improves speckle tracking myocardial deformation 

by reducing apoptosis in patients with rheumatoid arthritis P1383 

I. Ikonomidis, M. Anastasiou-Nana, J. Lekakis, S. Tzortzis, I. Andreadou, I. Paraskevaidis, 

P. Katsimbri, D.T. Kremastinos (Athens, GR) 

rimonabant improves heart function after myocardial infarction in the rat P1384 

S. Slavic, U.R. Kemnitz, M. Sommerfeld, T. Unger, E. Kaschina (Berlin, DE) 


Profile of endothelial markers in patients with metabolic syndrome and heart failure P1385 

M. Anton, G. Anton, S. Avram, I. Bruckner, M. Muraru (Bucharest, RO) 

early signs of global left ventricular dyssynchrony are revelaed by real-time 

3-dimensional echocardiography in high-risk type 2 diabetes patients and relates with 

higher coronary calcium score P1386 

E. De Marco, F.A. Gabrielli, G. Savino, R. Natali, B. Garramone, M. Savino, G. Comerci, 

A. Colucci, E. Bock, F. Loperfido (Rome, IT) 

repetitive measurements of Hba1c and nt-proBnP: divergent behavior of biomarkers 

in longstanding diabetes mellitus P1387 

S. Neuhold, M. Resl, M. Huelsmann, C. Rath, M. Clodi, C. Adlbrecht, R. Pacher 

(Vienna, AT) 


acute coronary symdrome complicated with heart failure and risk of long term 

reinfarction P1388 

P. Palau Sampio, J. Nunez Villota, J. Sanchis Fores, V. Bodi Peris, G. Minana Escriva, 

P. Merlos Diaz, E. Nunez, A. Llacer Escorihuela (Valencia, ES) 

Short recurrent periods of myocardial ischemia and subsequent reperfusion result in 

an atP- dependent inhibition of the cytochrome c- oxidase. is the second mechanism 

of respiratory control the key f P1389 

S. Vogt, B. Kadenbach, R. Ramzan, A. Rhiel, P. Weber, V. Koch, R. Moosdorf 

(Marburg, DE) 


Clinical characteristics and prognostic impact of left ventricular dysfunction in patients 

with unprotected left main disease undergoing percutaneous coronary interventions P1390 

S. Rekik, J. Brunet, F.X. Hager, G. Bayet, L. Meille, J.M. Quatre, J. Sainsous (Sfax, TN; 

Avignon, FR) 

inflamatory polymorphisms and atrial fibrillation in patients with heart failure P1391 

M.J. Ruiz Olgado (Salamanca, ES) 

Biological action of alpha-ketoglutarate in the heart and kidney - a metabolite 

identified through a metabolomic search in patients with heart failure P1392 

T. Nikolaidou, M. Mamas, D. Oceandy, L. Neyses (Manchester, GB) 

161 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 




Prolonged ejection and filling times and shortened total isovolumetric time are 

present at rest in patients with heart failure and normal ejection fraction (Hfnef) and 

fail to improve on exercise P1393 

F. W. G. Wenzelburger, Y.T. Tan, F.E.R.R.A.H. Choudhary, E.S.P. Lee, F. Leyva, G. Heatlie, 

J.E. Sanderson (Birmingham and Stoke On Trent, GB) 

lung remodelling in chronic heart failure: unique involvement of PtHrP and its receptor P1394 

K.-D. Schlueter, S. Forst, C. Conzelmann, J. Heger (Giessen, DE) 


effectiveness of a remote patient management program (motiva-Philips) in a heart 

failure unit in number of hospitalizations and days-in-hospital: the Carme study 

(Catalan remote management evaluation) P1395 

M. Domingo, J. Lupon, B. Gonzalez, A. Ramos, R. Lopez, E. Crespo, A. Urrutia, 

J. Valenzuela, R. Cabanes, R. Coll (Badalona and Barcelona, ES) 


greater adherence to the mediterranean diet contributes to the preservation of left 

ventricular systolic function and to the long term favourable prognosis of patients 

after an acute coronary event. P1396 

C. Chrysohoou, P. Aggelopoulos, C. Kastorini, I. Kehagia, K. Liontou, A. Tsiachris, 

A. Aggelis, D.B. Panagiotakos, C. Pitsavos, C. Stefanadis (Athens, GR) 

Heart failure causes of death: the impact of different etiologies P1397 

S. Mangini, S.M. Ferreira, F.D. Cruz, F.G. Marcondes-Braga, V.S. Issa, F. Bacal, E.A. Bocchi 


Quality of life in chronic heart failure patients from the norwegian heart failure registry P1398 

T. Hole, M. Grundtvig, L. Gullestad, B. Floenaes, A. Westheim (Alesund, Lillehammer and 

Oslo, NO) 

Clinical characteristics and in-hospital mortality of acute heart failure: the ofiCa study P1399 

D. Logeart, P. De Groote, J.J. Dujardin, G. Jondeau, Y. Juilliere, G. Mulak, L. Hittinger, 

M.F. Seronde, J.M. Tartiere, J.N. Trochu (Paris, Lille, Douai, Nancy, Creteil, Besancon, 

Toulon and Nantes, FR) 


effects of exercise training on nariuretics peptids in patients with chronic heart failure P1400 

D. Marinkovic, M. Deljanin-Ilic, S. Ilic, B. Ilic (Niska Banja, RS) 

efficacy of the cardiovascular rehabilitation in patients with congestive heart failure or 

after cardiac surgery. P1401 

M. Feola, E. Menditto, E. Nervo, E. Lombardo, C. Taglieri, S. Piccolo, M. Peano, P. Vallauri 

(Fossano, IT) 

is chronotropic incompetence associated with poor outcome in cardiac rehabilitation? P1402 

A.S. Correia, A. Rocha, S.M. Oliveira, M. Paiva, A. Sousa, A. Lebreiro, A.I. Silva, V. Araujo, 

F.P. Pereira, M.J. Maciel (Porto, PT) 

162



impact of cardiac resynchronization therapy in the prognostic power of 

cardiopulmonary exercise testing P1403 

A. Toste, R. Soares, J. Feliciano, V. Andreozzi, M. Nogueira Da Silva, M. Oliveira, 

A. Galrinho, L. Branco, A. Abreu, R. C. Ferreira (Lisbon, PT) 

effect of sleep related breathing disorders in CHf on Qol and depression during 

cardiac rehabilitation program P1404 

E. Skobel (Aachen, DE) 

Comparative effects of interval training and endurand training on 24-h blood 

pressure and exercise tolerance in hypertensive patients with chronic heart failure P1405 

G. Caminiti, M. Volterrani, A. Cerrito, G. Marazzi, R. Massaro, A. Mancuso, B. Sposato, 

G. Rosano (Rome, IT) 

age-related effects of exercise training on diastolic function in chronic heart failure 

patients and healthy subjects P1406 

M. Sandri, V. Adams, N. Mangner, D. Teupser, J. Thiery, G. Schuler, S. Gielen (Leipzig, DE) 

Hypertension and exercise: risk, protection and metabolic adaptation P1407 

K.-D. Schlueter, M. Rebelo, R. Schreckenberg (Giessen, DE) 

Nursing 

Physical and psychosocial determinants of quality of life in heart failure patients P1408 

M.G. Oliveira, W.A. Martins, M.A.R. Manhaes, L.S.N. Barros, L.B. Oliveira, R.W. Cevolo, 

E.P. Campos, M.M.P. Quintao, S.L.S.M.C. Chermont, E.T. Mesquita (Teresópolis, RJ and 

Niteroi, BR) 

nursing diagnosis for hospitalized patients with cardiovascular disorders P1409 

A.C. Cavalcanti, J.M.V. Pereira, G.C. Queluci, D.M.S. Correia, E.T. Mesquita, K.M. Cassiano, 

R.F. Santana, T.C.F. Guimaraes (Niteroi, BR) 

nursing diagnoses in patients with heart failure P1410 

A.C. Cavalcanti, D.M.S. Correia, G.C. Queluci, E.T. Mesquita, G.C.A. Vieira, J.M.V. Pereira, 

C.S. Arruda, R.O.M. Santos (Niteroi, BR) 

group education to patients with heart failure and their partners P1411 

A. Stromberg, P. Johansson (Linkoping, SE) 


one year impact of a specific low salt educational program in heart failure patients P1412 

A. Boireau, C. Pege, C. Drouard, A. Piccini, F. Funck, P. Jourdain (Pontoise and Paris, FR) 

Clinical Performance measures in Heart failure: preliminary results of a cross-sectional 

study of trieste Cardiovascular registry. P1413 

A. Di Lenarda, L. Massa, F. Humar, G. Russo, M. Merlo, G. Faganello, A. Cherubini, 

F. Brun, B. Pinamonti, G. Sinagra (Trieste, IT) 

influence on mortality of a outpatient clinic for very elderly patients with heart failure 

and high comorbidity P1414 

C. Rodriguez Pascual, A. Vilches-Moraga, E. Paredes-Galan, M.J. Lopez-Sanchez, 

A. Ferrero Marinez, M. Torrente (Vigo, ES) 

only few prognostic factors are correlated with daily-life symptoms in ischemic cardiac 

heart failure patients. P1415 

J.Y. Tabet, M.C. Malergue, M. Guenoun, F. Paganelli, P. Jourdain, P. Meurin, D. Not, 

D. Guedj (Villeneuve Saint Denis, Massy, Marseille, Pontoise, LYON and Paris, FR) 

163 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 




the prevalence of type D personality and its impact on the life quality in Siberian 

patients with left ventricular systolic dysfunction P1416 

O.I. Raih, A. N. Sumin, E.V. Korok, A.V. Karpovich, Y.A.E. Bohan, O.L. Barbarash 

(Kemerovo, RU) 

Unstable plaques induced by marble-burying behavior are stabilized by exercise 

training in experimental atherosclerosis P1417 

C. Kishimoto, C. Kishimoto, K. Shimada, T. Murayama, M. Yokode, M. Fujita, T. Kita 

(Kyoto, JP) 

Other 

Pattern of ventilatory defects in systolic heart failure P1418 

J. Ajuluchukwu, A.M.A.M. Mbakwem, O.M. Ajuluchukwu, E.O. Bandele (Lagos, NG) 

Predictors of life quality in nYHa iii chronic heart failure patients P1419 

L. Voronkov, L. Parashchenjuk, O. Semenenko (Kyiv, UA) 

Daily handgrip training affects arm ergoreflex, but not nYHa class in heart failure 

patients P1420 

T. Lelyavina, M.Y.U. Sitnikova Maria (St Petersburg, RU) 

Hyperparathyroidism and disturbances of calcium and phosphorus metabolism in 

chronic heart failure in comparison with arterial hypertension patients P1421 

E. Reznik, G. Gendlin, G. Storozhakov, V. Volinkina, V. Guschina, M. Tursheva, I. Baranich 

(Moscow, RU) 

isopotential and isointegral QrS and St maps in post-infarction heart failure P1422 

I. Mozos, M. Hancu (Timisoara, RO) 

evaluation of carotid intima media thickness in patients of ischemic vascular disease P1423 

G. B. Ramteke, D. Uraiya, A. Bajpai (Indore, IN) 

the lipidic spectrum of blood in patients wiyh chronic obstructive pulmonary diseases 

during acute myocardial infarction P1424 

G. Dadashova, A. Mursalova (Baku, AZ) 

Quality of life and health related depression in chronic heart failure patients. the 

national cardiovascular disease prevention and treatment program, PolKarD 

2007-2009 P1425 

M. Fedyk-Lukasik, B. Wizner, W. Musial, J. Gorski, T. Rywik, T. Grodzicki (Krakow, Bialystok, 

Gdansk and Warsaw, PL) 

CASE REPORT PRESENTATIONS 

Stent thrombosis as a result of right ventricular pacing in patients with severely 

impared left ventricular function - case report P1426 

S. Salinger, Z. Perisic, D. Milic, T. Kostic, S. Apostolovic, M. Zivkovic, N. Bozinovic, D. Ilic, 

N. Krstic, L. Todorovic (Nis, RS) 

fetal cardiac rhabdomyoma with tuberous sclerosis in fetus and infants P1427 

A. Jurko Jr, A. Jurko (Martin, SK) 

Heart failure caused by left atrial myxoma - case report P1429 

M. Damjanovic, G. Koracevic, D. Djordjevic-Radojkovic, M. Pavlovic, S. Apostolovic, 

Z. Perisic (Nis, RS) 

164



implant of autologous stem cells in patients with severe idiopathic dilated 

myocardiopathy with satisfactory clinical response: evaluation by magnetic resonance. 

(CaSe rePort) P1430 

O. T. Greco, J.L.B. Jacob, A. Soares, M. A. Ruiz, A. B. Santos, A. C. Abreu 

(Sao Jose do Rio Preto, BR) 

takotsubo cardiomyopathy and cardiogenic shock - a case report P1431 

E. L. Figueiredo, A.A. Loures-Vale, R.D.F. Melo, L.L. Neiva, G.R. Silva, J.R. Araujo 

(Belo Horizonte and Barbacena, BR) 

Danon disease- phenotype of a new lamP-2 mutation in a Czech family with four 

affected members - Case report - P1432 

M. Kubanek, M. Elleder, S. Stastna, H. Vlaskova, M. Sramko, M. Kotrc, J. Vrbska, J. Sikora, 

I. Malek, I. Pirk (Prague, CZ) 

rapid deterioration of the left ventricle function in glycogen storage disease type i. P1433 

T. Kovacevic-Preradovic, M. Bojic, S. Srdic (Banja Luka, BA) 

axial flow pump left ventricular assist device (lVaD) as destination therapy: a single 

center experience P1434 

T. Ben Gal, Z. Iakobishvili, M. Abuhazira, V. Yaari, D. Hasdai, A. Battler, E. Porath, 

B. Medalion (Petah Tikva, IL) 

long term intraaortic baloon pump support improves hemodynamics and reverses 

end organ dysfunction in patients with end stage heart failure who require cardiac 

surgery P1435 

N. Diakos, J. Terrovitis, S. Drakos, L. Katsaros, D. Koudoumas, I. Pozios, E. Tseliou, 

S. Theodoropoulos, M.H. Yacoub, J. Nanas (Athens, GR; Harefield, GB) 

Persistent right sided heart failure caused by the serious tricuspidal regurgitation after 

the mitral valve replacement in the past P1436 

L. Pohludkova, K. Zeman (Frydek-Mistek, CZ) 

Case of acute mitral insufficiency resulted from chord abruption of myxomatously 

altered mitral valve due to extreme physical activity P1437 

L. Kardashevska, Y.S. Mikhailichenko (Donetsk, UA) 

large left atrium myxoma presenting as congestive heart failure - casereport. P1438 

B. Holek (Trinec, CZ) 

Cardiac tamponade as a manifestation of post partum heart failure P1439 

P. Stravopodis, G. Kalpakou, K. Liveris (Zakynthos, GR) 

Case report - Heart failure and acute anaemia: from diagnosis to management P1440 

E. Greco, R. Greco, P. Tricarico Rosano (Belvedere M.mo (CS) and Milano, IT) 

Stable end-stage heart failure complicated with decompensated end-stage cardiac 

cirrhosis. a case report. P1441 

E. Karapatsoudi, A. Ioannidis, K. Oikonomou, I. Karantoumanis, K. Karali, M. Ntalapascha, 

M. Papitsas, K. Koskinas, P. Makridis (Edessa, GR) 

165 

tUeSDaY 

PoSterS

tUeSDaY 

PoSterS 

noteS 

166

UPDATE PDATE & WIN IN 

BE A WINNER 

By completing your “my eSC” profile, 

you will be automatically entered 

into a prize draw 

20 Lucky Winners will each win 

an iPod touch 

(loaded with all available 

e-versions of Abridged 

ESC Practice Practice Guidelines) 

PlUS 

a Compendium 

of Abridged ESC 

Guidelines 

(New Edition) 

BE SEEN 

TO ACT 

RESPONSIBLY 

Identify yourself within your 

scientific community & enhance your 

active contribution to the Society 

ESC 

CongrESS 

2010 28 AuguSt - 1 SEptEmbEr 

Provide your electronic contact details 

to reduce unnecessary printing & 

mailing. resources that can be better 

used on our life-saving, scientific & 

educational initiatives 

www.escardio.org 

Photo courtesy of Apple 

BE THE FIRST 

TO KNOW 

“Less is More” 

By sharing your contact information 

and fields of interest with us, you will 

receive only the very latest & most 

relevant information to you 

Receive your journal journal on time* time* 

BE 

ENVIRONMENTALLY 

FRIENDLY 

By providing us with your contact 

details & subscribing to electronic 

communications you will help us 

save paper, reduce unnecessary 

mailings & reduce waste 

Visit www.escardio.org/raisemyprofile 

to enter your details 

Deadline: last day of the eSC Congress 2010 (1 September 2010) 

Join us at the World’s leading cardiovascular congress in the 

european green Capital, Stockholm (28 august - 1 September) 

Together we are making a difference... 

Thank you for your cooperation! 

* By providing a specific delivery address, you will guarantee receipt of your copies of the European Journal of Heart Failure in 2011 and 2012 (included in the Heart 

Failure 2010 standard registration fee, Members of the HFA of the ESC and both Nurse & Student registration fees). 

The Prize draw terms and conditions are available on www.escardio.org. The prize draw will take place on 15 September 2010. Pictures for illustration purposes only. 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

e XHi B itorS 

P 

O 

S 

T 

E 

R 

S 

A REA 

Access to 

Level 3 

168 

G5 

A5 

H5 H4 

H6 

I5 

I6 

J6 

J7 

B3 

J5 

A2 

Room 

Frankfurt 

Room 

Stuttgart 

Room 

Hamburg 

From 

Registration Area 

K2 

B2 

G4 

A4 

H2 

H3 

I3 

J3 

B1 

C1 

D2 

F4 

F5 

F6 

G1 

G2 

G3 

J1 

To level 1 

K1 

exhibition floor Plan 

Publishers' Row 

D1 

F3 

E3 

Access to 

Level 3 

H1 

F2 

• ALERE (formerly Inverness Medical) I3 

• BG Medicine, Inc. F6 

• BMEYE BV G4 

• BRAHMS Aktiengesellschaft H2 & H3 

• Cardiola AG D2 

• Experimetria Ltd. G1 

• European Society of Cardiology A2 

• GE Healthcare B1 

• German Competence Network E3 

Heart Failure 

E1 

• HF2011 - Gothenburg Sweden F5 

• Hellenic Cardiological Society F2 

• HRA Research G2 

• Medispec Ltd. F3 

• Medtronic A4 

• Orion Corp. Orion Pharma B3 

• Oxford University Press H1 

• Pfizer Ltd H4 

• Philips Healthcare G3 

• ResMed Europe J3 

• Robert Bosch Healthcare GmbH C1 

• Scisense Inc. F4 

• SERVIER J5 & K2 

• Thoratec Corporation B2 

• Vifor Pharma Ltd. A5 

• Wisepress Online Bookshop J1 

• Zoll CMS GmbH D1

e XHi B itorS 

Exhibitors at Heart Failure 2010: 

These descriptions were supplied by exhibitors, they have not been evaluated or endorsed 

by the HFA of the ESC 

ALERE (formerly Inverness Medical) I3 

Rue des Vignerons 1A 

1110 Morges 

Switzerland 

Tel: +41 218 047 140 - Fax: +41 218 020 933 

Email: info@alere.com 

Web Site: www.alere.com 

Alere (formerly Inverness Medical) has a complete cardiovascular portfolio: Rapid Point of 

Care diagnostic tests in risk assessment (complete Lipid profiles), anticoagulant therapy 

management (PT/INR), diagnosis and assessment of HF (BNP), AMI (Myo, CK-MB, TnI), 

thromboembolic events (D-dimer) and Acute Kidney Injury (NGAL). 

Cholestech LDX ® , INRatio ® 2, Triage ® Systems. 

BG Medicine, Inc. F6 

610N Lincoln Street 

02451 Waltham 

United States of America 

Tel: +1 781 890 1199 - Fax: +1 781 895 1119 

Email: communications@bg-medicine.com 

Web Site: www.bg-medicine.com 

BG Medicine is a life sciences company focused on the discovery, development, and 

commercialization of novel diagnostics based on biomarkers to improve patient outcomes 

and contain healthcare costs. BGM’s first commercialized product is BGM Galetin-3, an in 

vitro diagnostic assay to aid in identifying high-risk heart failure patients. 

169 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

e XHi B itorS 

BMEYE BV G4 

AMC Suite K2-245 

Meibergdreef 9 

1105 AZ Amsterdam 

Netherlands 

Tel: +31 205 665 838 - Fax: +31 206 976 424 

Email: leonie.bekenkamp@bmeye.com 

Web Site: www.bmeye.com 

BMEYE is a dynamic technology-based company that develops innovative medical devices 

with broad application in clinical settings that require cardiovascular monitoring. Specifically, 

BMEYE produces patient monitors that non-invasively measure continuous blood pressure 

and cardiac output. BMEYE aims at bringing safe, precise and easy to use hemodynamic 

monitoring devices to every patient who can benefit at all points along the care path. 

BRAHMS Aktiengesellschaft H2 & H3 

Neuendorfstrasse 25 

16761 Hennigsdorf 

Germany 

Tel: +49 330 288 30 

Email: brahms@brahms.de 

Web Site: www.brahms.de www.procalcitonin.com 

BRAHMS AG is focused on research and development of a number of biomarkers which 

have demonstrated potential efficacy in the diagnosis of infectious and cardiovascular 

diseases. Innovative biomarkers facilitate earlier diagnosis and better therapy control, thus 

enabling clinicians to provide more efficient and economic patient care. 

Cardiola AG D2 

Gruezefeldstrasse 51 

8404 Winterthur 

Switzerland 

Tel: +41 522 346 600 - Fax: +41 522 346 609 

Email: info@cardiola.com 

Web Site: www.cardiola.com 

Cardiola is the developer and marketer of a proprietary, non invasive medical device for the 

treatment of acute and chronic heart failure. Patented Muscular Counterpulsation (MCP) is 

poised for treatment in a clinical, ambulatory or even patient at-home setting. It has been 

clinically validated and has already received CE clearance. 

170

e XHi B itorS 

EUROPEAN SOCIETY OF CARDIOLOGY A2 

2035 Route des Colles Les Templiers - BP 179 

06903 Sophia Antipolis 

France 

Tel: +33 492 947 600 - Fax: +33 492 948 669 

Email: communications@escardio.org 

Web Site: www.escardio.org 

The European Society of Cardiology (ESC) represents more than 61,000 cardiology 

professionals from across Europe and the Mediterranean. The ESC comprises 52 National 

Societies, 19 Working Groups, 5 Associations and 5 Councils. It also includes the distinguished 

community of ESC Fellows and Nurse Fellows. Its mission is “To reduce the burden of 

cardiovascular disease in Europe“. The ESC achieves this through a series of scientific and 

educational activities and its annual Congress, the largest medical meeting in Europe, held 

this year from 28 August -1 September 2010 in Stockholm, Sweden. 

Experimetria Ltd. G1 

Podmaniczky Str. 87 

1062 Budapest 

Hungary 

Tel: +36 126 901 91 - Fax: +36 135 334 51 

Email: info@experimetria.com 

Web Site: www.experimetria.com 

Experimetria Ltd. was founded in 1982 and during the past 27 years it has been developed 

continuously, that ensured its place on the world market. The company’s product scale 

ranges from pre-clinical research physiology, pharmacology, pathophysiology, applied 

anatomy experiments equipment till human diagnostic products. Our newest brand focuses 

on human diagnostic solutions. One of the main advantages of these systems is the ability 

to quickly provide the required data for adequate diagnostic due to the fast calculation, 

simply and compact design. This is the guarantee of being a reliable base for doctors. 

171 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

e XHi B itorS 

GE Healthcare B1 

Pollards Wood 

Nightingales Ln 

Chalfont, St Giles 

HP8 4SP Bucks 

United Kingdom 

Tel: +44 149 454 4000 - Fax: +44 149 449 8234 

Web Site: www.gehealthcare.com 

GE Healthcare provides transformational medical technologies and services that are shaping 

a new age of patient care. Our “healthymagination“ vision for the future invites the world 

to join us on our journey as we continuously develop innovations focused on reducing 

costs, increasing access and improving quality and efficiency around the world. 

German Competence Network Heart Failure E3 

Charité - Campus Virchow-Klinikum 

Medizinische Klinik m.S. Kardiologie 

Augustenburger Platz 1 

13353 Berlin 

Germany 

Email: kerstin.kuehn@charite.de 

The German Competence Network Heart Failure (CNHF) was established in June 2003 and 

is funded by the Federal Ministry of Research and Education. Its main purpose is to provide 

and nurture interdisciplinary cooperation between research and primary, secondary and 

tertiary health care. 

Heart Failure 2011 - Gothenburg Sweden F5 

Göteborg & Co 

Gothenburg Convention Bureau 

Box 29 

SE 401 20 Gothenburg 

Sweden 

Tel: +46 313 684 000 - Fax: +46 318 010 48 

Email: karin.arwidsson@goteborg.com 

Web Site: www.goteborg.com 

The Heart Failure Congress 2011 will be held in one of the most beautiful Swedish cities, 

Gothenburg. Situated at the heart of Scandinavia, centrally located between the Swedish, 

Danish and Norwegian capitals, Gothenburg has a strategic location which makes it a true 

gateway to Europe. Gothenburg has all the necessary ingredients that make it a world class 

city with hotels, restaurants, shops and entertainment within easy walking distance. 

172

e XHi B itorS 

Hellenic Cardiological Society F2 

6 Potamianou St. 

11528 Athens 

Greece 

Tel: +30 210 725 8004 - Fax: +30 210 722 6139 

Email: ophcs@hcs.gr 

Web Site: www.hcs.gr 

The Hellenic Cardiological Society was established in Athens on September 7th, 1948 as a 

scientific non-profit organization with 28 members. It now represents 2500 cardiologists 

and continues to grow. The Society is the largest and most influential in the country. 

HRA Research G2 

400 Lanidex Plaza 

07054 Parsippany 


Tel: +1 973 240 1200 - Fax: +1 973 463 1888 

Email: knielsen@hraresearch.com 

Web Site: www.hraresearch.com 

We are a market research firm whose team of experienced interviewers will be distributing 

carefully developed questionnaires. We’ll be gathering answers to vital marketing and clinical 

questions-answers that can affect the introduction of new products or the continuation of 

existing healthcare products and services. 

Medispec Ltd. F3 

20410 Observation Drive, Suite # 102 

20876 Germantown, MD 


Tel: +1 301 944 1575 - Fax: +1 301 972 6098 

Email: marketing@medispec.com 

Web Site: www.medispec.com 

Medispec’s Cardiospec - Optimal Cardiac Revascularization System Medispec’s innovative 

cardiac shockwave system, the CARDIOSPEC, uses Extracorporeal Shockwave Myocardial 

Revascularization (ESMR) technology for the treatment of patients diagnosed with 

myocardial ischemia, secondary to CAD. Using standard echocardiography to guide the 

shockwaves to the desired area it incorporates a paradigm shift in the way these patients 

can be treated. ESMR is the optimal alternative for these patients, complementing standard 

treatment procedures for revascularization. Clinical results show a significant improvement in 

CCS class, Exercise Tolerance, increase in myocardial perfusion and obviously improvement 

in myocardial contractility. 

173 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

e XHi B itorS 

Medtronic A4 

Route du Molliau 31 

Case postale 

1131 Tolochenaz 

Switzerland 

Tel: +41 218 027 000 - Fax: +41 218 027 918 

Email: christine.dettwiler@medtronic.com 

Web Site: www.medtronic.com 

At Medtronic, we’re committed to Innovating for Life by pushing the boundaries of medical 

technology and actually changing the way the world treats chronic disease. Join our 

symposium on May 30, 12:45-14:00 (Munich), and visit the Medtronic booth (A4) to see the 

latest innovative solutions for clinicians managing the heart failure patient. 

Orion Corp. Orion Pharma B3 

Orionintie 1A 

FI-02200 Espoo 

Finland 

Tel: +35 810 4261 - Fax: +35 810 426 3815 

Email: firstname.lastname@orionpharma.com 

Web Site: www.orion.fi/en/ 

Orion is an innovative European R&D-based pharmaceuticals and diagnostics company with 

an emphasis on developing medicinal treatments and diagnostic tests for global markets. 

Orion develops, manufactures and markets human and veterinary pharmaceuticals, active 

pharmaceutical ingredients as well as diagnostic tests. 

Oxford University Press H1 

Great Clarendon Street 

OX2 6DP Oxford 


Email: jnls.mkt@oxfordjournals.org 

Web Site: www.oup.com 

Oxford University Press publishes some of the most respected medical books and journals 

in the world including The ESC Textbook of Cardiovascular Medicine, and on behalf of the 

ESC, European Journal of Heart Failure and European Heart Journal. Visit our stand to 

browse books and pick up free copies of the journals. 

174

e XHi B itorS 

Pfizer Ltd. H4 

Walton Oaks 

Dorking Road Walton-on-the-Hill 

KT20 7NS Surrey 


Tel: +44 130 461 616 

Email: Selim.Sezgin@pfizer.com 

Web Site: www.pfizer.co.uk 

Pfizer Inc.: Working together for a healthier world TM . At Pfizer, we apply science and our 

global resources to improve health and well-being at every stage of life. We strive to set the 

standard for quality, safety and value in the discovery, development and manufacturing 

of medicines for people and animals. Our diversified global health care portfolio includes 

human and animal biologic and small molecule medicines and vaccines, as well as nutritional 

products and many of the world’s best-known consumer products. Every day, Pfizer 

colleagues work across developed and emerging markets to advance wellness, prevention, 

treatments and cures that challenge the most feared diseases of our time. Consistent with 

our responsibility as the world’s leading biopharmaceutical company, we also collaborate 

with health care providers, governments and local communities to support and expand 

access to reliable, affordable health care around the world. For more than 150 years, Pfizer 

has worked to make a difference for all who rely on us. 

Philips Healthcare G3 

Hewlett-Packard-Str. 2 

71034 Boeblingen 

Germany 

Tel: +49 703 146 329 13 - Fax: +49 703 146 322 02 

Email: melanie.Sarantos@philips.com 

Web Site: www.healthcare.philips.com/main/products/telehealth/products/motiva. 

wpd 

Philips Motiva, the interactive healthcare platform that connects patients with chronic 

conditions, e.g. heart failure, diabetes, and COPD, to their healthcare providers – via the 

home television and broadband connection. Motiva automates disease management 

activities, and engages patients with personalized daily inter-actions and education delivered 

through the home television. 

175 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

e XHi B itorS 

ResMed Europe J3 

Fjordveien 1 

1363 Hovik 

Norway 

Tel: +47 671 188 50 - Fax: +47 671 188 55 

Email: post@resmed.no 

Web Site: www.resmed.com 

ResMed is a leading developer, manufacturer and marketer of products for the screening, 

treatment and long-term management of sleep-disordered breathing (SDB) and other 

respiratory disorders. ResMed is committed to increasing education and awareness by 

supporting leading physicians and researchers exploring the link between SDB and lifethreatening 

diseases as heart failure, hypertension, and stroke. 

Robert Bosch Healthcare GmbH C1 

Stuttgarter Straße 130 

71301 Waiblingen 

Germany 

Email: info-bosch-healthcare@bosch.com 

Web Site: www.bosch-telemedizin.de 

Robert Bosch Healthcare GmbH is presenting an innovative range of products from patients 

terminals, through fast and secure transmission of health data (vital signs), to comprehensive 

evaluation software for healthcare professionals. 

Bosch Telehealth Plus enables interactive monitoring of patients with long-term conditions. 

The system helps healthcare professionals to identify even gradual changes in a 

patient´s condition so that treatments can be quickly modified to prevent serious health 

complications. 

Scisense Inc. F4 

3397 White Oak Rd. 

N6E 3A1 London 

Canada 

Tel: +1 519 680 7677 - Fax: +1 519 680 7718 

Email: sales@scisense.com 

Web Site: www.scisense.com 

Cardiac Function Assessment devices that directly measure Contractility, Ventricular Pressure 

and Absolute Ventricular Volume in Real Time. Catheter based sensors from 1.2F to 7.0F 

ensure minimum invasiveness and high fidelity signals for all animal sizes. Inter and Intra 

group comparison possible for hearts with Mycardial Infarction, Hypertrophy and various 

Myopathies. 

176

e XHi B itorS 

SERVIER J5 & K2 

35 Rue de Verdun 

92284 Suresnes 

France 

Tel: +33 155 723 859 - Fax: +33 155 725 295 

Email: marie-pascale.eon@fr.netgrs.com 

Servier is a private independent pharmaceutical company. The Company has developed 

drugs for the treatment of hypertension, cardiac ischemia, and heart failure. Procoralan 

(ivabradine), Vastarel MR (trimetazidine), Coversyl (perindopril), Coveram (perindoprilamlodipine), 

Preterax (perindopril-indapamide) and Natrilix SR (indapamide) are six of 

our major cardiovascular drugs. Procoralan (ivabradine) is indicated for the symptomatic 

treatment of chronic stable angina. Recently, the EMEA has approved extension of 

Procoralan’s indications to include combination with ß-blockers. Procoralan is currently 

under development for heart failure. 

Thoratec Corporation B2 

Burnett House 

Lakeview Court, Ermine Business Park 

PE29 6UA Huntingdon 


Tel: +44 148 045 5200 - Fax: +44 148 045 4126 

Email: europeaninfo@thoratec.com 

Web Site: www.thoratec.com 

With more than 14,000 patient implants and three decades of experience, Thoratec® 

Corporation offers the broadest portfolio of mechanical circulatory support devices. 

Thoratec’s product line includes the HeartMate ® LVAS, Thoratec PVAD and IVAD. 

Now the HeartMate II ® is CE and FDA approved for both Bridge to Transplantation and 

Destination Therapy. 

Vifor Pharma Ltd. A5 

Flughofstraaase 61 

CH-8152 Glattbrugg 

Switzerland 

Tel: +41 588 518 000 - Fax: +41 588 518 001 

Email: info@viforpharma.com 

Web Site: www.viforpharma.com 

Vifor Pharma is one of the world leaders in iron preparations for the treatment of iron 

deficiency and iron deficiency anaemia. Vifor Pharma’s intravenous iron product Ferinject © 

(ferric carboxymaltose) is expected to address unmet clinical needs and optimise the 

management of iron deficiency and iron deficiency anaemia. 

177 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

e XHi B itorS 

Wisepress Online Bookshop J1 

25 High Path 

SW19 2JL London 


Tel: +44 208 715 1812 - Fax: +44 208 715 1722 

Email: booking@wisepress.com 

Web Site: www.wisepress.com 

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and 

journals relevant to the themes of the meeting. Books can be purchased at the stand or, if 

you would rather not carry them, posted to you. 

Wisepress has a comprehensive medical and scientific bookshop online with great offers. 

Zoll CMS GmbH D1 

Emil Hoffmann Str. 47 

50996 Cologne 

Germany 

Tel: +49 223 687 870 - Fax: +49 223 687 877 

Email: rfiolic@zoll.lifecor.com 

Web Site: www.zoll.lifecor.com 

The LifeVest wearable cardioverter defibrillator (WCD) is a treatment option for sudden 

cardiac arrest that offers patients advanced protection and monitoring as well as improved 

quality of life. The LifeVest is the first wearable defibrillator. Unlike an implantable cardioverter 

defibrillator (ICD), the LifeVest is worn outside the body rather than implanted in the chest. 

This device continuously monitors the patient’s heart with dry, non-adhesive sensing 

electrodes to detect life-threatening abnormal heart rhythms. If a life-threatening rhythm is 

detected, the device alerts the patient prior to delivering a treatment shock, and thus allows 

a conscious patient to disarm the treatment shock. If the patient is unconscious, the device 

releases a gel over the therapy electrodes and delivers an electrical shock to restore normal 

rhythm. 

178

Name / Page Number 

S e SSionS 

Abstract Award Sessions 

Nursing Investigator Award ........................................................................................................................................................................33 

The Helmut Drexler Young Investigator Award for Basic Science....................................................................83 

The Philip Poole-Wilson Young Investigator Award for Clinical Research ...............................................22 


Advances in hypertrophic signalling ................................................................................................................................................29 

Back to the future: engineering for myocardial reconstruction ......................................................................18 

cGMP signaling in the failing heart: beyond NO? .........................................................................................................141 

Embryonic stem cells or iPS: what is the future? .................................................................................................................92 

Highlights of the congress: Basic Science translated for the clinician ......................................................143 

New drugs for heart failure: update 2010 .................................................................................................................................86 

State of the art: genomics in heart failure research .........................................................................................................33 

Targeting fibrosis in the heart: the forgotten problem .................................................................................................93 

Targeting integrins and arterial stiffness in heart failure ............................................................................................97 

The sarcoplasmic calcium pump as a therapeutic target in heart failure ................................................82 


Cardiology meets oncology: problems beyond cardiotoxicity ...........................................................................28 

Cardiotoxicity ...............................................................................................................................................................................................................17 

Predicting and monitoring of cardiotoxicity? ..........................................................................................................................21 


Exercise in chronic heart failure: translation in progress 

Joint Session with the heart failure Working group of the Brazilian Society 

of Cardiology ..........................................................................................................................................................................................................143 

Heart failure from a primary care perspective 

Joint session with WonCa (World organization of family Doctors) ..................................................96 

Heart failure management 2010 and beyond - what are the key issues for nursing? .............82 

How to deal with pain in the heart failure patient 

Joint session with the american association of Heart failure nurses (aaHfn).....................29 

Pregnancy associated heart disease .................................................................................................................................................92 

Quality of life in heart failure: how do the available measurement tools perform 

in practice? .....................................................................................................................................................................................................................22 

The predominance of women with heart failure: a global perspective 

Joint session with the asia-Pacific Society of Cardiology (aPSC) ...............................................................18 

Clinical Interactive Educational Sessions 

Acute heart failure .................................................................................................................................................................................................20 

Atrial fibrillation .........................................................................................................................................................................................................31 

Devices ...............................................................................................................................................................................................................................80 

Difficult chronic heart failure cases .....................................................................................................................................................16 

Hypertension ...............................................................................................................................................................................................................84 

179 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

S e SSionS 


Atrial fibrillation and heart failure 

Joint session with the european Heart rhythm association (eHra) ...................................................28 

Major co-morbidities in heart failure: diagnosis and treatment .........................................................................21 

Managing Congestion......................................................................................................................................................................................17 

Nutrition for Heart Failure ?! ......................................................................................................................................................................32 

The adenosine antagonists story of targeting the kidney in heart failure: 

status May 2010 .......................................................................................................................................................................................................85 

The cardio-renal syndrome in heart failure today ..........................................................................................................140 

Debates 

Award Ceremony followed by a Debate Session ...............................................................................................................90 

The Presidents Debate ......................................................................................................................................................................................12 

Diabetes 

Heart failure and diabetes ............................................................................................................................................................................81 

Heart failure and Diabetes: a challenge for the 21st century ...............................................................................85 

Heart failure core topics 

Acute heart failure – what you need to know to take care of your patient ........................................95 

Ageing and heart failure: difficult issues 

Joint session with the russian national Society of heart failure..............................................................142 

Blocking the RAAS in heart failure – past, present and future .........................................................................141 

HFPEF – all you need to know on Heart Failure with Preserved Ejection Fraction .....................91 

Highlights of the congress ........................................................................................................................................................................142 

Targeting anaemia and/or iron deficiency in heart failure – ready for prime time?! .................32 

What do we need to know about the indication for surgery in heart failure patient? ..........86 

Local Language Sessions 

Alles was Sie wissen sollten über...........................................................................................................................................................19 

Aus dem Labor ans Krankenbett – Klinische Anwendung 

grundlagenwissenschaftlicher Erkenntnisse ............................................................................................................................23 

Das kardio-renale Syndrom und Ko-Morbiditäten bei Herzinsuffizienz .....................................................30 

Technologie-basierte Ansätze bei Diagnostik und Therapie der 

Herzinsuffizienz .........................................................................................................................................................................................................34 

Moderated Posters 

Moderated Poster Session 1 .......................................................................................................................................................................40 

Moderated Poster Session 2 .......................................................................................................................................................................59 

Moderated Poster Session 3 ...................................................................................................................................................................100 

Moderated Poster Session 4 .................................................................................................................................................................... 119 

Moderated Poster Session 5 ....................................................................................................................................................................146 

180 

Name / Page Number

Name / Page Number 

S e SSionS 

Oral Abstract Sessions 

Judges choice: Basic Science .....................................................................................................................................................................87 

Judges choice: Clinical Research ...........................................................................................................................................................91 

Judges choice: Treatment Research ..................................................................................................................................................95 

Oral abstract session: Basic Science ...................................................................................................................................................97 

Poster Sessions 

Poster Session 1 ........................................................................................................................................................................................................41 

Poster Session 2 ........................................................................................................................................................................................................60 

Poster Session 3 .....................................................................................................................................................................................................101 



Satellite Sessions 

Biomarkers as an aid in cardio-pulmonary acute diseases 

Satellite Symposium organised by B.r.a.H.m.S .............................................................................................................98 

Biomarkers: optimising treatment guidance in heart failure 

mini-Satellite Symposium organised by Pfizer ltd. .......................................................................................................24 

Changing heart failure risk assessment 

Satellite Symposium organised by ge Healthcare........................................................................................................89 

Device therapy for heart failure: current and new indications 

Satellite Symposium organised by medtronic ....................................................................................................................25 

Die erweiterte nutzung kardialer marker von der akutversorgung bis 

in die arztpraxis 

Satellite Symposium organised by alere (formerly inverness medical) ...............................................26 

Emerging treatment opportunities in the management of heart failure: 

exploring novel strategies to optimize outcomes 

Satellite Symposium organised by novartis Pharma ag.......................................................................................25 

Galectin-3: a novel biomarker of fibrosis in heart failure 

mini-Satellite Symposium organised by Bg medicine, inc ..................................................................................88 

Helping patients with chronic heart failure: time to think again? 

Satellite Symposium organised by Vifor Pharma............................................................................................................88 

MADIT-CRT: Impact on clinical practice 

mini-Satelitte organised by Boston Scientific ......................................................................................................................35 

Managing heart failure by slowing heart rate with ivabradine 

Satellite Symposium organised by Servier ..............................................................................................................................24 

New hope, new life. The era of mechanical circulatory support is upon us 

mini-Satellite Symposium organised by thoratec europe ltd ........................................................................24 

Remote disease management in the heart failure patient 

Satellite Symposium organised by St Jude medical ....................................................................................................35 

181 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

S e SSionS 

Satellite Sessions 

The dynamic clinical utility of biomarkers across the spectrum of cardiovascular 

diseases 

Satellite Symposium organised by alere (formerly inverness medical) ...............................................89 

Which patients should be considered for cardiac resynchronization therapy? 

mini-Satellite Symposium organised by BiotroniK ................................................................................................88 

Special Session 

OPENING CEREMONY .....................................................................................................................................................................................14 

Technology solutions for heart failure: a 2010 update on devices and 

technologies 

Biomarkers in heart failure: what is their value compared to clinical assessments 

and routine laboratory values? ...............................................................................................................................................................80 

Devices in heart failure: Update 2010 .............................................................................................................................................94 

Device therapy for heart failure with normal ejection fraction: why should we try? ............140 

Fancy new devices for heart failure...................................................................................................................................................90 

Imaging heart failure 

Joint session with the european association of echocardiography (eae) ....................................31 

Major new developments in telehealth 

Joint session with the european Commission, Unit “iCt for Health“ ..................................................16 

New biomarkers in heart failure: ready for prime time? ............................................................................................84 

Telehealth for heart failure: what is the evidence from early trials 

Joint session with the european Commission, Unit “iCt for Health“ ....................................................13 

Telehealth: the next generation 


The way forward for improving heart failure care 


Troubleshooting in heart failure management .....................................................................................................................27 

Updates 

Best Papers 2009/2010 and What did I miss at ESC09, AHA09 and ACC10 ........................................13 

Late Breaking Trials - Session I ...................................................................................................................................................................27 

Late Breaking Trials - Session II .................................................................................................................................................................94 

New solutions for acute and chronic heart failure: update from industry ............................................81 

182 

Name / Page Number

CHAIRPERSONS / SPeaK erS 

Name Page(s)/Programme Nr(s) Name Page(s)/Programme Nr(s) Name Page(s)/Programme Nr(s 

Abraham W.T.: 110, 605, 674, 

701, 736, 742 

Adamopoulos S.: 22 

Adamopoulos S.: 1224 

Adams V.: 21 

Adams V.: 1222 

Albert N.: 33, 82 

Albert N.: 136 

Alonso Garcia M.A.: 89 

Alonso Garcia M.A.: 696 

Anand I.S.: 100 

Anand I.S.: 59, 642, 733, 748 

Angermann C.E.: 18 

Angermann C.E.: 135, 734 

Anker S.D.: 17, 22, 26, 27, 

81, 90, 98, 142 

Anker S.D.: 105, 165, 685 

Auricchio A.: 23, 59, 140 

Auricchio A.: 121 

Badano L.: 31 

Badano L.: 153 

Bakkers J.: 83 

Bakkers J.: 175 

Barrett D.: 55 

Bauersachs J.: 83 

Bauersachs J.: 142 

Bax J.J.: 89 

Bax J.J.: 687, 690, 691 

Bocchi E. A.: 1223 

Boehm M.: 24, 28, 31, 88 

Boehm M.: 45, 87, 90, 677, 681 

Brutsaert D.L.: 33, 82 

Carrio I.: 689 

Castagno D.: 68 

Celler B.: 20 

Celler B.: 56 

Chowienczyk P.: 763 

Clark A. L.: 133, 698, 1210 

Cleland J.G.F.: 16, 25, 80, 88 

Cleland J.G.F.: 7, 17, 94, 676 

Cohen-Solal A.: 143 

Cohen-Solal A.: 120, 693 

Comin-Colet J.: 32, 91 

Conraads V.: 17 

Conraads V.: 1219 

Cook S.A.: 83, 93 

Cook S.A.: 174 

Costanzo M.R.: 12 

Costanzo M.R.: 28, 51, 52, 743 

Cowie M.R.: 81 

Cowie M.R.: 92, 182, 658 

Creemers E.: 728 

Cuello F.: 146 

Cuello F.: 141 

Dahlstrom U. G.: 81 

Dahlstrom U.G.: 745 

De Keulenaer G.W.A.: 141 

De Keulenaer G.W.A.: 62 

De Windt L.J.: 138, 1229 

Denning C.: 92 

Denning C.: 42, 722 

Di Somma S.: 772 

Dickstein K.: 21, 31, 35, 

86, 88 

Dickstein K.: 1, 605, 673, 757, 

1214 

Dietz R.: 34 

Dietz R.: 26 

Diez Martinez J.: 731 

Doehner W.: 145, 655 

Doevendans P.A.F.M.: 33 

Doevendans P.A.F.M.: 725 

Ekman I.: 22, 33, 96 

Ekman I.: 134 

Ekman I. M.: 67 

Ellis T.: 21 

Erdmann E.: 19, 30, 88, 100 

Erdmann E.: 78, 657, 682 

Ertl G.: 123, 764 

Eschenhagen T.: 87, 92, 143 

Eschenhagen T.: 41 

Ewer M.: 28 

Ewer M.: 34 

Felker G.M.: 4 

Ferrari R.: 13 

Ferrari R.: 137 

Filippatos G.S.: 17, 20, 86, 94 

Filippatos G.S.: 101, 103, 161, 

618 

Fischmeister R.: 83 

Fischmeister R.: 1205 

Follath F.: 19, 84 

Force T.: 83 

Force T.: 31, 65 

Frenneaux M.P.: 97, 143 

Frenneaux M.P.: 156 

Fruhwald F.M.: 13, 119 

Gardiner P.: 612 

Gasparini M.: 90 

Gasparini M.: 127, 605 

Gatzoulis L.: 12, 20 

Gatzoulis L.: 5 

Gheorghiade M.: 32 

Gheorghiade M.: 666 

Giannitsis E.: 774 

183 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 



Gonzalez Juanatey J.R.: 20, 706 

Gottlieb S.: 648, 1199 

Greenberg B.H.: 112 

Guan K.: 1227 

Gullestad L.: 91 

Gullestad L.: 679 

Hajjar R.J.: 633, 664, 1225 

Hansen A.: 64 

Harada K.: 140 

Harada K.: 707, 1216 

Harding S.E.: 82 

Harding S.E.: 629 

Hasenfuss G.: 97 

Hasenfuss G.: 632 

Hassager C.: 96 

Haverkamp W.: 150, 151, 1191 

Hetzer R.: 24 

Hetzer R.: 44, 86, 660 

Heymans S.: 730 

Hilfiker-Kleiner D.: 29 

Hilfiker-Kleiner D.: 718 

Hillege H.: 119, 644 

Hobbs F.D.R.: 96 

Hobbs F.D.R.: 69, 759 

Hoerstrup S.P.: 40 

Hoes A.W.: 758 

Hondeghem L.: 63 

Inglis S.: 16, 39, 626 

Jaarsma T.: 33 

Jaarsma T.: 71, 684, 699, 1211 

Jankowska E.A.: 160, 643 

Janssens S.: 18, 29, 87 

Janssens S.: 1206 

Jondeau G.: 85 

Jondeau G.: 20, 158 

Just F.J.G.H.: 23 

184 

Klaerner G.: 613 

Klein G.: 97 

Kober L.: 25, 80 

Kober L.: 125 

Koehler F.: 23, 179, 703 

Komajda M.: 89 

Komajda M.: 6, 93, 652, 692 

Korb H.: 24 

Krum H.: 18, 27 

Krum H.: 61, 102, 103, 1202 

Lacolley P.: 761 

Lainscak M.: 140 

Lainscak M.: 708 

Laufs U.: 651 

Lehrach H.: 176 

Leor J.: 43 

Levy W.: 19, 128 

Linde C.: 13 

Lip G. Y. H.: 147, 151 

Lipicky R.: 605, 650 

Logeart D.: 84 

Lopez-Sendon J. L.: 141 

Lopez-Sendon J. L.: 33, 155, 746 

Lorenz K.: 140 

Luchner A.: 107 

Luprano J.: 53 

Maggioni A.P.: 22, 25 

Maggioni A.P.: 99, 100, 103, 

104, 732, 1213 

Maglaveras N.: 54 

Maisch B.: 40 

Maisch B.: 180, 659 

Maisel A.: 84 

Maisel A.: 118, 606 

Mann D.: 12, 22 

Mann D.: 622 

Mareev V.: 142 

Mareev V.: 642, 737 

Martin U.: 724 

Massie B.M.: 2, 27, 652, 747 

McDonagh T. A.: 25, 608 

McDonald K.: 94 

McDonald K.: 163 

McDonald M.A.: 113 

McGrady M.: 735 

McMurray J.J.V.: 12, 14, 22, 

27, 81, 88, 98 

McMurray J.J.V.: 14, 95, 667, 

686, 700, 1204 

Mebazaa A.: 52, 641, 663, 741 

Mehrhof F.: 143 

Melenovsky V.: 762, 1192 

Metra M.: 3, 91, 159, 649 

Meyns B.: 52, 744 

Mohacsi P.J.: 24 

Mohacsi P.J.: 83 

Mohr F. W.: 661 

Mueller B.: 647 

Mueller C.: 26, 40 

Mueller C.: 49, 108, 109, 607 

Murdoch C.E.: 729 

Nagel E.: 12, 154, 177 

Nanas J.: 21, 85 

Nathwani A.: 611 

Neuberger H.-R.: 149, 151 

Ng L.: 773 

Nieminen M.S.: 91 

Nieminen M.S.: 50, 52 

Noveanu M.: 771 

Oliva F.: 86 

Oliva F.: 662 

Papapetropoulos A.: 1207



Papp Z.: 18, 97 

Papp Z.: 665 

Parissis J. T.: 57, 619 

Paulus W.J.: 621, 697, 710 

Peacock W.F.: 80 

Peacock W.F.: 646, 694 

Persson H.: 20, 709 

Petrie M.: 27 

Petrie M.: 656, 749 

Pfeffer M.: 21 

Pfeffer M.: 164, 1201 

Pfeufer A.: 173 

Piepoli M.F.: 32 

Piepoli M.F.: 1220 

Pieske B. M.: 91, 97 

Pieske B. M.: 47, 148, 151, 183, 

1195 

Pina I.L.: 92, 119 

Pina I.L.: 36 

Pitsis A.: 86 

Pitsis A.: 705 

Pitt B.: 94 

Pitt B.: 623, 642 

Pokreisz P.: 1226 

Ponikowski P.: 14, 16, 22, 85, 

90, 94, 142 

Ponikowski P.: 114, 162, 1200 

Popescu B. A.: 152 

Rauchhaus M.: 28 

Rauchhaus M.: 32, 80 

Regitz-Zagrosek V.: 642, 719 

Ribeiro J.P.: 143 

Ribeiro J.P.: 1221 

Riley J.: 33 

Riley J. : 15 

Robinson S.: 16 

Robinson S.: 18 

Ronco C.: 20, 695, 740, 1196 

Rosano G. M. C.: 129, 618, 721 

Rosengren A.: 35 

Ruschitzka F.: 16, 95 

Ruschitzka F.: 654, 675 

Ryder M.: 33 

Ryder M.: 628, 760 

Schultheiss H. P.: 30 

Schultheiss H.P.: 48, 52, 609 

Schunkert H.: 81, 172 

Seferovic P.: 653, 1197 

Sejersted O. M.: 630 

Shah A.M.: 17 

Shah A.M.: 139, 618 

Shlyakhto E.V.: 141 

Shlyakhto E.V.: 1215 

Sliwa-Hahnle K.: 37, 717 

Solomon S.: 115, 652, 1194 

Springer J.: 131 

Stewart S.: 10, 70, 756 

Stork S.: 181, 720 

Strachan P.: 29, 33 

Strachan P.: 624 

Stromberg A.: 29 

Stromberg A.: 625 

Suter T. M.: 30, 66, 132 

Swedberg K.: 24, 142 

Swedberg K.: 58 

Tavazzi L.: 24, 32 

Tavazzi L.: 126 

Teerlink J.R.: 20, 90 

Teerlink J.R.: 122 

Thum T.: 727, 1209, 1228 

Trochu J.-N.: 95 

Trochu J.-N.: 84, 627 

Tschoepe C.: 144, 178, 640, 

1212 

Unger T.: 46, 1208, 1217 

Van Belle E.: 85 

Van Belle E.: 620 

Van Der Meer P.: 95 

Van Der Meer P.: 683 

Van Der Wal M.H.L.: 82 


van Veldhuisen D.J.: 22, 25, 

31, 88, 140 

van Veldhuisen D.J.: 98, 680, 

681, 702 

Vardas P.E.: 28, 94 

Vardas P.E.: 124, 1193 

Vechersky Y.: 1218 

Von Haehling S.: 130, 146, 157, 

610 

Voors A.A.: 11, 88, 111, 1198 

Wals J.: 22 

Westerteicher C.: 8 

Wolff A.: 614 

Wollert K.C.: 141 

Wollert K.C.: 79, 645 

Wrede C.: 106 

Xu Q.: 723 

Yu D.S.-F.: 92 

Yu D.S.-F.: 38 

Zannad F.: 24, 84, 93 

Zannad F.: 29, 60, 89, 678, 1203 

Zaza A.: 631 

Zeiher A.M.: 82, 726 

Zugck C.: 34 

Zugck C.: 9 

185 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Aakhus S.: P188, P232, P442, 

P923 

Aarones M.: P232 

Aass H.: P232 

Abboud S.: P270 

Abdel Dayem T. M.: P1114 

Abdel Hady Y.: P276 

Abdel Hamid M.A.G.D.Y.: P276 

Abdelsalam Z. M.: P1114 

Abdelshafy S.: P890 

Abdul Pari A. A.: P825 

Abdullaev T.A.: P483, P493, P862, 

P872, P873, P1067 

Abid L.: P412, P787 

Abizanda G.: P1147 

Abo Elmagd M.: P978 

Aboel Maaty M.: P1351 

Abou-Leisa R.: P1320 

Abraham W.: P1064 

Abreu A.: P374, P379, P821, 

P1166, P1289, P1403 

Abreu A. C.: P1430 

Abreu Gonzalez P.: P512 

Abu Assi E.: P1244, P1300 

Abuhab A.: P199, P414, P1000 

Abuhazira M.: P1045, P1434 

Accogli M.: P457, P1282 

Achremczyk P.: P1181 

Adam F.: P221, P406, P956 

Adam O.: P274 

Adamcova M.: P291 

Adamo M.: P240, P840 

Adamopoulos S.: P259, P1072 

Adams V.: 753, P1406 

Adamyan K.G.: P254 

Adlbrecht C.: P1387 

Aessopos A.: P1076 

Afanasyev B.: P1184 

Afiniwala M.: P378, P1137 

Afzal S.A.: 752 

Agabiti N.: P1165 

Agapitou V.: P977 

Agarkova I.: P1077 

Agarwal S.: P960 

Agazio A.: P583, P1368 

Ageev F.T.: P854 

Aggeli C.: P430 

Aggeli K.: P239 

Aggelis A.: P957, P1245, P1396 

Aggelopoulos P.: P413, P957, 

P1162, P1163, P1245, P1396 

Agmon Y.: 713 

Agoston Coldea L.: P898 

186 

Agostoni P.: P376 

Agrafiotis G.E.: P935, P1017 

Agren S.: 168 

Aguiar C.: P808, P1068 

Ahmadi F.: P383 

Ahmed D.: P440 

Ahn S.A.: P1332 

Ahn T.H.: P562, P947, P1288 

Ahrari S.: 169 

Ajuluchukwu J.: P1418 

Ajuluchukwu O.M.: P1418 

Akagami T.: P538, P548, P962 

Akashi Y.: P323 

Akashi Y.J.: P1361 

Akbulut H.: P191 

Akchurin R.S.: P238 

Akhmatov Y.A.R.: P1067 

Akhvlediani M.: P461 

Akkan D.: P435 

Aksoy S.M.: P830 

Al Mahmeed W.A.: P200 

Al Qaseer M.: P214 

Al Suwaidi J.: P200 

Alberca P.M.: P1102 

Alberca T.: P373 

Albertsson P.: P871 

Alcocer L.: P598, P1190 

Aleixo A.: P503, P602, P820, 

P897, P1139 

Alfieri A.B.: P1278 

Al-Hiti H.: P1085, P1327 

Alizade I.G.: P257 

Allaart C.P.: 73 

Allaberganov O.K.H.: P493 

Allen L.: P450, P1042 

Allolio B.: P479 

Almarichi S.: P1308 

Almeida A.G.: P204, P502, P1082, 

P1138 

Almeida H.: P1106 

Almeida I.: P1029, P1263 

Almeida J.: P198 

Almeida R.: P265, P475, P848, 

P1289 

Almeria C.: P1102 

Al-Mohammad A.: P853 

Alnabti A.A.: P200 

Alnagar W.: P320, P1141 

Al-Najjar Y.: P436, P824 

Alonso J.: P987 

Alonso-Briales J.H.: P428 

Alqaseer M.: P1005 

Altimir S.: P438, P576, P580, P777 

Name / Index Number 

Alvarez E.: P329 

Alvarez E.Z.E.Q.U.I.: P509 

Alves A.: P420 

Alves E.: P265, P475, P848, 

P1289 

Alves M.A.: P793 

Alves M.T.: P374, P1166 

Alves S.: P374, P1166 

Alves T.: P569 

Alzadjali M.A.: 72 

Alzand B.: P1188 

Alzueta J.: P836 

Amador P.: P282, P530, P1105 

Amaki M.: P302 

Amir O.: P818, P1266 

Ammar R.: P818, P1266 

Amorim S.: P1314, P1317 

Anastasiou-Nana M.: P193, P233, 

P318, P367, P553, P799, P918, 

P939, P965, P1230, P1253, 

P1364, P1383 

Anastasiou-Nana M.I.: P571 

Anastasiu M.: P507 

Anastasopoulou A.: P877 

Ancsin B.: P561, P813, P1023, 

P1272 

Andersen J.T.A.: 752 

Andersson K.B.: P310, P517, 

P1237 

Andrade H.: P983 

Andrade J.L.: P1313 

Andreadou I.: P1383 

Andreev D. A.: P375, P481 

Andrei C.L.: P541, P1269 

Andren B.: P253 

Andreou I.: P226, P855, P1132, 

P1271, P1275 

Andreozzi V.: P1403 

Anegon I.: P518 

Ang D.S.C.: 72 

Angelov A.: P1063 

Angermann C.E.: P251, 

P391, P441,479, P490, P566, 

P981,1119, P1127, P1233, P1260 

Angheben C.: P269 

Anghel M.: P1036 

Anisimov S.V.: P920 

Anker S.D.: 74, P273, P326, P336, 

P339, P470, P534, P542, P544, 

P574, 635, 754, P778, P1090, 

P1115,1172, P1375 

Antebi A.: P818, P1266 

Antognini P.: P480


Anton G.: P1385 

Anton M.: P1385 

Antonakis V.: P1021 

Antonakoudis G.: P1312 

Antoniades C.: P363 

Antoniazzi C.: P971, P1175 

Antonijevic N.: P1151 

Antonio N.: P459, P983 

Antonioli L.: P376 

Antoniou C.: P208, P957, P1162, 

P1163, P1245 

Antoniou E.: P1057, P1189 

Antoniucci M.E.: P814 

Antretter H.: P1315 

Antunes A.: P1263 

Antunes L.: P486 

Anzoletti Boscolo A.: P858 

Aokage M.: P1164, P1249 

Apostolo A.: P376 

Apostolova M.D.: P443 

Apostolovic S.: 74, P273, P452, 

P454, P816, P833, P1016, P1030, 

P1280, P1426, P1429 

Aquaro G.D.: P533 

Aquilani R.: P1150 

Ara J.: P438 

Arad M.: P270 

Arapi S.: P965 

Araujo J.R.: P1431 

Araujo V.: P588, P1402 

Arbasi M.C.: P550 

Archontakis S.: P222, P1021, 

P1038, P1271 

Arefi S. H.: P383 

Arfeli E.: P870 

Argiles J.M.: P1090 

Arhipov O.G.: P294, P504 

Ariano C.: P1062, P1124 

Arioli F.: P1278 

Ariza A.: P216 

Armentano C.: P550, P954 

Arnold M.: P335, P1274 

Arnold R.: P244, P884, P887 

Aro J.: P463 

Aronova E.: P1303 

Aronsen J.M.: P1173 

Aronson D.: 713, P1118 

Arroja I.: P503, P602, P820, P897, 

P1139 

Arroyo Ucar E.: P512 

Arruda C.S.: P590, P1410 

Arsenos P.: P208, P222, P226, 

P239, P429, P430, P827, P957, 

P1021, P1038, P1265, P1271, 

P1275 

Artemenko S.: P404, 755 

Arthur H.M.: 170, P984 

Artmeier-Brandt U.: P1254 

Arumugam D.: P263 

Arutyuno G. P.: P334 

Arutyunov G. P.: P1302, P1363 

Asai K.: P1164, P1249 

Asanin M.: P994, P1151, P1268 

Asensio-Lopez M.C.: 670 

Ashfield K.: P401 

Ashikaga K.: P323, P1361 

Ashour Z.: P320, P1141 

Ashrith G.: P1047 

Asif A.: P403 

Askevold E.T.: P188, P923 

Aspromonte N.: P478, P858 

Ata N.: P464, P1060 

Athanassopoulou S.: P208, P429 

Atkinson A.: P1359 

Atroschenko E.: P317, P834, 

P1283 

Attia W.: P978 

Audibert Mena L.: P384 

Auguadro C.: P1352 

Aukrust P.: P188, P232, P442, 

P600, P923, P1131 

Aulin J.: P253 

Averin E.: P474 

Avila C.: P841 

Avila M.S.: P842 

Avram S.: P1385 

Axente L.: P221 

Ayala Paredes F.: P515 

Ayub S.A.M.: P970 

Ayub-Ferreira S.M.: P260, P842, 

P856 

Azenha Balhau Jorge E.: P536, 

P829 

Azevedo A.V.: P564 

Azevedo O.: P198 

Aziz S.: P1179 

Azorin I.: P1121 

Azuaje F.: P236 

Baandrup U.: P205, P408, P1070 

Baartscheer A.: P874 

Babcak M.: P1094 

Babej S.: P407, P1248 

Babenko A.: P356 

Babich P.: P1018 

Bacal F.: P199, P260, P414, P489, 

P842, P856, P1000, P1052, 

a U t H orS 

P1294, P1313, P1397 

Bacal F.B.: P591, P970 

Baccheschi J.: P966 

Badano L.: P316, P905 

Baden D.: P989 

Badila E.: P831 

Badri M.: P1318 

Bae J.W.: P551 

Baglini R.: P293 

Baiocchi C.: P402 

Bajpai A.: P604, P1423 

Balagna M.: P1091 

Balazs E.: P1110 

Baldo M.P.: P243 

Ball J.: P369, P991 

Balogh A.: P516, P1342 

Banasiak W.: P207, P303, P778, 

P792, P964, P996, P1172 

Banaszewski M.: P802 

Bancala E.: P248 

Bandele E.O.: P1418 

Bania J.: P1340, P1341 

Banovic M.: P353, P567, P796, 

P1010, P1014 

Baptista R.: P223, P370, P427, 

P433, P536, P539, P805, P815, 

P829, P839, P1033 

Barakett N.: P560 

Baranich I.: P1421 

Baranova E.: P506, P1080 

Barasa A.: P372 

Barbarash L.: P1259 

Barbarash L.S.: P264, P1149 

Barbarash O.: P1259 

Barbarash O.L.: P264, P1149, 

P1416 

Barbati G.: P491, P492, P1311 

Barbici I.: P253 

Barbosa M.: P798 

Barbosa M.M.: P327, P1355 

Bardachenko N.: P1298 

Barison A.: P533 

Barmasheva A.: P393, P869 

Barnett D.: P853 

Barnett O.: P365 

Baron G.: P1323 

Baron S.: P1127 

Barra S.: P328, P794, P931, P999, 

P1029, P1107, P1263, P1276, 

P1357 

Barra S. N. C.: P416, P1025 

Barragan Acea A.: P851 

Barrera A.: P836 

187 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Barretto A.C.P.: P432, P1130 

Barros G.A.: P199 

Barros L.S.N.: P1178, P1408 

Barroso O.: P1106 

Bart B.: P1126, P1376 

Barthez O.: P364 

Bartos D.: P831 

Bartsch S.: P377 

Baruah R.: 75, P246, P249, P456 

Baruch N.: P972, P1176 

Bassanelli G.: P1278 

Bataiosu C.: P1037 

Batista R.: P217, P807 

Batistela V.: P432 

Battaglia D.: P529 

Battler A.: P425, P972, P1176, 

P1434 

Baudoin F.: P1320 

Bauer F.: P958 

Bauer M.: P1375 

Bauersachs J.: 672, P924 

Baugh J.: P313, P500, P514, 

P522, 770 

Baydina O.M.: P967 

Bayet G.: P1390 

Bazac M.: P831 

Bazhan S.S.: P926 

Bazhenova E.: P506, P1330 

Bazilevich A.Y.: P906 

Bechtold H.: P408 

Becka M.: P1254 

Becker A.: P1003 

Beckers P.: P545, P1334 

Begovic D.: P1324 

Behar S.: P425 

Belardinelli L.: P874 

Belcastro E.: P1154 

Belenkov I.U.N.: P926 

Belenkov Y.N.: P285, P1100, 

P1277 

Beleslin B.: P567 

Belhani D.: P896 

Belin A.: P1171 

Beliy S.: P1184 

Belli J.F.C.: P585 

Bellini F.: P358, P455 

Belonje A.M.S.: P1128 

Belu A.: P1081 

Belu E.: P345, P1037 

Belyaeva O.: P1080 

Belyaeva O.L.G.A.: P506 

Belyavskiy E.: P275, P1059 

Ben Gal T.: P425, P972, P1045, 

188 

P1176, P1434 

Bencardino G.: P519 

Benes J.: P366 

Bennett A.B.: P889 

Benshabat B.Y.: P405 

Berdeaux A.: P894 

Beresewicz A.: P1359 

Berezin A.: P892, P1382 

Berezina A.: P506, P1330 

Bergamini C.: P944, P1111 

Berge C.: P600 

Berge R. K.: P600 

Berger R.: P466 

Bergmann A.: P811 

Bergmann M. W.: P1006, P1135, 

P1234 

Bergmann P.: P1113 

Bergmann Sverrisdottir Y.: P871 

Berkovich O.: P506, P1080, 

P1330 

Berliner D.: P286, P441, P479, 

P490, P566, P1119, P1233, 

P1260 

Bermingham M.: 751 

Bernardez S.: P361, P584, P798 

Bernardez-Pereira S.: P569 

Bernardino L.: P530, P1105 

Berruezo A.: P1286 

Berta B.: P849 

Bertaux G.: P364 

Bertens L. C. M.: P581 

Bertens L.C.M.: P271 

Berthouze M.: 668 

Bertomeu Gonzalez V.: P1264 

Bertomeu Martinez V.: P1264 

Bertomeu V.: P288, P289, P290, 

P497, P499, P876 

Besaga E.: P342, P380 

Bestetti R.: P242 

Bettari L.: P1240, P1242, P1250, 

P1270 

Bettencourt N.: P563, P1231 

Bettencourt P.: P859 

Beyaztas A.: P1060 

Bezdenezhnykh A.V.: P264, P967, 

P1149 

Bezdenezhnykh N.A.: P1149 

Bezzina C.R.: P874 

Bhuiyan M.: P559 

Bianco N.: P1044 

Bicho M.: P1316 

Bickham G.: P438, P580, P777 

Biegus J.: P207, P792 


Bil J.: 639 

Bildirici U.: P218, P333, P975 

Bilibina A.A.: P920 

Bilim O.: P1034 

Bilostotska O.O.: P281 

Bilovol A.N.: P1058 

Binder L.: P886 

Birchall A.: P853 

Birdane A.: P464, P1060 

Birkeland J.A.K.: P1173 

Birkner E.: P868, P1373 

Birks E.J.: P469 

Bis J.: 715 

Biscaglia S.: P540, P916, P963, 

P1073, P1349 

Bisetti S.: P248, P458, P1013 

Bisping E.: 669 

Bistola V.: P318, P553, P1230, 

P1253 

Biswas J.: P523 

Bittencourt H.N.S.: P1355 

Bitter T.: P377, P543, P552, P572, 

P1362, P1365 

Bize A.: P894 

Bjornstad J. L.: P1155 

Black M.J.: P941 

Blanco Palacios G.: P512 

Blazejewski J.: P933 

Blengino S.: P1374 

Bloch K.D.: 636 

Bloemen J.A.M.: P513 

Blondheim D.: P210, P403, 

P1257 

Bobbert P.: P283, P1310 

Bobescu E.: P1036 

Bobrov A.: P247, P961, P1144 

Bobrov L.: P247, P961, P1144 

Boccanelli A.: P1165 

Bocchi E. A.: P1294 

Bocchi E.A.: P199, P219, P258, 

P260, P261, P432, P489, P585, 

P842, P856, P1052, P1130, 

P1397 

Bocchi E.B.: P591, P970 

Bochenek A.: 715 

Bock E.: P1386 

Bodanese L.C.: P564 

Bodi Peris V.: P1388 

Bodi V.: P225, P1026 

Bodnar A.: P1342 

Boehm M.: P274 

Boersma E.: P1355 

Boesma E.: P327


Bogaards S.J.P.: P1238 

Bohan Y.A.E.: P1416 

Bohov P.: P600 

Boireau A.: P971, P1175, P1412 

Boivin V.: P286, P1321 

Bojic Kolarski G.: P852 

Bojic M.: P1433 

Boldt K.: P441, P1119, P1260 

Bolshakova O.: P1080 

Boltzen U.: P1370 

Bonanno C.: P400, P596 

Bonaque-Gonzalez J.C.: P1251 

Bongiorni M.G.: P455 

Bonios M.: P1326, P1364 

Bontempi L.: P398, P840 

Boos C. J.: P1169 

Borbely A.: 634, P1238 

Bordier P.: P860 

Bordignon S.: P467, P564, P841, 

P932 

Bordonali T.: P240 

Borelli G.: P358, P455 

Boren J.: P501 

Borglum A.B.: 752 

Borgulya G.: P445 

Boricic M.: P353 

Boricic-Kostic M.: P567, P796 

Borodina O.S.: P1354 

Borodulin - Nadzieja L.: P573, 

P1182 

Borodulin-Nadzieja L.: P951, P996 

Borodzulia M.: P1330 

Boronat-Garcia M.: P1251 

Boroni C.: P1050 

Borota J.: P297 

Borsanyi T.: P561, P813, P1023, 

P1272 

Bortnik M.: P1066 

Bosa Ojeda F.: P851 

Boschetto P.: P540, P916 

Boschi F.: P1150 

Boschmann M.: P336 

Boshuizen H.C.: P985 

Boskovic S.: P850 

Bossi I.: P471 

Botelho A.: P1107, P1276, P1357 

Botker H.E.B.: P1056 

Botoni F: P299, P594 

Bougard R.S.: P469 

Bougon Dufay C.: P1171 

Bousquenaud M.: P343 

Bovtyushko P.: P1353 

Boyett M.: P1359 

Bozcali E.: P191 

Bozinovic N.: P1426 

Braman V.: P1064 

Bramanti F.: P255 

Brancalhao E.C.O.: P1007 

Branco L.: P1403 

Branco L.M.: P374 

Brandao L. C.: P326 

Brandt M. C.: P1337 

Branzi G.: P1374 

Brasolin B.: P804 

Brdar N.: P1151 

Breckler M.: 668, 767 

Brenner S.: P479, P490, P566, 

P1119, P1127, P1233 

Briceno L.: P1278 

Brili S.: P280 

Brilli S.: P208 

Brink M.: P1101 

Briston S.J.: P1237 

Bristow M.R.: P450, P1042 

Brito D.: P204, P801, P1035, 

P1316 

Brito J.: P1068 

Broch K.: P188 

Broda A.: P981 

Brodie D.A.: P469 

Broedbaek K.B.: 752 

Bronze L.: P602, P820, P897, 

P1139 

Bronzwaer J.G.F.: 73 

Browarek A.: P843, P1028 

Brown M.: P263 

Bruckner I.: P1385 

Bruggeman C.: 77, P195 

Bruguera J.: P1366 

Bruguera-Cortada J.: P451 

Brun F.: P1413 

Brunelli M.: P1284 

Brunet J.: P1390 

Bruni M.: P1150 

Brunner-La Rocca H. P.: 712 

Bruno N.: P804 

Bruno R.M.: P1170 

Bruthans J.: P579 

Buckley N.: P853 

Budaj-Fidecka A.: P922, P934 

Budanova M.: P356 

Buehler K.: P1101 

Buga L.: P812 

Bugarski S.: P352 

Bugatti S.: P1240, P1242, P1250, 

P1270 

a U t H orS 

Buhari S.: P213 

Burazor I.: P351, P1142 

Burazor M.: P351, P1142 

Burazor N.: P351 

Burazor Z.: P351 

Burger A.J.: P1118 

Burnett J.: 671 

Burnos S.: P1184 

Buser P.: P1101 

Buskens E.: P825 

Bussani R.: P492 

Butler J.: P911, P1008 

Butt M.: P904, P938, P1156 

Buzzetti F.: P1148 

Bylova N.: P334, P1363 

Bylova N. A.: P1302 

Byrne J.: P514 

Cabanas Grandio P.: P1300 

Cabanelas N.: P793 

Cabanes R.: P438, P580, P777, 

P1395 

Cabarkapa V.: P297 

Cabiati M.: P314, P547, P893, 

P945, P950, P1154, P1368 

Cabral C.: P277, P484, P486, 

P864, P1104, P1378 

Cabrera Bueno F.: P836 

Cacciatore G.: P1165 

Cachofeiro Ramos V.: P895 

Caeiro D.: P563, P1231 

Caetano F.: P328, P794, P931, 

P999, P1029, P1107, P1276 

Cagirci G.: P830 

Caira C.: P804 

Calabuig J.R.: P288, P497 

Caldeira D.: P482 

Cale R.: P1068 

Calicchia A.: P1102 

Calicchio F.: P358 

Caligaris F.: P532 

Calin Andrei C.: P507 

Callejo M.J.: P1177 

Calori G.: P1041 

Calovic Z.: P1010, P1014 

Calvi V.: P1305 

Calvier L.: P549 

Camacho Vazquez C.: P785 

Cambursano S.: P1091 

Caminiti G.: P986, P1405 

Campan M.: P547, P945, P950 

Campbell D. J.: P941 

Campeanu A.: P301 

Campello G.: P420 

189 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Campelo M.: P1314, P1317 

Campolo J.: P1050 

Campos E.P.: P1178, P1408 

Camprecios M.: P423 

Canani L.H.: P527 

Canario-Almeida F.: P198, P420 

Candido G.O.: P309 

Cannizzaro G.: P861, P1012 

Cannon C.: P1009 

Cano L.: P438, P580, P593, P777 

Cantatrione S.: P1062, P1124 

Canziani A.: P266 

Cao G.: 766 

Cao Y.: P213, P409 

Caobelli F.: P240 

Capderou A.: P1371 

Capdevila C.: P388 

Capewell S.: P579 

Caporotondi A.: P966 

Capotosto L.: P529 

Cappelli F.: P228 

Carasso C.S.: P405 

Cardinalli Neto A.: P242 

Cardoso D.A.: P564 

Cardoso G.: P1068 

Cardoso J.N.: P422, P1007, 

P1125 

Carlson C. R.: 637, P914 

Carlsson C.R.: P1089 

Carmeliet P.: P946 

Carniel E.: P496 

Caroll-Hawkins C.: P411 

Carp A.: P1103 

Carpinteiro L.: P838 

Carrasco Sanchez F.J.: P785 

Carrie D.: 750 

Carrier L.: 638 

Carrillo F.J.: P1313 

Carrington M.: P295, P1003 

Carroll S.: P824 

Carroll S.L.: P984 

Carson P.: P779 

Cartana R.: P803 

Cartwright E.: 765, P1320 

Cartwright E.J.: P1078 

Carubelli V.: P1240 

Caruso R.: P1050 

Carvajal De La Torre A.: P817 

Carvalho M. J.: P503 

Carvalho V.O.: P585 

Cascio C.: P293 

Caselli C.: P547, P893, P945, 

P950, P1154, P1368 

190 

Cassater D.: P944 

Cassiano K.M.: P1174, P1409 

Cassina T.C.: P330 

Castel M.A.: P803, P1286, P1295 

Castella M.: P803 

Castelvecchio S.: P266, P267, 

P476, P1291 

Castillo Martinez L.: P477 

Castillo-Martinez L.: P212 

Castro G.: P983 

Catalin G.: P936 

Catanzariti D.: P269 

Cattadori G.: P376 

Cattafi G.: P1013 

Cavalcanti A. C.: P1174 

Cavalcanti A.C.: P590, P1409, 

P1410 

Cavanaugh J.: P496 

Cavanna L.: P550 

Cavusoglu Y.: P464, P1060 

Cawley P.: P1040 

Cay S.: P830 

Cebola R.: P955, P1358 

Cecaro F.: P540, P916, P963, 

P1073, P1349 

Cech J.: P1054 

Ceconi C.: P540, P916, P963, 

P1073, P1349 

Celada S.: P1352 

Celec P.: P291 

Celestini A.C.: P437 

Celic V.: P350 

Celik S.: P776 

Celutkiene J.: P386 

Cemerlic-Adjic N.: P297, P352, 

P852 

Centeno A.: 769 

Cerejeira J.: P459 

Cerini M.: P398, P840 

Cerrito A.: P986, P1405 

Cesarelli M.: P396 

Cesaroni G.: P1165 

Cevolo R.W.: P1408 

Chae J.: P1345 

Chae K.: P446 

Chai P.: P1179 

Chakravarthy N.: P1306 

Chalazonitis A.: P918 

Chalikias G.: P387 

Champ-Rigot L.: P1171 

Chan M.: P335 

Chandrasekaran M.: P995 

Charaf F.: P523 


Charles N.: P203 

Chasnoits A.: P448 

Chatzikyriakou S.: P387 

Chekanov P.A.: P278 

Chen H.: 671 

Cheng J.-H.: P1333 

Cheng P.-S.: P1333 

Cheon S.Y.: P431 

Chermont S.: P203, P361, P569, 

P584 

Chermont S.L.S.M.C.: P1178, 

P1408 

Cherniavskiy A.: P404, 715, 755 

Chernyavina A.: P462 

Cherpanath-Paes C.: P368 

Cherubini A.: P1413 

Chilet M.: P1026 

Chin A.: P1318 

Chioncel O.: P1103 

Chioncel V.: P507 

Chioncel V.P.: P541 

Chivite D.: P388 

Chivite Guillen D.: P987 

Chizynski K.: P508, P511, P1153 

Chizzola P.R.: P260, P842, P856 

Cho E.J.: P902, P1109 

Cho M. C.: P551 

Cho M.C.: P231, P338 

Chodor P.: P1051 

Choi C.O.: P526 

Choi D.J.: P231, P338, P551 

Choi E.J.: P551 

Choi I.S.: P562, P1288 

Choi J.J.: P526 

Choi J.O.: P231, P338 

Chopra V.K.: P1306 

Chouchane I.: P1113 

Choudhary F.E.R.R.A.H: P1393 

Choy A.M.: 72, P781 

Christensen G.: P310, P517, 637, 

P914, P1131, P1155, P1237, 

P1339 

Christensen H.: P826 

Christensen S.: P959 

Christoforatou E.: P413 

Christopoulos C.: P211 

Chrustowicz A.: P521 

Chrysohoou C.: P208, P239, 

P413, P429, P957, P1038, P1132, 

P1162, P1163, P1245, P1396 

Chubenko E.: P1080 

Chun S.-Y.: P1069 

Chung W.B.: P1109


Chung W.-J.: P562, P947, P1288 

Ciccarelli A.: P1062, P1124 

Ciccone M.M.: P912 

Cicoira M.: P944, P1111 

Cifkova R.: P579 

Cilesiz D.: P537 

Cinelli A.: P1160 

Ciolac E.G.: P585 

Ciomag R.: P406, P507, P956, 

P1258, P1269 

Cioppa C.: P1062, P1124 

Cipriani M.: P248, P1013, P1055 

Ciurli C.: P583, P1368 

Cladellas M.: P451, P1366 

Clark A.L.: P227, P234, P319, 

P436, P811, P812, P824, P919, 

P1129 

Clark A.L.C.: P889 

Clark R.A.: P369, P991 

Cleland J.G.F.: P227, P234, P319, 

P369, P440, P510, P811, P812, 

P824, P889,903, P919, P928, 

P991,1129 

Clemente M.: P570 

Clementino N.C.D.: P327, P1355 

Clements I. P.: P557 

Clements S.: P546 

Clemenza F.: P293 

Clodi M.: P1387 

Cohen E.: P425 

Cohen Solal A.: P1247 

Cohen Tervaert J.W.: P1183 

Cohen Tervaert R.J.: P195 

Cokkinos D.V.: P325,1022 

Colin E.: P212, P477 

Colivicchi F.: P858 

Coll R.: P580, P1395 

Collier P.: P313, P500, P514, 

P522, 770 

Colomina Climent F.: P1264 

Colotti C.: P893 

Colucci A.: P1386 

Comerci G.: P519, P790, P900, 

P1386 

Comin-Colet J.: P451, 754, P1366 

Conceicao G.E.: P258, P261 

Conceicao-Souza G.E.: P219, 

P260, P432, P842, P856, P1052, 

P1130 

Condorelli G.: 635 

Conlon C.M.: P520, P888 

Conraads V.: P1334 

Conraads V.M.: P268, P545 

Conroy R.: P1005 

Constandoulakis P.: P325 

Conte L.: P455 

Contini M.: P376 

Conzelmann C.: P1394 

Cook C.: P1159 

Cook S.A.: P946 

Cooney H.C.: P305 

Corbellini D.: P1150 

Corbi G.: P396 

Corbi M.: P399 

Corbucci G.: 755 

Cordeiro J. A.: P242 

Cordeiro P.: P841 

Correa A.G.: P414, P1000 

Correa Vilchez C.: P789, P997 

Correia A.: P265 

Correia A.S.: P475, P588, P1289, 

P1402 

Correia C. E.: P277, P484, P486, 

P864 

Correia D.M.S.: P590, P1174, 

P1409, P1410 

Correia E.: P202, P535, P1104, 

P1146, P1378 

Correia M. J.: P602 

Correia M.J.: P820, P897, P1082, 

P1139 

Correia S.: P282, P1105 

Corsten M.F.: P307 

Cortes Morichetti M.: P529 

Cortes R.: P289, P290, P497, 

P499, P1121, P1323 

Cortez-Dias N.: P838 

Costa F.F.: P260 

Costa G.: P794, P931, P1029, 

P1276 

Costa M.: P794, P931, P1357 

Costa S.: P217, P223, P370, P427, 

P433, P536, P539, P805, P807, 

P815, P829, P839, P1033 

Cosulschi M.: P1037 

Cotez Quiroga G.: P973 

Couto R.: P808 

Cowie M.R.: P268 

Cox R.D.: 765 

Cozma D.: P354, P528, P1309 

Cozma D. C.: P1039 

Crespo E.: P576, P593, P1395 

Crijns H.J.: 77, P195, P1183, 

P1188 

Cristea A.: P599 

Cristovao J.: P459 

a U t H orS 

Critchley J.: P579 

Crowley J.: P982 

Crozatier B.: 767 

Crundall A.: P440 

Cruz D.: P858 

Cruz F.D.: P260, P1052, P1397 

Cruz F.D.C.: P591, P970 

Cruz Ferreira R.: P379 

Cruz L.G.: P585 

Csanady M.: P1110 

Cuko A.: P1278 

Cullington D.: P369, P440, P928, 

P991 

Cup J.: P537 

Curnis A.: P398, P840 

Curry J.: P1040 

Cvijanovic D.C.: P1377 

Cyrre C.: P932 

Czarnowska E.: P189, P192, 

P1335 

Czech M.: P597 

Czuriga D.: P516, P1238, P1342 

Czuriga I.: P1342 

Dabarian A.L.: P487 

Dadashova G.: P1424 

D’addio G.: P396 

Dahl C. P.: P600 

Dahl C.P.: P188, P442 

Dahl M.B.: P1339 

D’albuquerque L.A.C.: P1313 

D’aloia A.: P444 

Daly K.: P982 

Daly M. J.: P401 

D’ambrosi A.: P804 

Damico E.A.: P1130 

Damjanovic M.: P454, P816, 

P1016, P1030, P1429 

Damjanovic S.: P315, P1350 

Damy T.: P227, P262, P319 

Damy T.D.: P889 

Dan R.: P354, P528, P1309 

Danciu S.C.: P995 

Danilogorskaya Y.A.: P1100, 

P1277 

Danko B.: P337 

Danzmann L.C.: P467, P527, 

P564, P932 

Darago A.: P953, P1307 

Dargie H.J.: P546, P988 

Daskalov I.: P899, P901, P1348 

Dasoveanu M.: P406, P541, 

P1258 

Dassen T.: 166 

191 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Datcu G.: P1036 

Davel A.P.C.: P243 

David C.: P482 

Davies D.W.: P246, P249, P456 

Davies S.J.: P1117 

Davis G.: P450, P1042 

Dawkins I.: P305, P313, P520, 

751, P888 

Dayter I. I.: P1302 

De Bakker J.M.T.: P874 

De Bernardi A.: P1091 

De Beurs M.: P368 

De Boer R.A.: P1084 

De Cock C.C.: 73 

De Curtis G.: P529 

De Feo S.: P861, P1012 

De Giuli F.: P1160 

De Groote P.: P1180, P1399 

De Jong R. M.: P575 

De La Fuente Cid R.: P819 

De La Fuente Galan L.: P885, 

P887, P1329 

De Laat S.: P984 

De Laet N.: P1267, P1285 

De Marco E.: P519, P790, P900, 

P1386 

De Marco F.: P471 

De Maria R.: P891, P1050 

De Maria R.D.M.: P437 

De Masi De Luca G.: P457, P1282 

De Proft M.: P1011 

De Rivas B.: P289 

De Roest G.J.: 73 

De Sutter J.: P1267, P1285 

De Teresa E.: P836 

De Teresa Galvan E.: P428 

De Vecchis R.: P1062, P1124 

De Voogt W.G.: P368 

De Vries A. E.: P575 

Decobelli F.: P1041 

Decoodt P.: P1113 

Degiannis D.: P1072 

Degiovanni A.: P1066 

Dehina L.: P896 

Dei Cas L.: P240, P398, P444, 

P840, P1240, P1242, P1250, 

P1270 

Dekany M.: P561, P813, P1023, 

P1272 

Dekleva M.: P1083 

Dekleva M.N.: P1324 

Del Carlo C.H.: P422, P1125 

Del Magro F.: P1240 

192 

Del Maschio A.: P1041 

Del Ry S.: P314, P547, P893, 

P945, P950, P1154, P1368 

Delahaye F.: P958 

Delaru V.: P474 

Delgado J.: P418, P799, P1230 

Delgado Moreno M.: P973 

Delgado Silva J.: P328, P999 

D’elia E.: P1352 

Deljanin-Ilic M.: P1400 

Dell’era G.: P1066 

Demerdash S.H.: P1114 

Demerouti E.: P325 

Demirustu C.: P464, P1060 

Dennert R.: 77, P195, P307, 

P1183, P1188 

Denvir M.A.: P601, P822 

Depellegrin A.: P492 

Descotes J.: P896 

Deshko M.S.: P1031, P1262 

Despas F.: 750 

Deswarte G.: P262 

Dettori O.: P529 

Deubner N.: P286, P479, P490, 

P566, P1119, P1127, P1233 

Devadathan S.E.N.: P211 

Devarapally S.R.: P979 

Devaux Y.: P236, P307, P343, 

P913 

Dexter J.: P411 

D’hooge J.: 636 

Di Donato M.: P266, P267, P476, 

P1291 

Di Lenarda A.: P491, P492, P496, 

P1311, P1413 

Di Somma S.: P1369 

Diakos N.: P918, P1187, P1292, 

P1435 

Dias P.: P265, P475, P848, P1289 

Diaz-Molina B.: P857 

Dib N.: P404 

Dickstein K.: P190, 754, P1131 

Didenko M.: P247, P1144 

Dieplinger B.: P237 

Dierckx R.: P1011 

Dieterle T.: P1101 

Dietz R.: P251, P391, P1079 

Dievart F.: P1180 

Diez C.: P438, P580, P593, P777 

Diez J.: P549, P1147 

Dilaveris P.: P222, P226, P239, 

P430, P827, P1021, P1038, 

P1265, P1271, P1275 


Dima I.: P239, P827, P1021 

Dimitriadis K.: P430, P1265 

Dimkovic S.: P357 

Dimopoulos A.: P325 

Dimopoulos M.A.: P855 

Dimopoulos S.: P977, P1187, 

P1326 

Dina O.: P541 

Dinanian S.: P1371 

Dinca V.G.: P936 

Diniz M.S.: P798 

Dionisio O.: P277, P486 

Distefano G.: P1049 

Dixon L. J.: P401 

Djordjevic J.: P351 

Djordjevic Radojkovic D.: P454, 

P816, P1016, P1030, P1429 

Djordjevic V.: P816, P1016, P1030 

Djurkovic M.: P537 

Djuwita R.A.T.N.A.: P786 

Dmitrieva R.I.: P920 

Dobosiewicz M.: P917 

Dobrovolsky A. B.: P1098 

Dobrzynski H.: P1359 

Doehner W.: 74, P273, P326, 

P336, P339, P452, P534, P542, 

P544, P574, P1115, P1280, 

P1375 

Doerler J.: P1315 

Doerner A.: P311 

Doesch A.: P776 

Dohi Y.: P1344 

Doi T.: P538, P548, P962 

Doletsky A. A.: P375, P481 

Dolgushev D.: P220, P1353 

Dolzhenko M.N.: P906 

Domingo M.: P576, P593, P1395 

Dominguez H.: 716 

Dominguez Rodriguez A.: P512 

Dominguez-Franco A.J.: P428 

Dominici F.P.: 766 

Donal E.: P958 

Donato L.: P1102 

Donea M.: P1036 

Doney A.: P781 

Donk P.M.: P368 

Donnely L.: P781 

Donoiu I.: P447, P1243, P1301 

Donova T.I.: P443 

Donovan G. C.: P469 

Dores H.: P503, P602, P820, 

P897, P1139 

Dorobantu M.: P831


Dorofeykov V.V.: P915 

Doroshenko E.M.: P1031, P1262 

Dosenko V.: P1002 

Douskou M.: P324 

Draagos A.: P1075 

Dracea O.-D.: P447, P1301 

Dragulescu D.: P1336 

Dragulescu S. I.: P1039 

Dragulescu S.I.: P1309, P1336 

Drakos S.: P1292, P1364, P1435 

Dreschler C.B.R.: P564 

Dresselaers T.: 636 

Dritsas A.: P1022 

Drouard C.: P1412 

Drozdz J.: P1153 

Dubi D.S.: P405 

Dubiel J.S.: P597 

Dubiel M.: P597 

Dubois-Rande J.L.: P227, P319 

Dubovik T.: P1112 

Dudley Jr S.C.: P1099 

Dudziak J.: P933 

Duengen H.D.: 74, P251, P452 

Duengen H.-D.: 166, P449, P833, 

P1279, P1280 

Duenser M.: P866 

Dujardin J.J.: P1399 

Dumonteil N.: 750 

Dungen H.D.: P273 

Dunn M.: P514 

Duquesnes N.: 767 

Duran Torralbo D.: P973 

Durao D.D.: P793 

Durdik P.: P498 

Dusceac D.: P301 

Dusek L.: P224, P410, P578, 

P1108 

Dutka R.Y.: P828 

Duveau D.: P262 

Dwivedi G.: P904, P938, P1156 

Dworatzek E.: P930 

Ebermann L.: P311 

Eckerle L. G.: 768, P952 

Edelmann F.: 74, 166, P273, 

P452, P833, P886, P1280 

Eder A.: 638 

Edes I.: 634, P953, P1238, P1307, 

P1342 

Edner M.: P835 

Egstrup K.: P797 

Egyed A.: P1110 

Ehler E.: P1077 

Ehlermann P.: P955, P1024 

Eicher J.C.: P958 

Eicher J.-C.: P364 

Eisa M. A.: P1114 

Eiskjaer H.E.: P1056 

Eisner D.A.: P1237 

Eivindson G.: P250, P837, 

P1281 

Ekman I.: P465 

El Naggar W.: P1161 

El Ramly M.: P1161 

El Sayed M.H.: P1351 

El Shahed G.S.: P1351 

Elami E.A.: P405 

Elder E.D.H.: P781 

Elices Teja J.: P1300 

Elleder M.: P1432 

Ellouz M.: P412, P787 

Elmahallawy N.: P1074 

El-Menyar A.: P200 

Elmissiri A.M.A.B.I.S.: P1351 

Elosua R.: P1366 

Elsasser A.: P1186 

Elvas L.: P459 

Emanuel C.: P209, P1261 

Emdin M.: 76, P228, P230, P255, 

P533, P583, P587, P893, P942, 

P1170, P1368 

Emmert M.Y.: P1077 

Engelen M. A.: P844, P1048, 

P1296 

Engelfriet P.: P985 

Engin V. S.: P1019 

Enjuanes Grau C.: P512 

Enkeshafi A.: P1252 

Entok E.: P1060 

Eranki V.: P995 

Eraranta A.: P1235 

Erbibou S.: P518 

Erfanian M.: P518 

Eriksson U.: P283 

Ermacora D.: P316, P905 

Eroshenko O.: P523 

Ertas G.: P218, P333, P975 

Ertl G.: P441, P479, P490, P566, 

672, P924, P981, P1119, P1127, 

P1233, P1260 

Eschenhagen T.: 638, P833 

Esmailidehaj M.: P943 

Espindula C.: P968 

Esplugas E.: P216, P388 

Ess M.: P235, P439 

Estornell J.: P399 

Esu F.: P845, P846 

a U t H orS 

Eva Brozova E.: P930 

Evangelista L.: 168 

Evdokimov D.O.: P264 

Evdokimov V.: P241 

Evdokimova A.: P241 

Everett L.: P1169 

Ezzat M.: P978 

Fabbri L.M.: P540, P916 

Faber J.: P826 

Faber L.: P1365 

Fabregat O.: P399 

Facchini M.: P1374 

Faden G.: P444 

Faganello G.: P1413 

Fagyas M.: P953, P1307 

Fainyk A.Y.: P828 

Faistauer A.: P564 

Falcao-Pires I.: P1238 

Falk K.: P465 

Falk V.: P1077 

Faller H.: P981 

Falletta C.: P293 

Fan T.M.: P1099 

Fanelli D.: P1013 

Farag N.: P1161 

Faragasso E.: P540, P916, P963, 

P1073, P1349 

Faria R.: P202, P209, P277, P484, 

P486, P535, P864, P1104, P1146, 

P1261, P1378 

Farias A.Q.: P1313 

Farkas J.: 166 

Farmakis D.: P318, P418, P553, 

P799, P1076 

Faustino A.: P794, P1029 

Faustino A. C.: P931, P1107, 

P1276 

Faustino C.: P1357 

Favale S.: P912 

Favilli R.: P402 

Febo O.: P966, P1150 

Fechner H.: P1239 

Fedele F.: P804 

Fedorenco O.: P1359 

Fedotov P.A.: P915 

Fedyainova A.: P247, P1144 

Fedyk-Lukasik M.: P597, P1181, 

P1425 

Fehri W.: P560 

Feijao A.: P502 

Feitosa F.S.: P842 

Feld F.Y.: P405 

Feldman M.D.: P355 

193 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Feliciano J.: P379, P821, P948, 

P1143, P1166, P1403 

Felix S. B.: 768, P952 

Felker G.M.: P417, P450, P1042 

Felley A.: P1077 

Felsoci M.: P434, P1246 

Feng Q.-Z.: P1428 

Fenske W.: P479 

Feola M.: P1299, P1401 

Fernandes A.: P1316 

Fernandes A.A.: P895 

Fernandes L.C.M.: P1087 

Fernandes M.: P198 

Fernandez Pastor J.: P836 

Fernandez-Friera L.: P322 

Ferraironi A.F.: P437 

Ferrara N.: P396 

Ferrari F.: P540 

Ferrari P.: P891 

Ferrari R.: P916, P963, P1073, 

P1349 

Ferreira C.A.: P487 

Ferreira D.K.: P564 

Ferreira F.: P379, P948 

Ferreira J.: P808, P1068 

Ferreira M.J.: P983 

Ferreira N.: P563, P1231 

Ferreira P.: P202, P209, P484, 

P535, P1261 

Ferreira R. C.: P1143, P1403 

Ferreira R.C.: P374, P821, P948, 

P1166 

Ferreira S.A.: P585 

Ferreira S.M.: P489, P1397 

Ferreira Santos L.: P1146 

Ferrero Marinez A.: P1414 

Ferrero-Martinez A.: P1273 

Ferri A.: P540, P916, P963, 

P1073, P1349 

Figueira J.: P808 

Figueiredo A.B.: P870, P908 

Figueiredo E. L.: P1431 

Figueroa C.: P598, P1190 

Figuinha F.: P260 

Filali T.H.: P560 

Filipiak K.J.: P922, P934 

Filippatos G.: P318, P553, 754, 

P778, P965, P1172 

Filippi A.: P891 

Filter M.: P449 

Finocchiaro G.: P491, P492, 

P1311 

Finsen A. V.: 637 

194 

Finsen A.V.: P1131, P1155 

Fiorelli A. I.: P1294 

Fiorelli A.I.: P258, P261, P489 

Fiorentini C.: P376 

Fischer J.: P1032 

Fiuzat M.: P206, P417, P450, 

P779, P998, P1020, P1042, 

P1241 

Flaherty M.: P579 

Flamarique A.: P1177 

Fleck E.: P196, P980 

Flierl U.: P924 

Floch F.: P1297 

Floenaes B.: P1398 

Flores V.: P598, P1190 

Florescu N.: P1037 

Florholmen G.: P914, P1339 

Flyvbjerg A.: P826, P1375 

Follath F.: P418, P799, P1230 

Fomin A.A.: P285 

Fonseca C.: P503, P602, P820, 

P897, P1139 

Fonseca S.: P841 

Fontana M.: 76, P255, P533, 

P583, P587 

Fontanella B.: P240, P1242 

Fontanelli A.: P400, P596 

Fontes-Carvalho R.: P563, P1231 

Forastiere F.: P1165 

Ford I.: P988 

Foremny J.: P346 

Foresti A.: P1250 

Forhecz Z.: P445, P809 

Forhecz Z.S.: P810 

Forleo C.: P912 

Forssmann W.G.: P949 

Forst S.: P1394 

Forster T.: P1110 

Forte S.F.: P437 

Fortuno M.A.: P549, P1147 

Foster S.: P211 

Foti G.: P1055 

Fouad H.: P937 

Fountoulaki K.: P553 

Fox K.F.: P980 

Fraccarollo D.: 672, P924 

Fragasso G.: P1041, P1278 

Franchini A.: P986 

Franciosa P.: P529 

Francis D.P.: 75, P246, P249, 

P456 

Francis L.: P822 

Franco F.: P217, P223, P370, 


P427, P433, P536, P539, P805, 

P807, P815, P829, P839, P1033 

Franke J.: P929, P1024, P1032, 

P1120 

Frankenstein L.: P776, P929, 

P955, P1024, P1032, P1120 

Franzoni I.: P1148 

Franzwa J.: P1047 

Fratoni L.: P478 

Freitas Jr A. F.: P1294 

Freixa R.: P423 

Frey R.: P215, P1009, P1254 

Frick M.: P235, P439, P1315 

Frigerio M.: P248, P471, P1013, 

P1055 

Frigiola A.: P266, P267, P1291 

Fritsch M.F.: P382 

Froehlich H.: P1120 

Frohlich K.: P1233 

Frystyk J.: P826 

Fucili A.: P540, P916, P963, 

P1073, P1349 

Fuente R.N.: P309 

Fujita K.: P206 

Fujita M.: P1319, P1417 

Fujiwara H.: P806, P1255 

Fujiwara T.: P806 

Fukunami M.: P1116 

Funck F.: P1175, P1412 

Funck R.: P408 

Furiozzi F.: P402 

Furtado M.: P1313 

Furukawa Y.: P1116 

Fusco A.: P861, P1012 

Gabbai-Saldate P.: P782, P783 

Gabrielli F.A.: P519, P790, P900, 

P1386 

Gabutti A.: 76, P255, P583, P942 

Gackowski A.: P521 

Gaddi R.: P402 

Gagliardotto P.: P267 

Gago E.: P857 

Gaita D.: P1039 

Gala A.: P868, P1373 

Galajda Z.: P953 

Galati A.: P457, P1282 

Galinier M.: 750, P958 

Galisteo Almeda L.: P785 

Galjee M.A.: P907 

Galkova L.: P426 

Gallego A.: P373 

Gallego M.: P570 

Galrinho A.: P1403


Galuppo P.: 672 

Galyavi R.: P1092 

Galyavich A.: P1092 

Gama P.: P277, P484, P486, 

P535, P864, P1104, P1146, 

P1261, P1378 

Gama V.: P563, P1231 

Garascia A.: P248, P1055 

Garcia A.: P803 

Garcia Acuna J.M.: P1244 

Garcia De Burgos F.: P288, P497, 

P499, P1323 

Garcia E.L.: P932 

Garcia Gonzalez M. J.: P851 

Garcia M.: P308, P322, P467 

Garcia Moran E.: P244, P884, 

P885, P887, P1329 

Garcia Saiz M.M.: P851 

Garcia-Cueto C.: P857 

Garcia-Lopez A.: P308, P322 

Garcia-Rodenas R.: P1251 

Garramone B.: P519, P790, P900, 

P1386 

Garrido Servant A.: P1264 

Garrido-Bravo I.P.: P1251 

Garty M.: P425 

Gasparini M.: P458 

Gato Varela M.: P204 

Gatto L.G.: P437 

Gatzoulis K.: P222, P226, P239, 

P430, P827, P1021, P1038, 

P1265, P1271, P1275 

Gaudio G.V.: P1148 

Gauthier C.: P518 

Gavazzi A.: P891 

Gavina C.: P863 

Gavira J.J.: P1147 

Gebker R.: P980 

Gegenhuber A.: P237 

Gelbrich G.: 74, P251, P273, 

P391, P441, P452, P833, P886, 

P981, P1119, P1260 

Geleijnse M.L.: P327, P1355 

Gelis L.: P847 

Geller J.-C.: P1284 

Gencer E.: P464 

Gendlin G.: P1421 

Genth-Zotz S.: P339 

Gentilini R.: P402 

George R.S.: P469 

Georgiopoulos G.: P881 

Gerritse B.: P268 

Gersak B.: P879 

Geshi T.: P304 

Ghaleh B.: P894 

Ghali J.: P1064 

Gheorghe G.: P599, P1308 

Ghiadoni L.: P1170 

Ghio S.: P458 

Ghommidh M.: P560 

Ghosh S.: P411, P919, P1128, 

P1129 

Gialernios T.: P222, P226, P430, 

P827, P1021, P1265, P1271, 

P1275 

Giamouzis G.: P911, P1008 

Gianfagna P.: P316, P905 

Giani F.G.: 766 

Giannakopoulos K.: P877, P1057, 

P1189 

Giannessi D.: P314, P547, P893, 

P945, P950, P1154, P1368 

Gianni W.G.: P330 

Giannini F.: P492 

Giannoni A.: 75, 76, P255, P583, 

P587 

Giasi A.: P1062, P1124 

Gibbons S.: 765 

Gibelin P.: P958 

Gielen J.: P545 

Gielen S.: 753, P1406 

Giga V.: P567 

Giglio A.: P1374 

Gil R.J.: P189, P192, P1335 

Gillijns H.: 636 

Giordano A.: P1160 

Giordano P.: P455 

Giordano U.: P845 

Giorgi A.: P814 

Giorgi M.C.P.: P1052 

Giro C.: P569 

Giubbini R.: P240 

Giuca A.: P447, P1243, P1301 

Giura G.: P1102 

Gjestvang F.T.: P250, P837, P1281 

Gkouziouta A.: P259, P1072 

Glezeva N.: P522, 770 

Glowacki J.: P1051 

Glowczynska R.: P922, P934 

Goedecke L.: P478 

Goeldner K.: P495 

Goerbig-Campbell J.: P1047 

Goeser S.: P776 

Goethals M.: P1011 

Goh P.P.: P213, P409 

Goktekin O.: P464 

a U t H orS 

Golab J.: 639 

Goldstein M.: P1252 

Golenischa V.: P448 

Golovenko E.N.: P300 

Gombos T.: P445, P809, P810 

Gomes P.: P328, P416, P794, 

P931, P999, P1025, P1029, 

P1263 

Gomes P. L.: P1107, P1276 

Gomes R.: P1068 

Gomez Del Valle C.: P1177 

Gomez Otero I.: P819 

Gomez Salvador I.: P244, P884, 

P885, P887, P1329 

Goncalves A.: P265, P475, P848, 

P1289 

Goncalves L.: P217, P370, P433, 

P459, P539, P983 

Goncalves S.: P282, P530, P1105 

Goncalvesova E.: P245, P407, 

P974 

Goncalvsova E.: P1248 

Goncharik D.: P448 

Gonzalez B.: P438, P576, P580, 

P593, P777, P1395 

Gonzalez Costello J.: P388 

Gonzalez D.: P212, P477 

Gonzalez G.: P1366 

Gonzalez Juanatey J.R.: P288, 

P329, P819 

Gonzalez R.: P570 

Gonzalez Ramirez A.: P789, P997 

Gonzalez Rodriguez L.: P817 

Gonzalez T.: P570 

Gonzalez-Bermudez I.: P1053 

Gonzalez-Costello J.: P216 

Gonzalez-Juanatey J.R.: P509, 

P817, P1027, P1244, P1300 

Gonzalez-Robledo G.: P451 

Goode K.: P227, P319, P510, 

P811, P919, P1129 

Goode K.M.: P234, P440, P812, 

P824, P928 

Goode K.M.G.: P889 

Goodkova A.: P278, P869, P910 

Goodkova A.I.A.: P393 

Goodkova A.Y.: P920 

Goossens V.: 77 

Gorenek B.: P464 

Gori M.: P891 

Gorobets E.: P432 

Gorski J.: P1181, P1425 

Goscinska-Bis K.: 715 

195 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Gotsis E.: P1076 

Gotzsche L.G.: P1056 

Gouadon E.: P1371 

Gouveia C.V.: P199 

Gouveia L.: P361 

Grabowski M.: P922, P934 

Gradinac S.: P1186 

Grajek S.: P867 

Grajkowska W.: P192 

Grammatikopoulos K.Y.R.: P935, 

P1017 

Grander W.: P866 

Granja C.: P420 

Grativvol K.M.: P1007 

Grativvol P.S.: P1007 

Grdinic A.: P1083 

Greco E.: P1440 

Greco O. T.: P1430 

Greco R.: P1440 

Gregorova Z.: P426 

Greinacher A.: 768 

Grigorian L.: P499, P876, P1027, 

P1323 

Grigorian Shamagian L.: P329, 

P819 

Grigorian Shamagian L.I.L.I.A.N.: 

P509 

Grigoryan S.: P272 

Grillias P.: P965 

Grillo M.T.: P316, P905 

Grishaev S.: P1353 

Grishin I.R.: P238 

Grodzicki T.: P597, P1425 

Groessl T.: P1239 

Grollier G.: P1171 

Gronau P.: P331 

Grosse A.: P1284 

Grosu A.: P891 

Grube M.: P274 

Gruhle S.: P287 

Grundtvig M.: P1398 

Grupi C.J.: P1052 

Gruson D.: P1095, P1332 

Grutter G.: P845, P846 

Grzesiak A.: P1090 

Guardado J.: P198 

Guardado J.M.: P420 

Guazzi M.G.: P437 

Guazzotti G.P.: P966 

Guder G.: P581, P1043, P1127, 

P1233 

Gudkov A.Y.A.: P869 

Gudkov Y.A.: P278 

196 

Gueder G.: P479 

Guedes V.C.: P594 

Guedj D.: P1415 

Gueffet J.P.: P1297 

Guenoun M.: P1415 

Guenther S.: P441, P1260 

Guerreiro E.: P1106 

Guida P.: P912 

Guideri S.: P891 

Guillen Garcia S.: P1264 

Guimaraes G.: P585 

Guimaraes G.V.: P842, P1052 

Guimaraes T.C.F.: P1174, P1409 

Guliyev F.A.: P1343 

Gullestad L.: P188, P232, P442, 

P600, P923, P1131, P1398 

Gupta R.: P1061 

Gupta R.C.: P1256 

Gupta S.: P378 

Gurgenyan S.: P1140, P1322 

Gurovich V.: P210, P403, P1257 

Guschina V.: P1421 

Gustafsson F.: P435 

Gusy B.: P449 

Gut S.: P929 

Gutleben K.J.: P1287 

Gutmann M.: 712 

Gziut A.I.: P192 

Haddad H.: P335 

Hadzegova A.: P1303 

Hager F.X.: P1390 

Hagerman I.: P253 

Haggui A.: P560 

Haghikia A.: 635 

Hagikura A.: P1344 

Hajek T.: P1054 

Hajjar R.J.: P308, P322 

Hajlaoui N.: P560 

Halbirk M.H.: P1056 

Hallen J.: P1367 

Haltmayer M.: P237 

Hamad H.: P379, P821, P948 

Hambrecht R.: 753 

Hamdani N.: 634 

Hamed G.: P890 

Hamid S.: P1284 

Hamilton-Smith K. M.: P601 

Hamm C.: P949 

Hammami R.: P412, P787 

Hammer A.: P466 

Hammerman H.: 713 

Hamodraka E.: P367 

Han K.-R.: P431, P1069 


Han S.W.: P338, P1136 

Hana S.: P800 

Hancu M.: P1422 

Hanon O.: P1180 

Hansen A.: 638 

Hansen A.M.S.H.: P797 

Hansen M. L.: 716 

Haouala H.: P560 

Harbar M.O.: P828 

Hardy J.: P1169 

Harkness K.: 170 

Harnek J.: P1293 

Harsfalvi J.: P953 

Hartman K.: P544 

Hartman O.: P1172 

Hartmann O.: P778 

Hartmann S.: P1321 

Hartyanszky I.: P849 

Hasdai D.: P425, P1434 

Hasegawa T.: P302 

Hasenfuss G.: P1360 

Hashimura K.: P302 

Hasic A.: 637, P1155 

Hassager C.: P435, 716 

Hassan A.: P1161 

Hatala R.: P245 

Hattori M.: P589 

Hatzis G.: P363 

Haverkamp W.: P1279 

Haydock P. M.: P371 

Haynes R.: P904, P938, P1156 

Hayredinova O.P.: P967 

Hazarapetyan L.G.: P272 

Heatlie G.: P321, P1117, P1393 

Hegab Z.: 765, P1078 

Hegarova M.: P1327 

Heger J.: P1394 

Heidary A.: 169 

Heintze J.: P1287 

Heinz C.: P534 

Heinzel F.R.: P331, 669 

Heiss G.: P960 

Heitmann M.: P959 

Hekkala L.: P554 

Hekmatpou D.: P383 

Helewski K.: P603 

Helgerson S.: P1290 

Hendrichova M.: P1096 

Hendriks M.L.: 73 

Hennigan B.: P1346 

Henriksson P. H.: P835 

Henriques C.: P1146 

Herda L. R.: 768, P952


Herdynska M.: P346 

Herijgers P.: 636 

Hermans H.: 636 

Hernandez Baldomero I.F.: P512 

Hernandez Baravoglia C.M.: P293 

Hernandez P.: P428 

Hernandez V.: P373 

Hernandez-Garcia J.M.: P428 

Herranz A.: P451, P1366 

Herrmann-Lingen C.: 166, P452 

Herzog E.: P979 

Herzog W.: P391 

Hess G.: P929, P1120 

Hetherington A.: P1040 

Hetzer R.: P494 

Heymans S.: 77, P195, P307, 

P946, P1183, P1188 

Hickey A.: P1159 

Hiemann N.: P494 

Higuchi M.L.: P489 

Hildebrandt B.: P326 

Hilfiker-Kleiner D.: 635, P1131 

Hill L.: P401 

Hillebrandt P.: P826 

Hillege H.: P825 

Hillege H.L.: P194, P575 

Hinterbuchner L.: P382 

Hirai M.: P791 

Hirano E.: P1319 

Hirt M.N.: 638 

Hisatome I.: P791, P795 

Hittinger L.: P227, P262, P319, 

P894, P1399 

Hizar H.B.: P582 

Hjelm C.: 168 

Hjelvang B.R.H.: 752 

Hobkirk J.: P227, P319 

Hochadel M.: P1024 

Hodge D.O.: P557 

Hoefer D.: P1315 

Hoekstra T.: P385 

Hoerstrup S.P.: P1077 

Hoes A.W.: P256, P271, P513, 

P581, P976, P1043 

Hoffmann D.: 672 

Hoffmann W.: 768 

Hofstra L.: P307 

Hole T.: P1398 

Holek B.: P1438 

Holzendorf V.: P441, P1119, 

P1260 

Hong J.Y.: P431 

Hong K.S.: P431 

Hong K.-S.: P1069 

Honorato R.: P1294 

Honton B.: 750 

Hoogenveen R.T.: P985 

Hoppe U. C.: P1337 

Hoque M.: P1137 

Horacek J.M.: P878, P909 

Horak J.: P1096 

Horkay F.: P849 

Horstkotte D.: P377, P543, P552, 

P572, P1287, P1362, P1365 

Hoskote S.: P979 

Hoskova L.: P488 

Howlett J.: P335 

Howlett J.G.: P990 

Hoymans V. Y.: P545 

Hozayen S.: P978 

Hozien S.: P1161 

Hrbackova H.: P488 

Hsu C. H.: P1333 

Huber K.: P537 

Huda N.: P1137 

Hude P.: P883, P1046, P1108 

Huelsmann M.: P1387 

Huica R.: P936 

Hulinska D.: P488 

Humar F.: P1413 

Hummel A.: 768 

Husberg C.: P1131, P1339 

Hussein S.: P494 

Hutuleac R.: P466 

Hyshova N.: P961 

Iacopino S.: P457, P1282 

Iacoviello M.: P912 

Iacovoni A.: P891 

Iakobishvili Z.: P425, P1045, 

P1434 

Ianni B.M.: P487 

Ibatov A.: P390, P940 

Iervasi A.: 76 

Iglesias Diaz C.: P1027 

Ignaszewski A.: P335 

Ihm S.H.: P902, P1109 

Ikeda Y.: P832 

Ikonomidis I.: P193, P418, P799, 

P939, P1230, P1253, P1383 

Ilic B.: P1400 

Ilic D.: P1426 

Ilic I.: P816, P1030 

Ilic S.: P1400 

Iliesiu A.: P301 

Iliodromitis E.: P318 

Iliopoulos T.I.: P332 

a U t H orS 

Ilsar I.: P1256, P1290 

Ingle L.: P824 

Inglis S.C.: P369, P991 

Inigo C.: P1147 

Inkrot S.: 74, 166, P449, P452, 

P833, P1279, P1280 

Inomata T.: P1086 

Insel J.: P1252 

Ioannidis A.: P312, P1441 

Ionac A.: P354, P528, P1309 

Ionescu D.-D.: P345, P447, P524, 

P1037,1081, P1243, P1301 

Iouchtchouk E.: P1303 

Iqbal J.: P822 

Irigoyen M.C.: P309 

Irkin O.: P1002 

Ishibashi Y.: P323 

Ishibashi-Ueda H.: P832 

Ishida K.: P791, P795 

Ishikawa K.: P308, P322 

Isnard R.: P958 

Isopoussu E.: P1123 

Issa V.S.: P260, P585, P842, P856, 

P970, P1397 

Issa V.S.I.: P591 

Istratoaie O.: P345, P565, P1301 

Itai K.: 714 

Iudice G.: P255 

Ivanov S.V.: P264, P1149 

Ivanovic B.: P505, P555 

Ivanovic B.I.: P1377 

Ivosevic T.: P1151 

Iwasaki Y.: P1116 

Iwinski J.: P470 

Iyigun U.: P201 

Izumi T.: P485, P1086 

Izumo M.: P323 

Jaarsma T.: 171, P194, P385, 

P575, P825, P1128, P1176 

Jabir M.: P781 

Jachec W.: P868, P1373 

Jacob J.L.B.: P1430 

Jacquet A.: P896 

Jahandar Lashki D.: P449 

Jahnke C.: P196, P980 

Jahns R.: P286, P479, P490, 

P566, P1127, P1233, 

P1321 

Jakl G.: P537 

Jakovljevic D.J.: P469 

Jan A.: P313, P500 

Jang W.: P1020 

Jankovic R.: P454 

197 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Jankovic Tomasevic R.: P816, 

P1016, P1030 

Jankowska E.: P339 

Jankowska E. A.: P207, P303, 

P778, P792, P964, P996, P1172, 

P1340, P1341 

Janoskuti L.: P445, P809, P810 

Janssens S.: 636 

Jany B.: P1233 

Japp A.G.: P601 

Jaquet Herter M.: P1244 

Jaquet K.: P359, P1006 

Jarai R.: P537 

Jarosz A.: P472, P823 

Jarstadmarken H. O.: 637 

Javorsky G.: P263 

Jebavy L.: P909 

Jedelsky P.: P366 

Jeker U.: 712 

Jelic V.: P1010, P1014 

Jenke A.: P283 

Jenkins A.J.: P941 

Jeon E.-S.: P231, P338, P551 

Jeon H.K.: P902, P1109 

Jeong J.W.: P526 

Jeric T.: P542 

Jia G.: P206 

Jimenez S.: P373 

Jimenez-Navarro M.F.: P428 

Joelle G.F.: P1237 

John B.: P1117 

Johnsen S.P.: P797 

Johnson F.: P1047 

Johnson P.: 754 

Jolle G.F.: P517 

Jondeau G.: P1399 

Jones D.P.: P1099 

Joo H.-Z.: P1279 

Jordan A.: P290, P876 

Jorge E.: P807, P839, P1033 

Jorge E.J.: P995 

Joshi P.: P604 

Jourdain P.: P958, P971, P1175, 

P1412, P1415 

Jovanovic A.: P949 

Jovanovic V.: P353 

Jovelic A.: P352 

Joyce E.: P982 

Juarez Prera R.: P512 

Juilliere Y.: P1399 

Julius B.: 712 

Jung H.O.: P902, P1109 

Jung R.: P352 

198 

Jurko A.: P498, P865, P1427 

Jurko Jr A.: P498, P865, P1427 

Juvonen T.: P340, P1157 

Kaan A.M.: P335 

Kaar G.: P237 

Kacprzak M.: P1097 

Kadenbach B.: P1389 

Kadir S.: P211 

Kafarskay L. I.: P334 

Kaikkonen L.: P292, P1123 

Kajimoto K.: P1164, P1249 

Kalarus Z.: P472, P823, P1051 

Kaldara E.: P233, P977, P1364 

Kalicinska E.: P303 

Kalinkin A.: P1059 

Kallistratos M. S.: P1022 

Kallvikbacka-Bennet A.: P227, 

P319 

Kalogeropoulos A.: P571 

Kaloudis K.: P332 

Kalpakou G.: P1439 

Kammoun S.: P412, P787 

Kanagaratnam P.: P246, P456 

Kanagartnam P.: P249 

Kanakakis J.: P1364 

Kandolf R.: P287, P495, 768 

Kang W.C.: P562, P947, P1288 

Kanzaki H.: P302 

Kaplunova V.Y.: P285 

Karaca I.: P191 

Karali K.: P312, P1441 

Karantoumanis I.: P312, P1441 

Karapatsoudi E.: P312, P1441 

Karas S.: P877, P1057, P1189 

Karasek D.: P917, P933 

Karaskov A.: P404, 715 

Karatolios K.: P395 

Karatzas D.: P553 

Karavidas A.: P965 

Karavolias G.: P1072 

Karayannis G.: P911, P1008 

Karayeva N.T.: P257 

Karck M.: P473 

Kardashevska L.: P1437 

Karetnikova V.: P1259 

Karia D.: P378, P1044, P1137 

Karkkola L.: P292 

Karmakar P.: P559 

Karonova T.: P506 

Karpovich A.V.: P1416 

Karstagoulis E.: P222, P226, P827, 

P1265, P1275 

Kartalis A.: P881 


Kasatzker M.: P210, P403, P1257 

Kaschina E.: P1090, P1384 

Kashtalap V.: P1259 

Kaski J.C.: P512 

Kasner M.: P341, P586, P1232 

Kastanayan A.: P523 

Kastner J.: P460 

Kastorini C.: P413, P429, P957, 

P1162, P1396 

Kataoka H.: P392 

Katarzynska-Szymanska A.: P867 

Kato M.: P791, P795 

Kato Y.: P791 

Katra R.P.: P1306 

Katsaros L.: P1187, P1435 

Katsimbri P.: P1383 

Katus H.: P929, P1120, P1358 

Katus H.A.: P776, P955, P1024, 

P1032 

Kautzner J.: P1085 

Kavouras C.: P1265 

Kavouria E.: P881 

Kawasaki M.: P1116 

Kawase Y.: P308, P322 

Kaya Z.: P776 

Kaymaz C.: P1019 

Kazory A.: P1252 

Keeble T.: P1293 

Keen F.: P1169 

Kehagia I.: P1396 

Kelleher C.: P520, P888 

Keller C.: P1337 

Kelly D.: P236 

Kelly D.J.: P941 

Kemnitz U.R.: P1384 

Kendel F.: P981 

Kenny J.F.: P941 

Keppens C.: P1011 

Kerkela R.: P292, P554, P1123 

Kersting G.: P394 

Khair O.A.: P904, P938, P1156 

Khaleva O.: P234, P510, P812, 

P903 

Khalifa E.: P1141 

Khalifa E. A.: P320 

Khan A.: P214, P982 

Khemache A.: P1175 

Khouri T.: P1352 

Khubulava G.: P247, P1144 

Khusanov S.H.: P483, P862 

Kiczak L.: P1340, P1341 

Kida K.: P323, P1361 

Kihm L.: P1358


Kikuchi Y.: P558 

Kilgallon C.: P378 

Kilic T.: P218, P333, P975 

Kilpatrick R.: P1129 

Kim B.R.: P562, P947, P1288 

Kim H.J.: P1136 

Kim H.Y.: P902, P1109 

Kim J.: P919, P1128, P1129 

Kim J.H.: P902, P1109, P1338 

Kim J.J.: P231, P338, P551 

Kim M. H.: P1338 

Kim M.J.: P902 

Kim M.-K.: P1069 

Kim N.H.: P526 

Kim S.-E.: P431, P1069 

Kim S.J.: P526 

Kim W.: P446, P1345 

Kim Y. D.: P1338 

Kimura G.: P1344 

Kinoshenko K.U.: P281 

Kinugasa Y.: P791, P795 

Kirkpatrick R.: P401 

Kirmos V.: P506 

Kirsch M.: P262 

Kishimoto C.: P284, P589, P1158, 

P1319, P1417, P1417 

Kishko N.: P1094 

Kisko A.: P1094 

Kiss R.G.: P561, P813, P1023, 

P1272 

Kistorp C.: P826 

Kita T.: P589, P1158, P1417 

Kitakaze M.: P302 

Kitsiou A.: P877 

Kitsiou A. N.: P1057, P1189 

Kivikko M.: P780 

Kjaergaard J.: P435, 716 

Klauss V.: P389 

Kleber F.X.: P389 

Kleijn S.A.: 73 

Kleta S.: P886 

Kleut M.: P350 

Klicheva O.B.: P862 

Kliebe C.: P568 

Kliebe F.: P568 

Klingel K.: P287, P495, P1236 

Kliver E.: P404, 755 

Kloetzel P.M.: P1236 

Klugman S.: P471 

Kmec J.: P1094 

Knezevic I.: P879 

Knopps K.: P1169 

Knotter N.: P368 

Knyazeva L.V.: P1100, P1277 

Knyazkova I.: P1058 

Ko J.: P446, P1345 

Kobayashi M.: P485 

Kober L.: P435, 716 

Kober L.K.: 752, P889 

Koch V.: P1389 

Kochanowski J.: P934 

Kocijancic A.: P315, P1350 

Kockskaemper A.: P886 

Kockskamper J.: P331, 669 

Koeda Y.: 714 

Koepp U.: P250, P837, P1281 

Koh S.: P323 

Kohler I.: P467, P564, P932 

Kok W.E.: P368 

Kokosadze N. V.: P334 

Kolar M.: P366 

Kolchurina A. V.: P481 

Koller B.: P866 

Kolodziej P.: P1181 

Kolsut P.: P337 

Komiyama T.: P1319 

Komlev A.E.: P238 

Komuda K.: P843 

Kondracka A.: P922, P934 

Konduracka E.: P521 

Kongsgaard E.: P232 

Konopka A.: P802 

Konstandin M.: P776 

Konstantakis E.: P233 

Konstantinidis S.: P387 

Kontopidi V.: P233, P1364 

Koobi P.: P1235 

Kopeleva M.: P1303 

Koracevic G.: P1016, P1030, 

P1429 

Korczyk D.: P1159 

Kordosis G.E.: P935, P1017 

Korewicki J.: P470, P843, P1028, 

P1181 

Korinek J.: P1108 

Kormali L.: P280, P362, P363 

Kornhall B.: P1293 

Korok E.V.: P264, P1416 

Korsunskaya M. I.: P334 

Kosaka T.: P936 

Kosevic D.: P1083 

Koskinas K.: P312, P1441 

Kosnik M.: P542 

Kostareva A.A.: P278, P920 

Kostic T.: P454, P1426 

Kostin S.: P485 

a U t H orS 

Kosugi R.: P1086 

Kosztin A.: P813, P1272 

Kotrc M.: P1432 

Kotrogiannis I.: P855, P1132 

Kotrogiannis J.: P208, P429 

Kotsch K.: P495 

Kottam A.: P355 

Kotwica A.: P601 

Koudoumas D.: P1292, P1435 

Kouremenos N.: P1336 

Kouvelas N.: P332 

Kouznetsova T.: P307 

Kovacevic M.: P352 

Kovacevic-Preradovic T.: P1433 

Koval O.A.: P1331 

Kovalenko E.: P241 

Kovalenko O.: P448 

Kowalczuk A.: P346 

Kowalski J.: P508, P511 

Kozanli I.: P537 

Kozar-Kaminska K.: P1028 

Kozdag G.: P218, P333, P975 

Kozhukhov S.: P993, P1002 

Koziolova N.: P229, P462 

Kozlenok A.: P506, P1080 

Kozlenok A.V.: P869, P910 

Kozlovskiy V.A.: P1058 

Kraai I. H.: P575 

Kraetzschmar J.: P1254 

Krakowiak B.: P207, P964 

Krause K.: P359, P1006 

Kravari M.: P1187 

Krehbiehl N.: P1133 

Krejci J.: P883, P1046, P1108 

Kremastinos D.: P318, P367, 

P553, P965, P1230 

Kremastinos D.T.: P193, P418, 

P939, P1383 

Krikunova O.: P1303 

Krishnan R.: P1020 

Kristen A.: P776 

Krljanac G.: P994, P1268 

Kroemer H.K.: P274, 768 

Krotin M.: P1083 

Krstic M.: P351, P1142 

Krstic N.: P1426 

Kruszewski M.: P337 

Krutikov A.N.: P910 

Kubanek M.: P488, P1432 

Kubitz H.: P1296 

Kubota I.: P925, P1034 

Kuchibhatla M.: P1020 

Kuck K.H.: P359, P1006 

199 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Kuehl U.: P1310 

Kuehne A.: P930 

Kujawa M.: 639 

Kuklina M. D.: P375, P481 

Kukwa W.: P922, P934 

Kulcsar I.: P1103 

Kunde J.: P445, P809 

Kung T.: P326, P339, P534, P574, 

P1115 

Kupec J.: P453, P1015 

Kurbanov R.D.: P483, P493, 

P862, P872, P873, P1067 

Kurlyanskaya E.: P317, P834, 

P1283 

Kuryata O. V.: P344,1298 

Kuzmina T.V.: P1354 

Kuznetsova T.: P1183 

Kuznetzova I.A.: P869 

Kvaloy H.: 637 

Kycina P.: P1071 

Kyriacou A.: P246, P249, P456 

Kyriacou A.A.: 75 

Kyriazis J.: P881 

Kyyak Y.: P365 

La Rovere M.T.: P396, P397,966, 

P1150 

Labat C.: P549 

L’abbate A.: P228 

Lacalzada Almeida J.: P851 

Lacchini S.: P309 

Lacolley P.: P549, P1147 

Ladage D.: P308, P322 

Ladd S.: P1020 

Lado Lado F.: P819 

Lafuente Taboada R.: P817 

Lagoeiro Jorge A.J.: P1087 

Lahera V.: P895 

Lahidheb D.: P560 

Laing J.: P853 

Lainscak M.: 74, 166, P273, P452, 

P542, 754, P833, P1280 

Lak L.L.: P405 

Lambert V.: P1371 

Lamp B.: P394 

Lampropoulos K.M.: P332 

Lampropoulou G.: P877 

Lancia A.: P814 

Landolina M.: P458 

Lang C.C.: 72, P781 

Langer C.: P543 

Langwieser N.: P927 

Lanska V.: P579 

Laoutaris I. D.: P1022 

200 

Lappin D.: P982 

Lara Padron A.: P512, P851 

Larina V.: P1126, P1376 

Larionov P.: P404, 755 

Lasica R.: P994 

Lasseter K.: P1009 

Lattuada G.: P1041 

Latypov R.S.: P238 

Laucevicius A.: P386 

Laufs U.: P274 

Laurent A.C.: 767 

Laurent G.: P364 

Lauwers C.: P288, P289, P497 

Lavall D.: P274 

Lax A.: 670 

Laynez Cerdena I.: P851 

Lazar M.: P936 

Lazareva I.: P847 

Lazaros G.: P222, P226, P1038, 

P1245 

Lazikova Z.: P1071 

Lazovic M.: P351, P1142 

Lazzarini V.: P1240, P1242, P1250 

Le Bret E.: P1371 

Leal S.: P602, P820, P897, P1139 

Leal S. R. N.: P503 

Lebar P.L.: P582 

Lebedev D.: P347 

Leblanc M.-H.: P335 

Lebreiro A.: P859, P1314, P1317, 

P1402 

Lebreiro A.M.: P588 

Ledakowicz-Polak A.: P1001, 

P1153 

Ledwidge M.: P305, P313, P500, 

P514, P520, P522, P595, 751, 

770, P888, P1346 

Lee E.S.P.: P321, P1117, P1393 

Lee J.D.: P304, P1158 

Lee J.H.: P431, P1069 

Lee K.H.: P947, P1288 

Lee M.M.: P1136 

Lee R.: P1290 

Lee S.: P446, P1345 

Lee S. E.: P1338 

Lee S.H.: P231, P338 

Lee S.R.: P446, P1345 

Lefroy D.: P246, P249, P456 

Lehinant S.: P949 

Lehmkuhl H.B.: P494 

Lehnart S.E.: P1360 

Leitao A.: P503 

Leitao Marques A.: P328, P416, 


P931, P999, P1025, P1357 

Leitao Marques A.M.: P794, 

P1029, P1107, P1276, P1263 

Leite-Moreira A.F.: 634 

Leitner L.: P460 

Lekakis J.: P193, P367, P939, 

P1383 

Lelyavina T.: P424, P1420 

Lenco J.: P878 

Leners B.: P343 

Lennie T.L.: 167 

Lenz C.: P394 

Leonard F.: P343, P913 

Leonardo F.: P861, P1012 

Leong G.E.R.A.R.D.: P409 

Leong K. T. G.: P213 

Leoni L.: P1305 

Lesault P.F.: P262 

Leskinen H.: P1157 

Lesman I.: P385 

Lesny P.: P407, P974, P1248 

Lessa M.A.: P968 

Leszek P.: P337, P1181 

Lettieri J.T.: P1009 

Levi Y.: P210, P403, P1257 

Lewinter C.: P369, P889, P928, 

P991 

Lewinter K.: P227, P319 

Lewis B.S.: P818, P1266 

Lewis C.: P214, P1004 

Lewis C.C.: P1005 

Leyva F.: P321, P1304, P1393 

Lezoualc’h F.: 668, 767 

Libbus I.: P1306 

Libianto R.: P781 

Licio F.V.: P1087 

Lilla Della Monica P.: P1049 

Lim S.: P213 

Lim S.J.: P431, P1069 

Lima L.L.: P841 

Lima M.V.: P1007 

Lima-Costa M. F.: P197 

Lindbom M.: P501 

Lindemberg S.: P584 

Lindenfeld J.: P779 

Lindner D.: P341, P1122 

Linhares J.M.: P203 

Linssen G. C. M.: P194 

Lionetti V.: P547, P893, P1342 

Liontou C.: P1162 

Liontou K.: P413, P1163, P1396 

Lip G.Y.H.: P904, P938, P1156 

Lipari A.: P398, P840


Lipp M.: P1131 

Lipperman L.M.: P405 

Lippi M.E.: P986 

Lisboa L.F.: P414 

Liska B.: P245, P407, P1248 

Liu P.: P335 

Liu P.-Y.: P1333 

Liu T.: P1167 

Liveris K.: P1439 

Livieratos T.: P935, P1017 

Lizak M. K.: P472 

Lizak M.K.: P823 

Ljubas J.: P468 

Llacer A.: P225, P1026 

Llacer Escorihuela A.: P1388 

Lobao B.: P282 

Lober J.: P1232 

Loeffler M.: P981 

Lofman I.: P253 

Loforte A.: P1049 

Logeart D.: P958, P1247, P1399 

Lohse M.J.: P286, P490, P1321 

Loisance D.: P262 

Lombardi C.: P206, P417, P779, 

P998, P1020, P1240, P1241, 

P1242, P1250, P1270 

Lombardi M.: P533 

Lombardo E.: P1299, P1401 

Londono O.: P992 

Londono Sanchez O.: P419, P577 

Lopatin U.: P474 

Loperfido F.: P519, P790, P900, 

P1386 

Lopes M.G.: P204, P502, P838, 

P1082, P1138 

Lopes M.J.: P530 

Lopes R.: P859 

Lopez Aguilar R.: P785 

Lopez Diaz J.: P244, P884, P885, 

P887, P1329 

Lopez E.: 769 

Lopez Moyano M.G.: P973 

Lopez N.: P549, P1147 

Lopez Palop R.: P1264 

Lopez R.: P576, P593, P1395 

Lopez Seijas C.: P1300 

Lopez-Sanchez M.J.: P1273, 

P1414 

Lorenco D.D.F.: P258 

Lorente V.: P216 

Lorkova L.: P366 

Lossnitzer N.: P391 

Lotrionte M.: P519, P790, P900 

Louch W.: P310 

Louch W.E.: P517, P1237 

Loureiro D.: P841 

Lourenco C.: P536, P839 

Lourenco C.N.: P217, P459, P983 

Lourenco P.: P859 

Loures-Vale A.A.: P1431 

Lousinha A.: P821, P948 

Lozano Herrera J.M.: P997 

Lozano Herrera L.: P789 

Lozano T.: P289, P290, P499 

Lozovaya T.: P506 

Luca’ F.: P228 

Lucas A.: 668 

Lucena A.: P968 

Ludka O.: P224, P426, P578 

Lukaschuk E.: P903 

Lukaschuk E.L.: P234 

Lukashenko V.: P1184 

Luknar M.: P407, P974, P1248 

Lunati M.: P248, P458, P1013 

Lunde I. G.: 637, P914 

Lunde P.K.: P1173, P1367 

Lunghetti S.: P402 

Lupon J.: P438, P576, P580, 

P593, P777, P1395 

Lupu S.: P898 

Luscher T.F.: 754 

Lutay Y.: P1002 

Luttik M.-L.: P825 

Luz Rodrigues H.: P1138 

Lycholip E.: P386 

Maass A.H.: P880 

Mabire J.P.: P1171 

Macarie C.: P1103 

Macaya C.: P1102 

Macchi A.: P1148 

Macera F.: P248, P471, P1013, 

P1055 

Maciel B.C.: P532, P870, P908 

Maciel M.J.: P531, P588, P863, 

P1314, P1317, P1402 

Mackiewicz U.: 639, P1359 

Maczewski M.: 639, P1359 

Madeira H.: P801, P1035 

Madeira H.C.: P1316 

Madkour M.: P978 

Madureira A.J.: P531, P1317 

Mady C.: P309, P487 

Maeder M.T.: 712 

Maehler A.: P336 

Maessen J.: 77 

Maestri R.: P396, P397, P966 

a U t H orS 

Magenta G.B.: P248 

Magini A.: P376 

Magoutas A.: P325 

Mahaffey K.W.: P779 

Mahmoodzadeh S.: P930 

Mahmoud Y.: P1074 

Mahoney D. W.: P296 

Mahr C.: P995 

Maiandi C.: P398, P840, P1270 

Mainar L.: P497 

Maines M.: P269, P1305 

Maisch B.: P205, P251, P395, 

P408, P568, P875, P1070 

Maisel A.: P782, P783 

Majstorovic A.: P350 

Mak G.: P500 

Makdisse M.: P1000 

Makdisse M.R.: P414 

Makita S.: 714 

Makridis C.: P312 

Makridis P.: P312, P1441 

Malacky T.: P245 

Malagoli A.: P550, P954 

Malagu M.: P963, P1073, P1349 

Malakos I.: P881 

Maldonado M.A.: P467, P841 

Malek F.: P453, P1096 

Malek I.: P488, P1085, P1327, 

P1432 

Malergue M.C.: P1415 

Malfatto G.: P1374 

Malliaras K.: P1292 

Maltinti M.: P314 

Maluskova J.: P488 

Maly J.: P909 

Mamas M.: P1392 

Mamas M.A.: 765 

Mammini C.: P583, P942 

Manankil M.: P995 

Mancone M.: P804 

Mancuso A.: P1405 

Manerba A.: P1270 

Manetos C.: P977, P1326 

Manfredi M.: P1352 

Manginas A.: P259 

Mangini S.: P199, P414, P489, 

P1000, P1294, P1397 

Mangner N.: 753, P1406 

Manhaes M.A.R.: P1178, P1408 

Manhenke C.: P190 

Manica A.: P269 

Manis G.: P222, P226, P430, 

P1265, P1275 

201 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Manisty C.H.: 75 

Manito N.: P216, P388 

Manole G.: P936 

Manoli E.: P259 

Manolis A. J.: P1022 

Manolis A.J.: P1312 

Manoussakis M.N.: P324 

Mansy S.: P978 

Mantini V.: P330 

Manzano Fernandez S.: P1251 

Mapelli M.: P240 

Marafoni L.: P968 

Marazzi G.: P986, P1405 

Marbury T.: P1009 

Marchese N.: P790 

Marchiori G.: P335, P1274 

Marcolino M. S.: P327, P1355 

Marcondes-Braga F.G.: P1397 

Mardanov B.U.: P493, P872, 

P873, P1067 

Mareev V.: P1059 

Mareev V.I.U.: P926 

Margari Z.: P1326, P1364 

Margitfalvi P.: P245 

Margonato A.: P1041, P1148, 

P1278 

Marinkovic D.: P1400 

Marin-Neto J.A.: P870 

Marino P.: P1066 

Marino R.: P1369 

Mariotti R.: P358, P455 

Markus R.: P1272 

Markussis V.: P325 

Marona M.: P802 

Marosi E.: P561, P813, P1023, 

P1272 

Maroz-Vadalazhskaya N.: P1112 

Marques F.: P532, P908 

Marrero Rodriguez F.: P851 

Marta D.S.: P936 

Martin A.: P1286 

Martin De La Fuente P.: P789, 

P997 

Martin Luengo C.: P570 

Martin M.: P857 

Martin P.H.: P1113 

Martinelli L.: P471, P1050 

Martinez Dolz L.: P876, P1121, 

P1323 

Martinez Huertas S.: P789, P997 

Martinez M.: P895 

Martinez Martinez-Espejo M.D.: 

P1251 

202 

Martinez Mateo V.: P1295 

Martinez N.: P399 

Martinez Quesada M.M.: P973 

Martinez-Gonzalez J.: P895 

Martins E.: P863, P1314, P1317 

Martins H.: P217, P223, P370, 

P427, P433, P536, P539, P805, 

P807, P815, P829, P839, P1033 

Martins S.: P502, P838 

Martins V.M.: P793 

Martins W.A.: P584, P1178, P1408 

Martos R.: P500, P1004 

Mascarell B.: P225 

Mascarenhas J.: P859 

Masci P.G.: P533 

Masciocco G.: P248, P471, 

P1013, P1055 

Masenko V.: P275 

Masenko V.P.: P854 

Masi L.: P1170 

Masoura K.: P1021, P1271 

Massa L.: P1413 

Massaro R.: P1405 

Massing M.: P960 

Masson G.: P968 

Masutani M.: P962 

Masuyama T.: P548, P962 

Matejka G.: P871 

Mathe A.: P364 

Mathews E.: P1047 

Matic D.: P1151 

Matic M.: P1268 

Matic S.M.: P555 

Matos A.: P1146 

Matsumori A.: P937 

Matsumoto A.: P806 

Matsumoto A.Y.: P487 

Mattern S.: P566 

Matthes F.: P1360 

Matusik P.: P597 

Matzaraki V.: P965 

Maurice-Tison S.: P860 

Mavrogeni S.: P324, P325 

Mawartinah Msc T.R.I.: P786 

Maxeiner H.: P1133 

Mayet J.: 75, P246, P249, P456 

Mayr M.: 635 

Mazzu A.: P1009 

Mbakwem A.M.A.M.: P1418 

Mc Donald K.: P520, P888 

Mc Lean A.: P418, P799 

Mcadam B.: P214, P1004, P1005 

Mcalister F.A.: P369, P991 


Mcdonagh T. A.: P988 

Mcdonald K.: P305, P313, P500, 

P514, P522, P595, 751, 770, 

P1346 

Mcintyre H. F.: P371 

Mckelvie R.S.: 170, P990 

Mcmurray J.J.V.: P546 

Mcneill B.: P982 

Mcpherson B.: P1159 

Mebazaa A.: P418, P799, P1230, 

P1247 

Medalion B.: P1045, P1434 

Medvedeva E.: P847 

Meems L.M.G.: P880 

Mehic F.: P831 

Mehrhof F.: P449 

Mehrzad A.L.I.: P1040 

Meili-Butz S.: P1101 

Meille L.: P1390 

Meisel S.: P210, P403, P1257 

Melaiu O.: P547 

Melenovsky V.: P366, P1085, 

P1327 

Mello L.: P203, P584 

Meln I.A.: P920 

Melo R.D.F.: P1431 

Meloni S.: P480 

Meluzin J.: P1108 

Menachemi D.: P1337 

Mende M.: P1279 

Mendes L.: P282, P530, P1105 

Mendes P.: P370, P433, P536, 

P539, P807, P829, P839, P1033 

Mendes P.L.: P223, P427, P805, 

P815 

Mendez M.: P384 

Menditto E.: P1299, P1401 

Menezes M.G.: P932 

Menicanti L.: P266, P267, P476, 

P1291 

Mennuni S.: P804 

Menoret S.: P518 

Meregalli P. G.: P368 

Merhavi D.: P818, P1266 

Merlo M.: P491, P492, P496, 

P1075, P1311, P1413 

Merlos Diaz P.: P1388 

Merlos P.: P225, P1026 

Mesquita E.T.: P203, P361, P569, 

P584, P590, P1087, P1178, 

P1408, P1409, P1410 

Mestroni L.: P496 

Metallinos G.: P208, P957, P1162


Metaxa S.: P280, P362, P363 

Methusi P.: P295 

Metra M.: P206, P240, P398, 

P444, P840, P1240, P1242, 

P1250, P1270 

Metrich M.: 767 

Meurin P.: P1415 

Meyer T.: P875 

Miani D.: P316, P458, P905, 

P1305 

Michalakeas C.: P367 

Michelinakis N.: P233 

Mikhailichenko Y.S.: P1437 

Mikhailov A.: 769 

Miklik R.: P224, P434, P578, 

P1246 

Milani L.: P858 

Milasinovic G.: P353, P1010, 

P1014 

Milazzo F.: P1050 

Milesi G.: P1270 

Milic D.: P454, P1426 

Milicic D.: P468, P1232 

Miliou A.: P280, P362, P363, 

P1132 

Miljevic T.: P352 

Mill J.G.: P243 

Miller A.: P779 

Miller W. L.: P296 

Milli M.: P478 

Milliez P.: P1171 

Milosevic-Tosic M.: P297 

Mina’ C.: P293 

Minami Y.: P1164, P1249 

Minana Escriva G.: P1388 

Minana G.: P225, P1026 

Mincu D.: P507 

Mincu D.E.: P541 

Minnetdinov R.: P1092 

Minullina I.R.: P920 

Minuti E.: P358 

Miotto G.: P1091 

Miranda C.: P282, P530, P1105 

Miranda C.H.: P870 

Miranda F.: P374, P821, P948 

Mircheva L.: P1063 

Mirelis J.: P980 

Mirizzi G.: P942 

Mirkovic T.: P879 

Miro V.: P499, P876, P1323 

Mischie A.L.: P1269 

Misgeld C.: P534, P1115 

Mishra S.: P1061 

Missol-Kolka E.: 635 

Mistrorigo F.: P400 

Miteva K.: P1134 

Mitrovic V.: P949, P1186 

Mitsuke Y.: P304 

Mittelman M.: P425 

Miwa S.: 751 

Miyake F.: P323, P1361 

Miyamoto T.: P1255 

Mizukoshi K.: P323 

Mizuno K.: P1164, P1249 

Mizuno M.: P1249 

Mizuno T.: P1164 

Mocan T.: P898 

Moccetti T.M.: P330 

Moe G. W.: P990 

Moehlmann H.: P389 

Moertl D.: P466 

Mogelvang R.: P959 

Mohamed T.M.A.: P1078, P1320 

Mohammadi E.: P383 

Mohammed T.: 765 

Moibenko A.: P1002 

Moldoveanu E.: P936 

Molina Mora M.J.: P836 

Moll R.: P205, P408, P1070 

Moller J.E.: P435, 716 

Moller N.M.: P1056 

Molon G.: P1305 

Momcilov Popin T.: P852 

Mondillo S.: P402 

Monge J.: P503, P602, P820, 

P897, P1139 

Monsef D.: P890 

Mont L.: P1286 

Montalto A.: P1049 

Montano P.: P212 

Montastruc J.L.: 750 

Monteiro P.: P217, P223, P370, 

P427, P433, P536, P539, P805, 

P807, P815, P829, P839, P1033 

Montera M.W.: P798 

Montericcio V.: P476 

Montero A.: P1121 

Monti A.: P398 

Moon C.I.: P562 

Moosdorf R.: P395, P408, P1389 

Morales M.A.: P314 

Morales-Martinez D.: P465 

Morato M.: P400, P596 

Morbach C.: P441, P1119, P1260 

Moreira L.F.P.: P219, P1052 

Morel E.: 767 

a U t H orS 

Morelli I.: P358 

Moreno Escobar E.: P789 

Moreno Escobar E.D.: P997 

Moreno Terribas G.: P789, P997 

Morgado P.C.: P422, P1007, 

P1125 

Morgunov M.: P523 

Mori C.: 754 

Mori Y.: P534 

Morillas P.: P288, P289, P497, 

P876 

Morisson K.: P401 

Morita T.: P1116 

Mork H.K.: P310 

Mornos C.: P354, P528, P1039, 

P1309, P1336 

Morshedi A.: P943 

Mosadeghmehrjerdi M.: P943 

Moschouris P.: P881 

Moscoso Costa F.: P808, P1068 

Moser D.K.: 167 

Moshtaghion S.: P943 

Mosterd A.: P513, P976 

Mota B.: P203, P584 

Mota Gomez P.: P885 

Mota P.: P1357 

Moura B.: P1314 

Moure Gonzalez M.: P329, P509, 

P819 

Moutsopoulos H.M.: P324 

Mozos I.: P1422 

Mpouchla A.: P977, P1187, 

P1326 

Mrdovic I.: P994, P1151, P1268 

Mrochek A.: P448 

Mueck W.: P215, P1009, P1254 

Mueller C.: 768, P952 

Mueller S.: P776 

Mueller T.: P237 

Mueller-Tasch T.: P251, P391 

Mufti S.: P1133 

Mulak G.: P958, P1399 

Munakata R.: P1164, P1249 

Munhoz R.T.: P422, P1007, P1125 

Munkvik M.: P1367 

Munoz Garcia A.J.: P428 

Munoz M.C.: 766 

Munoz Rivas N.: P384 

Munoz-Esparza C.: P1251 

Munvkik M.: P1173 

Murai K.: P1164, P1249 

Muraru D.: P316, P905 

Muraru M.: P1385 

203 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Murayama T.: P589, P1158, 

P1417 

Mureddu G.F.: P1165 

Murin J.: P1071 

Murphy C.A.: P546 

Murphy J. J.: P1304 

Murphy N.F.: P313, P595 

Murray S.: P822 

Mursalova A.: P1424 

Murthy K.: P378 

Musetescu A.E.: P1081 

Musetescu R.: P524, P1037, 

P1081 

Musial W.: P1425 

Musil M.: P426 

Mussner-Seeber C.: P235, P439 

Mustafa E.-R.: P345, P565 

Mustafa R.-E.: P447 

Musters R.J.P.: P1238 

Mustonen E.: P1157 

Musumeci F.: P1049 

Mutlak D.: 713 

Muzzarelli S.: 712 

Myasoedova E.: P1145 

Myasoedova S.: P1145 

Myhre E.S.P.: P250, P837, P1281 

Myrda K.: P470 

Mytas D.: P877 

Nadziakiewicz P.: P1051 

Nagaplev M.: P523 

Najjar Y.: P812 

Naka T.: P538, P548, P962 

Nakai Y.: P806 

Nakamura M.: 714 

Nakamura Y.: P485 

Nakano A.: P304, P797 

Nanas J.: P233, P918, P1292, 

P1364, P1435 

Nanas S.: P977, P1187, P1292, 

P1326 

Nanea I.T.: P599, P1308 

Nanea T.: P301 

Napalkov D.A.: P300, P1380 

Napankangas J.: P340, P463, 

P1157 

Narusov O.: P275 

Nascimento B.: P569 

Nascimento C.: P209, P277, P535 

Nash P.: P982 

Nasierowska-Guttmejer A.: P189 

Nassar D. Y.: P279 

Nassar Y. S.: P890 

Nassiacos D.: P480 

204 

Nastas J.: P911, P1008 

Natali R.: P519, P790, P900, 

P1386 

Natynki A.: P554 

Naumov A.V.: P1031, P1262 

Navarro D.: P1026 

Nawrath K.: P930 

Naylor K.: P1040 

Nebot M.: P388 

Nedeljkovic I.: P315, P353, P567, 

P796, P1010, P1014, P1350 

Nedeljkovic M.: P567, P796 

Neder J.A.: P585 

Negi S.I.: P1099 

Neglia D.: P314 

Negm H.: P937 

Neiva L.L.: P1431 

Nelassov N.: P523, P1381 

Nelles M.: P955, P1024, P1032, 

P1120 

Nemec P.: P1046 

Nemes A.: P1110 

Nemkov A.: P1184 

Nenov K.: P1063 

Nervo E.: P1299, P1401 

Neskovic A.: 74 

Neskovic A.N.: P273 

Nespoli P.: P1313 

Nesralla I.: P467 

Nesralla I.A.: P841 

Nessler J.: P521 

Nesteruk Y.U.: P1184 

Neubert M.: P1079 

Neuhold S.: P1387 

Neukirch B.: P989 

Neumann T.: P251 

Neuzil P.: P453 

Newby D.E.: P601 

Newcomb A.N.: P941 

Neyko V. E.: P921 

Neyses L.: 765, P1078, P1320, 

P1392 

Ng L.L.: P236, P546 

Ngo Mandag N.: P1113 

Nguyien B.L.: P529 

Niaki M.: P995 

Nicholls R.: P234, P811 

Nicolaou A.: P326 

Nicolas C.: P343, P913 

Niedziela J.: P470 

Nielsen R.: P1056 

Nielsen S.N.: P1056 

Nielsen-Kudsk J.E.K.: P1056 


Nieto M.L.: P244, P884, P885, 

P887, P1329 

Nieto S.: P384 

Nieuwenhuis M.M.W.: 171 

Nifontov S.: P1080 

Nikitin N.: P903 

Nikitin N.P.: P319 

Niklewski T.: P1051 

Nikoghosyan K.: P1140, P1322 

Nikolaev V.O.: P286 

Nikolaidou T.: P1392 

Nikolaishvili G.: P1168 

Nikolaou M.: P418, P553, P799 

Nikolaychuk E.: P1330 

Nikolaychyk E.: P506 

Ninaber P. A.: P592 

Niranjan K.: P1381 

Nirula A.: P1064 

Nishi K.: P1255 

Nistorescu D.: P301 

Nizsaloczki E.: P1342 

Noack C.: P1234 

Nobili V.: P1369 

Noelker G.: P1287 

Noge S.: P806 

Nogueira Da Silva M.: P1403 

Noiman E.: P210, P1257 

Norman J.: P465 

Norrelund H.N.: P1056 

Noszczyk-Nowak A.: P1340, 

P1341 

Not D.: P1415 

Novak M.: P1015 

Novik G.A.: P910 

Nowak J.: P603, P778, P1172 

Nowak J.U.: P470 

Nowalany-Kozielska E.: P868, 

P1373 

Nowicka A.: P1181 

Nowis D.: 639 

Nranyan N.V.: P1347 

Ntalapascha M.: P312, P1441 

Ntsekhe M.: P1003 

Ntusi B.N.: P1318 

Nunan D.: P469 

Nunes Diogo A.: P502 

Nunes L.: P202, P209, P277, 

P535, P864, P1146, P1261 

Nunes M.C.P.: P327, P1355 

Nunez E.: P1026, P1388 

Nunez J.: P225, P1026 

Nunez Villota J.: P1388 

Nyegaard M.N.: 752


Nygard S.: P1155 

Nyolczas N.: P561, P813, P1023, 

P1272 

O Loughlin C.: P520 

Obradovic S.: P454 

Obzherina S.: P1145 

O’callaghan E.: 751 

Ocampo-Miguez J.: P1053 

Occhetta E.: P1066 

Oceandy D.: 765, P1320, P1392 

Ochiai M.E.: P422, P1007, P1125 

O’connor C.: P998, P1020, P1241 

O’connor C.M.: P206, P417, P779 

Oezcelik C.: P875, P1079 

Ogino K.: P791 

Oh D.J.: P431 

Oh D.-J.: P1069 

Oh S.K.: P526 

Ohlin H.: P1293 

Ohukainen P. J.: P340 

Ohyanagi M.: P538, P548, P962 

Oie E.: P1339 

Oie E. H.: P600 

Oikonomou E.: P362 

Oikonomou K.: P312, P1441 

Okabe T.: P589 

Okada T.: P1116 

Okado T.: P1344 

Okayama A.: 714 

Okelly N.: P411 

Oko-Sarnowska Z.: P867 

Okuyama Y.: P1116 

Olalla-Mercade E.: P428 

Oldenburg O.: P377, P543, P552, 

P572, P1287, P1362, P1365 

Olimulder M.: P907 

Oliva F.: P248, P268, P458, P471, 

P1013, P1055 

Oliveira A.: P863 

Oliveira A.S.: P856 

Oliveira B.M.R.: P299, P594 

Oliveira C.B.C.: P487 

Oliveira Caetano M. F.: P1106 

Oliveira E.: P374, P1166 

Oliveira E.S.: P856 

Oliveira G.: P968 

Oliveira Jr J.L.: P261, P489, P1294 

Oliveira Jr O. J.R.: P258 

Oliveira L.B.: P1178, P1408 

Oliveira M.: P1403 

Oliveira M.G.: P1178, P1408 

Oliveira S.: P265 

Oliveira S. M.: P475, P531, P588, 

P848, P863 

Oliveira S.M.: P1289, P1402 

Oliveira Santos J.: P1146 

Oliveira T.: P361 

Omar E.: P1346 

Omar S. H.: P279 

Omerovic E.: P501, P871 

Ometto R.: P400, P596 

Omiya K.: P323, P1361 

Omland T.: P1339 

Onoda T.: 714 

Onsy A.: P937 

Onut R.: P316, P905 

Onyshchenko O.: P903 

Opitz E.: P1236 

Opitz L.: P1360 

Opolski G.: P597, P922, P934 

Orban M.: P1108 

Orea-Tejeda J. I. A.: P212, P477 

Oreglia I.: P471 

Orekhova L.Y.U.: P393, P869 

Orlandi C.: P1064 

Orn S.: P190 

Orosa P.: P876, P1323 

Orr S.: P1169 

Orsi R.: P1091 

Ortega T.: P857 

Ortiz Alonso J.: P384 

Orynchak M.A.: P252, P921 

Osada N.: P1296 

Osawa E.: P856 

O’shaughnessy M.: P982 

O’shea D.: P1346 

Osmolovskaya Y.F.: P926 

Ostadal P.: P1096 

Ostojic D.: P377, P1287 

Ostojic M.: P567, P994, P1268 

Ostojic M.C.: P315, P796, P1350 

Ostrovskiy Y.: P317, P834, P847, 

P1283 

Osugi R.K.: P798 

Otasevic P.: P850, P1186 

Otaviano A. P.: P242 

Otero Ravina F.: P817, P1027 

O’toole L.: P853 

Otten R. M.: P575 

Oudejans I.: P513 

Ovchinnikov A.G.: P854 

Ovricenco D.-E.: P221 

Ovricenco E.: P956 

Ozabalova E.: P883, P1046 

Ozcelik C.: P494 

Ozturk M.: P1019 

a U t H orS 

Pabari P.: 75 

Pabari P.A.: P246, P249, P456 

Paccanaro M.: P596 

Pacher R.: P1387 

Paci C.P.: P330 

Pacreu S.: P419, P577 

Pacreu S.U.S.A.N.A.: P992 

Padeletti L.: P228 

Padeletti M.: P402 

Padella V.: P529 

Paetsch I.: P196, P980 

Paez Rubio I.: P785 

Paganelli F.: P1415 

Pais J.R.: P328, P999 

Paiva L.: P1029, P1263 

Paiva M.: P265, P475, P588, 

P848, P1289, P1402 

Pajares J.F.: P421 

Pal V.S.: P604 

Paland M.: P1115 

Palau P.: P225 

Palau Sampio P.: P1388 

Palermo P.: P376 

Palicka V.: P878 

Palloshi A.: P1278 

Palomino S.: P489 

Palus S.: P544, P1090 

Panagiotakos D.: P957, P1245 

Panagiotakos D.B.: P413, P1162, 

P1163, P1396 

Panasenko T.A.: P892, P1382 

Panchenko E. P.: P1098 

Panek A.N.: P494 

Panferov A.S.: P300 

Pankuweit S.: P205, P391, P395, 

P408, P875, P1070 

Panou F.: P318 

Panovsky R.: P1108 

Pantsios C.: P1187, P1364 

Papadimitriou C.A.: P855 

Papadimitriou G.: P877, P1057, 

P1189 

Papadopoulos C.: P193, P939, 

P1253 

Papadopoulou E.: P325 

Papageorgiou N.: P280, P362, 

P363 

Papagiannis N.: P881 

Papaioannou T.: P430 

Papamentzelopoulos S.: P325 

Papathanasiou A.: P571 

Papavasileiou M.: P877 

Papitsas M.: P312, P1441 

205 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Papp Z.: P516, 634, P953, P1238, 

P1307, P1342 

Parada-Pereira F.: P588 

Parashchenjuk L.: P1018, P1419 

Paraskevaidis I.: P193, P318, 

P367, P1253, P1383 

Parati G.: P1374 

Paredes L.U.I.S.: P577 

Paredes-Galan E.: P1053, P1273, 

P1414 

Parenica J.: P224, P410, P434, 

P578, P1246 

Parisi F.: P845, P846 

Parisis C.: P911, P1008 

Parissis J.: P1253 

Parissis J. T.: P318,418, P553,799, 

P965, P1230 

Park C.S.: P902, P1109 

Park D.G.: P431, P1069 

Park S. E.: P1338 

Park T. H.: P1338 

Parkhomenko A.: P993, P1002 

Parmon S.: P1381 

Parodi B.: P1091 

Parodi O.: P1050 

Parolini M.: P1050 

Parolini M.P.: P437 

Paroutoglou I.: P363 

Parskevaidis I.: P939 

Pascual T.: P576, P580, P777 

Pascual-Figal D.A.: 670, P1251 

Pashuk O.: P317, P834, P882, 

P1283 

Paskalev D.: P1063 

Paslawska U.: P1340, P1341 

Pasotti E.P.: P330 

Passino C.: 76, P228, P230, P255, 

P533, P583, P587, P942, P1170, 

P1368 

Pastormerlo L.E.: P583, P587, 

P942, P1368 

Pastor-Perez F.J.: P1251 

Pasztor E.T.: P1342 

Pater F.: P221 

Pathak A.: 750 

Patsouris E.: P571 

Paulis L.: P291 

Paulo C.: P859 

Paulus W.J.: 634, P1238 

Paunovic N.: P357 

Pauriah M.: P781 

Pavlidis A.: P1312 

Pavlovic K.: P297, P352 

206 

Pavlovic M.: P816, P1016, P1030, 

P1429 

Pavlyk S.S.: P828 

Pawlak A.: P189, P192, P1335 

Pawlicki L.: P508, P511 

Paya R.: P288, P290, P399, P1323 

Paz H.: P818, P1266 

Pazo Nunez M.: P1300 

Peano M.: P1401 

Pechanova O.: P291 

Peclin P.: P879 

Pedersen O. D.: 716 

Pederzoli L.: P861, P1012 

Pedrazzini T.: P1077 

Pedrigi M.C.: P1148 

Pedro M.: P204 

Pedroso E.R.P.: P299 

Peesoa-De-Melo L.M.: P219 

Pege C.: P1412 

Pego-Fernandes P.M.: P1052 

Peixoto S. V.: P197 

Pellens M.: 636 

Pellicer M.: P1026 

Pellissier A.: P1171 

Peltonen T.: P340, P1157 

Peltonen T. O. A.: P463 

Pena F.: P569 

Pena Gil C.: P1244 

Pena J.: P836 

Pena J.L.B.: P487 

Pencic B.: P350 

Peng J.: P1134 

Peperstraete B.: P1113 

Pepper J.: P849 

Perdikouris K.Y.R.: P935, P1017 

Perego G.B.: P1374 

Pereira A.: P198 

Pereira Barretto A. C.: P422, 

P1125 

Pereira E.: P1231 

Pereira F.P.: P1402 

Pereira G.A.C.M.: P1178 

Pereira J.: P863 

Pereira J.C.: P203 

Pereira J.M.V.: P1174, P1409, 

P1410 

Pereira M.: P265, P475, P848, 

P1289 

Pereira Y.M.: P798 

Pereira-Barreto A.C.: P1007 

Peres M.P.: P793 

Perez Bosca J.L.: P499 

Perez De Isla L.: P1102 


Perez Fernandez A.: P817 

Perez Villa F.: P1295 

Perez-Bosca J.: P399 

Perez-Villa F.: P803 

Perisic Z.: P454, P1426, P1429 

Perjes A.: P554 

Perrot A.: P494, P875, P1079 

Perrotta L.: P228 

Perseghin G.: P1041 

Persidskich J.: P448 

Perucci C.: P1165 

Perunicic J.: P994, P1268 

Pescariu S.: P354, P528, P1336 

Peschl S.: P394 

Pesic M.: P351 

Pesl M.: P1108 

Pessoa-De-Melo L.M.: P432, 

P1130 

Pestana T.: P530 

Peter J.: P927 

Peter M.: 712 

Peter S.: P1260 

Peter S.H.: P441 

Peters N.S.: P246, P249, P456 

Peters R.: P1159 

Petersen L.C.: P467 

Petersen M.: 752 

Peterson J.: P1337 

Petrak J.: P366 

Petrescu L.: P354, P528, P1039, 

P1309 

Petrie C.J.: P546 

Petrie J.: 72 

Petrov N.: P1184 

Petrovic I.: P353, P1010, P1014 

Petrovic M.: P315, P353, P567, 

P796, P1010, P1010, P1014, 

P1350 

Petrovic M.Z.: P1014 

Petrovic O.: P353, P796 

Petru J.: P453 

Pezawas T.: P460 

Pezzali N.: P398, P444, P840 

Pezzotti E.: P398, P840 

Pfeiffer A.: P1375 

Pfisterer M.E.: 712 

Pfrang J.: P924 

Pgava Z.: P1168 

Phelan D.: P500, P514, 770, 

P1346 

Philip J.-L.: P364 

Piacenti M.: P314 

Piccini A.: P1412


Piccolo S.: P1299, P1401 

Piepoli M. F.: P954 

Piepoli M.F.: P550 

Pieske B.: P331, 669, P886 

Pietri P.: P827 

Pietz D.: P875 

Pikkarainen S.: P1123 

Pilant D.: P1065 

Pinamonti B.: P491, P492, P1075, 

P1311, P1413 

Pinchas A.: P972 

Pineiro Diaz C.: P1027 

Pingitore A.: P533 

Pinho P.: P265, P475, P848, 

P1289 

Pinho T.: P531, P863, P1317 

Pinna G.D.: P396, P397, P966 

Pinter S.: P1110 

Pintya A.O.: P908 

Piotrowska M.: P843 

Piotrowski W.: P337 

Piovanelli B.: P1240, P1242, 

P1250 

Pipa J.: P486, P535, P864, P1104, 

P1378 

Pipa J.L.: P202, P209, P1261 

Piper C.: P572 

Pirani L.: P963, P1073, P1349 

Pires I.: 634 

Pirgakis V.: P965 

Piriou N.: P518, P1297 

Pirk I.: P1432 

Pirola A.: P399 

Pisica-Donose G.: P1180 

Pitsavos C.: P208, P413, P429, 

P957, P1162, P1163, P1245, 

P1396 

Pittaras A.: P1022 

Pittoni V.: P1369 

Piuhola J.: P554 

Piwowarska W.: P521 

Pla T.: P1121 

Plata C.: P803, P1286 

Plata Mosquera C.: P1295 

Platts D.: P263 

Ploch M.: P603 

Podbregar M.: P879 

Podesser B.: P516 

Podolecki T.: P1051 

Podrouzkova H.: P1108 

Poelz W.: P237 

Poelzl G.: P235, P439, P1315 

Pogranova Z.: P1071 

Poh K.: P213 

Pohjanjousi P.: P780 

Pohjolainen V.: P1157, P1235 

Pohludkova L.: P410, P1436 

Pokreisz P.: 636 

Pokrovskiy Y. A.: P334 

Pokushalov E.: P404, 715, 755 

Polak L.: P1001, P1153 

Polat V.: P191 

Poles J.P.: P582 

Poletti R.: 76, P230, P255, P587 

Polgar B.: P1272 

Polizzi V.: P1049 

Poller W.: P283 

Poloczkova H.: P883 

Polonetsky L.: P348, P349 

Polonski L.: P470, P603, P778, 

P1051, P1172 

Polos M.: P849 

Polyanskaya E.A.: P229 

Polymeropoulos E.: P1076 

Pomar J.L.: P803 

Pongas D.: P894 

Ponikowska B.: P996 

Ponikowski P.: P207, P303, 754, 

P778, P792, P964, P996, P1172, 

P1340, P1341 

Pontes M.R.N.: P527 

Poole-Wilson P.P.W.: P299, P594 

Popa A.: P221, P406, P956, 

P1258 

Popescu M.: P524, P1081 

Popin S.: P852 

Popov T.: P352 

Popova T.A.: P967 

Popovic D.: P315, P1350 

Porath E.: P1045, P1434 

Porsti I.: P1235 

Porterfield J.E.: P355 

Portig I.: P568 

Portillo Requena C.: P1264 

Portoles M.: P288, P289, P290, 

P499, P1121 

Posch M.: P875 

Posch M. G.: P494 

Posch M.G.: P1079 

Pospisilova J.: P366 

Possemiers N.: P545, P1334 

Post H.: P886 

Postmus D.: P825 

Postmus P.E.: P1328 

Postrach E.: P336 

Potena A.: P540, P916 

a U t H orS 

Poulimenos L.E.: P1022 

Poulsen H.E.P.: 752 

Pounis G.: P429 

Pozdisek Z.: P426 

Pozios I.: P918, P977, P1326, 

P1435 

Pozsonyi Z.: P445, P809, P810 

Pozzuto T.: P1239 

Prehar S.: 765, P1078, P1320 

Prescimone T.: P547, P893, P945, 

P950, P1154 

Prescott E.: P959 

Pretorius S.: P295 

Pribe R.: P955, P955 

Prinz C.: P543, P1365 

Prior D.L.: P941 

Priori S.G.: 669 

Privalova E.V.: P285, P1100, 

P1277 

Proclemer A.: P458 

Prohaszka Z.: P445, P809, P810 

Prohorova D.: 715, 755 

Pronicki M.: P1335 

Prontera C.: P314, P583, P587 

Prontera T.: P230 

Protsenko E.: P448 

Provenier F.: P1285 

Providencia L.A.: P217, P223, 

P370, P427, P433, P459, P536, 

P539, P805,807, P815, P829, 

P839, P983, P1033 

Providencia R.: P328, P416, P794, 

P931, P999, P1025, P1029, 

P1263 

Providencia R. A.: P1107, P1276 

Prtenjak G.: P297 

Przybylski R.: P1051 

Psarogiannakopoulos P.: P318 

Puceat M.: P1371 

Pudil R.: P878, P909 

Puetz V.: P377, P1287 

Pugliese V.: P1313 

Pujol De La Llave E.: P785 

Pujol R.: P987 

Pullen C.: P990 

Puntmann V.: P196 

Puntmann V.O.: P980 

Putnikovic B.: P273 

Puzzovivo A.: P912 

Pyrochkin V.M.: P1031, P1262 

Pyxaras S.: P1075 

Qian C.: P1084 

Quatre J.M.: P1390 

207 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Queluci G.C.: P590, P1174, 

P1409, P1410 

Quesada A.: P399 

Quintal N.: P1107 

Quintao M.: P361, P569 

Quintao M.M.P.: P584, P1178, 

P1408 

Quintao M.P.: P203 

Ra H.: P1137 

Rabaioli F.: P1091 

Rabinovich P.: P210, P403, P1257 

Rachok L.: P1112 

Radchenko O.V.: P281 

Radisic B.: P352 

Radlach H.-H.: 166 

Radoi M.: P1036 

Radu R.: P524, P1081 

Radu R.-I.: P447 

Radzevich A.: P241 

Raffa S.: P1284, P1369 

Raftopoulos L.: P1038, P1163, 

P1271 

Rahue W.: P1305 

Raih O.I.: P1416 

Rajic D.: P1151, P1268 

Ramires J.A.F.: P219, P422, P432, 

P1125, P1130 

Ramos A.: P576, P593, P1395 

Ramos B.: P598, P1190 

Ramos I.: P531, P1317 

Ramos R.: P821 

Ramteke G. B.: P604, P1423 

Ramunddal T.: P501 

Ramunndal T.: P871 

Ramzan R.: P1389 

Ranocchi F.: P1049 

Rao C.M.: P228 

Raposeiras Proupin S.: P819 

Raposeiras Roubin S.: P329, P509 

Rasoulian B.: P943 

Rastogi P.: P604 

Rastogi S.: P1061 

Ratajska A.: 639 

Rath C.: P1387 

Rau T.: P833 

Rauch U.: P1310, P1370 

Rauchhaus M.: P534, P1115 

Raunsoe J.: 716 

Rautaharju P.: P960 

Raweh A.: P1291 

Rayan M. M.: P1074 

Raymond R.: P1161 

Rdzanek H.: P1335 

208 

Rebelo M.: P1325, P1407 

Recchia F.: P893 

Recio Platero A.: P244 

Recuerda Casado C.: P973 

Reddan D.: P982 

Reddy R.R.: P1099 

Regitz-Zagrosek V.: P251, P391, 

P930 

Rehn T.A.: P1367 

Reichenbach A.: P1085, P1327 

Reid J.: P822 

Reinke Y.: P952 

Reis A.M.: P299, P594 

Reis M.M.: P489 

Reitan O.: P1293 

Rekik S.: P1390 

Remme C.A.: P874 

Remppis A.: P1032, P1358 

Renaud J.F.: P1371 

Rengo F.: P396 

Repasos E.: P1187 

Resl M.: P1387 

Revel Chion R.: P1349 

Revilla Orodea A.: P244, P884, 

P887 

Reznik E.: P1421 

Rhee K.: P446, P1345 

Rhee S.J.: P526 

Rhiel A.: P1389 

Ribas F.: P841 

Ribeiro A. L.: P197 

Ribeiro A.L.P.: P299, P594, P1355 

Ribeiro G.S.: P361, P569, P584 

Ribeiro Jr R.F.: P895 

Ribeiro M.L.: P1087 

Ribeiro S.: P502 

Ricci C.: P1291 

Ricci R.R.: P437 

Richard S.: P310 

Richter A.: P395, P875 

Rickenbacher P.: 712 

Ridocci Soriano F.: P399 

Rienstra M.: P194 

Rienzo M.: P894 

Rifaie O. A.: P1114 

Rigby A.S.: P440, P510 

Rigolli M.: P944 

Rigopoulos A.: P571 

Rigueiro Veloso P.: P1244 

Rincon S.: P598, P1190 

Ring M. R.: P835 

Ringe J.: P1134 

Riono P P.A.N.D.U.: P786 


Risnenko A. B.: P334 

Ristic A.: P205, P408 

Rivadossi F.: P1160 

Rivas C.: 766 

Riveiro A.L.P.: P327 

Rivera Otero M.: P288, P289, 

P290, P497, P499, P876, P1121, 

P1323 

Rizos I.: P571 

Rizzello V.: P1165 

Rizzo M.: P451, P1366 

Robbi E.: P397 

Robles R.: P225 

Roca J.: P216, P388 

Rocca P.: P891 

Rocha A.: P588, P1402 

Rocha B. F.: P242 

Rocha M.O.C.: P299, P594 

Rocha T.R.F.: P1130 

Rockel T.: P1127 

Rodino Janeiro B.: P329 

Rodino Janeiro B.R.U.N.O.: P509 

Rodrigo J.L.: P1102 

Rodrigues B.: P202, P209, P277, 

P484, P486, P535, P864, P1104, 

P1146, P1261, P1378 

Rodrigues D.: P983 

Rodrigues S.L.: P243 

Rodriguez C.: P857, P895 

Rodriguez J.: P388 

Rodriguez M.: P216 

Rodriguez Pascual C.: P1053, 

P1273, P1414 

Rodriguez Pedrosa I.: P851 

Rodriguez W.: P212, P477 

Rodriguez-Bailon I.: P428 

Rogers J.: P417, P998, P1241 

Rogiani S.: P480 

Roig E.: P803 

Roig Minguell E.: P1295 

Rokyta R.: P1054 

Rolfes- Peters M.: P592 

Rolland-Turner M.: P343, P913 

Roman Rego A.: P819 

Romanenko O.: P556 

Romanenko S. V.: P1331 

Romano M.: P396 

Romanov A.: P404, 715, 755 

Romanov Y.A.: P926 

Romanovskiy D.: P317, P834, 

P1283 

Romeo A.: P1242, P1250, P1270 

Romero Roman C.: P384


Romuk E.: P868, P1373 

Ronco C.: P858 

Rondano E.: P1066 

Rondinini L.: P358, P455 

Rosa I.: P1148 

Rosa L.V.: P487 

Rosanio S.: P529 

Rosano G.: P986, P1405 

Rosario I.: P503, P602, P820, 

P897, P1139 

Rosello E.: P288, P289, P290, 

P497, P499, P876, P1121 

Rosen R.L.: P405 

Rosengren A.: P372 

Rosjo H.: P1339 

Roso D.C.: P932 

Rossell G.: P995 

Rossi A.: P550, P944, P1111 

Rossignol P.: P549, P1147 

Rossoni L.V.: P243 

Rost M.: P566 

Rosu M.: P1039 

Rothman M.: P1293 

Roucka P.: P1054 

Rousseau M.F.: P1332 

Roussel J.C.: P262 

Roussel M.: 750 

Rouvellat C.: 750 

Roux J.F.: P515 

Rovithis D.: P911, P1008 

Roy-Giocosa J.: P1297 

Rozanski J.: P337 

Rozec B.: P518 

Rozenman Y.: P1337 

Rozentryt P.: P470, P778, P1172 

Rozman J.: P879 

Rubio J.: P884, P885, P1329 

Rucker-Martin C.: P1371 

Rud B.: P1367 

Rudys A.: P386 

Rueder C.: P927 

Ruifrok W.T.: P880, P1084 

Ruiter G.: P1328 

Ruiz F.: P1177 

Ruiz F.J.: P1177 

Ruiz Frutos C.: P785 

Ruiz M. A.: P1430 

Ruiz Olgado M.J.: P570, P1391 

Ruiz S.: P451, P1366 

Rumiz E.: P225 

Ruotolo G.: P1278 

Ruppert V.: P875 

Rus H.: P1036 

Rus Mansilla C.: P973 

Ruschel P.: P841 

Ruskoaho H.: P292, P340, P463, 

P554, P1123, P1157, P1235 

Russo C.: P1050 

Russo G.: P1413 

Russo M.: P1075 

Rutten F. H.: P1043 

Rutten F.H.: P256, P271, P513, 

P581, P976 

Rybakova M.G.: P869 

Ryder M.: P595 

Rydlewska A.: P207, P996 

Rysa J.: P340, P1157, P1235 

Ryu K.H.: P231, P338, P551, 

P1136 

Rywik T.: P337, P1181, P1425 

Ryzhkova D.V.: P1354 

Rzezak J.: P189, P192 

Saadi I.: P560 

Saatashvili G.: P1168 

Saavedra J.: P373 

Saba S.: P960 

Sabatier R.: P1171 

Sabax H.: P403 

Sabbah H.N.: P1061, P1256, 

P1290 

Sabbah M.S.: P1061, P1256, 

P1290 

Sabet S.: P1161 

Sablaturova M.: P426 

Sabry D.: P276 

Sacherer M.: P331 

Sacra C.: P457, P1282 

Sadowski J.: P521 

Sagic D.: P1186 

Saijo S.: P1255 

Saiko F.: P800 

Sainsous J.: P1390 

Sakadakis E.: P571 

Sakata K.: 714 

Sakoda T.: P538, P548, P962 

Salah O.: P560 

Salazar A.: P987 

Salcedo E.: P496 

Saldanha C.F.: P467 

Saleh A.: P937 

Salemi V.M.C.: P309,487 

Salinas-Riester G.: P1360 

Salinger Martinovic S.: P816, 

P1016, P1030 

Salinger S.: P454, P1426 

Salman N.: P818, P1266 

a U t H orS 

Salpeas V.: P571 

Salvador A.: P289, P290, P497, 

P1121 

Salvatori E.: P1369 

Salvia J.: P267, P476 

Salvioni E.: P376 

Samardzic J.: P468 

Samartzis L.: P977 

Sambin L.: P894 

Samimi Fard S.: P512 

Samir R.: P1351 

Samko A.: P926 

Sampaio F.: P563, P1231 

Samsuddin S.: 751 

Samuil I.: P800 

San Roman Calvar J.A.: P887 

San Roman J.A.: P244, P884, 

P885, P1329 

Sanchez A.: P212, P477 

Sanchez J.E.: P857 

Sanchez Ramos J. G.: P789, P997 

Sanchez-Mas J.: 670 

Sanchez-Salado J.C.: P216 

Sanchis Fores J.: P1388 

Sanchis J.: P225, P1026 

Sandach A.: P425 

Sandek A.: P339, P1375 

Sanderman R.: P385 

Sanderson J.E.: P321, P1117, 

P1393 

Sandesh D.: P1241 

Sandri M.: 753, P1406 

Sanfins V.: P198 

Santana R.F.: P1174, P1409 

Santer D.: P516 

Santillan C.: P212, P477 

Santini M.: P268, P458, P858, 

P1305 

Santos A. B.: P1430 

Santos B.F.: P1000 

Santos I.: P570 

Santos J.F.: P282, P1105 

Santos L.: P277, P484, P486, 

P864, P1106 

Santos L.F.: P202, P209, P535, 

P1104, P1261, P1378 

Santos M.: P859 

Santos N.: P374, P379, P948, 

P1166 

Santos O.: P202, P209, P277, 

P484, P486, P535, P864, P1104, 

P1261, P1378 

Santos P.: P1068 

209 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Santos R.O.M.: P1410 

Sapelnikov O.V.: P238 

Sarac M.: P1019 

Saraiva F.: P217, P370, P433, 

P459, P536, P539, P807, P829, 

P839, P1033 

Saraiva M.F.: P223, P427, P805, 

P815 

Sarano M. E.: P296 

Sarbash M.I.: P906 

Sarc I.: P542 

Sardesai U.: P604 

Sargento L.: P801, P838, P1035 

Saroglou G.: P259, P1072 

Sasaki N.: P832 

Sasov M.: P245 

Sato K.: 714 

Sato N.: P1164, P1249 

Sato Y.: P806, P1255 

Satoh T.: P304 

Satta J.: P340, P1157 

Saulle D.: P912 

Saura D.: 670 

Sauter M.: P287, P495 

Savelov N. A.: P334 

Savic L.: P994, P1268 

Savino G.: P1386 

Savino M.: P519, P790, P900, 

P1386 

Savisko A.: P1381 

Savvatis K.: P1236 

Sawa T.: P806, P1255 

Sazonova Y.U.: P356 

Sbaraglia F.: P1049 

Scalvini S.: P1160 

Scanu P.: P1171 

Scardovi A.B.S.: P437 

Scardulla C.: P293 

Schaefer A.: P924 

Schaefer E.: P844 

Schaidauer A.C.G.: P932 

Schalij I.: P1328 

Schalla S.: P1183 

Schaper J.: P485 

Scharin-Tang M.: P501 

Schaufelberger M.: P372 

Schedrina A.: P275 

Scheffold T.: P251 

Scheibenbogen C.: P283 

Schelcher C.: P1078 

Schellberg D.: P955, P1032 

Scherbakov N.: P574 

Scherer M.: P452 

210 

Scherr M.: 635 

Scheufen S.: P1133 

Schindler R.: 712 

Schlipp A.: P286, P490, P1321 

Schlossarek S.: 638 

Schlueter K.-D.: P1133, P1325, 

P1394, P1407 

Schmack B.: P473 

Schmahl D.: P1032 

Schmidinger H.: P460 

Schmidt A.: P215, 669 

Schmidt G.: P494 

Schmidt-Lucke C.: P1134, P1239 

Schmitt A.: P1024 

Schnackenburg B.: P196, P980 

Schneider C.: P359, P1006 

Schoenauer R.: P1077 

Schou M.: P435 

Schreckenberg R.: P1325, P1407 

Schroeder-Tanka J.M.: P368 

Schroen B.: P307, P946 

Schubert B. D.: P1337 

Schukro C.: P460 

Schuler G.: 753, P1406 

Schultheiss H.P.: P283, P311, 

P586, P927, P1232, P1239, 

P1310, P1370 

Schultheiss H.-P.: P341, P1122, 

P1134 

Schultz T.: P871 

Schulz U.: P1362 

Schulze K.: P586 

Schwartz C.: P343 

Schwartz L.: P984 

Schwartzmann P.V.: P908 

Schwarz J.: P927 

Schwarz M.: P537 

Schwarzbach V.: P1321 

Schwenger V.: P1358 

Sciarretta S.S.: P437 

Scipione A.R.: P1007 

Scipioni A.R.: P422, P1125 

Scott C.G.: P557 

Scotta D.: P1091 

Scotti C.: P1160 

Seca L.: P328, P416, P931, P999, 

P1025, P1029, P1107, P1276 

Seca L.F.: P794 

Sedej S.: P331, 669 

Sedinova M.: P366 

Sediva L.: P453 

Sedov V.: P1184 

Seferou M.: P877, P1057, P1189 


Segawa T.: 714 

Seidova N. M.: P1380 

Seifert I.: P377, P1287 

Sejersted O.M.: P310, P517, 

P1089, P1173, P1237, P1367 

Sekar B.: P1304 

Sekularac N.: P357 

Sela N.: P972 

Semenenko O.: P1419 

Semernin E.N.: P278, P869 

Sen N.: P830 

Sen S.: 75 

Senden J.M.: P1188 

Senges J.: P1024 

Senni M.: P891 

Seo S.Y.: P1136 

Seoane Blanco A.: P329, P509, 

P819 

Seow S.C.: P1179 

Seow Y.H.: P1179 

Sepsi M.: P224, P578 

Serban I.: P936 

Serban M.: P936 

Seredenina E.M.: P854 

Seronde M.F.: P1399 

Serov V.: P1356 

Serraf A.: P1371 

Serrat R.: P1366 

Severino S.: P1170 

Sevruc T.: P348, P349 

Sfirakis P.: P259 

Sgourakis P.: P881 

Shafieian G.: P788 

Shafik M.: P276 

Shah K.: P782 

Shahar E.: P960 

Shaheen M.A.: P1078 

Shaidullina A.: P1092 

Shao L.: P1372 

Shao S.: P1088 

Shapiro S.: P322 

Shaporova N.L.: P915 

Sharaevskiy O.A.: P906 

Sharashidze N.: P1168 

Shavgulidze K. B.: P1363 

Shaw L.K.: P417, P779 

Shchekochikhin D.: P1185 

Sheiban I.: P861, P1012 

Sheremeta O.M.: P921 

Sherman S.A.: P405 

Sherwi N.: P510, P812, P903 

Sherwi N.S.: P234 

Shibeko N.: P847


Shigemasa C.: P791, P795 

Shimada K.: P589, P1158, P1319, 

P1417 

Shin E.K.: P947, P1288 

Shin M.S.: P562, P947, P1288 

Shioji K.: P284 

Shirokova N.: P404, 755 

Shkolnik E.: P1303 

Shlyachto E.V.: P393 

Shlyakhto E.: P347, P424, P1080, 

P1330 

Shlyakhto E.V.: P278, P869, P910, 

P915,920 

Shochat M.: P210, P403, P1257 

Shofti S.R.: P405 

Shotan A.: P210, P403, P425, 

P1257 

Shukrullah I.: P1099 

Shulenin S.: P247, P1144 

Shutov A.: P1356 

Siasos G.: P855, P1132 

Sibellas F.: P1247 

Sideris S.: P827, P1038, P1275 

Sidorenko I.: P834, P1283 

Sierra B.: P1177 

Sievert H.: P1186, P1337 

Siew S.: P1359 

Siket Manyine I.: P1307 

Sikora J.: P1432 

Silang R.: P1009 

Sillje H.H.W.: P880, P1084 

Silva A.: P503, P602, P808, P820, 

P897, P1068, P1139 

Silva A.I.: P588, P1402 

Silva A.L.A.: P594 

Silva A.L.S.: P798 

Silva C. P.: P1294 

Silva D.: P838 

Silva D.M.: P1366 

Silva G.: P563, P1231 

Silva G.F.S.: P793 

Silva G.R.: P1431 

Silva H.: P859 

Silva I.C.M.: P309 

Silva J.: P416, P794, P931, P1025, 

P1107, P1276 

Silva M.: P983 

Silva M.H.C.R.: P327, P1355 

Silva Marques J.: P204, P502, 

P1082, P1138 

Silva R.: P440 

Silva S.: P374, P379, P821, P859, 

P948, P1143, P1166 

Silva-Cantillo D.: P451 

Silva-Cardoso J.: P1314, P1317 

Silva-Cardoso J.C.: P863 

Silverio R.: P1146 

Silvestre I.: P530 

Silvestre O. M.: P1313 

Simic A.: P1083 

Simic D.S.: P505, P555, P1377 

Simioniuc A.: P1154 

Simko F.: P291 

Simoes L.: P563 

Simoes M.V.: P532, P870, P908 

Simoes Marques Assuncao 

Caetano A. F.: P1357 

Simon G.: P549 

Simpson R.: P960 

Sinagra G.: P491, P492, P496, 

P1075, P1311, P1413 

Sinescu C.: P221, P406, P507, 

P956, P1258 

Sinescu C.J.: P541, P1269 

Singh R.: P200 

Sinikova M.Y.: P915 

Sinkiewicz W.: P917, P933 

Sinning D.: P586, P1232 

Sionis A.: P803 

Sipos D.: P1307 

Sirakova V.: P1063 

Sirera R.: P1121 

Sirotkova A.: P1046 

Sirvente R.: P309, P487 

Siswanto B.-B.: P786 

Sitges M.: P1286 

Sitnikova M.: P347, P356, P424 

Sitnikova Maria M.Y.U.: P1420 

Sittinger M.: P1134 

Siwolowski P.: P792 

Sjaastad I.: P310, 637, P1089, 

P1155, P1173, P1237, P1339, 

P1367 

Skaardal R.: P232 

Skalik R.: P573, P951, P1182 

Skobel E.: P1404 

Skoric B.: P468 

Skoularigis J.: P911, P1008 

Skrzep-Poloczek B.: P868, P1373 

Skrzypczak P.: P1341 

Skrzypek A.: P1379 

Skurk C.: P283, P1310 

Skvortsov A.: P275 

Slavic S.: P1384 

Slavov D.: P496 

Slettalokken G.: P1367 

a U t H orS 

Sliwa K.: P1003 

Sliwa-Hahnle K.: P295 

Sljivic A.: P350 

Sloan R.: P824 

Sloboda N.: P549 

Slysz A.: P1335 

Smid M.: P1054 

Smith H.J.: P232 

Smith J.: P411 

Smith W.: P1009 

Smolenski A.: 770 

Smyrnioudis N.: P881 

Snezhitsky V.A.: P1031, P1262 

Snitskaya N.A.: P294, P504 

Snytnikova A. V.: P375 

Soares A.: P1430 

Soares L.: P282, P530, P1105 

Soares R.: P1143, P1403 

Soares R.M.: P374, P379, P821, 

P948, P1166 

Soares-Silva C.S.: P1130 

Sobieszczanska-Malek M.: P843 

Sochanowicz B.: P337 

Sofia A.S.: P848 

Sohn H.Y.: P389 

Sokjer-Pedersen M.: P1367 

Sokolov A.N.: P926 

Sokolski M.: P207 

Solberg O.G.: P442, P923 

Soldati E.: P455 

Solik P.: P407, P1248 

Solis Villa J.: P384 

Solomakhina N.: P1185 

Soluri E.: P1369 

Sommerfeld M.: P1384 

Sonaglioni A.: P519, P900 

Song H.U.: P526 

Sonne K.: P1284 

Sonntag S.: P389 

Sonoda H.: P1344 

Soos P.: P473 

Soria F.: P290, P876, P1323 

Sotiropoulos I.: P222, P1038 

Soukhov V.: P220, P1353 

Sousa A.: P588, P859, P1314, 

P1317, P1402 

Sousa J.: P838 

Sousa O.: P563, P1231 

Souza G.E.: P585 

Souza L.E.: P309 

Soya O.V.: P1298 

Spadaro O.: P861, P1012 

Spargias K.: P325 

211 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Specchia G.: P1352 

Speck D.: P1169 

Spieker T.: P1296 

Spinar J.: P224, P410, P426, 

P434, P578, P1015, P1246 

Spinarova L.: P883, P1046, P1108 

Spinczyk B.: P603 

Spini S.: P478 

Spinnler M.T.: P1091 

Spoladore R.: P1041, P1278 

Sposato B.: P986, P1405 

Springer J.: P339, P544, 635, 

P1090 

Squire I.: P190 

Squire I.B.: P236, P546 

Sramko M.: P488, P1432 

Srdic M.: P1151 

Srdic S.: P1433 

Srebot V.: P358 

Staessen J.: P1183 

Staessen J.A.: P307 

Stakos D.: P387 

Stambolsky D.V.: P285 

Stangl K.: P1236 

Stankovic G.: P1151 

Stankovic I.: P273 

Stanley P.: P1320 

Stanojevic D.: P816, P1016, 

P1030 

Stanojlovic T.: P454 

Starling R.C.: P911, P1008 

Stasinos V.: P1253 

Stastna S.: P1432 

Stauch D.: P495 

Staudt A.: 768, P952 

Steedman T.: P546 

Stefanadis C.: P208, P222, P226, 

P239, P280, P362, P363, P413, 

P429, P430, P827, P855, P957, 

P1021, P1038, P1132, P1162, 

P1163, P1245, P1265, P1271, 

P1275, P1396 

Stefani C.M.: P932 

Stefanon I.: P895 

Stefanovic S.: P1142 

Stefanovic V.: P1142 

Stein R.: P972, P1176 

Steinberg C.H.: P515 

Steinbrecher J.H.: P1360 

Steiner S.: P466 

Stempen T.P.: P1031, P1262 

Stenslokken K.O.: P1339 

Stepanyan A.A.: P272 

212 

Stepinska J.: P802 

Steponeniene R.: P386 

Steurer M.: P1315 

Stevanovic A.: P357, P1083, 

P1324 

Stewart S.: P295, P369, P991, 

P1003 

Stich G.C.: P467 

Stienen G.J.M.: 634, P1238 

Stix G.: P460 

Stoehr A.: 638 

Stoerk S.: P391, P441, P479, 

P490, P566, P981, P1119, P1260 

Stoian I.: P1103 

Stoica E.: P1103 

Stojanovic V.: P351 

Stojcevic-Maletin J.: P297 

Stojsic Milosavljvic A.: P852, P852 

Stokfisz K.: P1097 

Stokke M. K.: P1237 

Stolf N.A.G.: P258, P261 

Stompor M.: P597 

Stork S.: P1127, P1233 

Storozhakov G.: P1421 

Stos B.: P1371 

Stosic Z.: P297 

Straburzynska-Migaj E.: P867 

Strachan P.H.: P984 

Strajean B.: P301 

Stravopodis P.: P1439 

Stridsberg M.: P1339 

Strnad H.: P366 

Stromberg A.: 168, P1411 

Struck J.: P811 

Strunz C.M.: P1130 

Struthers A.D.: 72, P781 

Stukalova O.V.: P926 

Stypmann J.: P844, P1048, P1296 

Su J.B.: P894 

Sugihara S.: P791, P795 

Sulaiman K.S.: P200 

Sulimov V.A.: P300, P1380 

Sumin A. N.: P264, P294, P504, 

P967, P1149, P1416 

Sundaresan P.R.: P1009 

Sundberg S.: P780 

Surovtseva M.: P462 

Suskovic S.: P542 

Suzic Lazic J.: P1324 

Suzuki K.: P323, P1361 

Suzuki S.: P925, P1034 

Suzuki Y.: P1047 

Sventzouri S.: P233 


Svet A. V.: P375, P481 

Svetlosak M.: P245 

Svistov A.: P1353 

Svitlyk H.V.: P828 

Svyatova N.: P1145 

Swedberg K.: P372, P465 

Swift F.: P517, P1089 

Swinnen M.: P946 

Sychev A.V.: P926 

Symon R.S.: 72 

Syrkin A. L.: P375, P481 

Szabo B.: P561, P813, P1023, 

P1272 

Szabo G.: P473 

Szabo T.: P336, P574, P1375 

Szabolcs Z.: P849 

Szachniewicz J.: P792 

Szadkowska I.: P508, P511 

Szalay G.: P287 

Szentmiklosi J.: P953 

Szerafin T.: P953 

Szokodi I.: P554 

Szperl M.: P337 

Szyda M.: P1097 

Szygula-Jurkiewicz B.: P603 

Szymkiewicz S.: P1044 

‘T Kindt H.: P1267 

Tabet J.Y.: P1415 

Taborsky M.: P453, P1015 

Taddei S.: P1170 

Tadic M.: P1377 

Tadic M.T.: P505, P555 

Taeger T.: P929, P955 

Taglieri C.: P1299, P1401 

Tahirovic E.: 74, 166, P449, P452, 

P833, P1280 

Takahama H.: P302 

Takahashi K.: P962 

Takano T.: P1164, P1249 

Takase H.: P1344 

Takatsu Y.: P806, P1255 

Takazawa K.: P485 

Takeishi Y.: P925, P1034 

Tan K.B.: P1117 

Tan M.: P213 

Tan P.T.: P1179 

Tan V.S.: P213 

Tan Y.T.: P321,1117, P1393 

Tanada Y.: P806, P1255 

Tanaka F.: 714 

Tanaka K.: P1116 

Tanaka T.: P485 

Tang W.H.W.: P1306


Tapia Ballesteros C.: P244, P884, 

P885, P887, P1329 

Tarasova O.V.: P920 

Tarazona N.: P1290 

Tardin O.: P361, P569 

Targonski R.: P1181 

Tartiere J.M.: P1399 

Tasic N.: P850 

Taskinen P.: P340, P463, P1157 

Tasoulis A.: P1187, P1326 

Tassisa D.: P1241 

Tassisa G.: P998 

Tassoulis A.: P918 

Tatjer Hernanz I.: P388 

Tatjer I.: P216 

Tavares J.: P1106 

Tavares Junior W.C.: P299 

Tavazzi L.: P268 

Tavlueva E.: P1259 

Tawfik M.: P1351 

Taylor M.: P496 

Teixeira Junior A.L.: P594 

Teixeira Junior A.L.A.: P299 

Teixeira M.: P563, P1231 

Teixeira M.M.: P299, P594 

Teixeira R.: P807, P829, P1033 

Tek M.: P464, P1060 

Tella A.M.: P421 

Teng L.L.: P1088, P1372 

Tentolouris C.: P855, P1132 

Teodorescu-Gabor I.: P1269 

Tepes Piser I.: P1103 

Tepljakova E.: P1381 

Terehov I.: P404, 755 

Tereschenko S.: P275 

Terrovitis J.: P233, P918, P977, 

P1292, P1364, P1435 

Tesic M.: P796 

Tettamanti M. E.: P244, P884, 

P885, P887, P1329 

Teupser D.: P1406 

Theobald K.: P274 

Theodoropoulos S.: P1292, P1435 

Theodoropoulos T. A. D.: P242 

Thiery J.: P1406 

Thomaidi A.: P387 

Thys F.: P1095 

Tibirica E.: P968 

Tichy M.: P878, P909 

Tillmanns J.: 672 

Timour Chah Q.: P896 

Tin L.: P1129 

Tirziu C.M.: P831 

Titaeva E. V.: P1098 

Tite V.: P1169 

Tkach N.: P342, P380 

Toader D.: P524, P1081 

Tobaruela Gonzalez A.: P785 

Toblli J.: 766 

Todorovic L.: P1426 

Todua F.: P461 

Toepper A.: 166, P449, P833, 

P1279, P1280 

Toft E.T.: P889 

Tokola H.: P292, P1123 

Tokunaga K.: P485 

Toli E.: P280, P362, P363 

Tolosana J.M.: P1286 

Tomandl J.: P1046 

Tomas Querol C.: P1295 

Tomasi L.: P1305 

Tomasik A.: P868, P1373 

Tomaszek A.: P1340, P1341 

Tomcikova D.: P224, P410, P434, 

P578, P1246 

Toncev A.: P357 

Toncev D.: P357 

Tonnesen T.: 637 

Tonnessen T.: P1155 

Torabi A.: P234, P510, P812, P903 

Toriyama T.: P1344 

Torp-Pedersen C.: P435, 716,752 

Torrado M.: 769 

Torrao A.: P203 

Torrens A.: P388 

Torrens Oses A.: P216 

Torrente M.: P1273, P1414 

Torres A.M.: P421, P423 

Torres F.: P203 

Torres M.A.: P467 

Torres M.A.R.: P564, P932 

Torrisi M.R.: P1369 

Torromeo C.: P1102 

Toste A.: P379, P821, P1143, 

P1403 

Toth A.: P849, P953, P1307, 

P1342 

Toumaniantz G.: P518 

Tousoulis D.: P280, P362, P363, 

P855, P1132 

Tovsrud N.: P1089 

Toyo-Oka T.: P485 

Trabelsi I.: P412, P787 

Trabulo M.: P1068 

Trafford A.W.: P1237 

Trajic S.: P1083 

a U t H orS 

Triantafyllidi H.: P193, P939 

Tricarico Rosano P.: P1440 

Trieb T.: P1315 

Trifunovic D.: P567, P796 

Trifunovic-Zamaklar D.: P353, 

P1010, P1014 

Trindade E.M.: P199 

Triposkiadis F.: P911, P1008 

Trivilou P.: P193, P939 

Trochu J.L.: P262 

Trochu J.N.: P518, P1297, P1399 

Trojnarska O.: P867 

Trukshina M.: P347 

Trukshina M.A.: P1354 

Trunfio S.: P1050 

Trussardi E.: P1160 

Tsaknakis T.: P911, P1008 

Tschirner A.: P544, P1090 

Tschoepe C.: P341, P586, P1122, 

P1134, P1232, P1236 

Tschope C.: P1239 

Tseliou E.: P233, P918, P977, 

P1292, P1326, P1435 

Tseluyko V.: P556 

Tseluyko V.I.: P281 

Tsiachris A.: P1396 

Tsiachris D.: P413, P1163 

Tsiahris D.: P430 

Tsiamis E.: P362, P1245 

Tsiapras D.: P1072 

Tsiatas M.: P855 

Tsioufis C.: P280 

Tsioufis K.: P226, P239 

Tsitlakidis K.: P367 

Tsitsinakis G.: P208, P413, P1162, 

P1163, P1245 

Tsoukas A.: P1312 

Tsouni P.: P881 

Tsoy I.A.: P872 

Tsujino T.: P548, P962 

Tsverava D.: P298, P306 

Tsverava M.: P298, P306 

Tsyganov A.: P247, P1144 

Tubaro M.: P858 

Tucker C.S.: P601 

Tumasyan L. R.: P254 

Turazza F.: P1013 

Turazza F. M.: P1055 

Turhan G.: P574 

Tursheva M.: P1421 

Tuzzolino F.: P293 

Tzanis G.: P1187, P1326 

Tziakas D.: P387 

213 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Tziovas A.R.: P935, P1017 

Tzortzis S.: P193, P939, P1383 

Ueda H.: P1116 

Ueda T.: P1158 

Ueland T.: P188, P232, P442, 

P600, P923, P1131 

Ugorski M.: P1340, P1341 

Ullrich J.: P286, P1321 

Ulmer H.: P235, P439 

Unalir A.: P464 

Unger S.: P215 

Unger T.: P1384 

Unsworth B.: 75 

Uraiya D.: P1423 

Ural D.: P218, P333, P975 

Ural E.: P218, P333, P975 

Urbaszek W.: P989 

Urrutia A.: P438, P576, P580, 

P593, P777, P1395 

Uscoiu G.: P301 

Ushakova L.: P348, P349 

Uslu I.: P1060 

Usoltseva E.: P1259 

Uzui H.: P304, P1158 

Vaccari A.: P1240, P1250 

Vaghee S.: 169 

Vaillant F.: P896 

Vaina S.: P239 

Vakalyuk I.I.: P252 

Vakalyuk I.P.: P252 

Vakhtangadze T.: P461 

Vakrou S.: P233 

Valdes M.: 670, P1251 

Valdespino-Trejo A.: P212,477 

Valente B.: P1143 

Valente B.T.: P379, P948 

Valente M.: P838 

Valenzuela J.: P576, P593, P1395 

Valero-Munoz M.: P895 

Valim L.R.: P432 

Valk M.: P513 

Valk M.J.M.: P976 

Vallauri P.: P1401 

Valle A.: P399 

Valle R.: P478, P858, P1299 

Valleggi A.: 76, P228, P533, P942 

Valleix F.: P1297 

Vallejo I.: P1295 

Vallisa D.: P550 

Valsecchi S.: P269 

Van Aelst N.L.C.: P946 

Van Baal P.H.M.: P985 

Van Berendoncks A. M.: P545 

214 

Van Camp G.: P1267, P1285 

Van Craenenbroeck E.: P1334 

Van De Werf F.: P946 

Van Der Laarse W.J.: P1328 

Van Der Palen J.: P907 

Van Der Velden J.: 634, P1238 


Van Dijk R. B.: P575 

Van Es J.: P907 

Van Gelder I.C.: P194 

Van Gilst W.H.: P880, P1084 

Van Heerebeek L.: 634 

Van Linthout S.: P1134, P1239 

Van Mourik Y.: P271, P581 

Van Paassen P.: P195, P1183 

Van Riet E.: P1043 

Van Riet E.E.S.: P256 

Van Rijen H.V.: P874 

Van Rossum A.C.: 73 

Van Suylen R.J.: 77 

Van Veldhuisen D.J.: 171, P194, 

P385, P575, P825, P880, P1084, 

P1128 

Van Velzen E.: P513 

Vandenwijngaert S.: 636 

Vanderheyden M.: P1011, P1337 

Vanderper A.: P360, P1152 

Vanhoutte D.: P946 

Vanoli E.: P1352 

Varbaro A.: P1305 

Varela Roman A.: P329, P819, 

P1027, P1244, P1300 

Varela Roman A.F.O.N.S.O.: P509 

Varga I.: P407, P1248 

Varin A.: 668 

Varounis C.: P965 

Vasatova M.: P878, P909 

Vasileiadis I.: P1057, P1189 

Vasiliadis I.: P877 

Vasiljevic Z.: P994, P1151, P1268 

Vassallo D.V.: P895 

Vassanelli C.: P944, P1111 

Vasyuk Y.: P1303 

Vatinian S.: P1140, P1322 

Vausort M.: P236 

Vavouranakis M.: P1265 

Vavuranakis E.: P280 

Vazquez Fernandez L.: P817 

Veelenturf A.H.M.: P368 

Veladar E.: P1099 

Velloso M.W.M.: P361, P584 

Velthuis S.: 77, P1188 

Venetsanou K.: P193, P553 


Ventura M.: P459 

Venturini L.: 635 

Verde A.: P471 

Veres G.: P849 

Vergara G.: P269 

Vergaro G.: 76, P228, P533, P942 

Verkerk A.O.: P874 

Verma N.: P378, P1137 

Vermes E.: P262 

Vermeulen R.C.W.: P907 

Verri M.: P1150 

Verschuren F.: P1095 

Verstreken S.: P1011 

Verzura G.: P240, P1242 

Vianello G.: P858 

Vicentini A.: P861, P1012 

Vida K.: P849 

Vidal B.: P1286 

Vidal Perez R. C.: P817, P1244, 

P1300 

Vidal Sampedro J.: P817 

Vidau P.: P857 

Vieira G.C.A.: P1410 

Vieira H.: P217 

Vieira J.L.: P219, P260, P432, 

P842, P856 

Vieira M.L.: P489 

Vieira M.L.C.: P1052 

Vieira P.V.: P591 

Vigliani F.: P1160 

Viglio S.: P1150 

Vignati C.: P376 

Vilas-Boas F.: P418, P799, P1230 

Vilches-Moraga A.: P1273, P1414 

Villa C.: P240 

Villani G.Q.: P550, P954 

Villani M.: P954 

Villegas E.B.: P421, P423 

Vind A.B.: P797 

Vinogradova N.: P348, P349 

Virgos Aller T.: P851 

Visconti G.: P458 

Visser F.C.: P907 

Vitarelli A.: P529 

Vitlianova K.: P443 

Vitovec J.: P883, P1015 

Vitulo P.: P293 

Vizcaya Ramos A.: P817 

Vizzardi E.: P444, P1270 

Vlachakos G.: P367 

Vlahakis L.: P918 

Vlaseros I.: P362 

Vlasinova J.: P1015


Vlaskova H.: P1432 

Vogelpohl I.: P311 

Vogt J.: P1287 

Vogt S.: P1389 

Voigt A.: P1236 

Vojacek J.: P878 

Volchan A.: P798 

Volinkina V.: P1421 

Volkova A. L.: P1302 

Volpe S.: P845, P846 

Volterrani M.: P986, P1405 

Von Birgelen C.: P907 

Von Haehling S.: P326, P339, 

P470, P534, P542, P574, P1090, 

P1115 

Von Harsdorf R.: P544 

Von Schacky C.: P566 

Von Wedel J.: P359 

Vondrakova D.: P453 

Vonk-Noordegraaf A.: P1328 

Voon V.: P500 

Voors A.A.: P194, P1128 

Vorobyeva N. M.: P1098 

Voronkov L.: P1018, P1419 

Vos M.A.: P331 

Voudris V.: P259, P1072 

Vranova J.: P1096 

Vrbska J.: P1432 

Vrints C.: P1334 

Vrints C. J.: P545 

Vujisic-Tesic B.: P315, P353, P567, 

P796, P1010, P1014, P1350 

Wachowiak-Baszynska H.: P867 

Wachter R.: P251, P886, P1280 

Wagner D.R.: P236, P343, P913 

Waltenberger J.: 77 

Walther S.: 669 

Wang L.J.: P779 

Wang M.: P1061, P1256, P1290 

Wang S.W.: P1428 

Wanichawan P.: P1089 

Wartski N.: P1337 

Watanabe M.: P302, P832 

Watson C.: P313, P500, P522 

Watson C.J.: P514, 770 

Weber P.: P1389 

Wedewardt J.: P1365 

Weir R. A. P.: P546 

Weithaeuser A.: P1370 

Welp H.: P844, P1048, P1296 

Wensing G.: P215, P1254 

Wenzel S.: P1133, P1325 

Wenzelburger F. W. G.: P1117, 

P1393 

Wenzelburger F.W.G.: P321 

Wergeland R.: P232 

West C.: P853 

Westenbrink B.D.: P880 

Westerheide N.: P543 

Westermann D.: P341, P1122, 

P1232 

Westermann W.: P586 

Westheim A.: P1398 

Weytjens C.: P1267, P1285 

Whinnett Z.I.: P246, P249, P456 

Wieckowski M.: 639 

Wielders J.P.M.: P513 

Wiggers H.W.: P1056 

Wika S.: P311 

Wikstrom G.: P253 

Wilcox-Adelman S. A.: 637 

Wilczek K.: P603, P1051 

Wilczynska J.: P922, P934 

Wilczynski G.: 639 

Wilde A.A.M.: P874 

Wilk S.: P283 

Willems A.M.: P1267, P1285 

Willenheimer R.: 754 

Williams A.: P1040 

Willson K.: 75 

Wisniacki N.: P1064 

Wisniewska J.: P1028 

Witkowska A.: P778, P1172 

Witte K.K.: P436, P824 

Wizner B.: P597, P1425 

Wojciechowska C.: P1373 

Wojciechowska C.A.: P868 

Wojnicz R.: P603 

Wojtkowska I.: P802 

Wolf J.-E.: P364 

Wolff R.: P818, P1266 

Wolffs P.: 77, P195 

Wolter J.S.: P1032 

Wolzt M.: P460 

Wong A.F.: P781 

Wong A.K.F.: 72 

Wong R. C. C.: P1179 

Wong Y.Y.: P1328 

Wozniak W.: P573, P951, P1182 

Wu J.R.: 167 

Xiao S.: P1167 

Xiao Z.: P1167 

Xie M.: P1167 

Xu M.: 770 

Xue Y.: P782, P783 

Yaari V.: P972, P1045, P1176, 

a U t H orS 

P1434 

Yacoub M.H.: P469, P1292, 

P1435 

Yakupov I.: P1092 

Yakush N.: P317, P834, P1283 

Yalcin F.: P201 

Yamada T.: P525, P1116 

Yamamoto E.: P806, P1255 

Yanagihara K.: P791, P795 

Yancy C.: P779 

Yaniv N.: P818, P1266 

Yanni J.: P1359 

Yassin A.: P234, P510, P812 

Yasumura Y.: P832 

Yaymaci M.: P218, P333, P975 

Yegorova Y.: P344 

Yeo Y.: P213 

Yeral N.: P201 

Yii M.: P941 

Yndestad A.: P188, P600, P1131 

Yokode M.: P589, P1158, P1417 

Yokota P.K.O.: P414, P1000 

Yoo N.J.: P526 

Yoshida C.: P962 

Youn H.J.: P902, P1109 

Yu C.M.: P268 

Yuan Z.: P284 

Yun K.H.: P526 

Yun S.H.: P338 

Yuschenko M.V.: P910 

Yvorra C.: P236 

Zaca V.: P1061 

Zaca’ V.: P402 

Zacharopoulou I.: P1336 

Zacharski M.: P1340, P1341 

Zafiriou M.P.: P1135 

Zafrir B.: P818, P1266 

Zago L.: P1305 

Zahidova K.: P1093, P1343 

Zahn R.: P1024 

Zakirov N.U.: P483, P862 

Zakliczynski M.: P472 

Zakliczynski M.W.: P823 

Zamora E.: P438, P777 

Zamorano J.L.: P1102 

Zanelli E.: P1160 

Zaniqueli D.: P243 

Zannad F.: P549, P1147 

Zanolla L.: P944, P1111 

Zaritskey A.Y.: P920 

Zatonsky S.: P523 

Zavaglia P.P.: P1127 

Zbyszynski B.: P1181 

215 

eXHiBitorS 

& inDeX

eXHiBitorS 

& inDeX 

a U t H orS 

Zdrojewski T.: P597 

Zdunek D.: P929, P1120 

Zechmeister C.: P1321 

Zeidan H.: P1074 

Zeier M.: P1358 

Zelarayan L.: P1135, P1234 

Zeman K.: P410, P1436 

Zembala M.: P346, P472, P603, 

P823, P1051 

Zeng D.: P874 

Zeng H.: P1167 

Zhadan A.: P556 

Zhang D.F.: P1372 

Zhang H.: P1359, P1372 

Zhang J.: P227, P234, P440, 

P510, P812, P903 

Zhang Z.: P1088 

Zhao Y.S.: P1428 

Zhao Y.T.: P1372 

216 

Zheleznyh E.A.: P1100, P1277 

Zheng X.Q.: P1428 

Zhu X.: P496 

Zhubrina E.S.: P854 

Zi M.: 765, P1078, P1320 

Zicha J.: P291 

Ziegler M.: P389 

Zielinska M.: P1001, P1097, 

P1153 

Zielinski T.: P843, P1028 

Zietsch C.: P1122 

Ziherl K.: P542 

Zisimopoulos I.: P1312 

Zisimos K.: P855, P1132 

Zissimos K.: P239, P827, P1021, 

P1271, P1275 

Zivkovic M.: P1426 

Zlochiver S.: P270 

Zobel T.: P1239 


Zohlnhoefer D.: P927 

Zolotaikina V.: P415 

Zotos P.: P918 

Zubaid M.Z.: P200 

Zucca F.: P989 

Zuern A.: P286 

Zugck C.: P391, P776, P929, 

P955, P1024, P1032, P1120, 

P1358 

Zuithoff N.P.A.: P513 

Zukhovitskaya E.V.: P1031, P1262 

Zuniga L.: P1027 

Zwart R.: P368 

Zykov K.: P275 

Zykov M.: P1259 

Zymlinski R.: P207, P792 

Zysko D.: P1340 

Zyw L.: 76

2011 

Heart eart Failure ailure 

Congress organised by the Heart Failure Association of the ESC 

Gothenburg 

Sweden 

21-24 May 2011 

www.escardio.org/HFA 

OB1 - Credit Photos: © K. Holmner, I. Johansson

Iron. Liberated. 

Ferinject® = improved physical performance 1 

Ferinject® = improved symptoms 1 

Ferinject® = improved quality of life 1 

1. Anker et al. N Engl J Med 2009; 361: 2436-48. 

Ferinject®: abbreviated prescribing information 

Please refer to local Summary of Product Characteristics (SPC) before prescribing 

Ferinject®. Pharmaceutical Form: Solution for injection/infusion. One milliliter of 

solution contains 50 mg of iron as ferric carboxymaltose. Each 2 ml vial contains 

100 mg of iron as ferric carboxymaltose. Each 10 ml vial contains 500 mg of iron as 

ferric carboxymaltose. Ferinject® is a dark brown, non-transparent, aqueous 

solution. Indications: Ferinject® is indicated for treatment of iron deficiency when 

oral iron preparations are ineffective or cannot be used. The diagnosis must be 

based on laboratory tests. Dosage and administration: The dose of Ferinject® is 

expressed in mg of elemental iron. Ferinject® must be administered only by the 

intravenous route: by bolus injection, during a haemodialysis session undiluted 

directly into the venous limb of the dialyser, or by drip infusion. In case of drip 

infusion Ferinject® must be diluted only in sterile 0.9% NaCl-solution. Cumulative 

dose The adequate cumulative dose of Ferinject® must be calculated for each 

patient individually. The cumulative dose required for Hb restoration and repletion 

of iron stores is calculated by the Ganzoni formula. Maximum tolerated single dose 

Intravenous bolus injection: Ferinject® may be administered up to a maximum 

single dose of 4 ml (200 mg of iron) per day but not more than three times a week. 

Intravenous drip infusion: Ferinject® may be administered up to a maximum 

single dose of 20 ml of Ferinject® (1000 mg of iron) but not exceeding 0.3 ml of 

Ferinject® (15 mg of iron) per kg body weight or the calculated cumulative dose. 

Do not administer 20 ml (1000 mg of iron) as an infusion more than once a 

week. Contraindications, Warnings, Precautions, Overdose: The use of Ferinject® 

is contraindicated in cases of known hypersensitivity to Ferinject® or any of its 

Mastering the art of iron therapy 

excipients, anaemia not attributed to iron deficiency, iron overload or disturbances 

in utilisation of iron, pregnancy in the first trimester. Parenterally administered iron 

preparations can cause hypersensitivity reactions, including anaphylactoid 

reactions, which may be potentially fatal. Therefore, facilities for cardio-pulmonary 

resuscitation must be available. In patients with liver dysfunction, parenteral iron 

should only be administered after careful risk/benefit assessment and should be 

avoided in patients with hepatic dysfunction. Paravenous leakage must be avoided. 

Parenteral iron must be used with caution in patients with acute or chronic 

infection, asthma, eczema or atopic allergies. Ferinject® should be stopped with 

ongoing bacteraemia. One ml of undiluted Ferinject® contains up to 0.24 mmol 

(5.5 mg) of sodium. Transfer of iron from Ferinject® to human milk is negligible 

(≤ 1%). Overdose of Ferinject® may eventually lead to haemosiderosis. Monitoring 

of iron parameters such as serum ferritin and transferrin saturation may assist 

in recognising iron accumulation. Undesirable effects: Common (1% to < 10%), 

uncommon (0.1% to < 1%), Common: Headache, dizziness, nausea, abdominal pain, 

constipation, diarrhoea, rash, injection site reaction, transient blood phosphorus 

decrease, alanine aminotransferase increased. Uncommon: Hypersensitivity 

including anaphylactoid reactions, paraesthesia, hypotension, flushing, dysgeusia, 

vomiting, dyspepsia, flatulence, pruritus, urticaria, myalgia, back pain, arthralgia, 

pyrexia, fatigue, chest pain, rigors, malaise, oedema peripheral, aspartate 

aminotransferase increased, gamma-glutamyltransferase increased, blood lactate 

dehydrogenase increased. Legal category: POM. Date of preparation: 07/09. 

For further information please contact our local representative or Vifor Pharma Ltd., 

Flughofstrasse 61, P.O. Box, CH-8152 Glattbrugg, Switzerland.

monday posters sessions - European Society of Cardiology

Transform your PDFs into Flipbooks and boost your revenue!

Delete template?

Save as template ?